WO2015028850A1 - Novel cytotoxic agents for conjugation of drugs to cell binding molecule - Google Patents

Novel cytotoxic agents for conjugation of drugs to cell binding molecule Download PDF

Info

Publication number
WO2015028850A1
WO2015028850A1 PCT/IB2013/058229 IB2013058229W WO2015028850A1 WO 2015028850 A1 WO2015028850 A1 WO 2015028850A1 IB 2013058229 W IB2013058229 W IB 2013058229W WO 2015028850 A1 WO2015028850 A1 WO 2015028850A1
Authority
WO
WIPO (PCT)
Prior art keywords
och
antibody
rio
cell
formula
Prior art date
Application number
PCT/IB2013/058229
Other languages
French (fr)
Inventor
Robert Yongxin Zhao
Original Assignee
Hangzhou Dac Biotech Co., Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hangzhou Dac Biotech Co., Ltd filed Critical Hangzhou Dac Biotech Co., Ltd
Priority to CN202210139534.7A priority Critical patent/CN115124573A/en
Priority to PCT/IB2013/058229 priority patent/WO2015028850A1/en
Priority to EP13892435.2A priority patent/EP3041846B1/en
Priority to NZ717003A priority patent/NZ717003A/en
Priority to US14/914,739 priority patent/US9988408B2/en
Priority to CA2921982A priority patent/CA2921982C/en
Priority to AU2013399485A priority patent/AU2013399485B2/en
Priority to CN201380079042.2A priority patent/CN107074879B/en
Priority to JP2016537393A priority patent/JP6332773B2/en
Publication of WO2015028850A1 publication Critical patent/WO2015028850A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/55—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug, i.e. a dimer, oligomer or polymer of pharmacologically or therapeutically active compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/68035—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a pyrrolobenzodiazepine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/553—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having one nitrogen atom as the only ring hetero atom
    • C07F9/5532—Seven-(or more) membered rings
    • C07F9/5535—Seven-(or more) membered rings condensed with carbocyclic rings or ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6558—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
    • C07F9/65583—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system each of the hetero rings containing nitrogen as ring hetero atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2887—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/54—F(ab')2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/626—Diabody or triabody
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Definitions

  • the present invention relates to novel cytotoxic agents, pyrrole [2, 1 - c][l,4]benzodiazepine (PBD) derivatives and their therapeutic use. These novel cytotoxic agents have therapeutic use as a result of delivering the pyrrolo[2,l-c][l,4]benzodiazepine (PBD) derivatives to a specific targeted cell population by chemically linking these derivatives to a cell binding agent.
  • ADCs Antibody-drug conjugates
  • the new ADC compounds which covalently incorporate the antitumor activity of a cytotoxic agent to a monoclonal antibody, have ability to deliver cytotoxic agents specifically to antigen-expressing tumor cells and then kill the tumor cells.
  • the ADC platform includes a growing repertoire of cytotoxic agents, linker technologies, antibody properties, and conjugation methods. An important key factor in generating an optimal ADC is the cytotoxic agents.
  • PBDs Pyrrolo[2,l -c] [l,4]benzodiazepines
  • DC-81 tomaymycin, porothramycin B, prothracarcin,
  • PBDs have potential not only as antitumor agents but also as gene regulators and probes of DNA structure (Hurley, L. J. Med. Chem. (1989), 32: 2027-2033).
  • the PBD dimers even some of them have been modified as a prodrug in antibody drug conjugates (WO 2012014147; WO 2012128868, WO 2012112687; WO 2011130616; Howard, P. et al Bioorg. Med. Chem. Lett. (2009), 19, 6463-6), are hardly soluble in a water based buffer solution, resulting in significant amount of antibody or protein aggregation.
  • novel PBD dimer derivatives which have good antitumor antibiotic activities and especially they are linkable and can facilitate conjugation to a cell surface binding ligand in a water based medium without leading to protein aggregation. Thus they can be used effectively in a conjugate with a cell binding molecule for treating cancers and immune disorders.
  • the first embodiment of this invention is to disclose cytotoxic agents, specifically, pyrrolo[2, l-c] [l,4]benzodiazepine derivatives which are potent cytotoxic agents and can be effectively used to block cell proliferation.
  • this invention is to disclose novel pyrrolo[2, l-c] [l,4]benzodiazepine derivatives, optionally linkable or linked to a cell binding agent to block cell proliferation.
  • — represents an optional single bond
  • U and U' independently represent I I: or the linking group (L') with the reactive group or a cell binding agent bonded thereto.
  • V and V are independently selected from the group consisting of 1 1. OH, -NI IOI I; an ether (-OR5); an ester (-OCOR 5, e.g.
  • R5, R5' and R5" are described below.
  • Z and /. ' the same or different, independently, represent N, ( ⁇ I. CR5, COH or COR5.
  • R5 is independently selected from Ci ⁇ Cs alkyl and aryl.
  • a sulfate OSO ⁇ M ⁇ OSO 3 H a sulfonamide represented by -SO iNRsR ' . cyano, an azido,— COR5, -OCOR5, -OCONR5R5', CF 3 , OR 5 , Aryl, heterocycle, or P ⁇ RsRs'Rs" and the linking group (L') witli the reactive group or a cell binding agent bonded thereto; Rs. Rs * and R5" are independently selected from 1 1. Ci ⁇ C & of alkyl, alkenyl, alkinyl, heteroalkyl, aryl, aryl alkyl. carbonylalkyl, or pharmaceutical salts.
  • Rs R 5 > and R 5 » can further be substituted with at least one substituent selected from -N(Ri)(R 2 ), -CQ 2 H, -SOU I. -ORi, - CO2R1, -CONRi, -PO2R1R2, POR1R2R3 and -PO3H.
  • L and L' are the same or inpendently a linker or a linker-cell binding molecule (Q) covalently bound cluster, or a linker which has a functional group on the linker that enables reaction with a cell-binding agent (CBA).
  • L when is a linker, is preferred a releasable linker, which has the formula of:— Ww— (Aa)r— I t— ; or— Ww— (Aa)r— I t— Q; or Q— Ww— (Aa)r— Tt— ; wherein: W is a Stretcher unit; w is 0 or 1 ; Aa is independently an Amino Acid unit; r is independently an integer ranging from 0 to 100;
  • the Stretcher unit W independently contains a self-immolative or a non-self-immolative component, peptidyl units, a hydra/one bond, a disulfide, an ester, an oxime, an amide, or a thioether bond.
  • the self-immolative unit includes, but are not limited to, aromatic compounds that are electronically similar to the para-aminobenzylcarbamoyl (PAB) groups such as 2- aminoimidazol-5-methanol derivatives, heterocyclic PAB analogs, beta-glucuronide, and ortho or para-am i noben/y I ace tal s.
  • PAB para-aminobenzylcarbamoyl
  • the self-immolative linker component has any combination of the self-immolative linker component.
  • (*) atom is the point of attachment of additional spacer or releasable linker units, or the cytotoxic agent, and/or the binding molecule (CBA);
  • X 1 , Y 1 , / and Z 3 are independently NH, or O, or S;
  • Z 1 is 1 1, or Nil, or O or S independently, v is 0 or 1 ;
  • Q 1 is independently II, OH, Ci ⁇ C 6 alkyl, (OCH 2 CH 2 ) classroom F, CI, Br, I, OR 5 , or SR 5 , NRsRs .
  • R5 and R 5 > are as defined above, preferably R 5 and R are independently selected from 1 1.
  • the non-self-immolative linker component is any one of the following structures:
  • the (*) atom is the point of attachment of additional spacer or releaseable linkers, the cytotoxic agents, and/or the binding molecules;
  • X 1 , Y 1 , Q 1 , R5, R5' are as defined above;
  • r is 0-100;
  • m, n and p are 0-6.
  • T is a linear, branched or cyclic alkyl, alkenyl, alkynyl or aryl having from 1 to 10 carbon atoms, or polyethylene glycol ( -( ' I lj( I I >( )- ) spacer; and t is 0, or 1-100.
  • T can also be that undergo cyclization upon amide bond hydrolysis, such as substituted and unsubstituted 4-aminobutyric acid amides, appropriately substituted bicyclo[2.2.1] and bicyclo[2.2.2] ring systems, and 2-aniinophenylpropionic acid amides.
  • L can be R5, OR5, SR5 or N R R- , thus Ri, R2, R3, R4, Rr, R 2 ⁇ R3' , or R4' , or U, or U', or V, or V on the formula (I) can be used to linked to Q via Stretcher units (Ww) or via Spacer units (Tt).
  • Q is a cell binding molecule, or a functional group that enables reaction with a cell- binding agent, or a functional group capable of reacting with a linker attached on a cell binding agent.
  • the function group is chosen from a thiol, an amine, a hydrazine, an alkoxylamino, a disulfide substituent, a maleimido, a haloacetyl group, a carboxy acid, an N- hydroxy succinimide ester, a ketone, an ester, an aldehyde, an alkynyl, an alkenyl, or protected thiol or disulfide group, such as SAc, SSKi or SSAr.
  • Ar is aromatic group or hetero aromatic group.
  • the present invention discloses a therapeutic composition
  • a therapeutic composition comprising: (1). an effective amount of one or more pyrrolo[2,l-c][l,4]benzodiazepine derivatives optionally linkable or linked to a cell binding agent, and (2). a pharmaceutically acceptable carrier, diluent, or excipient, of formula (I) ⁇ ( XIX ) of the patent application, to kill target cells or tissues containing target cells.
  • Figure 1 shows the synthesis of linkers for synthesis of benzodiazepine dimers.
  • Figure 2 shows the synthesis of linkers for synthesis of the conjugates of benzodiazepine dimers.
  • Figure 3 shows synthesis of linkers for synthesis of the conjugates of benzodiazepine dimers.
  • Figure 4 shows the synthesis of linkers and intermediates for the conjugates of benzodiazepine dimers.
  • Figure 5 shows synthesis of the intermediates and the conjugates of benzodiazepine dimers.
  • Figure 6 shows the synthesis of intermediates for the synthesis of benzodiazepine dimers.
  • Figure 7 shows the synthesis of intermediates for the synthesis of benzodiazepine dimers.
  • Figure 8 shows the synthesis of intermediates for the synthesis of benzodiazepine dimers.
  • Figure 9 shows the synthesis of intermediates for the synthesis of benzodiazepine dimers.
  • Figure 10 shows the synthesis of intermediates for the synthesis of benzodiazepine dimers.
  • Figure 1 1 shows the synthesis of intermediates and conjugates of benzodiazepine dimers.
  • Figure 14 shows the synthesis of conjugates of benzodiazepine dimers.
  • Figure 15 shows the synthesis of conjugates of benzodiazepine dimers.
  • Figure 16 shows the synthesis of conjugates of benzodiazepine dimers.
  • Figure 17 shows the synthesis of conjugates of benzodiazepine dimers.
  • Figure 18 shows the synthesis of conjugates of benzodiazepine dimers.
  • Figure 19 shows the synthesis of conjugates of benzodiazepine dimers.
  • Figure 21 shows the synthesis of conjugates of benzodiazepine dimers.
  • Figure 22 shows the synthesis of conjugates of benzodiazepine dimers.
  • Figure 23 shows the synthesis of conjugates of benzodiazepine dimers.
  • Alkyl means an aliphatic hydrocarbon group which may be straight or branched having 1 to 8 carbon atoms in the chain or cyclic. "Branched” means that one or much lower alkyl groups such as methyl, ethyl or propyl are attached to a linear alkyl chain.
  • alkyl groups include methyl, ethyl, n-propyl, i-propyl, n-butyl, t-butyl, n-pentyl, 3-pentyl, octyl, nonyl, decyl, cyclopentyl, cyclohexyl, 2,2-dimethylbutyl, 2, 3 -dimethyl butyl, 2,2- dimethylpentyl, 2,3-dimethylpentyl, 3,3-dimethylpentyl, 2,3,4-trimethylpentyl, 3-methylhexyl, 2,2-dimethylhexyl, 2,4-dimethylhexyl, 2,5-dimethylhexyl, 3,5-dimethylhexyl, 2,4- dimethylpentyl, 2-methylheptyl, 3-methylheptyl, n-heptyl, isoheptyl, n -octyl, and isoocty
  • Ci-Cs alkyl group can be unsubstituted or substituted with one or more groups including, but not limited to, -Ci ⁇ C 8 alkyl, -0-(C, ⁇ C 8 alkyl), -aryl, -C(0)R', -OC(0)R', -C(0)OR', - C(0)NH 2 , -C(0)NHR', -C(0)N(R') 2 -NHC(0)R', -S(0) 2 R', -S(0)R', -OH, -halogen (F, CI, Br or I), -N3, -Ni l . -NH(R'), -N(R') 2 and -CN; where each R' is independently selected from - Ci ⁇ Cs alkyl and aryl.
  • cyclic alkyl cycloalkyl and carbocycle
  • They mean a 3-, 4-, 5-, 6-, 7- or 8-membered saturated or unsaturated non-aromatic carbocyclic ring.
  • Representative Cs-Cs carhocycles include, but are not limited to, cyclopropyl, cyclobutyl, cyclopentyl, cyclopentadienyl, cyclohexyl, cyclohexenyl, 1,3- cyclohexadienyl, 1,4-cyclohexadienyl, cycloheptyl, 1,3-cycloheptadienyl, 1,3,5- cycloheptatrienyl, cyclooctyl, and cyclooctadienyl.
  • a C.3 ⁇ Cs carbocycle group can be unsubstituted or substituted with one or more groups including, but not limited to,— Ci ⁇ Cs alkyl, -OR 5 , -aryl, -C(0)R 5 , -OC(0)R 5 , -C(0)OR 5 , -C(0)NH 2 , -C(0)NHR 5 , -C(0)NR 5 R 5 - NHC(0)R 5 , -S(O) 2 R 5 , -S(0)R 5 , -OH, -halogen, -N 3 , -NH 2 , -NHR 5 , -NR 5 R 5 - and -CN; wherein R5 and R- - are independently H; Ci ⁇ Cs of alkyl, alkenyl, alkynyl, heteroalkyl, aryl, arylalkyl, or carbonylalkyl; or pharmaceutical salts.
  • C 3 ⁇ Cs carbocyclo refers to a C 3 ⁇ C 8 carbocycle group defined above wherein one of hydrogen atoms on the carbocycle is replaced with a bond.
  • Alkenyl refers to an aliphatic hydrocarbon group containing a carbon-carbon double bond and which may be straight or branched having 2 to 8 carbon atoms in the chain.
  • the alkenyl double bond may have "cis” and “trans” orientations, or alternatively, "E” and “/” orientations.
  • Exemplary alkenyl groups include, but are not limited to, ethylenyl or vinyl, propenyl or allyl, n-butenyl, i-butenyl, 3 ⁇ methylbut ⁇ 2-enyl, n-pentenyl, hexylenyl, heptenyl, octenyl.
  • Alkynyl or “alkinyl” means an aliphatic hydrocarbon group containing a carbon-carbon triple bond and which may be straight or branched having 2 to 8 carbon atoms in the chain.
  • exemplary alkynyl groups include ethynyl, propynyl, n-butynyl, 2-butynyl, 3-methylbutynyl, pentynyl, n-pentynyl, hexylynyl, heptynyl, and octynyl.
  • Heteroalkyl is C 2 ⁇ C8 alkyl in which one to four carbon atoms are independently replaced with a heteroatom from the group consisting of O, S and N.
  • Heterocycle refers to an aromatic or non-aromatic C 3 ⁇ Ci4 cai bocycle in which one to four of the ring carbon atoms are independently replaced with a heteroatom from the group of O, N, P, S and Se.
  • Preferable heteroatoms are oxygen, nitrogen and sulphur.
  • heterocyclics are also disclosed in The Handbook of Chemistry and Physics, 76* Edition, CRC Press, Inc., 1995-1996, p2-25 to 2-26, the disclosure of which is hereby incorporated by reference.
  • Preferred non aromatic heterocyclic include, but are not limited to pyrrolidinyl, pyrazolidinyl, imidazolidinyl, oxiranyl, tetrahydrofuranyl, dioxolanyl, tetrahydro-pyranyl, dioxanyl.
  • tetrahydropyranyl diliydropyranyl, tetrahydro-pyridyl, dihydropyridyl, tetrahydropyrinidinyl, dihydrothiopyranyl, a/epanyl, as well as the fused systems resulting from the condensation with a phenyl group.
  • Aryl or Ar refers to an aromatic or hetero aromatic group, composed of one or several rings, comprising three to fourteen carbon atoms, preferentially six to ten carbon atoms.
  • the term of hetero aromatic group refers one or several carbon on aromatic group, preferentially one, two, three or four carbon atoms are replaced by O, N, Si, Se, P or S, preferentially by O, S, N.
  • R 5 and R 5 > are independently H, alkyl, alkenyl, alkinyl, heteroalkyl, aryl, arylalkyl, carbonyl, or pharmaceutical salts.
  • heteroaryl refers to a 5 to 14, preferably 5 to 10 membered aromatic hetero, mono-, bi- or multicyclic ring.
  • examples include pyrrolyl, pyridyl, pyrazolyl, thienyl, pyrimidinyl, pyrazinyl, tetrazolyl, indolyl, quinolinyl, purmyl, imidazolyl, thienyl, thiazolyl, benzothiazolyl, furanyl, benzofuranyl, 1,2,4-thiadiazolyl, isothiazolyl, triazoyl, tetrazolyl, isoquinolyl, benzothienyl, isobenzofuryl, pyrazolyl, carbazolyl, benzimidazolyl, isoxazolyl, pyridyl-N-oxide, as well as the fused systems resulting from the condensation with a phenyl group.
  • Alkyl refers also to the corresponding "alkylene”, “cycloalkylene”, “alkenylene”, “alkynylene”, “arylene”, “heteroarylene”, “heterocyclene” and the likes which are formed by the removal of two hydrogen atoms.
  • Halogen atom refers to fluorine, chlorine, bromine or iodine atom; preferably bromine and chlorine atom.
  • “Pharmaceutically” or “pharmaceutically acceptable” refer to molecular entities and compositions that do not produce an adverse, allergic or other untoward reaction when administered to an animal, or a human, as appropriate.
  • “Pharmaceutically acceptable excipient” includes any carriers, diluents, adjuvants, or vehicles, such as preserving or antioxidant agents, fillers, disintegrating agents, wetting agents, emulsifying agents, suspending agents, solvents, dispersion media, coatings, antibacterial and antifungal agents, isotonic and absorption delaying agents and the like.
  • preserving or antioxidant agents such as preserving or antioxidant agents, fillers, disintegrating agents, wetting agents, emulsifying agents, suspending agents, solvents, dispersion media, coatings, antibacterial and antifungal agents, isotonic and absorption delaying agents and the like.
  • the use of such media and agents for pharmaceutical active substances is well known in the art. Except insofar as any conventional media or agent is incompatible with the active ingredient, its use in the therapeutic compositions is contemplated. Supplementary active ingredients can also be incorporated into the compositions as suitable therapeutic combinations.
  • pharmaceutical salts refer to derivatives of the disclosed compounds wherein the parent compound is modified by making acid or base salts thereof.
  • pharmaceutically acceptable salts include the con ventional non-toxic salts or the quaternary ammonium salts of the parent compound formed, for example, from non-toxic inorganic or organic acids.
  • non-toxic salts include those derived from inorganic acids such as hydrochloric, hydrobromic, sulfuric, sulfamic, phosphoric, nitric and the like; and the salts prepared from organic acids such as acetic, propionic, succinic, tartaric, citric, methanesulfonic, benzenesulfonic, glucuronic, glutamic, benzoic, salicylic, toluenesulfonic, oxalic, fumaric, maleic, lactic and the like.
  • Further addition salts include ammonium salts such as tromethamine, triethanolamine, meglumine, epolamine, etc., metal salts such as sodium, potassium, calcium, zinc or magnesium.
  • the pharmaceutical salts of the present invention can be synthesized from the parent compound which contains a basic or acidic moiety by conventional chemical methods.
  • such salts can be prepared by reaction of the free acid or base forms of these compounds with a stoichiometric amount of the appropriate base or acid in water or in an organic solvent, or in a mixture of the two.
  • non-aqueous media like ether, ethyl acetate, ethanol, isopropanol, or acetonitrile are preferred. Lists of suitable salts are found in Remington's Pharmaceutical Sciences, 17 ed., Mack Publishing Company, Huston, PA, 1985, p i 418, the disclosure of which is hereby incorporated by reference.
  • cytotoxic dimer compound are used interchangeably. They are intended to include compounds for which a structure or formula or any derivative of thereof has been disclosed in the present invention or a structure or formula or any derivative thereof that has been incorporated by reference.
  • the term also includes, stereoisomers, geometric isomers, tautomers, solvates, metabolites, salts (e.g., pharmaceutically acceptable salts) and prodrugs, and prodrug salts of a compound of all the formulae disclosed in the present invention.
  • the term also includes any solvates, hydrates, and polymorphs of any of the foregoing. The specific recitation of "stereoisomers,” “geometric isomers,” “tautomers,” “solvates,”
  • inline reactive reagent refers to a reagent that is capable of reacting with an imine group.
  • imine reactive reagent includes, but is not limited to, sulfites (H 2 SQ 3 , H 2 SO 2 or a salt of HSO 3 " , SO : ' or HSOj formed with a cation), metabisulfite (H 2 S 2 O5 or a salt of S 2 O5 2" formed with a cation), mono, di, tri, and tetra-thiophosphates (PO 3 SH 3 , PO 2 S 2 H 3 , POS 3 H 3 , PS 4 H 3 or a salt of PO 3 S 3" , PO 2 S 2 3" , POS 3 3” or P formed with a cation), thio phosphate esters ( ( R O bPS( OR ).
  • the cation is a monovalent cation, such as Na + or K + .
  • the imine reactive reagent is selected from sulfites, hydroxyl amine, urea and hydrazine. More preferably, the imine reactive reagent is NaHS(3 ⁇ 4 or KI ISO;.
  • Cell binding agents or “Cell binding molecules” may be of any kind presently known, or those become known, and include peptides and non-peptides. Generally, these can be antibodies (especially monoclonal antibodies) or a fragment of an antibody that contains at least one binding site, lymphokines, hormones, growth factors, nutrient-transport molecules (such as transferrin), or any other cell binding molecule or substance (such as vitamins).
  • cell binding agents that can be used include:
  • mAb monoclonal antibodies
  • - lymphokines such as IL-2, 11 . -3, 11 . -4, 11 . -6;
  • hormones such as insulin, TRI I (thyrotropin releasing hormones), MSH (melanocyte- stimulating hormone), steroid hormones, such as androgens and estrogens;
  • EGF EGF
  • TGFa insulin like growth factor
  • IGF-I insulin like growth factor
  • IGF-II insulin like growth factor
  • M-CSF M-CSF
  • GM-CSF GM-CSF ⁇ Burgess, Immunology Today 5, 155-158 (1984) ⁇
  • Monoclonal antibodies can be produced in the well known state of art technology.
  • the technology permits the production of extremely selective cell binding agents in the form of specific monoclonal antibodies.
  • the well known in the art are techniques for creating monoclonal antibodies produced by immunizing mice, rats, hamsters or any other mammal with the antigen of interest such as the intact target cell, antigens isolated from the target cell, whole virus, attenuated whole virus, and viral proteins such as viral coat proteins.
  • an anti-CD20 antigen monoclonal antibody known as Rituximab is a chimeric (mouse/human) monoclonal antibody and it was the first therapeutic antibody approved by the United States Food and Drug Administration for treatment of relapsed or refractory low- grade or follicular NHL (Leonard, J. P. et al, Clin. Cane. Res. 10:5327-5334 (2004)).
  • Another anti-CD20 antibody is a human monoclonal antibody targeting an epitope different from that of rituximab and most other CD20 directed antibodies. It was approved by US FDA for treating chronic lymphocytic leukemia and has also shown potential in treating Follicular non-IIodgkin's lymphoma, Diffuse large B cell lymphoma, rheumatoid arthritis and relapsing remitting multiple sclerosis (Coiffier, B. et al Blood 111 : 1094-100 (2008); Zhang, B. MAbs 1 (4): 326-31 (2009)).
  • Afutuzumab (now called obinutuzumab) has been developed (Robak, T (2009) Current opinion in investigational drugs (London, England: 2000) 10 (6): 588-96).
  • Obinutuzumab is fully humanized IgGl type II anti-CD20 antibody and it selectivity binds to the extracellular domain of the human CD20 antigen on malignant human B cells.
  • an anti-CD 19 antigen monoclonal antibody B4 is a murine IgGi, that binds to the ( " 1 ) 1 9 antigen on B cells ⁇ Nadler et al, 131 J.
  • the anti- CD22 antibodies that include RFB4 (Mansfield, E. et al., Blood 90:2020-2026 (1997)), CMC-544 (DiJoseph, J. I .. Blood 103: 1807-1814 (2004)) and LI .2 (Pawlak-Byczkowska, E. J. et al, Cancer Res. 49:4568-4577 (1989)) can be used as potential therapies for B cell cancers and other B cell proliferative diseases.
  • the LL2 antibody (formerly called HPB-2) is an IgG2a mouse monoclonal antibody directed against the CD22 antigen (Pawlak-Byczkowska, E. .1. et al. (1989), supra).
  • the anti CD33 antigen monoclonal antibody named Gemtuzumab was first monoclonal antibody conjugated with a cytotoxic drug to treat acute myelogenous leukemia (AML) (P. F. Bross et al Clin Cancer Res 7 (6): 1490-6).
  • a similar anti CD33 antigen antibody, named My9-6 is a murine IgGi antibody that binds specifically to the CD33 Antigen ⁇ .I. I ).
  • GM-CSF antibody which binds to myeloid cells can be used as a cell binding agent to diseased cells from acute myelogenous leukemia.
  • IL-2 antibody which binds to activated T-cells, can be used for prevention of transplant graft rejection, for therapy and prevention of graft-versus-host disease, and for the treatment of acute ⁇ -cel l leukemia.
  • MSI I antibody which binds to melanocytes, can be used for the treatment of melanoma. NOVEL CYTOTOXIC AGENTS AND THEIR CONJUGATION OF THE INVENTION.
  • the PBD dimer derivatives according to the present invention comprises one or more pyrrolo[2,l-c][l,4]benzodiazepine derivatives, optionally linkable or linked to a cell binding agent via a linking group.
  • the linking group is part of a chemical moiety that is covalently bound to a pyrrolo[2,l-c][l,4]benzodiazepine derivative through conventional methods.
  • the PBD dimer derivatives disclosed in the present invention have the formula (I) show
  • — represents an optional single bond
  • R5 is independently selected from Ci-Cs alkyl and aryl.
  • Rs, Rs * and R5" are independently selected from H, Ci ⁇ Cs of alkyl, alkenyl, alkinyl, heteroalkyl, aryl, arylalkyl, carbonylalkyl, or pharmaceutical salts.
  • Rs. Rs and Rs can further be substituted with at least one substituent selected from -N( R ] )( R 2 ), -C0 2 H, -SOU I, -OR] , - CO2R1, -CONRi, -PO2R1R2, POR1R2R3 and -PO3H.
  • I is a linker, or a linker-cell binding molecule covalently bound cluster, or a linker has a functional group on the linker that enables reaction with a cell-binding agent.
  • L when is a linker, is preferred a releasable linker, which is a chain of atoms selected from C, N, O, S, Si, B and P that covalently connects the cell-surface binding ligand (CBA) to the PBD
  • the linker may have a wide variety of lengths, such as in the range from about 2 to about 100 atoms.
  • the atoms used in forming the linker may be combined in all chemically relevant ways, such as forming alkylene, alkenylene, and alkynylene, ethers, polyoxyalkylene, esters, amines, iniines, polyamines, hydrazines, hydra/ones, amides, ureas, semicarbazides, carbazides, alkoxy amines, alkoxylamines, urethanes, amino acids, acyloxylamines, oximes, aldoximes, ketoximes, amidoximes, hydroxamic acids, and many others.
  • the atoms forming the releasable linker (L) may be either saturated or unsaturated, or may be radicals, or may be cyclized upon each other to form divalent cyclic structures, including cyclo alkanes, cyclic ethers, cyclic amines, arylenes, heteroarylenes, and the like in the linker.
  • L has the formula of :— -Ww— (Aa)r— I t— ; or— Ww— (Aa)r— I t— Q; or Q— Ww— (Aa)r— Tt— ; wherein: W is a Stretcher unit; w is 0 or 1 ; Aa is independently an amino acid unit; r is independently an integer ranging from 0 to 100; The Stretcher unit W may independently contain a self-immolative or a non-self-immolative component, peptidyl units, a hydrazone bond, a disulfide, an ester, oxime, or thioether bonds.
  • self- immolative units include, but are not limited to, aromatic compounds that are electronically similar to the para-aminobenzylcarbamoyl (PAB) group such as 2-aminoimidazol-5-methanol derivatives (Hay et al. (1999) Bioorg. Med. ( "hem. Lett. 9, 2237), heterocyclic PAB analogs, beta-glucuronide, and ortho or para-aminobenzylacetals.
  • PAB para-aminobenzylcarbamoyl
  • the self-immolative linker component has any one of the following structures:
  • (*) atom is the point of attachment of additional spacer or releasable linker units, or the cytotoxic agent, and/or the binding molecule (CBA);
  • X 1 , Y 1 , / and Z 3 are independently NH, or O, or S;
  • Z 1 is II, or NH, or O or S independently, v is 0 or 1 ;
  • R5 and R 5 > are as defined above, preferably R 5 and R are independently selected from 1 1.
  • the non-self-immolative linker component is any one of the following structures:
  • the (*) atom is the point of attachment of additional spacer or releaseable linkers, the cytotoxic agents, and/or the binding molecules;
  • X 1 , Y 1 , Q 1 , R5, R5' are as defined above;
  • r is 0-100;
  • m, n and p are 0-6.
  • Spacers is a linear, branched or cyclic alkyl, alkenyl, alkynyl or aryl having from 1 to 10 carbon atoms, or polyethylene glycol (-( 'I lj( I IjO- ) spacer; and t is 0, or 1-100.
  • Spacers can be used that undergo cyclization upon amide bond hydrolysis, such as substituted and unsubstituted 4-aminobutyric acid amides (Rodrigues et al (1995) Chemistry Biology 2:223), appropriately substituted bicyclo[2.2.1] and bicyclo[2.2.2] ring systems (Storm et al (1972) .1. Amer. Chem. Soc. 94:5815) and 2-aminophenylpropionic acid amides (Amsberry, et al (1990) J. Org. Chem. 55:5867). Elimination of amine -containing drugs that are substituted at glycine (Kingsbury et al (1984) .1. Med. Chem.
  • L can be 5, OR5, SR5 , NHR5, or NRsR .
  • Ri, R 2 , R3, R4, Rr, R 2 . R 3 ', or R 4 ', or U, or U', or V, or V on the formula (I) can be used to linked to Q via Stretcher units (Ww) or via Spacer units (Tt) when the compound is used for conjugation to a cell binding agent.
  • Q is a cell binding molecule (CBA), or a functional group that enables reaction with a cell-binding agent or a functional group capable of reacting with a linker attached on a cell binding agent.
  • the function group is chosen from a thiol, an amine, a hydrazine, an alkoxylamino, a disulfide substituent, a maleimido, a haloacetyl group, an N-hydroxy succinimide ester, or protected thiol or disulfide group, such as SAc, SSR 5 or SSAr.
  • releasable linker refers to a linker that includes at least one bond that can be broken under physiological conditions, such as a pH-labile, acid-labile, base-labile, oxidatively labile, metabolically labile, biochemically labile, or enzyme-labile bond. It is appreciated that such physiological conditions resulting in bond breaking do not necessarily include a biological or metabolic process, and instead may include a standard chemical reaction, such as a hydrolysis or substitution reaction, for example, an endosome having a lower pH than cytosolic pH, and/or disulfide bond exchange reaction with a intracellular thiol, such as a millimolar range of abundant of glutathione inside the malignant cells.
  • physiological conditions resulting in bond breaking do not necessarily include a biological or metabolic process, and instead may include a standard chemical reaction, such as a hydrolysis or substitution reaction, for example, an endosome having a lower pH than cytosolic pH, and/or disulfide bond exchange reaction with a intracellular
  • the Stretcher unit W may independently contain a self-immolative spacer, peptidyl units, a hydra/one bond, disulfide or thiolether bonds.
  • a binding molecular (CBA) has a functional group that can form a bond with a functional group of a Stretcher.
  • Useful functional groups that can be present on a binding molecular, either naturally or via chemical manipulation include, but are not limited to, sulfhydryl (— SH), amino, hydroxyl, carbonyl, the anomeric hydroxyl group of a carbohydrate, and carboxyl.
  • Preferred functional groups are sulfhydryl, carboxy and amino. Sulfhydryl groups can be generated by reduction of an intramolecular disulfide bond of a Ligand.
  • sulfhydryl groups can be generated by reaction of an amino group of a lysine moiety of a binding molecular using 2-iminothiolane (Traut's reagent) or thiol actone or another sulfhydryl generating reagent, such as modifies T with a disulfide bond linker, or a thiol ester following by reduction or hydrolysis respectively.
  • releasable linkers (L) include, but not limited:
  • m, Aa, t, n, Q, R 3 , R 4 , and R5 are described above;
  • Re, R 7 , and R 8 are the same or different and independently chosen from H; halide; Ci ⁇ C 8 of alky I. aryl, alkenyl, alkynyl, ether, ester, amine or amide, which optionally substituted by one or more halide, CN, NRiR 2 , CF 3 , OR,.
  • K is NR,. O, S, Se, B or Het.
  • novel PBD derivatives of the invention have the formula (II), (HI), and (TV).
  • V and V are independently selected from the group consisting of OH, an ether such as -OR5, an ester (e.g. an acetate), such as -QCOR5, -COOR5, a carbonate such as -OCOOR5, a carbamate such as -OCONR5R5', a cyclic carbamate, such that NIO and CI 1 are a part of the cycle, a urea such as -NRCONR5R5', a thiocarbamate such as -OCSNHR5, a cyclic thiocarbamate such that NIO and C I 1 are a part of the cycle, -SI I, a sulfide such as -SR5, a sulphoxide such as -SQR5, a sulfone such as -SOOR5, a sulphite (sulfite) such as -SO 3 " , a bisulphite such as -OSO 3 " , a
  • Rs. Rs' and Rs ' * are independently selected from H, Ci ⁇ Cs of alkyl, alkenyl, alkinyl, heteroalkyl, aryl, arylalkyl, carbonylalkyl, or pharmaceutical salts.
  • Rs. Rs and R- can further be substituted with at least one substituent selected from -N( R ] )( R ? ), -CO 2 H, -SOU I, -ORi, - CO2R1, -CONRi, -PO2R1R2, POR1R2R3 and -PO3H or M (Na, K, Ca, ammonium or the other pharmaceutically acceptable salt), or linked a cell binding agent via Stretcher units (Ww) or via Spacer units (Tt).
  • the PHI) derivatives of formula (I), (II), ( III ), and (IV) are represented by the following formulas (V), (VI), (VII), (VIII), (IX), (X), (XI), (XII), (XIII), (XIV), (XV), (XVI):
  • U, LP, V, V, n, n', X, X' and L are the same as defined in formula (I).
  • Re and e' are the same or independently as R5 as described in formula (I), preferably R graffiti and R, * arc Ci ⁇ Cs of alkyl, alkenyl, alkinyl, aryl, cyclic, cyclohetero, haloalkyl, alkoxy, haloalkoxy alkylamino; or halogen; or -N0 2 ; or -CN; or H; or linked a cell binding agent via Stretcher units (Ww) or via Spacer units (Tt).
  • W, w, T, and t are as defined in Formula (I).
  • Aa, n, and Q are the same in the Formula (I) or (II).
  • Q is 11, Ci ⁇ C & of alkyl, alkenyl, alkinyl, aryl, cyclic, cyclohetero, haloalkyl, alkoxy, haloalkoxy alkylamino; or halogen; or -N0 2 ; or -CN; -SH; -SSCH 3 ; -SSAc; -SSAr; -SS-Pyridine; -SS ⁇ Ar(-N0 2 ); -S- cell binding agent; or a function group of NHS ester, pentafluorophenyl ester; alkyloxy amine; aldehyde; ketone; carboxyl acid; hydrazine; amine; or thiolactone; or linked a cell binding agent via Stretcher units (Ww) or via Spacer units (Tt).
  • W, w, T, and t are as defined
  • D is H, -N0 2 , SQ 3 ⁇ , CN, or F; K
  • the compounds and process of the present invention can be prepared in a number of ways well known to those skilled in the art.
  • the compounds can be synthesized, for example, by application or adaptation of the methods described in the examples, or variations thereon as appreciated by the skilled artisan.
  • the appropriate modifications and substitutions will be readily apparent and well known or readily obtainable from the scientific literature to those skilled in the art. In particular, such methods can be found in Richard C. Larock, Comprehensive Organic Transformations, A Guide to Functional Group Preparations, Two Volume Set, 2nd Edition, Wiley Publishers, 2010.
  • cytotoxic agents of the present invention may contain one or more
  • asymmetrically substituted carbon atoms may be isolated in optically active or racemic forms, all chiral, diastereomeric, racemic forms and all geometric isomeric forms of a structure are intended, unless the specific stereochemistry or isomeric form is specifically indicated. It is well known in the art how to prepare and isolate such optically active forms. For example, mixtures of stereoisomers may be separated by standard techniques including, but not limited to, resolution of racemic forms, normal, reverse-phase, and chiral chromatography, preferential salt formation, recrystallization, and the like, or by chiral synthesis either from chiral starting materials or by deliberate synthesis of target chiral centers.
  • cytotoxic agents of the present invention may be prepared by a variety of synthetic routes.
  • the reagents and starting materials are commercially available, or readily synthesized by well-known techniques by one of ordinary skill in the arts. All substituents, unless otherwise indicated, are as previously defined.
  • suitable solvents include: hydrocarbons, which may be aromatic, aliphatic or cyeloaliphatie hydrocarbons, such as hexane, cyclohexane, benzene, toluene and xylene; hydrocarbons containing halogens, such as chloroform, dichloromethane, dichloroethane; amides, such as dimethylaclamide or dimethylformamide; alcohols such as ethanol and methanol and ethers, such as diethyl ether and tetrahydrofuran.
  • hydrocarbons which may be aromatic, aliphatic or cyeloaliphatie hydrocarbons, such as hexane, cyclohexane, benzene, toluene and xylene
  • hydrocarbons containing halogens such as chloroform, dichloromethane, dichloroethane
  • amides such as dimethylaclamide or dimethylformamide
  • the reactions can take place over a wide range of temperatures, from -100 °C - 300°C, preferably from 0°C to 100°C.
  • the time required for the synthetic reaction may also vary widely, depending on many factors, notably the reaction temperature and the nature of the reagents and can be from 5 second to 4 weeks, more preferably from 10 min to 20 hours.
  • the cytotoxic agents prepared may be isolated or purified from the reaction mixture by conventional means, such as evaporating or distilling off the solvent from the reaction mixture, or after distilling off the solvent from the reaction mixture, pouring the residue into water followed by extraction with a water- immiscible organic solvent and then distilling off the solvent from the extract. It may also involve various well known techniques, such as re-ciystallization, re-precipitation or the various chromatography techniques, notably column chromatography, preparative thin layer
  • the present invention also provides a conjugate molecule comprising at least one PBD derivative covalently linked to a cell binding agent (CBA) through the linking group of the crosslinker (L).
  • a conjugate molecule comprising at least one PBD derivative covalently linked to a cell binding agent (CBA) through the linking group of the crosslinker (L).
  • said conjugate comprises one to twenty molecules of PBD derivatives according to the invention covalently linked to a cell binding agent through the linking group of the linker of the PBD derivatives.
  • the conjugates of a cell surface binding molecule - cytotoxic agent are illustrated in the formula (I):
  • R , , R 2 , R 3 , R4, Rr, R 3 ⁇ R» ⁇ U, V, U' or V on the formula (I) can be used to linked to a cell-binding molecule (CBA) via L' , or via Stretcher units (Ww) or via Spacer units (Tt).
  • CBA, I . * , W, w. T, and t are as described through the patent application.
  • the conjugates of the invention are i llustrated in the formula (
  • L are described above in Formula (I).
  • L' is the same or independently L as defined in Formula (I).
  • Drug loading may range from 1 to 20 drug moieties (D) per cell binding agent and is preferred the average number of 2-8 drug moieties per cell binding agent in a molecule of Formula (IX) - (XIV).
  • CBA is antibody in preparations of ADC
  • the preferred drug loading is 3-6 drug per antibody andthe average number of drug moieties per antibody from conjugation reactions may be characterized by conventional means such as mass
  • the quantitative distribution of the conjugates in terms of the drug loading may also be determined.
  • separation, purification, and characterization of homogeneous the conjugates where drug loading is a certain value from the conjugates with the drug loadings may be achieved by means such as reverse phase HPLC or electrophoresis.
  • the Cell binding agents may be of any kind and include peptides and non-peptides.
  • the cell binding agents include, but are not limited to, large molecular weight proteins such as, for example, full-length antibodies (polyclonal and monoclonal antibodies); single chain antibodies; fragments of antibodies such as Fab, Fab', F(ab') 2 , l ⁇ . [Parham, J .
  • lymphokines such as IL-2, 11 . -3, I I -4, IL-6, GM-CSF, interferon-gamma (IFN- ⁇ ); hormones such as insulin, TRI I (thyrotropin releasing hormones), M SI I (melanocyte- stimulating hormone), steroid hormones, such as androgens and estrogens, melanocyte - sl i mulating hormone ( MSI I ): growth factors and colony-stimulating factors such as epidermal growth factors (EGF), granulocyte-macrophage colony-stimulating factor (GM-CSF), transforming growth factors (TGF), such as TGFa, ⁇ , insulin and insulin like growth factors (IGF-I, IGF-II) G-CSF, M-CSF and GM-CSF [Burgess, Immunology Today, 5, 155-158 (1984)] ; vaccinia growth factors (VGF); fibroblast growth factors (FGFs); smaller molecular growth factors (VG
  • the linker used for the conjugation of this invention includes, but not limited to, a disulfide linker, a thioether linker, an amide bonded linker, a peptidase-labile linker, a photolabile linker, an acid-labile linkers (such as hydrazone liner), an esterase -labile linker, an oxidatively labile linker, a metabolically labile linker, a biochemically labile linker.
  • the linker is linked to the cell binding agent via a function reactive towards for instance thiol and amino functions of the cell binding agent coming from reduced disulfide bonds and lysine residues respectively. More particularly, said derivative is linked through the —CO— group to the amino function of the lysine residue of said cell binding agent, so as to form an amide bond.
  • the linker may be composed of one or more linker components.
  • exemplary linker components include 6-maleimidocaproyl ("MC"), rnaleimidopropanoyl ("MP”), valine - citrulline (“val-cit” or “vc”), alanine -phenylalanine ("ala-phe” or “af '), glycine-glycine, p- aminobenzyloxycarbonyl (“PAB”), N-succinimidyl 4-(2-pyridylthio)pentanoate (“SPP”), N- succinimidyl 4-(N-maleimidomethyl)cyclohexane-l carboxylate (“SMCC”), N-Succinimidyl (4-iodo-acetyl)aminobenzoate (“SIAB”), ethyleneoxy (— CH 2 CH 2 0— ) as one or more repeating units (“EO” or "PEO”).
  • the linker may be a "
  • conjugates of the invention are monoclonal
  • antibodies used for conjugation of cyotoxic agents in this prevention include, but are not limited to, 3F8 (anti-GD2), Abagovomab (anti CA-125), Abciximab (anti CD41 (integrin alpha-lib), Adalimumab (anti-TNF-a), Adecatumumab (anti- EpCAM, ( ' 1 )326 ), Afelimomab (anti-TNF-a); Afutuzumab (anti-CD20), Alacizumab pegol (anti-VEGFR2), ALD518 (anti-IL-6), Alemtuzumab (Campath, MabCampath, anti- CD52), Altumomab (anti-CEA), Anatumomab ( anti-TAG-72), Anrukinzumab (IMA-638, anti-IL-13), Apolizumab (anti-HLA-DR), Arcitumomab (anti-CEA
  • CR6261 anti-Influenza A hemagglutinin
  • Dacetuzumab anti-CD40
  • Daclizumab Zaenapax, anti-CD25 (a chain of IL-2 receptor)
  • Daratumumab anti-CD38 (cyclic ADP ribose hydrolase)
  • Denosumab Prolia, anti-RAN L
  • Detumomab an ti-B -lymphoma cell
  • Efalizumab (Raptiva, anti-LFA-1 (CD 11a), Efungumab (Mycograb, anti-Hsp90), Flotuzumab (anti-SLAMF7), Elsilimomab (anti-IL-6), Enlimomab pegol (anti-ICAM-1 (CD54)),
  • Epitumomab (anti-episialin), Epratuzumab (anti-CD22), Erlizumab (anti-ITGB2 (CD 18)), 1 j tumaxomab (Rexomun, anti-HER2/neu, CD3), Llaraci/umab (Abegrin, anti-integrin ⁇ ⁇ ⁇ 3), Exbivirumab ( anti-hepatitis B surface antigen), Fanolesomab (NeutroSpec, anti-CD 15),
  • Faralimomab (anti-interferon receptor), Farletuzumab (anti-folate receptor 1), Felvizumab (anti- respiratory syncytial virus), Fezakinumab (anti-IL-22), Figitumumab (anti-IGF-1 receptor), Fontolizumab (anti-IFN- ⁇ ), Foravirumab (anti-rabies virus glycoprotein), Fresolimumab (anti- TGF- ⁇ ), Galiximab (anti-CD80), Gantenerumab (anti- beta amyloid), Gavilimomab (anti- CD147 (basigin)), Gemtuzumab (anti-CD33), Girentuximab (anti-carbonic anhydrase 9),
  • ilembatumumab (CR011, anti-GPNMB), Golimumab (Simponi, anti-TNF-a ).
  • Gomiliximab (anti-CD23 (IgE receptor)), Ibalizumab (anti-CD4), Ibritumomab (anti-CD20), Igovomab (Indimacis-125, anti-CA-125), Imciromab (Myoscint, anti-cardiac myosin), Infliximab
  • Mapatumumab (anti-TRAIL-Rl), Maslimomab (anti- T-cell receptor), Matuzumab (anti- EGFR), Mepolizumab (Bosatria, anti-IL-5), Metelimumab (anti-TGF beta 1), Milatuzumab (anti-CD74), Minretumomab (anti-TAG-72), Mitumomab (BEC-2, anti-GD3 ganglioside), Morolimumab (anti-Rhesus factor), Motavizumab (Numax, anti-respiratory syncytial virus), Muromonab-CD3 (Orthoclone OKT3, anti-CD3), Nacolomab (anti-C242), Naptumomab ( anti- 5T4), Natalizumab (Tysabri, anti-integrin o ).
  • Nebacumab (anti-endotoxin), Necitumumab (anti- EGFR), Nerelimomab (anti-TNF-a), Nimotuzumab (Theracim, Theraloc, anti-EGFR), Nofetumomab, Ocrelizumab (anti-CD20), Odulimomab (y ⁇ folimomab, anti-LFA-1 (GDI la)), Ofatumumab (Arzerra, anti-CD20), Olaratumab (anti-PDGF-R a), Omalizumab (Xolair, anti- IgE Fc region), Oportuzumab (anti-EpCAM), Oregovomab (OvaRex, anti-CA-125),
  • Otelixizumab (anti-CD3), Pagibaximab (anti-lipoteichoic acid), Palivizumab (Synagis, Abbosynagis, anti-respiratory syncytial vims), Panitumumab (Vectibix, ABX-EGF, anti- EGI R ), Panobacumab (anti-Pseudomonas aeruginosa), Pascolizumab (anti-IL-4), Pemtumomab (Theragyn, anti-MUCl), Pertuzumab (Omnitarg, 2C4, anti-IIER2/neu), Pexelizumab (anti-C5), Pintumomab (anti-adenocarcinoma antigen), Priliximab (anti-CD4), Pritumumab (anti- vimentin), PRO 140 (anti-CCR5), Racotumomab (1E10, anti-(N
  • Ramucirumab (anti-VEGFR2), Ranibizumab (Lucentis, anti-VEGF-A), Raxibacumab (anti- anthrax toxin, protective antigen), Regavirumab (anti-cytomegalovirus glycoprotein B), Reslizumab (anti-IL-5), Rilotumumab (anti-HGF), Rituximab (MabThera, Rituxanmab, anti- CD20), Robatumumab (anti-IGF-1 receptor), Rontalizumab (anti-IFN-a), Rovelizumab (LeukArrest, anti-CDl l, CD 18), Ruplizumab (Antova, anti-CD 154 (CD40L)), Satumomab (anti-TAG-72), Sevirumab (anti-cytomegalovirus), Sibrotuzumab (anti-FAP), Sifalimumab (anti-IFN-a), Siltuximab (anti-IL-6
  • Vepalimomab (anti-AOC3 (VAP-1), Visilizumab (Nuvion, anti-CD3), Vitaxin (anti-vascular integrin avb3), Volociximab (anti-integrin 5 ⁇ ), Votumumab (HumaSPECT, anti-tumor antigen CTAA16.88), Zalutumumab (HuMax-EGFr, (anti-EGFR), Zanolimumab (HuMax-CD4, anti- CD4), Ziralimumab (anti-CD 147 (basigin)), Zolimomab (anti-CD5), Etanercept (Enbrel®), Alefacept (Amevive®), Abatacept (Orencia®), Rilonacept (Arcalyst), 14F7 [anti-IRP-2 (Iron Regulatory Protein 2)], 14G2a (anti-GD2 ganglioside, from Nat.
  • VAP-1 Visilizumab
  • Vitaxin
  • ImmuRAIT from Immunomedics for NHL
  • Lym-1 anti-IILA-DRlO, Peregrine Pharm. for Cancers
  • MAK-195F anti-TNF (tumor necrosis factor; TNFA, TN I ' -alpha; TNFSF2), from Abbott / Knoll for Sepsis toxic shock
  • MEDI-500 [T10B9, anti-CD3, ⁇ 3 ⁇ 4 ⁇ (T cell receptor alpha/beta), complex, from Medlmmune Inc for Graft-versus-host disease]
  • RING SCAN anti-TAG 72 (tumour associated glycoprotein 72), from Neoprobe Corp.
  • LymphoCide Immunomedics, NJ
  • Smart ID 10 Protein Design Labs
  • Oncolym Techniclone Inc, CA
  • Allomune BioTransplant, CA
  • anti-VEGF Geneentech, CA
  • CEAcide Immunomedics, NJ
  • IMC-1C11 ImClone, NJ
  • Cetuximab ImClone, NJ
  • antibodies as binding ligands include, but are not limited to, are antibodies against the following antigens: Aminopeptidase N (CD13), Annexin Al, B7-H3 (CD276, various cancers), CA125 (ovarian), CA15-3 (carcinomas), CA19-9 (carcinomas), L6 (carcinomas), Lewis Y (carcinomas), Lewis X (carcinomas), alpha fetoprotein (carcinomas), CA242
  • p53 nonmutant NY-ESO-1 , GD2, CEA, MelanA/MART 1 , Ras mutant, gplOO, p53 mutant, Proteinases (PR1), bcr-abl, Tyrosinase, Survivin, hTERT, Sarcoma translocation breakpoints, EphA2, PAP, ML-IAP, AFP, EpCAM, ERG (TMPRSS2 ETS fusion gene), NA17, PAX3, ALK, Androgen receptor, Cyclin B l , Polysialic acid, MYCN, RhoC, TRP-2, GD3, Fucosyl GM1, Mesothelin, PSCA, MAGE Al, sLe(a), CYP1B 1 , PLAC1 , GM3, BORIS, I n.
  • PR1 Proteinases
  • bcr-abl Tyrosinase
  • EphA2 PAP ML-
  • Particularly monoclonal antibodies are produced by immunizing mice, rats, hamsters or any other mammal with the antigen of interest such as the intact target cell, antigens isolated from the target cell, whole virus, attenuated whole virus, and viral proteins.
  • Splenocytes are typically fused with myeloma cells using polyethylene glycol (PEG) 6000.
  • Fused hybrids are selected by their sensitivity to HAT (hypoxanthine-aminopterin- thymine).
  • I lybridomas producing a monoclonal antibody useful in practicing this invention are identified by their ability to immunoreact specified receptors or inhibit receptor activity on target cells.
  • a monoclonal antibody used in the present invention can be produced by initiating a monoclonal hybridoma culture comprising a nutrient medium containing a hybridoma that secretes antibody molecules of the appropriate antigen specificity.
  • the culture is maintained under conditions and for a time period sufficient for the hybridoma to secrete the antibody molecules into the medium.
  • the antibody-containing medium is then collected.
  • the antibody molecules can then be further isolated by well-known techniques, such as using protein-A affinity chromatography; anion, cation, hydrophobic, or size exclusive chromatographies (particularly by affinity for the specific antigen after Protein A, and sizing column
  • DMEM Dulbecco's minimal essential medium
  • antibody-producing cell lines can also be created by techniques other than cell fusion, such as direct transformation of B lymphocytes with oncogenic DNA, or transfection with an oncovirus, such as Epstein-Barr virus (EBV, also called human herpesvirus 4 (HHV-4)) or Kaposi's sarcoma-associated herpesvirus (KSHV).
  • EBV Epstein-Barr virus
  • HHV-4 human herpesvirus 4
  • KSHV Kaposi's sarcoma-associated herpesvirus
  • a monoclonal antibody may also be produced via an anti-receptor peptide or peptides containing the carboxyl terminal as described well-known in the art. See Niman et al, Proc. Natl. Acad. Sci. USA, 80: 4949-4953 (1983); Geysen et al, Proc. Natl. Acad. Sci. USA, 82: 178-182 (1985); Lei et al. Biochemistry 34(20): 6675-6688, (1995). Typically, the anti-receptor peptide or a peptide analog is used either alone or conjugated to an immunogenic carrier, as the immunogen for producing anti-receptor peptide monoclonal antibodies.
  • phage display technology which can be used to select a range of human antibodies binding specifically to the antigen using methods of affinity enrichment. Phage display has been thoroughly described in the literature and the construction and screening of phage display libraries are well known in the art, see, e.g., Dente et al, Gene. 148(1):7-13 (1994); Little et al, Biotechnol Adv.
  • humanization of antibodies are more common methods of humanization of antibodies.
  • Fully human antibodies can also be prepared by immunizing transgenic mice, rabbits, monkeys, or other mammals, carrying large portions of the human immunoglobulin heavy and light chains, with an immunogen.
  • mice are: the Xenomouse (Abgenix/Amgen.), the HuMAb-Mouse (Medarex/BMS), the Veloci. Mouse
  • site-directed mutagenesis in the variable region of an antibody can result in an antibody with higher affinity and specificity for its antigen (Brannigan et al, Nat Rev Mol Cell Biol. 3: 964-70, (2002)); Adams et al, .1 Immunol Methods. 231 : 249-60 (1999)) and exchanging constant regions of a mAb can improve its ability to mediate effector functions of binding and cytotoxicity.
  • Antibodies immunospecific for a malignant cell antigen can also be obtained
  • nucleotide sequence encoding antibodies immunospecific for a malignant cell antigen can be obtained commercially, e.g., from the GenBank database or a database like it, the literature publications, or by routine cloning and sequencing.
  • DNA encoding hybridoma-derived monoclonal antibodies or phage display Fv clones of the antibody can be readily isolated and sequenced using conventional procedures (e.g. by using oligonucleotide primers designed to specifically amplify the heavy and light chain coding regions of interest from hybridoma or phage DNA template).
  • the DNA can be placed into expression vectors, which are then transfected into host cells such as E. coli cells, simian COS cells, Chinese hamster ovary (CHO) cells, or myeloma cells that do not otherwise produce immunoglobulin protein, to obtain the synthesis of the desired monoclonal antibodies in the recombinant host cells (Skerra et al., Curr.
  • Antibodies can also be produced by using an expression system in which the quantitative ratio of expressed polypeptide components can be modulated in order to maximize the yield of secreted and properly assembled antibodies. Such modulation is accomplished at least in part by simultaneously modulating translational strengths for the polypeptide components.
  • the produced antibody protein is further purified to obtain preparations that are substantially homogeneous for further assays and uses. Standard protein purification methods known in the art can be employed.
  • the exemplary purification procedures fractionation on immunoaffinity (such as Protein A columns) or ion-exchange columns, ethanol precipitation, reverse phase 1 1 PLC chromatography on silica or on a cation-exchange resin such as DEAE, chromatofocusing, SDS- PAGE, ammonium sulfate precipitation, and gel filtration using, for example, Sephadex G-75.
  • immunoaffinity such as Protein A columns
  • ion-exchange columns ethanol precipitation
  • reverse phase 1 1 PLC chromatography on silica or on a cation-exchange resin such as DEAE chromatofocusing
  • SDS- PAGE sodium sulfate precipitation
  • gel filtration using, for example, Sephadex G-75.
  • a peptide or protein that bind/block/target or in some other way interact with the epitopes or corresponding receptors on a targeted cell can be used as a binding molecule.
  • These peptides or proteins could be any random peptide or proteins that have an affinity for the epitopes or corresponding receptors and they don't necessarily have to be of the immunoglobulin family.
  • These peptides can be isolated by similar techniques as for phage display antibodies (Szardenings, J Recept Signal Transduct Res. 23(4): 307-49, 2003). The use of peptides from such random peptide libraries can be similar to antibodies and antibody fragments.
  • binding molecules of peptides or proteins may be conjugated on or linked to a large molecules or materials, such as, but is not limited, an albumin, a polymer, a liposome, a nano particle, as long as such attachment permits the peptide or protein to retain its antigen binding specificity.
  • a large molecules or materials such as, but is not limited, an albumin, a polymer, a liposome, a nano particle, as long as such attachment permits the peptide or protein to retain its antigen binding specificity.
  • Any one of several different reactive groups on a cell binding agent, preferably on an antibody, can be a conjugation site, such as ⁇ -amino groups in lysine residues, pendant carbohydrate moieties, carboxylic acid groups, disulfide groups, and thiol groups.
  • a conjugation site such as ⁇ -amino groups in lysine residues, pendant carbohydrate moieties, carboxylic acid groups, disulfide groups, and thiol groups.
  • the cytotoxic agents of this invention can be directly conjugated (linked) to a cell binding agent, or via a bifunctional linker or a crosslinking agent to a cell binding agent.
  • the bifunctional linker possess two reactive groups; one of which is capable of reacting with a cell binding agent while the other one reacts with one or more molecules of cytotoxic agent of the invention.
  • the bifunctional crosslinkers are well known in the art (see, for example, U.S. Pat. No. 5,208,020; ] sal m and Dent in Bioconjugation chapter 5, p 218-363, Groves Dictionaries Inc. New York, 1999).
  • bifunctional linker examples include: N-succinimidyl-3-(2- pyridyldithi (propionate (SPDP), N-succinimidyl-4-(2-pyridyldithio)butyrate (SPDB), N- succinimidyl-4-(2-pyridyldithio)pentanoate (SPP), N-succinimidyl-3-(2-pyridyldithio)- butyrate (SDPB), 2-iminothiolane, N-succinimidyl-4-(5-nitro-2-pyridyldithio) butyrate
  • SNPB N-succinimidyl 4-(5-nitro-2-pyridyldithio)-pentanoate
  • SSNPB N-sulfosuccinimidyl- 4-(5-nitro-2-pyridyldithio) butyrate
  • SMNP N-sullosuccinimidyl 4-(5-nitro-2-pyridyldithio)-pentanoate (SSNPP), 4-succinimidyl-oxycarbonyl-a-methyl-a-(2-pyridyldithio)-toluene (SMPT), N- sulfosuccinimidyl-4-methyl-4-(5-nitro-2-pyridyldithio)pentanoate (SSMNP); N-succinimidyl-
  • glutaraldehyde bis-azido compounds (such as bis(p-azidobenzoyl) hexanediamine), bis- diazonium derivatives (such as bis-(p-diazoniumbenzoyl)-ethylenedianiine), diisocyanates (such as toluene 2 , 6-diisocyanate) , and bis-active fluorine compounds (such as 1 ,5-difluoro- 2,4-dinitrobenzene), gamma-maleimidobutyric acid N-succinimidyl ester (GMBS), E- maleimidocaproic acid N-hydroxysuccinimide ester (EMCS), 5-maleimidovaleric acid NHS, HBVS, N-succinimidyl-4-(N-maleimidomethyl)-cyclohexane-l-carboxy-(6-amidocaproate) (a "long chain" analog of SMCC (LC-SMCC)),
  • Photoreactive Crosslinkers ANB-NOS (N-5-Azido-2-nitrobenzoyloxysuccinimide), N I IS- Diazirine (SDA)
  • SDA NHS-Diazirine
  • SDA SDA
  • NHS-LC-Diazirine SDA
  • SDA SDA
  • NHS-LC-Diazirine SDA
  • SDA SDA
  • NHS-LC-Diazirine Sulfo-LC ⁇ SDA
  • BMB (1,4-Bismaleiniidobutane), BMDB (l,4-Bismaleiniidyl-2,3-dihydroxybutane),
  • BMH Bismaleimidohexane
  • BMOE Bismaleimidoethane
  • DTME Dithiobismaleimido- ethane
  • ⁇ Tris(2-maleimidoethyl)amine
  • SVSB succinimidyl-(4- vinylsulfone
  • the bis-maleknide or bis-2-pyridyldithiol reagents allow the attachment of the thiol group of a thiol-containing cell binding agent (such as antibody) to a thiol-containing drug moiety, label, or linker intermediate, in a sequential or concurrent fashion.
  • a thiol-containing cell binding agent such as antibody
  • Other functional groups besides maleimide and pyridyldithiol, which are reactive with a thiol group of a cell binding agent, drug moiety, label, or linker intermediate include iodoacetamide,
  • bromoacetamide vinyl pyridine, disulfide, pyridyl disulfide, isocyanate, and isofhiocyanate.
  • the linker may be composed of one or more linker components.
  • the exemplary linker components are:
  • X 1 , ⁇ ', /. and Z 3 are independently NH, or O, or S; /.' is 1 1, or NH, or O or S independently, v is 0 or 1; Q 1 is independently H, OH, Ci ⁇ C6 alkyl, (OCH 2 CH 2 ) n F, CI, Br, I, O 5 , or SR.. NKsR .
  • N NR 5
  • N R 5 , NR 5 5', N0 2 , SOR 5 R5., S0 2 R 5 , S0 3 R 5 , OS0 3 R 5 , PR 5 Rs', POR 5 R 5 ., P0 2 R 5 R 5 -, OPOi OR H OR ).
  • R5 and R are independently selected from H, Ci-Cs of alkyl; C 2 ⁇ Cs of alkenyl, alkynyl, heteroalkyl; C 3 ⁇ Cs of aryl, heterocyclic, carbocyclic, cycloalkyl, heterocycloalkyl, heteroaralkyl, alkylcarbonyl; or pharmaceutical cation salts
  • the (*) atom is the point of attachment of additional spacer or releaseable linkers, the cytotoxic agents, and/or the binding molecules;
  • X 1 , Y 1 , Q 1 , K , Rv and r are as defined in Formula (I);
  • m, n and p are 0-6.
  • Exemplary linker components may include 6-maleimidocaproyl ("MC"),
  • the linker may comprise amino acid residues.
  • Exemplary amino acid linker components include a dipeptide, a tripeptide, a tetrapeptide or a pentapeptide.
  • Exemplary dipeptides include: valine-citrulline (VC or val-cit), alanine -phenylalanine (af or ala- phe).
  • Exemplary tripeptides include: glycine-valine-citrulline (gly-val-cit) and glycine-glycine- glycine (gly-gly-gly).
  • Amino acid residues which comprise an amino acid linker component include those occurring naturally, as well as minor amino acids and non-natural ly occurring amino acid analogs, such as citruUine.
  • Amino acid linker components can be designed and optimized in their selectivity for enzymatic cleavage by particular enzymes, for example, a tumor-associated protease, cathepsin B, C and D, or a plasmin protease.
  • cell-binding agent In the cell-binding agent - drug conjugates of the invention, cell-binding agent (CBA) is conjugated to one or more drug moieties (Drug, or PBD derivatives), e.g. about 1 to about 20 drug moieties per cell-binding agent, through a bifunctional linker (L).
  • drug moieties drug, or PBD derivatives
  • L bifunctional linker
  • the conjugate of Formula (IX), (X), (XI), (XII), (XIII), and (XIV) may be prepared by several routes, employing organic chemistry reactions, conditions, and reagents known to those skilled in the art, including: (1) the first modification of cell-binding agent (CBA) with a crosslinker (L) in an aqueous buffer pH 3 - 9 having optionally 0 ⁇ 30% organic co-solvents to introduce reactive disulfide, maleimido, haloacetyl, hydrazide, nitrile, alkynyl, alkyloxyamino or aldehyde groups on the cell-binding agent, to form a covalent bonded CBA-L.
  • CBA cell-binding agent
  • L crosslinker
  • the CBA-L molecule then reacts with a drug moiety ( Drug) of formula (I) to generate a cell binding agent - dmg conjugate; or (2) the first modification of dmg moiety (Drug) of the formula (I) with a crosslinker (L) in organic media or in an aqueous buffer i I 3 - 9 having optionally 0 - 99% organic co-solvents to introduce a reactive disulfide, maleimido, haloacetyl, hydrazide, nitrile, alkynyl, alkyloxyamino, aldehyde, N-hydroxysuccinimide (NHS) or pentafluorophenyl ester group on the drug moiety (a covalent bonded Dmg-L molecule).
  • Drug drug moiety
  • Drug drug of formula (I)
  • a crosslinker (L) in organic media or in an aqueous buffer i I 3 - 9 having optionally 0 -
  • the Drug- 1 , molecule then reacts with a cell binding agent (CBA), or pre-modified CBA to generate a cell binding agent - dmg conjugate; or (3) directly through reaction of a cell - binding agent with drug moieties of formula (I) bearing reactive function groups of disulfide, maleimido, haloacetyl, hydrazide, nitrile, alkynyl, alkyloxyamino, aldehyde, N-hydroxysuccinimide (NI IS) or pentafluorophenyl esters in an aqueous buffer pH 3 - 9 having optionally 0 - 30% organic co- solvents.
  • CBA cell binding agent
  • NI IS N-hydroxysuccinimide
  • the thiol or amine groups on a cell-binding agents are nucleophilic and capable of reacting to form covalent bonds with electrophilic groups on linker reagents and drug-linker intermediates including: (i) active esters such as NHS esters, HOBt esters, haloformates, and acid halides; (ii) alky I and benzyl halides, such as haloacetamides; (iii) aldehydes, ketones, carboxyl, and maleimide groups; and (iv) disulfides, including pyridyl disulfides, via sulfide exchange.
  • active esters such as NHS esters, HOBt esters, haloformates, and acid halides
  • alky I and benzyl halides such as haloacetamides
  • aldehydes ketones, carboxyl, and maleimide groups
  • disulfides including pyridyl disulfides, via
  • Nucleophilic groups on antibodies or proteins include, but are not limited to: (i) N- terminal amine groups, (ii) side chain amine groups, e.g. lysine, (iii) side chain thiol groups, e.g. cysteine, and (iv) sugar hydr xy I or amino groups where the antibody is glycosylated. Amine, thiol, and hydroxy!
  • linker moieties and linker-cytotoxic agent moieties including: (i) active esters such as Nl IS esters, I lOBt esters, haloformates, and acid halides; (ii) alkyl and benzyl halides such as haloacetamides; (iii) aldehydes, ketones, carboxyl, and maleimide groups.
  • Certain antibodies have reducible interchain disulfides, i.e. cysteine bridges which may be made reactive by treatment with a reducing agent such as I ) IT
  • cysteine bridge will thus form, theoretically, two reactive thiol nucleophiles.
  • sulfhydryl groups can be introduced into antibodies through modification of lysine residues, e.g., by reacting lysine residues with 2-iminothiolane (Traut's reagent), resulting in conversion of an amine into a thiol.
  • Reactive thiol groups may be introduced into an antibody by introducing one, two, three, four, or more cysteine residues (e.g., by preparing variant antibodies comprising one or more non-native cysteine amino acid residues).
  • free thiol on the cell binding agents can be conjugated to the thiol-reactive groups, such as, a maleimide, an iodoacetamide, a pyridyl disulfide, or other thiol-reactive groups on the cytotoxic agents, or linker-cytotoxic agent intermediates of the invention.
  • Some unconjugated free thiols on the antibodies can be reoxidized to reform interchain and intrachain disulfide bonds.
  • Antibody-drug conjugates of the invention may also be produced by reaction between an electrophilic group on an antibody, such as an aldehyde or ketone carbonyl group, with a nucleophilic group on a linker reagent or drug.
  • an electrophilic group on an antibody such as an aldehyde or ketone carbonyl group
  • nucleophilic groups on a linker reagent or drug include, but are not limited to, hydrazide, oxime, amino, hydrazine, thiosemicarbazone, hydrazine carboxylate, and arylhydrazide.
  • an antibody is modified to introduce electrophilic moieties that are capable of reacting with nucleophilic substituents on the linker reagent or drug.
  • the sugars of glycosylated antibodies may be oxidized, e.g. with periodate oxidizing reagents, to form aldehyde or ketone groups which may react with the amine group of linker reagents or drug moieties.
  • the resulting imine Schil l base groups may form a stable linkage, or may be reduced, e.g. by borohydride reagents to form stable amine linkages.
  • reaction of the carbohydrate portion of a glycosylated antibody with either galactose oxidase or sodium meta-periodate may yield carbonyl (aldehyde and ketone) groups in the antibody that can react with appropriate groups on the drug (Hermanson, Bioconjugate Techniques).
  • antibodies containing N-terminal serine or threonine residues can react with sodium meta-periodate, resulting in production of an aldehyde in place of the first amino acid (Geoghegan & Stroh, (1992) Bioconjugate ( "hem. 3: 138-146; U.S. Pat. No. 5,362,852).
  • Such an aldehyde can be reacted with a drug moiety or linker nucleophile.
  • E includes, but is not limited to, such as hydroxysuccinimidyl esters (NHS, Sulfo-NHS, etc), 4-nitrophenyl esters, pentafluorophenyl esters, tetrafluorophenyl (includes sulfo- tetrafluorophenyl) esters, anhydrides, acid chlorides, sulfonyl chlorides, isocyanates and isothiocyanates.
  • K ' and R" are independently H or d or ( ⁇ l l ; J is F, CI, Br, I, tosylate (TsO), mesylate (MsO), nitrophenol, dinitrophenol, or pentaflourophenol.
  • the resulting product is a mixture of the cell binding agent-cytoxic agent conjugates with a distribution of one or more drug moieties attached to an antibody.
  • the average number of drugs per antibody may be calculated from the mixture by a dual HI .ISA antibody assay, which is specific for antibody and specific for the drug.
  • Individual conjugate molecules may be identified in the mixture by mass spectroscopy and separated by HPLC, e.g. hydrophobic interaction chromatography.
  • a homogeneous conjugate with a single loading value may be isolated from the conjugation mixture by electrophoresis or chromatography.
  • the loading (drug/antibody ratio) of an ADC may be controlled in different ways, e.g., by: (i) limiting the molar excess of drug-linker intermediate or linker reagent relative to antibody, (ii) limiting the conjugation reaction time or temperature, (iii) partial or limiting reductive conditions for cysteine thiol modification, (iv) engineering by recombinant techniques the amino acid sequence of the antibody such that the number and position of lysine or cysteine residues is modified for control of the number and/or position of linker-drug attachments (such as thioMab or thioFab).
  • the cell-binding agent -- drug conjugate, preferably antibody-drug conjugates (ADC) of the present invention may be used to treat various diseases or disorders, e.g. characterized by the overexpression of a tumor antigen.
  • exemplary conditions or hyperproli lenitive disorders include benign or malignant tumors; leukemia and lymphoid malignancies.
  • Others include neuronal, glial, astrocytal, hypothalamic, glandular, macrophagal, epithelial, stromal, blastocoelic, inflammatory, angiogenic and immunologic, including autoimmune disorders.
  • the conjugates of the invention are used in accordance with the compositions and methods of the invention for the treatment of cancers.
  • the cancers include, but are not limited. Adrenocortical Carcinoma, Anal Cancer, Bladder Cancer, Brain Tumor (Adult, Brain Stem Glioma, Childhood, Cerebellar Astrocytoma, Cerebral Astrocytoma, Ependymoma, Medulloblastoma, Supratentorial Primitive Neuroectodermal and Pineal Tumors, Visual Pathway and Hypothalamic Glioma), Breast Cancer, Carcinoid Tumor, Gastrointestinal, Carcinoma of Unknown Primary, Cervical Cancer, Colon Cancer, Endometrial Cancer, Esophageal Cancer, I ntrahepatic Bile Duct Cancer, Ewings Family of Tumors (PNET), Extracranial Germ Cell Tumor, Eye Cancer, Intraocular Melanoma, Gallbladder Cancer, Gastric Cancer (Sto-
  • Lymphocytic Chronic Myelogenous, Hairy Cell
  • Lip and Oral Cavity Cancer Liver Cancer
  • Lung Cancer Non-Small Cell, Small Cell
  • Lymphoma AIDS-Related, Central Nervous System, Cutaneous T-Cell, Hodgkin's Disease, Non-Hodgkin's Disease, Malignant
  • the compounds and the conjugates of the invention are used in accordance with the compositions and methods of the invention for the treatment or prevention of an autoimmune disease.
  • the autoimmune diseases include, but are not limited, Achlorhydra Autoimmune Active Chronic Hepatitis, Acute Disseminated Encephalomyelitis, Acute hemorrhagic leukoencephalitis, Addison's Disease, Agammaglobulinemia, Alopecia areata, Amyotrophic Lateral Sclerosis, Ankylosing Spondylitis, Anti-GBM/TBM Nephritis, Antiphospholipid syndrome, Antisynthetase syndrome, Arthritis, Atopic allergy, Atopic Dermatitis, Autoimmune Aplastic Anemia, Autoimmune cardiomyopathy, Autoimmune hemolytic anemia, Autoimmune hepatitis, Autoimmune inner ear disease, Autoimmune lymphoproliferative syndrome, Autoimmune peripheral neuropathy, Autoimmune pancreatitis,
  • Dysfunction Syndrome Chronic inflammatory demyelinating polyneuropathy, Chronic recurrent multifocal ostomyelitis, Chronic lyme disease, Chronic obstructive pulmonary disease, Churg-Strauss syndrome, Cicatricial Pemphigoid, Coeliac Disease, Cogan syndrome, Cold agglutinin disease, Complement component 2 deficiency, Cranial arteritis, CREST syndrome, Crohns Disease (a type of idiopathic inflammatory bowel diseases), Cushing's Syndrome, Cutaneous leukocytoclastic angiitis, Dego's disease, Dercum's disease, Dermatitis herpetiformis, Dermatomyositis, Diabetes mellitus type 1, Diffuse cutaneous systemic sclerosis, Dressler's syndrome, Discoid lupus erythematosus, Eczema, Endometriosis, Enthesitis-related arthritis, Eosinophilic fasciitis, Epidermo
  • Rheumatoid fever Sarcoidosis, Schizophrenia, Schmidt syndrome, Schnitzler syndrome, Scleritis, Scleroderma, Sjogren's syndrome, Spondyloarthropathy, Sticky blood syndrome, Still's Disease, Stiff person syndrome, Subacute bacterial endocarditis, Susac's syndrome, Sweet syndrome, Sydenham Chorea, Sympathetic ophthalmia, Takayasu's arteritis.
  • Temporal arteritis (giant cell arteritis), Tolosa-Hunt syndrome, Transverse Myelitis, Ulcerative Colitis (a type of idiopathic inflammatory bowel diseases), Undifferentiated connective tissue disease, Undifferentiated spondyloarthropathy, Vasculitis, Vitiligo, Wegener's granulomatosis, Wilson's syndrome, Wiskott-Aldrich syndrome
  • a binding molecule used for the conjugate for the treatment or prevention of an autoimmune disease includes, but are not limited to, anti-elastin antibody; Abys against epithelial cells antibody; Anti-Basement Membrane Collagen Type IV Protein antibody; Anti-Nuclear Antibody; Anti ds DNA; Anti ss DNA, Anti Cardiolipin Antibody IgM, IgG; anti-celiac antibody; Anti Phospholipid Antibody IgK, IgG; Anti SM Antibody; Anti Mitochondrial Antibody; Thyroid Antibody; Microsomal Antibody, T-cells antibody; Thyroglobulin Antibody, Anti SCI .-70; Anti-Jo; Anti-U.sub.
  • the binding molecule for the conjugate in the present invention can bind to either a receptor or a receptor complex expressed on an activated lymphocyte which is associated with an autoimmune disease.
  • the receptor or receptor complex can comprise an immunoglobulin gene superfamily member (e.g. CD2, ( 1)3, ( " 1 )4. CDS, CD19, CD22, CD28, ( " 1)79. CD90, CD 152/CTLA-4, PD-1 , or ICOS), a TNF receptor superfamily member (e.g. CD27, CD40, CD95/Fas, ( " 1) 134/0X40. ( 1) 137/4- 1 BB.
  • an immunoglobulin gene superfamily member e.g. CD2, ( 1)3, ( " 1 )4.
  • TNF receptor superfamily member e.g. CD27, CD40, CD95/Fas, ( " 1) 134/
  • useful binding ligands that are immunospecific for a viral or a microbial antigen are humanized or human monoclonal antibodies.
  • viral antigen includes, but is not limited to, any viral peptide, polypeptide protein (e.g. HIV gpl2(), HIV nef, RSV F glycoprotein, influenza vims neuraniiniida.se. influenza virus hemagglutinin, HTLV tax, herpes simplex virus glycoprotein (e.g. gB, gC, gD, and gE) and hepatitis B surface antigen) that is capable of eliciting an immune response.
  • polypeptide protein e.g. HIV gpl2(), HIV nef, RSV F glycoprotein
  • influenza vims neuraniiniida.se. influenza virus hemagglutinin HTLV tax
  • herpes simplex virus glycoprotein e.g. gB, gC, gD, and
  • microbial antigen includes, but is not limited to, any microbial peptide, polypeptide, protein, saccharide, polysaccharide, or lipid molecule (e.g. a bacteria, fungi, pathogenic protozoa, or yeast polypeptide including, e.g., LPS and capsular polysaccharide 5/8) that is capable of eliciting an immune response.
  • microbial antigen includes, but is not limited to, any microbial peptide, polypeptide, protein, saccharide, polysaccharide, or lipid molecule (e.g. a bacteria, fungi, pathogenic protozoa, or yeast polypeptide including, e.g., LPS and capsular polysaccharide 5/8) that is capable of eliciting an immune response.
  • antibodies available I for the viral or microbial infection include, but are not limited to, Palivizumab which is a humanized anti- respiratory syncytial virus monoclonal antibody for the treatment of RSV infection; PR0542 which is a CD4 fusion antibody for the treatment of HIV infection; Ostavir which is a human antibody for the treatment of hepatitis B virus; PROTVIR which is a humanized IgG.sub.l antibody for the treatment of cytomegalovirus; and anti-LPS antibodies.
  • Palivizumab which is a humanized anti- respiratory syncytial virus monoclonal antibody for the treatment of RSV infection
  • PR0542 which is a CD4 fusion antibody for the treatment of HIV infection
  • Ostavir which is a human antibody for the treatment of hepatitis B virus
  • PROTVIR which is a humanized IgG.sub.l antibody for the treatment of cytomegalovirus
  • anti-LPS antibodies include, but are not limited to, Palivizumab which is
  • binding molecules -cytotoxic agent conjugates of this invention can be used in the treatment of infectious diseases.
  • infectious diseases include, but are not limited to,
  • Acinetobacter infections Actinomycosis, African sleeping sickness (African trypanosomiasis), AIDS (Acquired immune deficiency syndrome), Amebiasis, Anaplasmosis, Anthrax,
  • Aspergillosis Astrovirus infection, Babesiosis, Bacillus cereus infection, Bacterial pneumonia, Bacterial vaginosis, Bacteroides infection, Balantidiasis, Baylisascaris infection, B virus infection, Black piedra, Blastocystis hominis infection, Blastomycosis, Venezuelan hemorrhagic fever, Borrelia infection, Botulism (and Infant botulism), Brazilian hemorrhagic fever,
  • Clostridium difficile infection Coccidioidomycosis, Colorado tick fever, Common cold (Acute viral rhinopharyngitis; Acute coryza), Creutzfeldt-jakob disease, Crimean-Congo hemorrhagic fever, Cryptococcosis, Cryptosporidiosis, Cutaneous larva migrans, Cyclosporiasis,
  • Cysticercosis Cytomegalovirus infection, Dengue fever, Dientamoebiasis, Diphtheria,
  • I H D I lantavirus Pulmonary Syndrome, Helicobacter pylori infection, Hemolytic -uremic syndrome, Hemorrhagic fever with renal syndrome, Hepatitis A, Hepatitis B, Hepatitis C, Hepatitis D, Hepatitis E, Herpes simplex, Histoplasmosis, Hookworm infection, Human bocavirus infection, I luman ewingii ehrlichiosis, I luman granulocytic anaplasmosis, I luman metapneumovirus infection, I luman monocytic ehrlichiosis, I luman papillomavirus infection, I luman parainfluenza virus infection, Hymenolepiasis, Epstein-Barr Virus Infectious
  • Mononucleosis (Mono), Influenza, Isosporiasis, Kawasaki disease, Keratitis, Kingella kingae infection, Kuru, Lassa fever, Legionellosis (Legionnaires' disease), Legionellosis (Pontiac fever), Leishmaniasis, Leprosy, Leptospirosis, Listeriosis, Lyme disease (Lyme borreliosis), Lymphatic l ilariasis (Elephantiasis), Lymphocytic choriomeningitis, Malaria, Marburg
  • Onychomycosis Tinea versicolor (Pityriasis versicolor), Toxocariasis (Ocular Larva Migrans), Toxocariasis (Visceral Larva Migrans), Toxoplasmosis, Trichinellosis, Trichomoniasis, Trichuriasis (Whipworm infection), Tuberculosis, Tularemia, Ureaplasma urealyticum infection, Venezuelan equine encephalitis, Venezuelan hemorrhagic fever, Viral pneumonia, West Nile Fever, White piedra (Tinea blanca), Yersinia pseudotuberculosis infection, Yersiniosis, Yellow fever, Zygomycosis.
  • the binding molecules, more preferred antibodies described in this patent that are against pathogenic strains include, but are not limit.
  • Escherichia coli 0157:H7, Bunyaviridae family Hepatitis A Virus, Hepatitis B Virus, Hepatitis C Virus, Hepatitis D Virus, Hepatitis E Vims, Herpes simplex vims 1 , Heipes simplex vims 2, Histoplasma capsulatum, Ancylostoma duodenale and Necator americanus, Hemophilus influenzae, Human bocavims, Ehrlichia ewingii, Anaplasma phagocytophilum, Human metapneumovirus.
  • Ehrlichia chaffeensis Human papiUomavims, Human parainfluenza viruses, Hymenolepis nana and Hymenolepis diminuta, Epstein-Barr Vims, Orthomyxoviridae family, Isospora belli, Kingella kingae, Klebsiella pneumoniae, Klebsiella ozaenas, Klebsiella rhinoscleromotis, Kuru prion, Lassa virus, Legionella pneumophila, Legionella pneumophila, Leishmania genus, Mycobacterium leprae and Mycobacterium lepromatosis, Leptospira genus, Listeria monocytogenes, Borrelia burgdorferi and other Borrelia species, Wuchereria bancrofti and Brugia malayi, Lymphocytic choriomeningitis virus (LCMV), Plasmodium genus, Marburg virus, Measles vims, Burkholder
  • Staphylococcus aureus Streptococcus pyogenes, Strongyloides stercoralis, Treponema pallidum, Taenia genus, Clostridium tetani, Trichophyton genus, Trichophyton tonsurans, Trichophyton genus, Epidermophyton floccosum, Trichophyton rubruni, and Trichophyton mentagrophytes, Trichophyton rubrum, Hortaea wasneckii, Trichophyton genus, Malassezia genus, Toxocara canis or Toxocara cati, Toxoplasma gondii, Trichinella spiralis, Trichomonas vaginalis, Trichuris trichiura, Mycobacterium tuberculosis, Francisella tularensis, Ureaplasma urealyticum, Venezuelan equine encephalitis virus, Vibrio colerae, Guanarito virus, West Nile virus, Tri
  • antibodies as a binding ligand in this invention for treatment of viral disease include, but are not limited to, antibodies against antigens of pathogenic viruses, including as examples and not by limitation: Poxyiridae, Herpesviridae, Adenoviridae, Papovaviridae, Enteroviridae, Picornaviridae, Parvoviridae, Reoviridae, Retroviridae, influenza viruses, parainfluenza viruses, mumps, measles, respiratory syncytial virus, rubella, Arboviridae, Rhabdoviridae, Arenaviridae, Non-A/Non-B Hepatitis virus, Rhinoviridae, Coronaviridae,
  • Rotoviridae Oncovirus [such as, HBV (Hepatocellular carcinoma), I IPV (Cervical cancer, Anal cancer), Kaposi's sarcoma-associated herpesvirus (Kaposi's sarcoma), Epstein-Barr virus (Nasopharyngeal carcinoma, Burkitt's lymphoma, Primary central nervous system lymphoma), MCPyV (Merkel cell cancer), SV40 (Simian virus 40), HCV (Hepatocellular carcinoma),
  • I I H .V-1 (Adult T-cell leukemia/lymphoma)], Immune disorders caused virus: [such as Human Immunodeficiency Virus (AIDS)]; Central nervous system virus: [such as, JCV (Progressive multifocal leukoencephalopathy), MeV (Subacute sclerosing panencephalitis), LCV
  • Cardiovascular virus such as CBV ( Pericardii is. Myocarditis)
  • Respiratory system/acute viral nasopharyngil is/viral pneumonia: [Epstein-Barr virus (EBV infection/Infectious
  • Digestive system virus [MuV (Mumps), Cytomegalovirus (Cytomegalovirus esophagitis); Adenovirus (Adenovirus infection); Rotavirus, Noro virus, Astrovirus, Coronavims; HBV (Hepatitis B vims), CBV, HAV (Hepatitis A vims), HCV (Hepatitis C vims), HDV (Hepatitis D virus), HEV (Hepatitis E vims), HGV (Hepatitis G virus)]; Urogenital virus [such as, BK vims, MuV (Mumps)].
  • the present invention also concerns pharmaceutical compositions comprising the conjugate of the invention together with a pharmaceutically acceptable carrier for treatment of cancer and autoimmune disorders.
  • the method for treatment of cancer, autoimmune disorders, infectious diseases or viral disease can be practiced in vitro, in vivo, or ex vivo.
  • in vitro uses include treatments of cell cultures in order to kill all cells except for desired variants that do not express the target antigen; or to kill variants that express undesired antigen.
  • Examples of ex vivo uses include treatments of hematopoietic stem cells ( I ISC) prior to the performance of the transplantation (IISCT) into the same patient in order to kill diseased or malignant cells.
  • I ISC hematopoietic stem cells
  • IISCT hematopoietic stem cells
  • the bone marrow cells After incubation the bone marrow cells are washed with medium containing serum and returned to the patient by i.v. infusion according to known methods. In circumstances where the patient receives other treatment such as a course of ablative chemotherapy or total-body irradiation between the time of harvest of the marrow and reinfusion of the treated cells, the treated marrow cells are stored frozen in liquid nitrogen using standard medical equipment.
  • the cell binding agent -cytotoxic agent conjugates of this invention will be supplied as solutions or as a lyophilized solid that can be redisolved in sterile water for injection.
  • suitable protocols of conjugate administration are as follows. Conjugates are given weekly for 8 weeks as an i.v. bolus. Bolus doses are given in 50 to 500 ml of normal saline to which human serum albumin (e.g. 0.5 to 1 ml , of a concentrated solution of human serum albumin, 100 mg/mL) can be added. Dosages will be about 50 ⁇ « to 20 mg/kg of body weight per week, i.v. (range of 10 ⁇ « to 200 mg/kg per injection). 8 weeks after treatment, the patient may receive a second course of treatment. Specific clinical protocols with regard to route of administration, excipients, diluents, dosages, times, etc., can be determined by the skilled clinicians.
  • Examples of medical conditions that can be treated according to the in vivo or ex vivo methods of killing selected cell populations include malignancy of any types of cancer, autoimmune diseases, graft rejections, and infections (viral, bacterial or parasite).
  • the amount of a conjugate which is required to achieve the desired biological effect will vary depending upon a number of factors, including the chemical characteristics, the potency, and the bioavailability of the conjugates, the type of disease, the species to which the patient belongs, the diseased state of the patient, the route of administration, all factors which dictate the required dose amounts, delivery and regimen to be administered.
  • the cell binding agent -cytotoxic agent conjugates of this invention may be provided in an aqueous physiological buffer solution containing 0.1 to 10% w/v conjugates for parenteral administration.
  • Typical dose ranges are from 1 g/kg to 0.1 g/kg of body weight per day; a preferred dose range is from 0.01 mg/kg to 20 mg/kg of body weight per day or an equivalent dose in a human child.
  • the preferred dosage of drug to be administered is likely to depend on such variables as the type and extent of progression of the disease or disorder, the overall health status of the particular patient, the relative biological efficacy of the compound selected, the formulation of the compound, the route of administration (intravenous, intramuscular, or other), the
  • the cell binding agent -cytotoxic agent conjugates of the present invention are also capable of being administered in unit dose forms, wherein the term "unit dose" means a single dose which is capable of being administered to a patient, and which can be readily handled and packaged, remaining as a physically and chemically stable unit dose comprising either the active conjugate itself, or as a pharmaceutically acceptable composition, as described hereinafter.
  • typical total daily dose ranges are from 0.01 to 100 mg/kg of body weight.
  • unit doses for humans range from 1 mg to 3000 mg per day.
  • the unit dose range is from 1 to 500 mg administered one to four times a day, and even more preferably from 10 mg to 500 mg, once a day.
  • Conjugatess provided herein can be formulated into pharmaceutical compositions by admixture with one or more pharmaceutically acceptable excipients.
  • Such unit dose compositions may be prepared for use by oral administration, particularly in the form of tablets, simple capsules or soft gel capsules; or intranasaUy, particularly in the form of powders, nasal drops, or aerosols; or dermal ly. for example, topically in ointments, creams, lotions, gels or sprays, or via trans-dermal patches.
  • the compositions may conveniently be administered in unit dosage form and may be prepared by any of the methods well known in the pharmaceutical art.
  • compositions for example, as described in Remington: The Science and Practice of Pharmacy, 21 th ed.; Lippincott Williams & Wi lkins: Philadelphia, PA, 2005.
  • Preferred formulations include pharmaceutical compositions in which a compound of the present invention is formulated for oral or parenteral administration.
  • tablets, pills, powders, capsules, troches and the like can contain one or more of any of the following ingredients, or compounds of a similar nature: a binder such as microcrystalline cellulose, or gum tragacanth; a diluent such as starch or lactose; a disintegrant such as starch and cellulose derivatives; a lubricant such as magnesium stearate; a glidant such as colloidal silicon dioxide; a sweetening agent such as sucrose or saccharin; or a flavoring agent such as peppermint, or methyl salicylate.
  • a binder such as microcrystalline cellulose, or gum tragacanth
  • a diluent such as starch or lactose
  • a disintegrant such as starch and cellulose derivatives
  • a lubricant such as magnesium stearate
  • a glidant such as colloidal silicon dioxide
  • a sweetening agent such as sucrose or saccharin
  • a flavoring agent such
  • Capsules can be in the form of a hard capsule or soft capsule, which are generally made from gelatin blends optionally blended with plasticizers, as well as a starch capsule-
  • dosage unit forms can contain various other materials that modify the physical form of the dosage unit, for example, coatings of sugar, shellac, or enteric agents.
  • Other oral dosage forms syrup or elixir may contain sweetening agents, preservatives, dyes, colorings, and flavorings.
  • the active compounds may be incorporated into fast dissolve, modil ied-relea.se or sustained-release preparations and formulations, and wherein such sustained-release formulations are preferably bi-modal.
  • Preferred tablets contain lactose, cornstarch, magnesium silicate, croscarmellose sodium, povidone, magnesium stearate, or talc in any combination.
  • Liquid preparations for parenteral administration include sterile aqueous or non-aqueous solutions, suspensions, and emulsions.
  • the liquid compositions may also include binders, buffers, preservatives, chelating agents, sweetening, flavoring and coloring agents, and the like.
  • Nonaqueous solvents include alcohols, propylene glycol, polyethylene glycol, vegetable oils such as olive oil, and organic esters such as ethyl oleate.
  • Aqueous carriers include mixtures of alcohols and water, buffered media, and saline.
  • biocompatible, biodegradable lactide polymer, lactide/glycolide copolymer, or polyoxyethylene-polyoxypropylene copolymers may be useful excipients to control the release of the active compounds.
  • Intravenous vehicles can include fluid and nutrient replenishers, electrolyte replenishers, such as those based on Ringer's dextrose, and the like.
  • Other potentially useful parenteral delivery systems for these active compounds include ethylene- vinyl acetate copolymer particles, osmotic pumps, implantable infusion systems, and liposomes.
  • formulations for inhalation which include such means as dry powder, aerosol, or drops. They may be aqueous solutions containing, for example, polyoxyethylene-9-lauryl ether, glycocholate and deoxycholate, or oily solutions for administration in the form of nasal drops, or as a gel to be applied intranasally.
  • Formulations for buccal administration include, for example, lozenges or pastilles and may also include a flavored base, such as sucrose or acacia, and other excipients such as glycocholate.
  • Formulations suitable for rectal administration are preferably presented as unit-dose suppositories, with a solid based carrier, such as cocoa butter, and may include a salicylate.
  • Formulations for topical application to the skin preferably take the form of an ointment, cream, lotion, paste, gel, spray, aerosol, or oil.
  • Carriers which can be used include petroleum jelly, lanolin, polyethylene glycols, alcohols, or their combinations.
  • Formulations suitable for transdermal administration can be presented as discrete patches and can be lipophilic emulsions or buffered, aqueous solutions, dissolved and/or dispersed in a polymer or an adhesive.
  • the cell binding agent -cytotoxic agent conjugates of this invention are administered concurrently with the other known or will be known therapeutic agents such as the chemotherapeutic agent, the radiation therapy, immunotherapy agents, autoimmune disorder agents, anti-infectious agents or the other antibody-drug conjugates, resulting in a synergistic effect.
  • the synergistic drugs or radiation therapy are administered prior or subsequent to administration of a conjugate, in one aspect at least an hour, 12 hours, a day, a week, a month, in further aspects several months, prior or subsequent to administration of a conjugate of the invention.
  • the synergistic drugs include, but not limited to:
  • Chemotherapeutic agents a).
  • Alkylating agents such as [Nitrogen mustards:
  • DNA Topoisomerase Inhibitors such as [Epipodophyllins: (9- aminocamptothecin, camptothecin, crisnatol, etoposide, etoposide phosphate, irinotecan, teniposide, topotecan,); Mitomycins: (mitomycin C)]; d).
  • Anti- metabolites such as ⁇ [Anti- folate: 1 )1 U K inhibitors: (methotrexate, trimetrexate); IMP dehydrogenase Inhibitors:
  • Hormonal therapies such as ⁇ Receptor antagonists: [Anti-estrogen: (megestrol, raloxifene, tamoxifen); I .1 IR1 I agonists: (goscrclin, leuprolide acetate); Anti-androgens: (bicalutamide, flutamide)] ; Retinoids/Deltoids: [Vitamin D3 analogs: (CB 1093, EB 1089 KI I 1060, cholecalciferol, ergocalciferol); Photodynamic therapies: (verteporfin, phthalocyanine, photosensitizer Pc4, demethoxy-hypocrellin A); Cytokines: (Interferon-alpha, Interferon- gamma, tumor necrosis factor (TNFs), human proteins containing a TNF domain)] ⁇ ; f).
  • Kinase inhibitors such as BIBW 2992 (anti-EGFR/Erb2), imatinib, gefitinib, pegaptanib, sorafenib, dasatinib, sunitinib, erlotinib, nilotinib, lapatinib, axitinib, pazopanib.
  • vandetanib ⁇ 7080 (anti- VEGFR2), mubritinib, ponatinib (AP24534), bafetinib (INNO-406), bosutinib (SKI-606), cabozantinib, vismodegib, iniparib, raxolitinib, CYT387, axitinib, tivozanib, sorafenib, bevacizumab, cetuximab, Trastuzumab, Ranibizumab, Panitumumab, ispinesib; g). Others: such as gemcitabine, epoxomicins (e. g.
  • carfilzomib carfilzomib
  • bortezomib thalidomide, lenalidomide, pomalidomide, tosedostat, zybrestat, PLX4032, STA-9090, Stimuvax, allovectin-7, Xegeva, Provenge, Yervoy, Isoprenylation inhibitors (such as Lovastatin), Dopaminergic neurotoxins (such as l-methyl-4-phenylpyridinium ion), Cell cycle inhibitors (such as staurosporine), Actinomycins (such as Actinomycin IX dactinomycin), Bleomycins (such as bleomycin A2, bleomycin B2, peplomycin), Anthracyclines (such as daunorubicin, doxorubicin (adriamycin), idarubicin, epimbicin.
  • Isoprenylation inhibitors such as Lovastatin
  • pirarubicin pirarubicin, zorubicin, mtoxantrone, MDR inhibitors (such as verapamil), Ca 2+ ATPase inhibitors (such as thapsigargin), vismodegib, Histone deacetyla.se inhibitors (Vorinostat, Romidepsin. Panobinostat, Valproic acid, Mocetinostat (MGCD0103), Belinostat, PCI-24781 , Entinostat, SB939, Resminostat, Givinostat, AR-42, CUDC-101 , sulforaphane, Trichostatin A) ; Thapsigargin, Celecoxib, glitazones, epigallocatechin gal late.
  • MDR inhibitors such as verapamil
  • Ca 2+ ATPase inhibitors such as thapsigargin
  • vismodegib Histone deacetyla.se inhibitors
  • An anti-autoimmune disease agent includes, but is not limited to, cyclosporine, cyclosporine A, aminocaproic acid, azathioprine, bromocriptine, chlorambucil, chloroquine, cyclophosphamide, corticosteroids (e.g. amcinonide, betamethasone, budesonide,
  • hydrocortisone hydrocortisone, flunisolide, fluticasone propionate, fluocortolone danazol, dexamethasone, Triamcinolone acetonide, beclometasone dipropionate), 1 )1 ⁇ . enanercept,
  • An anti-infectious disease agent includes, but is not limited to, a).
  • Aminoglycosides amikacin, astromicin, gentamicin (netilmicin, sisomicin, isepamicin), hygromycin B, kanamycin (amikacin, arbekacin, be kanamycin. dibekacin, tobramycin), neomycin (framycetin, paromomycin, ribostamycin), netilmicin, spectinomycin, streptomycin, tobramycin, verdamicin; b).
  • Amphenicols azidamfenicol, chloramphenicol, florfenicol, thiamphenicol ; c).
  • Ansamycins geldanamycin, herbimycin; d).
  • Carbapenems biapenem, doripenem, ertapenem,
  • Cephems carbacephem (loracarbef), cefacetrile, cefaclor, cefradine, cefadroxil, cefalonium, cefaloridine, cefalotin or cefalothin, cefalexin, cefaloglycin, cefamandole, cefapirin, cefatrizine, cefazaflur, cefazedone, cefazolin, cefbuperazone, cefcapene, cefdaloxirne, cefepime, cefminox, cefoxitin, cefprozil, eel Vox ad inc.
  • ceftezole cefuroxime, cefixime, cefdinir, cefditoren, cefepime, cefetamet, cefmenoxime, cefodizime, cefonicid, cefoperazone, ceforanide, cefotaxime, cefotiam, cefozopran, cephalexin, cefpimizole, cefpiramide, cefpirome, cefpodoxime, cefprozil, cefquinome, cefsulodin, ceftazidime, cefteram,tititibuten, ceftiolene, ceftizoxime, criztobiprole, ceftriaxone, cefuroxime, cefuzonam, cephamycin (cefoxitin, cefotetan, cefmetazole), oxacephem (flomoxef, latamoxef); f).
  • Glycopeptides bleomycin, vancomycin (oritavancin, telavancin), teicoplanin (dalbavancin), ramoplanin; g).
  • Glycylcyclines e. g. tigecycline; g).
  • ⁇ -Lactamase inhibitors pen am (sulbactam, tazobactam), clavam (clavulanic acid); i). Lincosamid.es: clindamycin, lincomycin; j).
  • Lipopeptides daptomycin, A54145, calcium -dependent antibiotics (CDA); k).
  • Macrolides azithromycin, cethromycin, clarithromycin, dirithromycin, erythromycin, flurithromycin, josamycin, ketolide (telithromycin, cethromycin), midecamycin, miocamycin, oleandomycin, rifamycins (rifampicin, rifampin, rifabutin, rifapentine), rokitamycin, roxithromycin, spectinomycin, spiramycin, tacrolimus (FK506), troleandomycin, telithromycin; 1).
  • Monobactams aztreonam, tigemonam; m).
  • Oxazolidinones linezolid; n).
  • Penicillins
  • amoxicillin ampicillin (pivampicillin, hetacillin, bacampicillin, metampicillin, talampicillin), azidocillin, azlocillin, benzylpenicillin, benzathine benzylpenicillin, benzathine
  • gemilloxacin grepafloxacin, kano trovafloxacin, levofloxacin, lomelloxacin, marbofloxacin, moxifloxacin, nadifloxacin, norfloxacin, orbifloxacin, ofloxacin, pefloxacin, trovafloxacin, grepafloxacin, sitafloxacin, sparfioxacin, temafloxacin, tosufloxacin, trovafloxacin; q).
  • Strep togramins pristinamycin, quinupristin/dalfopristin); r).
  • Sulfonamides mafenide, prontosil, sulfacetamide, sulfamethizole, sulfanilimide, sulfasalazine, sulfisoxazole, trimethoprim, trimethoprim-sulfamethoxazole (co-trimoxazole); s).
  • Steroid antibacterials e.g. fusidic acid; t).
  • Tetracyclines doxycycline, chlortetracycline, clomocycline, demeclocycline, lymecycline, meclocycline, metacycline, minocycline, oxytetracycline, penimepicycline, rolitetracycline, tetracycline, glycylcyclines (e.g. tigecycline); u).
  • antibiotics include annonacin, arsphenamine, bactoprenol inhibitors (Bacitracin), DADAL/A inhibitors (cycloserine), dictyostatin, discodermolide, eleutherobin, epothilone, ethambutol, etoposide, faropenem, fusidic acid, furazolidone, isoniazid, laulimalide, metronidazole, mupirocin, mycolactone, NAM synthesis inhibitors (e. g.
  • fosfomycin nitrofurantoin, paclitaxel, platensimycin, pyrazinamide, quinupristin/dalfopristin, rifampicin (rifampin), tazobactam tinidazole, uvaricin;
  • Anti-viral drugs a). Entry/fusion inhibitors: aplaviroc, maraviroc, vicriviroc, gp41 (enfuvirtide), PRO 140, ( 1)4 (ibalizumab); b). Integrase inhibitors: raltegravir, elvitegravir, globoidnan A; c). Maturation inhibitors: bevirimat, becon; d). Neuraminidase inhibitors: oseltamivir, zanamivir, peramivir; e).
  • Nucleosides &_nucleotides abacavir, aciclovir, adefovir, amdoxovir, apricitabine, brivudine, cidofovir, clevudine, dexelvucitabine, didanosine (ddl), elvucitabine, emtricitabine (FTC), entecavir, famciclovir, fluorouracil (5-FU), 3'-fruoro- substituted 2', 3 ' -dideoxynucleoside analogues (e.g.
  • ⁇ -1-thymidine and p-l-2'-deoxycytidine penciclovir, racivir, ribavirin, stampidine, stavudine (d4T), taribavirin (viramidine), telbivudine, tenofovir, trifluridine valaciclovir, valganciclovir, zalcitabine (ddC), zidovudine (AZT); f).
  • Non- nucleosides amantadine, ateviridine, capravirine, diarylpyrimidines (etravirine, rilpivirine), delavirdine, docosanol, emivirine, efavirenz, foscarnet (phosphonoformic acid), imiquimod, interferon alfa, loviride, lodenosine, methisazone, nevirapine, NOV-205, peginterferon alfa, podophyllotoxin, rifampicin, rimantadine, resiquimod (R-848), tromantadine; g).
  • Protease inhibitors amprenavir, atazanavir, boceprevir, darunavir, fosamprenavir, indinavir, lopinavir, nelfinavir, pleconaril, ritonavir, saquinavir, telaprevir (VX-950), tipranavir; h).
  • anti-virus drugs abzyme, arbidol, calanolide a, ceragenin, cyanovirin-n, diarylpyrimidines, epigallocatechin gal I ate (EGCG), foscarnet, griffithsin, taribavirin (viramidine), hydroxyurea, KP-1461 , miltefosine, pleconaril, portmanteau inhibitors, ribavirin, seliciclib.
  • EGCG epigallocatechin gal I ate
  • griffithsin taribavirin (viramidine)
  • hydroxyurea KP-1461
  • miltefosine pleconaril
  • portmanteau inhibitors ribavirin, seliciclib.
  • immunotheraphy drugs e.g. imiquimod, interferons (e.g. ⁇ , ⁇ ), granulocyte colony-stimulating factors, cytokines, Interleukins ( II .- 1 ⁇ 11. -35 ).
  • antibodies e. g. imiquimod, interferons (e.g. ⁇ , ⁇ ), granulocyte colony-stimulating factors, cytokines, Interleukins ( II .- 1 ⁇ 11. -35 ).
  • antibodies e. g.
  • trastuzumab pertuzumab, bevacizumab, cetuximab, panitumumab, infliximab, adalimumab, basiliximab, daclizumab, omalizumab
  • Protein-bound drugs e.g., Abraxane
  • an antibody conjugated with drugs selected from calicheamicin derivative, of maytansine derivatives (DM1 and DM4) , ( ' ( '- 1065 and duocarmycin minor groove binders, potent taxol derivatives, doxorubicin, auristatin antimitotic drugs e. g.
  • Tris(2 ⁇ (benzyloxy)ethyl)phosphine oxide (6.03 g, 13.33 mmol) in THF (100 ml) was added Pd/C (0.31 g, 10% Pd/C, 50% wet) in a hydrogenation bottle. The mixture was shaken for 4 h, filtered through Celite (filter aid), concentrated to afford the title compound (2.33 g, 96% yield) without further purification.
  • Example 7 ((2-(methylsulfinothioyl)ethyl)phosphoryl)bis(ethane-2 , 1 -diyl) bis(4- methylbenzenesulf onate) (13).
  • TsO ⁇ SSCH 3 TsO Bis(2-hydroxyethyl)(2-(methylsulfinothioyl)ethyl)phosphine oxide ( 1.01 g, 4.13 mmol) in CH 2 C1 2 (30 ml) and pyridine (15 ml) was added TsCl (2.00 g, 10.52 mmol). The mixture was stirred at RT for 6 h, concentrated and purified on SK ) 2 column eluted with EtOAc/hexane (1 :5 -1 :3) to afford the title compound (1.98 g, 87% yield). ESI MS m/z+ 575.2 (M + Na).
  • Tris(2-carboxyethyl)phosphine hydrochloride (7.0 g, 24.42 mmol) was co- evaporated with EtOH (2 x 100 ml), dissolved in CH 3 OH (200 ml) at 4 °C, and then thionyl chloride (9.0 ml ., 122.29 mmol) was added. The resulting mixture was stirred for at RT overnight, concentrated, and dried over vacuum to provide the title compound (7.0 g, 98% yield), ESI MS m//+ 293.2 (M + H).
  • TCEP Tris(2-carboxyethyl)phosphine hydrochloride
  • Example 14 ((3-(methylsulfinothioyl)propyl)phosphoryl)bis(propane-3, l-diyl) bis(4- methylbenzenesulfonate) (33) HO ⁇ s ⁇ P ⁇ s ⁇ SSCH 3 ⁇ Ts ° ⁇ P « ⁇ SSCH 3
  • the compound was highly potent towards Raj i cells, with IC5 0 values between 5.0-11 pM measured at 37 °C, 5 days incubation.
  • Example 40 Sodium (1 I S, 1 l aS. l l 'S, 1 l a'S)-8,8'-((((2-mercaptoethyl )phosphory )bis-(ethane- 2,l -diyl))bis(oxy))bis(7-methoxy-2-methylene-5-oxo-2,3,5,10,l l,l la-hexahydro-lH- benzo[e] pyrrole [ 1 ,2-a] [ 1 ,4]diazepine- 1 1 -sulfonate)
  • Example 41 Sodium (1 lS, l laS,l l'S, l la'S)-8,8'-((((2-((l-(4-((2,5-dioxopyrrolidin-l-yl)oxy)- 4-oxobutyl)-2,5-dioxopyrrolidin-3-yl)thio)ethyl)phosphoryl)bis(ethane-2, l - diyl))bis(oxy))bis(7-methoxy-2-mefhylene-5-oxo-2, 3,5, 10, 11, 1 la-hexahydro-lll- benz
  • Succinimidyl 4-(N-maleimido) butyrate (3.4 mg, 0.012 mmol) in DMA (0.5 ml . ) was added sodium (11S, 1 laS,l l'S, l l a'S)-8,8'-((((2-mercaptoethyl)phosphoryl)bis(ethane-2, l- diyl))bis(oxy))bis(7-methoxy-2-mefhylene-5-oxo-2, 3,5, 10, 11, 1 la-hexahydro-lH- benzo[e]pyrrolo[l ,2-a] [l,4]diazepine-l l ⁇ sulfonate) (5.0 mg, 0.0059 mmol).
  • Example 42 A conjugate of a PBD derivative to an antibody with a thioether linkage and its specific antitumor activity of the patent.
  • the conjugate was purified and buffer exchanged into 250 mM Glycine, 10 mM Histidine, 1 % sucrose, 0.01 %' Tween-20, 50 ⁇ sodium bisulfite formulation buffer, pi I 6.0, using NAP desalting columns (Illustra Sephadex G-25 DNA Grade, GE Healthcare). Dialysis was performed in the same buffer for 4 hours at room temperature utilizing Slide-a-Lyzer dialysis cassettes (ThermoScientific 20,000 MWCO).
  • the purified conjugate was found to have an average of 3.8 PBD derivative molecules linked per antibody (by LC-MS), 99% monomer (by size exclusion chromatography), ⁇ 0.1 % unconjugated drug (by dual-column reverse -phase HPLC analysis) and a final protein concentration of 1.1 mg/ml.
  • Example 43 (11 aS)-7-Methoxy-8-(2-((2-(((S)-7-methoxy-2-methylene-5-oxo- 2,3,5, 10, 1 1, 1 la-hexahydro-l H-benzo[e]pyrrolo[l,2-a] [l,4]diazepin-8-yl)oxy)ethyl)(2- (methylsulfinothioyl)ethyl)phosphoryl)-ethoxy)-2-methylene-2,3-dihydro- lH- benzo[e]pyrrolo[l ,2-a] [ 1 ,4]diazepin-5( 1 laH)-one
  • Example 45 2,5-Dioxopyrrolidin-l-yl 4-( ( 2-( ( 2-( ( ( S )-7-methoxy-2-methylene-5-oxo- 2,3,5, 10, l l, l la-hexahydro-lH-benzo[e]pyrrolo[l,2-a] [l,4]diazepin-8-yl)oxy)ethyl)(2-(((S)-7- methoxy-2-methylene-5-oxo-2,3,5, l la-tetrahydro-lH-benzo[e]pyrrolo[l,2-a] [l,4]diazepin-8-
  • Example 46 A conjugate of a PBD derivative to an antibody with a disulfide bond linkage and its specific antitumor activity of the patent.
  • the conjugate was purified and buffer exchanged into 250 mM Glycine, 10 mM Histidine, 1 % sucrose, 0.01 % Tween-20, 50 ⁇ sodium bisulfite formulation buffer, pH 6.0, using NAP desalting columns ( Illustra Sephadex G-25 DNA Grade, GE Healthcare). Di lysis was performed in the same buffer for 4 hours at room temperature utilizing Slide-a-Lyzer dialysis cassettes (ThermoScientific 20,000 MWCO). The purified conjugate was found to have an average of 3.6 PBD derivative molecules linked per antibody (by LC-MS), 99% monomer (by size exclusion
  • Example 49 Bis(2-bromoethyl)phosphinic acid
  • Ammonium hypophosphite (8.00 g, 96 mmol) and hexamethydisilazane (20.0 ml .. 96 mmol) was heated at 120 °C for 1 h under argon.
  • dibromoethane (60.0 ml . ) was added, and the mixture was stirred for 8 h at 120 °C.
  • the formed trimethylbromosilane and excess dibromoethane were removed under vacuum.
  • 100 ml , of aqueous ethanol (1 : 1) were added dropwise to the residue and refluxed for 0.5 h.
  • Example 52 Ethyl (2-(((S)-7 -methoxy-5-oxo-2 ,3 ,5 , 10, 1 1 ,1 la-hexahydro-lH-benzo[e]pyrrolo[l ,2- a] [l,4]diazepin-8-yl)oxy)ethyl)(2-(((S)-7-methoxy-5-oxo-2,3,5, l la-tetrahydro- lH- benzo[e]pyrrolo[l ,2-a] [l,4]diazepin-8-yl)oxy)ethyl)phosphinate
  • Example 53 Ethyl (2-(((S)-7-methoxy-5-oxo-10-(4-(pyridin-2-yldisulfanyl)butanoyl)- 2,3,5,10,l l,l la-hexaliydro-lH-benzo[e]pyrrolo[l,2-a] [l,4]diazepin-8-yl)oxy)ethyl)(2-(((S)-7- methoxy-5-oxo-2,3,5,l la-tetrahydro-lH-benzo[e]pyrrolo[l ,2-a][T,4]diazepin-8-
  • Example 54 A conjugate of a PBD derivative to an antibody with a disulfide bond linkage and it
  • the mAbs (5 mg/mL, especially engineered cysteine -riched CD22 or ( 1)20 antibodies ) in PBS buffer containing 50 mM sodium borate, pH 7.8, were treated with dithiothreitol (DDT) (10 mM final) at 37 °C for 30 min. After gel filtration (G-25, PBS containing ImM DTPA), thiol determination using 5,5 '-dithiobis(2-nitrobenzoic acid) indicated that there were approximately 7-8 thiols per mAb.
  • DDT dithiothreitol
  • the reaction was stirred for 6 hours at 30 °C. The reactions were quenched with excess cysteine.
  • the conjugate was purified and buffer exchanged into 250 mM Glycine, 10 mM Histidine, 1% sucrose, 0.01% Tween-20, 50 ⁇ sodium bisulfite formulation buffer, pH 6.0, using NAP desalting columns (Illustra Sephadex G-25 DNA Grade, GE Healthcare). Dialysis was performed in the same buffer for 4 hours at room temperature utilizing Slide-a-Lyzer dialysis cassettes
  • ThermoScientific 20,000 MWCO ThermoScientific 20,000 MWCO.
  • the purified conjugate was found to have an average of 3-4 PBD derivative molecules linked per antibody (by I .( '-MS ). 99% monomer (by size exclusion chromatography), ⁇ 0.2% unconjugated cysteine-quenched drug (by dual-column reverse-phase IIPLC analysis) and a final protein concentration of 2. mg/ml (Protein concentration and drug loading were determined by spectral analysis at 280 and 254 nm, respectively) In Vitro potency measurement against Raji cells in 37 °C, 5 day incubation
  • Example 60 (((3-(4-(2,5-dioxo-2,5-dihydro-lH-pyrrol-l-yl)-N-methylbutanamido)- propyl)(methyl)-amino)phosphoryl)bis(ethane-2,l -diyl)
  • Example 63 (((3-(pyridin-2-yldisulfanyl)propyl)amino)phosphoryl)bis(ethane-2, 1 -diyl) bis(4- methylbenzenesulfonate)
  • reaction mixture was filtered through a thick celite bed, washed the bed with CH 2 CI 2 , evaporated, redissolved in CH 2 C1 2 , charged with m-CPBA (2.07 g, 12.1 mmol), and then vigorously stirred for 1 h at room temperature. 6 h. Then the solution was evaporated, purified on S1O 2 column eluted with EtAc/CH 2 Cl 2 (1 : 15 - 1 :8) to afford the title compound (2.25 g, 85% yield). MS (ESI) for C 9 Hi 5 Na0 7 P calcd. 289.0 (M + Na), found 289.0.
  • Example 68 P,P-Bis((((2S,3aR)-2-fluoro-8-methoxy- 10-oxo-l ,2,3,3a, 10, 10a-hexahydro- benzo[b]cyclo-penta[e]azepin-7-yl)oxy)methyl)-N-(3-(pyridin-2-yldisulfanyl)propyl)- phosphinic amide
  • Example 69 N-(3-((bis(2-(((2S,3aR)-2-fluoro-8-methoxy-10-oxo-l ,2,3,3a, 10, 10a- hexahydrobenzo[b]cyclopenta[e] azepin-7-yl)oxy)ethyl)phosphoryl)(methyl)amino)-propyl)- -(2,5-dioxo-2,5-dihydro- 1 H-pyrrol- 1 -yl)-N-methylbutanamide
  • Example 70 N-(3-((bis(2-(((2S,3aR)-2-fluoro-8-methoxy-10-oxo-l ,2,3,3a,10,10a- hexahydrobenzo[b]cyclopenta[e]azepin-7-yl)oxy)ethyl)phosphoryl)(methyl)amino) ⁇ propyl) ⁇ -methy] -4-(pyridin-2-yldisulfanyl)butanamide
  • Example 73 In Vitro Cytotoxicity Assays.
  • cytotoxic potencies were then assessed using a WS 1 -8 based cell viability assay and surviving cells were measured by developing with WST-8 (2-7 hours). The absorbance in each well was measured and the surviving fraction of cells at each concentration was plotted to reveal the cytotoxicity and/or antigen specificity (of the conjugates). The potency and specificity of the antibody-drug conjugates were measured against antigen-expressing cells, with and without the additions of an excess amount of blocking unconjugated antibody to show specificity of the killing effect.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Cell Biology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Endocrinology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Virology (AREA)
  • Transplantation (AREA)
  • Toxicology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

Provided are cytotoxic agents, pyrrolo[2,1-c][1,4]benzodiazepine (PBD) derivatives, their conjugates with a cell-binding agent, the preparation and the therapeutic uses in the targeted treatment of cancers, autoimmune disorders, and infectious diseases.

Description

NOVEL CYTOTOXIC AGENTS FOR CONJUGATION OF DRUGS
TO CELL BINDING MOLECULE
DECRIPTION
FIELD OF THE INVENTION
The present invention relates to novel cytotoxic agents, pyrrole [2, 1 - c][l,4]benzodiazepine (PBD) derivatives and their therapeutic use. These novel cytotoxic agents have therapeutic use as a result of delivering the pyrrolo[2,l-c][l,4]benzodiazepine (PBD) derivatives to a specific targeted cell population by chemically linking these derivatives to a cell binding agent.
BACKGROUND OF THE INVENTION
Since the successful launches of Brentuximab vedotin (Adcetris) and Trastuzumab emtansineo (Kadcyla), Antibody-drug conjugates (ADCs) have currently become a promising therapeutic modality for the clinical management of cancer. The new ADC compounds, which covalently incorporate the antitumor activity of a cytotoxic agent to a monoclonal antibody, have ability to deliver cytotoxic agents specifically to antigen-expressing tumor cells and then kill the tumor cells. The ADC platform includes a growing repertoire of cytotoxic agents, linker technologies, antibody properties, and conjugation methods. An important key factor in generating an optimal ADC is the cytotoxic agents.
Pyrrolo[2,l -c] [l,4]benzodiazepines (PBDs) are a well-known class of sequence- selective DNA-binding agents derived from various Streptomyces species. Well-known members of this include DC-81 , tomaymycin, porothramycin B, prothracarcin,
mazethramycin, porothramycin, prothracarcin, sibanomycin, neothramycin, chicamycin, abbemycin, sibiromycin and anthramycin (I. O'Neil et al. Tetrahedron Letters 2003, 44, 7809-7812 ; L. Cipolla, et al, Anti-Cancer Agents in Medicinal Chemistry, 2009, 9, 1-31 ; L, Hurley, J. Antibiot. 1977, 30, 349.; K. Schimizu, et al. J. Antibiot 1982, 35, 992.; J. Lown, et al. Biochem. Pharmacol. 1979, 28, 2017.; D. Thurston, et al. Chem. Rev. 1994, 94, 433; P. Molina, et al. Tetrahedron 1995, 51, 5617; A. Kamal, et al. Chem. Commun. 1996, 385; A.
Kamal, et al. Tetrahedron Lett. 1996, 37, 6803). These agents exert their antitumor antibiotics activity by the formation of a covalent adduct in the minor groove of a DNA with preference of a three base pairs of Pu-G-Pu (where Pu = purine; G = guanine) sequences, wherein their ( Ί 1 -position is electrophilic, enabling the molecules to alkylate the NI l > group of a guanine in the minor groove of DNA (Thurston, D. Molecular Aspects of Anticancer Drug- DNA
Interactions; The Macmillan Press Ltd.: London, UK, 1993, pp 54-88, D. Antonow and D. Thurston, Chem. Rev. 201 1 , 111, 2815-2864; P. Dervan, Science 1989, 232, 464.; L, Hurley, J. Med. Chem. 1989, 32, 2027.; D. Thurston, Chem. Br. 1990, 26, 767). Moreover, PBDs have potential not only as antitumor agents but also as gene regulators and probes of DNA structure (Hurley, L. J. Med. Chem. (1989), 32: 2027-2033).
Thurston and co-workers reported the first C8/C 8 '-linked PBD dimer (DSB-120) in which two DC-81 subunits are joined through their aromatic A-ring at phenol positions by an inert propyldioxy linkage (D. Thurston, et al., J. Org. Chem. 1996, 61, 8141). These C8/C8'- diether-linked PBD dimers exhibit higher DNA binding affinity, at least twice compared to the monomer DC-81. The three carbon space ((n=3) C8/C8' -linked PBD dimer analog (DSB- 120) covalently bind to a 5'-Pu-GATC-Py sequence by crosslinking opposite-strand guanines separately by 2 base pairs, span six DNA base pairs ( Kali man, K. et al .1. Am. Chem.
Soc.(2009), 131 (38), 13756-13766; Martin, C. et al Biochemistry (2005), 44(11), 4135-4147). The more extended PBD dimer (n = 5) can span an extra base pair and cross-link the 5'-Pu- GA(T/A)TC-Py sequence (S. Hopton and A. Thompson, Biochemistry 2011, 50(21), 4720- 4732, M. Smellie, et al, Biochemistry 2003, 42(27), 8232-8239; Gregson, S. et al J. Med. Chem. (2004), 47(5), 1161 -1174). Among the C8/C8'-linked dimmers, the one with five carbon chain showed the highest cytotoxicities in most of the tested cell lines (Thurston, D. et al, J. Org. Chem. 1996, 61 , 8141 ; Kamal, A. et al., Curr. Med. Chem. - Anti-cancer Agents, 2002, 2, 215-254, Gregson, S. et al J. Med. Chem. (2004), 47(5), 1161-1174). Since the introduction of C8/C8'-linked PBD dimer, a number of structurally modified PBD dimers have been synthesized and evaluated for their biological activity, particularly for their DNA binding ability and antitumor activity (see US patents 8,383,618; 8,372,831; 8,217,167;
8,318,726; 8,153,627; 7,754,694; 7,741,319; 7,704,924; 7,612,062; 7,608,615; 7,557,099; 7,528,128; 7,528,126; 7,476,664; 7,465,724; 7,429,658; 7,407,951 ; 7,312,210; 7,265,105; 7,189,710; 7,183,054; 7,173,026; 7,067,51 1 ; 7,056,913; 7,049,311 ; 7,015,215; 6,979,684; 6,951,853; 6,939,869; 6,884,799; 6,800,622; 6,683,073; 6,660,856; 6,562,806; 6,362,331 ; Seifert, .1. et al. Org. Biomol. Chem. (2012), 10(34), 6850-6860; Rahman, Ket al .1. Antimicro. Chem. (2012), 67(7), 1683-1696. Hartley, J. et al Cancer Research (2010), 70(17), 6849-6858; Hartley, J. et al Invest. New Drugs (2012), 30(3), 950-958; Howard, P. et al WO 2011130613; Hartley, J. et al Expert Opin. Invest. Drugs (2011), 20(6), 733-744; Howard, P. et al Bioorg. Med. Chem. Lett. (2009), 19(22), 6463-6466; Cipolla, L. et al Anti-Cancer Agents Med. Chem. (2009), 9(1), 1-31 ; Tiberghien, Ar. Bioorg. Med. Chem. Lett. (2008), 18(6), 2073- 2077; Purnell, B. et al Bioorg. Med. Chem. Lett. (2006), 16(21), 5677-5681 ; Kamal, A. Bioorg. Med. Chem. (2006), 14(2), 385-394; Howard, P. et al WO 2005085259; Kumar, R. et al Eur. .1. Med. Chem. (2005), 40(7), 641 -654; Kamal. A. et al Bioorg. Med. Chem. (2004), 12(20), 5427-5436; Wilkinson, G. Invest. New Drugs (2004), 22(3), 231-240; Kumar, R. et al Mini-Reviews Med. ( 'hem. (2003), 3(4), 323-339; Gregson, S. el al Bioorg. Med. ( 'hem. Lett. (2001), 11(21), 2859-2862; Reddy, B. et al Anti-Cancer Drag Design (2000), 15(3), 225-238; Damayanthi, Y. et al J Org ( "hem 1999, 64, 290-292). Some structures of these dimers are shown in the Table 1. Interestingly, only the PBD dimers which have flexible linkers between two PBD subunits to form none distorting interstrand cross-links within the minor groove of DNA have been shown significantly increased the potency comparing to the PBD monomer. So far, a number of these compounds have been selected for preclinical studies but unfortunately most of them did not proceed beyond that stage mainly because of problems related to poor bioavailability. Therefore some of these PBD dimers have been conjugated to a cell binding agent, such as an antibody to enhance their bioavailability and therapeutic efficacy (see US patents 8,426,402; 8,404,678; 8,163,736; 8,097,238; Commercon, A., et al. WO 2012014147; I K 2963007, Howard, P., et al WO 2011130598; Howard, P. et al WO 2011130613; Howard, P. et al WO 2011130616; Commercon, A. et al WO 2011023883; Bouchard, I I. et al WO 2009016516 Gauzy, L. et al Eur. Pat. Appl. EP 2019104; Gauzy, I ..; Zhao, Robert; et al WO 2007085930; Masterson, L. Bioorg. Med. ( "hem. Let. (2006), 16(2), 252-256; Li, W. et al WO 2012128868; Fishkin, N. et al WO 2012112687; Chari, R. WO 2012112708; Zhilina, Z. et al Bioconj. Chem. (2004), 15(6), 1182-1192; Kamal, A. et al MedChemComm (2011), 2(8), 780-8. Masterson, L. et al Bioorg. Med. Chem. Lett. (2006), 16(2), 252-6; Sagnou, M. et al Bioorg. Med. Chem. Lett. (2000), 10(18), 2083-2086; Rahman, K. M., et al. J Med Chem 2013, 56, 2911-35; Kamal, A. et al. Bioorg Med Chem Lett 2012, 22, 571-8; Hsieh, M. C, et al. Toxicol Appl Pharmacol 2011, 255, 150-9; Lee, C. et al, Chem Biol Interact 2009, 180, 360-7; Reddy, B. et al Anticancer Drug Des 2000, 15, 225-38).
However, the PBD dimers, even some of them have been modified as a prodrug in antibody drug conjugates (WO 2012014147; WO 2012128868, WO 2012112687; WO 2011130616; Howard, P. et al Bioorg. Med. Chem. Lett. (2009), 19, 6463-6), are hardly soluble in a water based buffer solution, resulting in significant amount of antibody or protein aggregation. Here we disclose novel PBD dimer derivatives which have good antitumor antibiotic activities and especially they are linkable and can facilitate conjugation to a cell surface binding ligand in a water based medium without leading to protein aggregation. Thus they can be used effectively in a conjugate with a cell binding molecule for treating cancers and immune disorders.
Table 1. Some of the published Pyrrolo[2,l-c] [l,4]benzodiazepine (PBD) dimers
Figure imgf000006_0001
Sulfate produg of a
FBI) dimer
Figure imgf000007_0001
C8/C-C2 amide- linked FBI) dimer o
C2/C2'- linked FBI) dimer s
Figure imgf000007_0002
SUMMARY OF THE INVENTION
The first embodiment of this invention is to disclose cytotoxic agents, specifically, pyrrolo[2, l-c] [l,4]benzodiazepine derivatives which are potent cytotoxic agents and can be effectively used to block cell proliferation. In particular, this invention is to disclose novel pyrrolo[2, l-c] [l,4]benzodiazepine derivatives, optionally linkable or linked to a cell binding agent to block cell proliferation. The novel cytotoxic agents and their conjugates to a cell bin
Figure imgf000007_0003
or their pharmaceutically acceptable salts, hydrates, or hydrated salts, or the polymorphic crystalline structures of these compounds or their optical isomers, racemates, diastereomers or enantiomers.
wherein
— represents an optional single bond;
= represents either a single bond or a double bond;
It provided that when = represents a single bond, U and U' , the same or different, independently represent I I: or the linking group (L') with the reactive group or a cell binding agent bonded thereto. V and V , the same or different, are independently selected from the group consisting of 1 1. OH, -NI IOI I; an ether (-OR5); an ester (-OCOR5, e.g. an acetate); a carbonate ( -OCOQR5); an amine ( -NR5R5', -NR5CQR5', -NRsNRs'NRs"); a carbamate ( -OCONR5R5'); a guanidinum ( -N R-i( ( =N 1 1 ) N R-i * R * * ) : an amino acid, or peptide (-NRsCO(Aa)t, wherein Aa is an amino acid or a polypeptide containing between t =1- 100 amino acid units; a optionally substituted 5- or 6- membered nitrogen-containing heterocycle (such as piperidine, tetrahydropyrrole, pyrazole, morpholine); a cyclic carbamate, such that U and V, and/or U'and V are a part of the cycle; a urea ( NRs( NR ' Rs" ): a thiocarbamate ( -OCSNHR5); a cyclic thiocarbamate such that U and V, and U'and V are a part of the cycle; a thiol (-S1 1 ); a sulfide such as -SR5; a sulphoxide ( - SOR5); a sulfone ( -SOOR5); a sulphite (-SO3, HS03, 1 IS( or a salt of 1 IS( )\ SO/ or -HS02 ~); a bisulphite (-OSO3); a sulfonamide (-NR5SOOR5'); metabisulfite ( i 1 S >( )- or a salt of S2O52'"); Mono-,di-, tri-, and tetra-thiophosphate (PO3SH3, P02S2H2, POS3H2, PS4H2 or a salt of PO3S3", P02S2 3~, POS3 3", PS4 3"); thiophosphate ester (R50)2POSR5'); thiosulfate ( HS203 or a salt of S203 2" ); dithionite ( I IS20.) or a salt of S1O4 2"); phosphorodithioate(P(=S)(OR5)(S)(OH) or a salt thereof form with a cation); optionally cyclic amine such that U and V, and U'and V are a part of the cycle; a hydroxylamine derivative (-NR5OR5'); hydroxamic acid ( Rs( '(=0)NOI I or a salt formed with a cation); formaldehyde sulfoxylate (HOCH2S02 ", or its salts); an amide ( -NR5COR5 ; an azido (-N3); a cyano; a halo; a trialkyl, a phosphoramidate (phosphoramidic acid), or
triaiylphosphonium; an aminoacid-derived group; or the linking group (L') with the reactive group or a cell binding agent bonded thereto. The R5, R5' and R5" are described below.
and when = represents a double bond, U and U' are absent; V and V represent I I ; 1, m, n, Γ , m' and n' are the number 0, 1, 2, 3, 4, 5 or 6.
X, X' , Y and Y* the same or different, independently, represent N, O, S, an alkyl, such as ( H i or CHR5, an alkene, such as =( 'H- or =CR5-, an ether, such as -C( ORs )I I-.
Z and /.' the same or different, independently, represent N, ( Ί I. CR5, COH or COR5. R5 is independently selected from Ci~Cs alkyl and aryl.
Ri , R2, R3, R.i. R | * . R}' R3 ' , and R.j * are the same or different and independently chosen from -I I. an optionally substituted linear, branched or cyclic alkyl, alkenyl or alkynyl having from 1 to 10 carbon atoms, a polyethylene glycol unit— (OCH2CH2)tRs, halogen, guanidinium [-NH(C=NH)NH2] , -OR5, -NR5R5', -N02, -NCO, -NR5COR5', --SR5, a sulfoxide represented by -SOR5, a sulfone represented by— SO2R5, a sulfonate --S( )V +.—SOU I. a sulfate OSO < M \ OSO3H, a sulfonamide represented by -SO iNRsR ' . cyano, an azido,— COR5, -OCOR5, -OCONR5R5', CF3, OR5, Aryl, heterocycle, or P^RsRs'Rs" and the linking group (L') witli the reactive group or a cell binding agent bonded thereto; Rs. Rs* and R5" are independently selected from 1 1. Ci~C& of alkyl, alkenyl, alkinyl, heteroalkyl, aryl, aryl alkyl. carbonylalkyl, or pharmaceutical salts. Rs R5> and R5» can further be substituted with at least one substituent selected from -N(Ri)(R2), -CQ2H, -SOU I. -ORi, - CO2R1, -CONRi, -PO2R1R2, POR1R2R3 and -PO3H.
q = 0, 1 or 2.
In addition, R2 and R3 join together, or R2' and R ¾* join together to form a = (double bond), =0 (ketone), =S, =NRs, -( '(=( ))R-, or a double bond containing group =( 'RsRs" : and Ri and R2join together, or Rf and R2' join together, or R3 and Re join together, or R3' and Κ.Γ join together form an aromatic, heterocyclic, or heteroaryl ring.
L and L' are the same or inpendently a linker or a linker-cell binding molecule (Q) covalently bound cluster, or a linker which has a functional group on the linker that enables reaction with a cell-binding agent (CBA). L, when is a linker, is preferred a releasable linker, which has the formula of:— Ww— (Aa)r— I t— ; or— Ww— (Aa)r— I t— Q; or Q— Ww— (Aa)r— Tt— ; wherein: W is a Stretcher unit; w is 0 or 1 ; Aa is independently an Amino Acid unit; r is independently an integer ranging from 0 to 100;
The Stretcher unit W independently contains a self-immolative or a non-self-immolative component, peptidyl units, a hydra/one bond, a disulfide, an ester, an oxime, an amide, or a thioether bond. The self-immolative unit includes, but are not limited to, aromatic compounds that are electronically similar to the para-aminobenzylcarbamoyl (PAB) groups such as 2- aminoimidazol-5-methanol derivatives, heterocyclic PAB analogs, beta-glucuronide, and ortho or para-am i noben/y I ace tal s. Preferably, the self-immolative linker component has any
Figure imgf000009_0001
wherein the (*) atom is the point of attachment of additional spacer or releasable linker units, or the cytotoxic agent, and/or the binding molecule (CBA); X1, Y 1 , / and Z3 are independently NH, or O, or S; Z1 is 1 1, or Nil, or O or S independently, v is 0 or 1 ; Q1 is independently II, OH, Ci~C6 alkyl, (OCH2CH2)„ F, CI, Br, I, OR5, or SR5, NRsRs . N=NR5, N=R . NRsRy NO >.
SORsRs . SO2R5, SO3R5, OSO3R5, PRsRs . PORsRs . POjRsRs . OPO(OR5)(OR5 , or
( Κ Ί I )P( X ORsf OR^ ) wherein R5 and R5> are as defined above, preferably R5 and R are independently selected from 1 1. Ci~Cs of alkyl; C^-Cs of alkenyl, alkynyl, heteroalkyl; C3~Cg of aryl, heterocyclic, carbocyclic, cycloalkyl, heterocycloalkyl, heteroaralkyl, alkylcarbonyl; or pharmaceutical cation salts.
The non-self-immolative linker component is any one of the following structures:
(CH2)nCO(OCH2CH2)rOCH3 (CH2)nCON(CH2CH20)rCOCH3
(Ct^Ct^O),* . * H;
Figure imgf000010_0001
Figure imgf000011_0001
Wherein the (*) atom is the point of attachment of additional spacer or releaseable linkers, the cytotoxic agents, and/or the binding molecules; X1, Y1, Q1, R5, R5' are as defined above; r is 0-100; m, n and p are 0-6.
Spacers (T) is a linear, branched or cyclic alkyl, alkenyl, alkynyl or aryl having from 1 to 10 carbon atoms, or polyethylene glycol ( -( ' I lj( I I >( )- ) spacer; and t is 0, or 1-100. T can also be that undergo cyclization upon amide bond hydrolysis, such as substituted and unsubstituted 4-aminobutyric acid amides, appropriately substituted bicyclo[2.2.1] and bicyclo[2.2.2] ring systems, and 2-aniinophenylpropionic acid amides.
In addition L can be R5, OR5, SR5 or N R R- , thus Ri, R2, R3, R4, Rr, R2\ R3' , or R4' , or U, or U', or V, or V on the formula (I) can be used to linked to Q via Stretcher units (Ww) or via Spacer units (Tt).
Q is a cell binding molecule, or a functional group that enables reaction with a cell- binding agent, or a functional group capable of reacting with a linker attached on a cell binding agent. The function group is chosen from a thiol, an amine, a hydrazine, an alkoxylamino, a disulfide substituent, a maleimido, a haloacetyl group, a carboxy acid, an N- hydroxy succinimide ester, a ketone, an ester, an aldehyde, an alkynyl, an alkenyl, or protected thiol or disulfide group, such as SAc, SSKi or SSAr. Ar is aromatic group or hetero aromatic group.
In a second embodiment, the present invention discloses a therapeutic composition comprising: (1). an effective amount of one or more pyrrolo[2,l-c][l,4]benzodiazepine derivatives optionally linkable or linked to a cell binding agent, and (2). a pharmaceutically acceptable carrier, diluent, or excipient, of formula (I) ~ ( XIX ) of the patent application, to kill target cells or tissues containing target cells. BRIEF DESCRIPTION OF THE DRAWINGS
Figure 1 shows the synthesis of linkers for synthesis of benzodiazepine dimers.
Figure 2 shows the synthesis of linkers for synthesis of the conjugates of benzodiazepine dimers.
Figure 3 shows synthesis of linkers for synthesis of the conjugates of benzodiazepine dimers. Figure 4 shows the synthesis of linkers and intermediates for the conjugates of benzodiazepine dimers.
Figure 5 shows synthesis of the intermediates and the conjugates of benzodiazepine dimers.
Figure 6 shows the synthesis of intermediates for the synthesis of benzodiazepine dimers.
Figure 7 shows the synthesis of intermediates for the synthesis of benzodiazepine dimers. Figure 8 shows the synthesis of intermediates for the synthesis of benzodiazepine dimers.
Figure 9 shows the synthesis of intermediates for the synthesis of benzodiazepine dimers.
Figure 10 shows the synthesis of intermediates for the synthesis of benzodiazepine dimers.
Figure 1 1 shows the synthesis of intermediates and conjugates of benzodiazepine dimers.
Figure 12 shows the synthesis of conjugates of benzodiazepine dimers.
Figure 13 shows the synthesis of conjugates of benzodiazepine dimers.
Figure 14 shows the synthesis of conjugates of benzodiazepine dimers.
Figure 15 shows the synthesis of conjugates of benzodiazepine dimers.
Figure 16 shows the synthesis of conjugates of benzodiazepine dimers.
Figure 17 shows the synthesis of conjugates of benzodiazepine dimers.
Figure 18 shows the synthesis of conjugates of benzodiazepine dimers.
Figure 19 shows the synthesis of conjugates of benzodiazepine dimers.
Figure 20 shows the synthesis of conjugates of benzodiazepine dimers.
Figure 21 shows the synthesis of conjugates of benzodiazepine dimers.
Figure 22 shows the synthesis of conjugates of benzodiazepine dimers. Figure 23 shows the synthesis of conjugates of benzodiazepine dimers.
DETAILED DESCRIPTION OF THE INVENTION DEFINITIONS:
"Alkyl" means an aliphatic hydrocarbon group which may be straight or branched having 1 to 8 carbon atoms in the chain or cyclic. "Branched" means that one or much lower alkyl groups such as methyl, ethyl or propyl are attached to a linear alkyl chain. Exemplary alkyl groups include methyl, ethyl, n-propyl, i-propyl, n-butyl, t-butyl, n-pentyl, 3-pentyl, octyl, nonyl, decyl, cyclopentyl, cyclohexyl, 2,2-dimethylbutyl, 2, 3 -dimethyl butyl, 2,2- dimethylpentyl, 2,3-dimethylpentyl, 3,3-dimethylpentyl, 2,3,4-trimethylpentyl, 3-methylhexyl, 2,2-dimethylhexyl, 2,4-dimethylhexyl, 2,5-dimethylhexyl, 3,5-dimethylhexyl, 2,4- dimethylpentyl, 2-methylheptyl, 3-methylheptyl, n-heptyl, isoheptyl, n -octyl, and isooctyl. A Ci-Cs alkyl group can be unsubstituted or substituted with one or more groups including, but not limited to, -Ci~C8 alkyl, -0-(C,~C8 alkyl), -aryl, -C(0)R', -OC(0)R', -C(0)OR', - C(0)NH2, -C(0)NHR', -C(0)N(R')2-NHC(0)R', -S(0)2R', -S(0)R', -OH, -halogen (F, CI, Br or I), -N3, -Ni l . -NH(R'), -N(R') 2 and -CN; where each R' is independently selected from - Ci~Cs alkyl and aryl.
A "cyclic alkyl" , "cycloalkyl" and
Figure imgf000013_0001
carbocycle" can be used interchangeably. They mean a 3-, 4-, 5-, 6-, 7- or 8-membered saturated or unsaturated non-aromatic carbocyclic ring. Representative Cs-Cs carhocycles include, but are not limited to, cyclopropyl, cyclobutyl, cyclopentyl, cyclopentadienyl, cyclohexyl, cyclohexenyl, 1,3- cyclohexadienyl, 1,4-cyclohexadienyl, cycloheptyl, 1,3-cycloheptadienyl, 1,3,5- cycloheptatrienyl, cyclooctyl, and cyclooctadienyl. A C.3~Cs carbocycle group can be unsubstituted or substituted with one or more groups including, but not limited to,— Ci~Cs alkyl, -OR5, -aryl, -C(0)R5, -OC(0)R5, -C(0)OR5, -C(0)NH2, -C(0)NHR5, -C(0)NR5R5- NHC(0)R5, -S(O) 2R5, -S(0)R5, -OH, -halogen, -N3, -NH2, -NHR5, -NR5R5- and -CN; wherein R5 and R- - are independently H; Ci~Cs of alkyl, alkenyl, alkynyl, heteroalkyl, aryl, arylalkyl, or carbonylalkyl; or pharmaceutical salts. R5 and R can further be substituted with at least one substituent selected from -N(Rs)(R5'), -C02H, -SOU I . -OR5, -C02Rs, -CONR5, and - PO3H.
A "C3~Cs carbocyclo" refers to a C3~C8 carbocycle group defined above wherein one of hydrogen atoms on the carbocycle is replaced with a bond.
Alkenyl refers to an aliphatic hydrocarbon group containing a carbon-carbon double bond and which may be straight or branched having 2 to 8 carbon atoms in the chain. The alkenyl double bond may have "cis" and "trans" orientations, or alternatively, "E" and "/" orientations. Exemplary alkenyl groups include, but are not limited to, ethylenyl or vinyl, propenyl or allyl, n-butenyl, i-butenyl, 3~methylbut~2-enyl, n-pentenyl, hexylenyl, heptenyl, octenyl.
"Alkynyl" or "alkinyl" means an aliphatic hydrocarbon group containing a carbon-carbon triple bond and which may be straight or branched having 2 to 8 carbon atoms in the chain. Exemplary alkynyl groups include ethynyl, propynyl, n-butynyl, 2-butynyl, 3-methylbutynyl, pentynyl, n-pentynyl, hexylynyl, heptynyl, and octynyl.
"Heteroalkyl" is C2~C8 alkyl in which one to four carbon atoms are independently replaced with a heteroatom from the group consisting of O, S and N.
"Heterocycle" refers to an aromatic or non-aromatic C3~Ci4 cai bocycle in which one to four of the ring carbon atoms are independently replaced with a heteroatom from the group of O, N, P, S and Se. Preferable heteroatoms are oxygen, nitrogen and sulphur. Suitable
heterocyclics are also disclosed in The Handbook of Chemistry and Physics, 76* Edition, CRC Press, Inc., 1995-1996, p2-25 to 2-26, the disclosure of which is hereby incorporated by reference. Preferred non aromatic heterocyclic include, but are not limited to pyrrolidinyl, pyrazolidinyl, imidazolidinyl, oxiranyl, tetrahydrofuranyl, dioxolanyl, tetrahydro-pyranyl, dioxanyl.
dioxolanyl, piperidyl, piperazinyl, morpholinyl, pyranyl, imidazolinyl, pyrrolinyl, pyrazolinyl, thiazolidinyl, tetrahydrothiopyranyl, dithianyl, thiomorpholinyl, dihydro-pyranyl,
tetrahydropyranyl, diliydropyranyl, tetrahydro-pyridyl, dihydropyridyl, tetrahydropyrinidinyl, dihydrothiopyranyl, a/epanyl, as well as the fused systems resulting from the condensation with a phenyl group.
"Aryl" or Ar refers to an aromatic or hetero aromatic group, composed of one or several rings, comprising three to fourteen carbon atoms, preferentially six to ten carbon atoms. The term of hetero aromatic group refers one or several carbon on aromatic group, preferentially one, two, three or four carbon atoms are replaced by O, N, Si, Se, P or S, preferentially by O, S, N. The term aryl or Ar also refers to a aromatic group, wherein one or several H atoms are replaced independently by alkyl, F, CI, Br, I, O R5, or SR5, N R5R5-, N=NRs, ^Rs. NRsRs-, NO2 SOR5R5, SO2R5, SO3R5, OSO3R5, PRsRss POR5R5', P05R5-, OPO3R5R5', or P( ),RsR wherein R5 and R5> are independently H, alkyl, alkenyl, alkinyl, heteroalkyl, aryl, arylalkyl, carbonyl, or pharmaceutical salts.
The term "heteroaryl" or aromatic heterocycles refers to a 5 to 14, preferably 5 to 10 membered aromatic hetero, mono-, bi- or multicyclic ring. Examples include pyrrolyl, pyridyl, pyrazolyl, thienyl, pyrimidinyl, pyrazinyl, tetrazolyl, indolyl, quinolinyl, purmyl, imidazolyl, thienyl, thiazolyl, benzothiazolyl, furanyl, benzofuranyl, 1,2,4-thiadiazolyl, isothiazolyl, triazoyl, tetrazolyl, isoquinolyl, benzothienyl, isobenzofuryl, pyrazolyl, carbazolyl, benzimidazolyl, isoxazolyl, pyridyl-N-oxide, as well as the fused systems resulting from the condensation with a phenyl group.
"Alkyl", "cycloalkyl", "alkenyl", "alkynyl", "aryl", "heteroaryl", "heterocyclic" and the like refer also to the corresponding "alkylene", "cycloalkylene", "alkenylene", "alkynylene", "arylene", "heteroarylene", "heterocyclene" and the likes which are formed by the removal of two hydrogen atoms.
"Halogen atom" refers to fluorine, chlorine, bromine or iodine atom; preferably bromine and chlorine atom.
"Pharmaceutically" or "pharmaceutically acceptable" refer to molecular entities and compositions that do not produce an adverse, allergic or other untoward reaction when administered to an animal, or a human, as appropriate.
"Pharmaceutically acceptable excipient" includes any carriers, diluents, adjuvants, or vehicles, such as preserving or antioxidant agents, fillers, disintegrating agents, wetting agents, emulsifying agents, suspending agents, solvents, dispersion media, coatings, antibacterial and antifungal agents, isotonic and absorption delaying agents and the like. The use of such media and agents for pharmaceutical active substances is well known in the art. Except insofar as any conventional media or agent is incompatible with the active ingredient, its use in the therapeutic compositions is contemplated. Supplementary active ingredients can also be incorporated into the compositions as suitable therapeutic combinations.
As used herein, "pharmaceutical salts" refer to derivatives of the disclosed compounds wherein the parent compound is modified by making acid or base salts thereof. The
pharmaceutically acceptable salts include the con ventional non-toxic salts or the quaternary ammonium salts of the parent compound formed, for example, from non-toxic inorganic or organic acids. For example, such conventional non-toxic salts include those derived from inorganic acids such as hydrochloric, hydrobromic, sulfuric, sulfamic, phosphoric, nitric and the like; and the salts prepared from organic acids such as acetic, propionic, succinic, tartaric, citric, methanesulfonic, benzenesulfonic, glucuronic, glutamic, benzoic, salicylic, toluenesulfonic, oxalic, fumaric, maleic, lactic and the like. Further addition salts include ammonium salts such as tromethamine, triethanolamine, meglumine, epolamine, etc., metal salts such as sodium, potassium, calcium, zinc or magnesium.
The pharmaceutical salts of the present invention can be synthesized from the parent compound which contains a basic or acidic moiety by conventional chemical methods. Generally, such salts can be prepared by reaction of the free acid or base forms of these compounds with a stoichiometric amount of the appropriate base or acid in water or in an organic solvent, or in a mixture of the two. Generally, non-aqueous media like ether, ethyl acetate, ethanol, isopropanol, or acetonitrile are preferred. Lists of suitable salts are found in Remington's Pharmaceutical Sciences, 17 ed., Mack Publishing Company, Huston, PA, 1985, p i 418, the disclosure of which is hereby incorporated by reference.
The term "compound", "cytotoxic agent", "cytotoxic compound," "cytotoxic dimer" and
"cytotoxic dimer compound" are used interchangeably. They are intended to include compounds for which a structure or formula or any derivative of thereof has been disclosed in the present invention or a structure or formula or any derivative thereof that has been incorporated by reference. The term also includes, stereoisomers, geometric isomers, tautomers, solvates, metabolites, salts (e.g., pharmaceutically acceptable salts) and prodrugs, and prodrug salts of a compound of all the formulae disclosed in the present invention. The term also includes any solvates, hydrates, and polymorphs of any of the foregoing. The specific recitation of "stereoisomers," "geometric isomers," "tautomers," "solvates,"
"metabolites," "salt" "prodrug," "prodrug salt," "conjugates," "conjugates salt," "solvate," "hydrate," or "polymorph" in certain aspects of the invention described in this application shall not be interpreted as an intended omission of these forms in other aspects of the invention where the term "compound" is used without recitation of these other forms.
The term "inline reactive reagent" refers to a reagent that is capable of reacting with an imine group. Examples of imine reactive reagent includes, but is not limited to, sulfites (H2SQ3, H2SO2 or a salt of HSO3 ", SO : ' or HSOj formed with a cation), metabisulfite (H2S2O5 or a salt of S2O52" formed with a cation), mono, di, tri, and tetra-thiophosphates (PO3SH3, PO2S2H3, POS3H3, PS4H3 or a salt of PO3S3", PO2S2 3", POS3 3" or P formed with a cation), thio phosphate esters ( ( R O bPS( OR ). RsSl l, R5SOH, R5SO2H, R5SO3H), various amines (hydroxyl amine (NH2OH), hydrazine (NH2NH2), NH2OR5, R5NHR5-, NH2R5), NH2-CO-NH2, NH2-C(=S)-NH2), thiosulfate (H2S2O3 or a salt of S2O3 2" formed with a cation), dithionite (H2S2O4 or a salt of S2O42" formed with a cation), phosphorodithioate ( P(=S )( ( )Rs )( Sl l )( 01 l ) or a salt thereof formed with a cation), hydroxamic acid ( R ( '(=0 )NI IOI 1 or a salt formed with a cation), bydrazide (R5CONHNH2), formaldehyde sulfoxylate (HOCH2SO2H or a salt of HOCH2SO2 formed with a cation, such as I lOCI I2SO2 Na+ ), glycated nucleotide (such as GDP-mannose), fludarabine or a mixture thereof, wherein R and R are each independently a linear or branched alkyl having 1 to 8 carbon atoms and can be substituted with at least one substituent selected from -N( R )( K? * ). -C02H, -SOU I. - OR5, -CO2R5, -CONR5, and -PO3II; R5 and R5' can be further optionally substituted with a substituent for an alkyl described herein; Preferably, the cation is a monovalent cation, such as Na+ or K+. Preferably, the imine reactive reagent is selected from sulfites, hydroxyl amine, urea and hydrazine. More preferably, the imine reactive reagent is NaHS(¾ or KI ISO;.
"Cell binding agents" or "Cell binding molecules" may be of any kind presently known, or those become known, and include peptides and non-peptides. Generally, these can be antibodies (especially monoclonal antibodies) or a fragment of an antibody that contains at least one binding site, lymphokines, hormones, growth factors, nutrient-transport molecules (such as transferrin), or any other cell binding molecule or substance (such as vitamins).
More specific examples of cell binding agents that can be used include:
- monoclonal antibodies (mAb);
- single chain antibodies;
- fragments of antibodies such as Fab, Fab', F(ab')2, Fv, {Parham, J. Immunol. 131, 2895- 2902 (1983); Spring et al, .1. Immunol. 1 13, 470-478 (1974); Nisonoff et al, Arch. Biochem. Biophys. 89, 230-244 (I960) } , fragments produced by a Fab expression library, anti-idiotypic (anti-Id) antibodies, CDR's, and epitope-binding fragments of any of the above which
immunospecifically bind to cancer cell antigens, viral antigens or microbial antigens.
- interferons;
- peptides; or conjugated proteins or peptides ;
- lymphokines such as IL-2, 11 . -3, 11 . -4, 11 . -6;
- hormones such as insulin, TRI I (thyrotropin releasing hormones), MSH (melanocyte- stimulating hormone), steroid hormones, such as androgens and estrogens;
- growth factors and colony-stimulating factors such as EGF, TGFa, insulin like growth factor (IGF-I, IGF-II) G-CSF, M-CSF and GM-CSF { Burgess, Immunology Today 5, 155-158 (1984) } ; vitamins, such as folate and
- transferrin { O'Keefe et al, .1. Biol. ( "hem. 260, 932-937 (1985) } .
Monoclonal antibodies (mAb), mAb single chain or fragments can be produced in the well known state of art technology. The technology permits the production of extremely selective cell binding agents in the form of specific monoclonal antibodies. The well known in the art are techniques for creating monoclonal antibodies produced by immunizing mice, rats, hamsters or any other mammal with the antigen of interest such as the intact target cell, antigens isolated from the target cell, whole virus, attenuated whole virus, and viral proteins such as viral coat proteins.
Selection of appropriate cell binding agents is a matter of choice that depends upon the particular cell population that is to be targeted, but in general monoclonal antibodies are preferred if an appropriate one is available. For example, an anti-CD20 antigen monoclonal antibody, known as Rituximab is a chimeric (mouse/human) monoclonal antibody and it was the first therapeutic antibody approved by the United States Food and Drug Administration for treatment of relapsed or refractory low- grade or follicular NHL (Leonard, J. P. et al, Clin. Cane. Res. 10:5327-5334 (2004)). Another anti-CD20 antibody, known as Ofatumumab, is a human monoclonal antibody targeting an epitope different from that of rituximab and most other CD20 directed antibodies. It was approved by US FDA for treating chronic lymphocytic leukemia and has also shown potential in treating Follicular non-IIodgkin's lymphoma, Diffuse large B cell lymphoma, rheumatoid arthritis and relapsing remitting multiple sclerosis (Coiffier, B. et al Blood 111 : 1094-100 (2008); Zhang, B. MAbs 1 (4): 326-31 (2009)). A third-generation, humanized and glyco-engineered anti-CD20 mAb for the treatment of B-cell lymphoid malignancies named Afutuzumab (now called obinutuzumab) has been developed (Robak, T (2009) Current opinion in investigational drugs (London, England: 2000) 10 (6): 588-96). Obinutuzumab is fully humanized IgGl type II anti-CD20 antibody and it selectivity binds to the extracellular domain of the human CD20 antigen on malignant human B cells. Similarly, an anti-CD 19 antigen monoclonal antibody B4 is a murine IgGi, that binds to the ( "1 ) 1 9 antigen on B cells {Nadler et al, 131 J. Immunol. 244-250 (1983) } and can be used if the target cells are B cells or diseased cells that express CD19 antigen such as in non-IIodgkin's lymphoma or chronic lymphoblastic leukemia. In addition, the anti- CD22 antibodies that include RFB4 (Mansfield, E. et al., Blood 90:2020-2026 (1997)), CMC-544 (DiJoseph, J. I .. Blood 103: 1807-1814 (2004)) and LI .2 (Pawlak-Byczkowska, E. J. et al, Cancer Res. 49:4568-4577 (1989)) can be used as potential therapies for B cell cancers and other B cell proliferative diseases. The LL2 antibody (formerly called HPB-2) is an IgG2a mouse monoclonal antibody directed against the CD22 antigen (Pawlak-Byczkowska, E. .1. et al. (1989), supra). Furthermore, the anti CD33 antigen monoclonal antibody, named Gemtuzumab was first monoclonal antibody conjugated with a cytotoxic drug to treat acute myelogenous leukemia (AML) (P. F. Bross et al Clin Cancer Res 7 (6): 1490-6). A similar anti CD33 antigen antibody, named My9-6 is a murine IgGi antibody that binds specifically to the CD33 Antigen { .I. I ). Griffin et al 8 Leukemia Res., 521 (1984) } and can be used to target cells express CD33 as in the disease of acute myelogenous leukemia (AML). Additionally, GM-CSF antibody which binds to myeloid cells can be used as a cell binding agent to diseased cells from acute myelogenous leukemia. IL-2 antibody, which binds to activated T-cells, can be used for prevention of transplant graft rejection, for therapy and prevention of graft-versus-host disease, and for the treatment of acute Ί -cel l leukemia. MSI I antibody, which binds to melanocytes, can be used for the treatment of melanoma. NOVEL CYTOTOXIC AGENTS AND THEIR CONJUGATION OF THE INVENTION.
The PBD dimer derivatives according to the present invention comprises one or more pyrrolo[2,l-c][l,4]benzodiazepine derivatives, optionally linkable or linked to a cell binding agent via a linking group. The linking group is part of a chemical moiety that is covalently bound to a pyrrolo[2,l-c][l,4]benzodiazepine derivative through conventional methods.
The PBD dimer derivatives disclosed in the present invention have the formula (I) show
Figure imgf000019_0001
or their pharmaceutically acceptable salts, hydrates, or hydrated salts, or the polymorphic crystalline structures of these compounds or their optical isomers, racemates, diastereomers or enantiomers.
wherein
— represents an optional single bond;
= represents either a single bond or a double bond ;
It provided that when = represents a single bond, U and U', the same or different, independently represent II; or the linking group (Ε') with the reactive group or a cell binding agent bonded thereto.
V and V, the same or different, are independently selected from the group consisting of OH, -NHOH; an ether (-OR5); an ester (-OCORs,e.g. an acetate); a carbonate ( -OCOOR5); an amine ( -NR5R5', -NR5CQR5\ -NR5NR5'NR5"); a carbamate ( -OCONR5R5'); a guanidinum (-- NR-(C=NI DNR-'Rs * ); an amino acid, or peptide ( - -NR COtAa),. wherein Aa is an amino acid or a polypeptide containing between t =1- 100 amino acid units; a optionally substituted 5- or 6- membered nitrogen-containing heterocycle (such as piperidine, tetrahydropyrrole, pyrazole, morpholine); a cyclic carbamate, such that U and V, and/or U'and V are a part of the cycle; a urea ( -NRsCONRs'Rs"); a thiocarbaniate ( -OCSNHR5); a cyclic thioearbamate such that U and V, and U'and V are a part of the cycle; a thiol (-SII); a sulfide such as -SR5; a sulphoxide ( - SOR5); a sulfone ( -SOOR5); a sulphite (-SO3, HS03, HS02, or a salt of HSO3", SO: ' or -HSQ2 ~); a bisulphite (-OSO3); a sulfonamide (-NR5SOOR5'); metabisulfite ( H2S2O5 or a salt of S2O52"); Mono-.dk tri-, and tetra-thiophosphate (PO3SH3, PO2S2H2, POS3H2, PS H2 or a salt of PO3S3", P( S..\ POS3 3 ", PS4 3"); tliiophosphate ester (R50)2POSR5'); thiosulfate ( HS203 or a salt of S203 2" ); dithionite (HS204 or a salt of S2O4 2"); phosphorodithioate(P(=S)(OR5)(S)(OH) or a salt thereof form with a cation); optionally cyclic amine such that U and V, and U'and V are a part of the cycle; a hydroxylamine derivative (-NR5OR5'); hydroxamic acid ( RsC(=0)NOI I or a salt formed with a cation); formaldehyde sulfoxylate ( I I( X 'H>S( )_V , or its salts); an amide ( NRs( Rs ): an azido (-N3); a cyano; a halo; a trialkyl, a phosphoramidate (phosphoramidic acid), or
triaiylphosphonium; an aminoacid-derived group; or the linking group (L') with the reactive group or a cell binding agent bonded thereto. The R5, Rs' and Rs" are described below.
and when = represents a double bond, U and U' are absent; V and V represent I I ; 1, m, n, F, m' and n* are the number 0, 1, 2, 3, 4, 5 or 6.
X, X', Y and Y* the same or different, independently, represent N, O, S, an alkyl, such as CH2 or CHRs, an alkene, such as =( Ί I- or =CRs-, an ether, such as < ( ORs )I 1-.
Z and /." the same or different, independently, represent N, CH, CR5, COH or COR5. R5 is independently selected from Ci-Cs alkyl and aryl.
Ri, R2, R3, R4, R i " . R.>\ R3 ' , and R4' are the same or different and independently chosen from -H, an optionally substituted linear, branched or cyclic alkyl, alkenyl or alkynyl having from 1 to 10 carbon atoms, a polyethylene glycol unit --(( Χ Ί Ι Ί Ι ΐ,Κ,, halogen, guanidinium [-NH(C=NH)NH2], -OR5, -NR5R5', -NO?., -NCO, -NR5COR5', -SR5, a sulfoxide represented by -SOR5, a sulfone represented by— SO2R5, a sulfonate --S( )>"M+,—SO U I, a sulfate -OSO3 M \ OSO3II, a sulfonamide represented by -SO2NR5R5' , cyano, an azido,— COR5, --OCOR5, -OCONR5R5', CF3, OR5, Aryl, heterocycle, or P( ( ) )RsRs*K " - and the linking group (L') with the reactive group or a cell binding agent bonded thereto;
Rs, Rs* and R5" are independently selected from H, Ci~Cs of alkyl, alkenyl, alkinyl, heteroalkyl, aryl, arylalkyl, carbonylalkyl, or pharmaceutical salts. Rs. Rs and Rs can further be substituted with at least one substituent selected from -N( R ] )( R2 ), -C02H, -SOU I, -OR] , - CO2R1, -CONRi, -PO2R1R2, POR1R2R3 and -PO3H.
q = 0, 1 or 2.
In addition, R2 and R3 join together, or R>' and R3' join together to form a = (double bond), =0 (ketone), =S.
Figure imgf000020_0001
)Rs, or a double bond containing group =( 'RsRs* : and R| and Rj join together, or R | * and R2' join together, or R3 and R4join together or R3' and R * join together form an aromatic, heterocyclic, or heteroaryl ring.
I , is a linker, or a linker-cell binding molecule covalently bound cluster, or a linker has a functional group on the linker that enables reaction with a cell-binding agent. L, when is a linker, is preferred a releasable linker, which is a chain of atoms selected from C, N, O, S, Si, B and P that covalently connects the cell-surface binding ligand (CBA) to the PBD
derivatives. The linker may have a wide variety of lengths, such as in the range from about 2 to about 100 atoms. The atoms used in forming the linker may be combined in all chemically relevant ways, such as forming alkylene, alkenylene, and alkynylene, ethers, polyoxyalkylene, esters, amines, iniines, polyamines, hydrazines, hydra/ones, amides, ureas, semicarbazides, carbazides, alkoxy amines, alkoxylamines, urethanes, amino acids, acyloxylamines, oximes, aldoximes, ketoximes, amidoximes, hydroxamic acids, and many others. In addition, it is to be understood that the atoms forming the releasable linker (L) may be either saturated or unsaturated, or may be radicals, or may be cyclized upon each other to form divalent cyclic structures, including cyclo alkanes, cyclic ethers, cyclic amines, arylenes, heteroarylenes, and the like in the linker.
Preferabably L has the formula of :— -Ww— (Aa)r— I t— ; or— Ww— (Aa)r— I t— Q; or Q— Ww— (Aa)r— Tt— ; wherein: W is a Stretcher unit; w is 0 or 1 ; Aa is independently an amino acid unit; r is independently an integer ranging from 0 to 100; The Stretcher unit W may independently contain a self-immolative or a non-self-immolative component, peptidyl units, a hydrazone bond, a disulfide, an ester, oxime, or thioether bonds. The examples of self- immolative units include, but are not limited to, aromatic compounds that are electronically similar to the para-aminobenzylcarbamoyl (PAB) group such as 2-aminoimidazol-5-methanol derivatives (Hay et al. (1999) Bioorg. Med. ( "hem. Lett. 9, 2237), heterocyclic PAB analogs, beta-glucuronide, and ortho or para-aminobenzylacetals.
Preferably, the self-immolative linker component has any one of the following structures:
Figure imgf000021_0001
wherein the (*) atom is the point of attachment of additional spacer or releasable linker units, or the cytotoxic agent, and/or the binding molecule (CBA); X1, Y1, / and Z3 are independently NH, or O, or S; Z1 is II, or NH, or O or S independently, v is 0 or 1 ; Q1 is independently II, OH, Ci~C6 alkyl, (OCH2CH2)„ F, CI, Br, I, OR,, or SR5, NR5R5>, N=NR5, N=R5, NR5R5\ N02, SORsR, . SO2R5, SO3R5, OSO3R5, PRsR , POR Rs . POjR R, . OPO( OR M ORv ). or OCI l )P( )( ORs( OR, ) wherein R5 and R5> are as defined above, preferably R5 and R are independently selected from 1 1. Ci~Cs of alkyl; C^-Cs of alkenyl, alkynyl, heteroalkyl; C3~Cg of aryl, heterocyclic, carbocyclic, cycloalkyl, heterocycloalkyl, heteroaralkyl, alkylcarbonyl; or pharmaceutical cation salts.
The non-self-immolative linker component is any one of the following structures:
(CH2)nCO(OCH2CH2)rOCH3 (CH2)nCON(CH2CH20)rCOCH3
(Ct^Ct^O),* . * H;
Figure imgf000022_0001
Figure imgf000023_0001
Wherein the (*) atom is the point of attachment of additional spacer or releaseable linkers, the cytotoxic agents, and/or the binding molecules; X1, Y1, Q1, R5, R5' are as defined above; r is 0-100; m, n and p are 0-6.
Spacers (T) is a linear, branched or cyclic alkyl, alkenyl, alkynyl or aryl having from 1 to 10 carbon atoms, or polyethylene glycol (-( 'I lj( I IjO- ) spacer; and t is 0, or 1-100.
Spacers can be used that undergo cyclization upon amide bond hydrolysis, such as substituted and unsubstituted 4-aminobutyric acid amides (Rodrigues et al (1995) Chemistry Biology 2:223), appropriately substituted bicyclo[2.2.1] and bicyclo[2.2.2] ring systems (Storm et al (1972) .1. Amer. Chem. Soc. 94:5815) and 2-aminophenylpropionic acid amides (Amsberry, et al (1990) J. Org. Chem. 55:5867). Elimination of amine -containing drugs that are substituted at glycine (Kingsbury et al (1984) .1. Med. Chem. 27: 1447) is also examples of self-immolative spacer useful in the cell-binding agent - cytotoxic agent conjugates of the present invention. In addition L can be 5, OR5, SR5, NHR5, or NRsR . thus Ri, R2, R3, R4, Rr, R2 . R3', or R4', or U, or U', or V, or V on the formula (I) can be used to linked to Q via Stretcher units (Ww) or via Spacer units (Tt) when the compound is used for conjugation to a cell binding agent.
Q is a cell binding molecule (CBA), or a functional group that enables reaction with a cell-binding agent or a functional group capable of reacting with a linker attached on a cell binding agent. The function group is chosen from a thiol, an amine, a hydrazine, an alkoxylamino, a disulfide substituent, a maleimido, a haloacetyl group, an N-hydroxy succinimide ester, or protected thiol or disulfide group, such as SAc, SSR5 or SSAr.
The term releasable linker refers to a linker that includes at least one bond that can be broken under physiological conditions, such as a pH-labile, acid-labile, base-labile, oxidatively labile, metabolically labile, biochemically labile, or enzyme-labile bond. It is appreciated that such physiological conditions resulting in bond breaking do not necessarily include a biological or metabolic process, and instead may include a standard chemical reaction, such as a hydrolysis or substitution reaction, for example, an endosome having a lower pH than cytosolic pH, and/or disulfide bond exchange reaction with a intracellular thiol, such as a millimolar range of abundant of glutathione inside the malignant cells.
The Stretcher unit (— W— ), when present, may link a targeted binding molecular unit (CBA) to an amino acid unit (--Aa— h or links T when an A a is not present. The Stretcher unit W may independently contain a self-immolative spacer, peptidyl units, a hydra/one bond, disulfide or thiolether bonds. In this regard a binding molecular (CBA) has a functional group that can form a bond with a functional group of a Stretcher. Useful functional groups that can be present on a binding molecular, either naturally or via chemical manipulation include, but are not limited to, sulfhydryl (— SH), amino, hydroxyl, carbonyl, the anomeric hydroxyl group of a carbohydrate, and carboxyl. Preferred functional groups are sulfhydryl, carboxy and amino. Sulfhydryl groups can be generated by reduction of an intramolecular disulfide bond of a Ligand. Alternatively, sulfhydryl groups can be generated by reaction of an amino group of a lysine moiety of a binding molecular using 2-iminothiolane (Traut's reagent) or thiol actone or another sulfhydryl generating reagent, such as modifies T with a disulfide bond linker, or a thiol ester following by reduction or hydrolysis respectively.
Specific examples of the releasable linkers (L) include, but not limited:
-(CR5R6)m(Aa)r(CR7R8)n(OCH2CH2)tQ,
Figure imgf000024_0001
-(Aa)r( CR5R6)m(CR7R8)„(OCH2CH2)tQ, -(CR5R6)m(CR7R8)„(OCH2CH2)r(Aa)tQ, -(CR5R6)m-
Figure imgf000024_0002
t(OCH2CH2)rQ, -(CR5R6)ra(NRiiCO)(Aa)t(CR9Rio)n-(OCH2CIi2)rQ, CR5R6)m(Aa)t(NRuCO)(CR9Rio)„(OCH2CH2)rQ,-(CR5R6)m(OCO)(Aa)t(CR9Rio)„.
(OCH2CH2)rQ, -(CR5R6)m(OCNR7)(Aa)t(CR9R1o)n(OCH2CH2)rQ, -(CR5R6)m(CQ)(Aa)t_ (CR9Rio)n(OCH2CH2)rQ, -(('R.R.WNR, iCO)(Aa),(CR9Ri0)„(OCH2CH2)rQ, -(CR R,,),,,. (OCO)(Aa)t(CR9Rio)„(OCH2CH2)rQ, -(CR5R6)m(OCNR7)(Aa)t(CR9Ri0)n(OCH2CH2)rQ, -(( R.sR„W(:())(Aa),(('R9RinU<)('II,CH:),Q. -((•R,R(,)m-p enyl-C()(Aa),(CR7R.s)„Q. - (CR5R6)ra-furyl-CO(Aa)t(CR7Rs)nQ, -(CR5R6)m-oxazolyl-CO(Aa)t(CR7R8)nQ, -(( R R,,),,,- thiazolyl-CO(Aa)t(CCR7R8)„Q, -(CR5R6)rthienyl-CO(CR7R8)„Q, -(CR5R6)r
i II l i da/t > 1 y 1 -C 0( ( ' R 7 R8 )„Q . -(('R5R„)rmtH'pliolino-('()( Aa)|(('R7R,s)„Q. -(('RsR„),pipeia/ino- CO(Aa)t(CR7Rg)„Q, -(CR5R6)t-N-methylpiperazin-CO(Aa)t(CR7Rs)„Q, ~(CR5R)m- (Aa)tphenyl-Q, -( ( 'RsK„ ),„-( Aa ), lury I -Q. -(CR5R6)m-oxazolyl(Aa)t-Q, -(('RsK„)m- thiazolyl(Aa)t-Q, -(('RsR(,),„-lhienyl-(Aa)iQ. -(( 'RsR,,)i„-imida olyl(Aa),-Q, -(C RsR„),„- morpholino~(Aa)tQ, -(( 'RsRi.im-pipera/ino-tAaliQ. -(( 'RsR„) i-N-methylpipera/ini>-( Aa),Q. - (CR5R6)m(Aa)r(CR7Rs)„(OCH2CH2)tQ, - (CR5R6)m(CR7R8)n(Aa)r(OCH2CH2)tQ, - (Aa)r( CR5R6)m(CR7R8)n(OCH2CH2)tQ, - (CR5R6)m(CR7R8)„(OCH2CH2)r(Aa)tQ, - (CR5R6)m(CR7= CR8)(CR9Rio)„(Aa)t(OCH2CH2)rQ, -K(CR5R6)m(NRi iCO)(Aa)t(CR9Rio)n(OCH2CH2)rQ, - (C R5R6)m(Aa)t(NRiiCO)(CR9Rio)„(OCH2CH2)rQ, -K(CR5R6)m(OCO)(Aa)t(CR9Ri0)„(OCH2CH2) rQ, -K(CR5R6)m(OCNR7)(Aa)t(CR9Rio)„(OCH2CH2)rQ, - (CR5R6)m(CO)(Aa)t(CR9Ri0)„(OCH 2CH2)rQ, -K(CR5R6)m(NRiiCO)(Aa)t(CR9Rio)n(OCH2CH2)rQ, -K(CR5R6)m(OCO)(Aa)t(CR9Ri o)„(OCH2CH2)rQ, ~K(CR5R6)m(OCNR7)(Aa)t(CR9R10)n(OCH2CH2)rQ, - (CR5R6)m(CO)(Aa)t( CR9R10)„(OCH2CH2)rQ, -K(CR5R6)m-phenyl-CO(Aa)t(CR7R8)nQ, - (CR5R6)m- furyl-CO(Aa)t(CR7R8)nQ, -K(CR5R6)n OxazolyK:0(Aa)t(CR7R8)nQ, -K(CR5R6)m- thiazolyl-CO(Aa)t(CCR7R8)nQ, - (CR5R6)rthienyl-CO(CR7R8)nQ, - (CR5R6)t- imidazolyl-CO(CR7R8)nQ, -K(("R R„)inii>rpholin(>-('()(Aa)i(("R7R8)nQ. -K(( 'K-iR„),pipera/ino -CO(Aa)t(CR7R8)nQ, - (('RsR,,),-N-mcl ylpipcra/in--('()(Aa),(('R7R8)tlQ. -K(CR5R)m- (Aa)tphenyl-Q, - K( ( ' Rs R„ ),„-( A a ), lury 1 -Q. -KK'RsR. m-oxa/olyHAaii-Q. -KK'RsR,,),,,- thiazolyl(Aa)t-Q,
Figure imgf000025_0001
-K(('RsR())m-iinida/olyl(Aa), -Q, -K(("RsR„)m- morpholino-(Aa)tQ, - (CR5R6)m-piperazino-(Aa)tQ, - (CR5R6)mN-methylpiperazino-(Aa)tQ.
Wherein m, Aa, t, n, Q, R3, R4, and R5 are described above; Re, R7, and R8 are the same or different and independently chosen from H; halide; Ci~C8of alky I. aryl, alkenyl, alkynyl, ether, ester, amine or amide, which optionally substituted by one or more halide, CN, NRiR2, CF3, OR,. Aryl, heterocycle, S(0)R,, S02Ri, -C02II, -SO3II, -OR,, -C02Ri, -CONR,, - P02RiR2, -PO3H or P(0)RiR2R3; K is NR,. O, S, Se, B or Het.
The compounds of the general formula (I) having geometrical and stereoisomers are also a part of the invention. A preferred stereoisomer of the formula (I) is presented by the following formula (la) a
Figure imgf000026_0001
wherein X, X', Y, Y' , Z, /.". 1, 1', m, m\ n, n" . R R2, Κ. R3, R3\ ¾» L are the same as defined in formula (I).
In another preferred embodiment according to formula (I), the novel PBD derivatives of the invention have the formula (II), (HI), and (TV).
Figure imgf000026_0002
Figure imgf000027_0001
wherein X, Χ', Y, Υ', Z, Ζ', 1, Γ, m, m*. η, η', R| . Κι ". R2, R . Κ ¾. R3', 4, R4', I . are the same as defined in formula (I)
V and V the same or different are independently selected from the group consisting of OH, an ether such as -OR5, an ester (e.g. an acetate), such as -QCOR5, -COOR5, a carbonate such as -OCOOR5, a carbamate such as -OCONR5R5', a cyclic carbamate, such that NIO and CI 1 are a part of the cycle, a urea such as -NRCONR5R5', a thiocarbamate such as -OCSNHR5, a cyclic thiocarbamate such that NIO and C I 1 are a part of the cycle, -SI I, a sulfide such as -SR5, a sulphoxide such as -SQR5, a sulfone such as -SOOR5, a sulphite (sulfite) such as -SO3 ", a bisulphite such as -OSO3 ", a sulfonamide such as -NRSOOR, an amine such as -NRR', optionally cyclic amine such that NIO and CI 1 are a part of the cycle, a hydroxylamine derivative such as - NR5OR5', an amide such as -NR5COR5', -NRsCONRs Rs . an azido such as --N3, a cyano, a halo, a trial kyl or triarylphosphonium, an aminoacid-derived group.
V" is (=)( ). ( = ) I I. HN-CONR5R5' , HN-COR5, (=)N-COOR5, (=)N-0-R5
Rs. Rs' and Rs' * are independently selected from H, Ci~Cs of alkyl, alkenyl, alkinyl, heteroalkyl, aryl, arylalkyl, carbonylalkyl, or pharmaceutical salts. Rs. Rs and R- can further be substituted with at least one substituent selected from -N( R ] )( R? ), -CO2H, -SOU I, -ORi, - CO2R1, -CONRi, -PO2R1R2, POR1R2R3 and -PO3H or M (Na, K, Ca, ammonium or the other pharmaceutically acceptable salt), or linked a cell binding agent via Stretcher units (Ww) or via Spacer units (Tt).
In certain embodiments, the PHI) derivatives of formula (I), (II), ( III ), and (IV) are represented by the following formulas (V), (VI), (VII), (VIII), (IX), (X), (XI), (XII), (XIII), (XIV), (XV), (XVI):
Figure imgf000027_0002

Figure imgf000028_0001
Figure imgf000029_0001
wherein U, LP, V, V, n, n', X, X' and L are the same as defined in formula (I). Re and e' are the same or independently as R5 as described in formula (I), preferably R„ and R,* arc Ci~Cs of alkyl, alkenyl, alkinyl, aryl, cyclic, cyclohetero, haloalkyl, alkoxy, haloalkoxy alkylamino; or halogen; or -N02; or -CN; or H; or linked a cell binding agent via Stretcher units (Ww) or via Spacer units (Tt). W, w, T, and t are as defined in Formula (I).
In certain embodiments, the cytotoxic agent and its conjugate of this invention are any
Figure imgf000029_0002
(XVIII- 1) 
Figure imgf000030_0001
5
Figure imgf000031_0001
Figure imgf000032_0001
-24)
Figure imgf000033_0001
Figure imgf000034_0001
(XVIII-40)
Figure imgf000035_0001
Figure imgf000036_0001
Figure imgf000037_0001
(XVIII-64)
(XVIII-65)
(XVIII-66)
(XVIII-67)
(XVIII-68)
(XVIII-69)
Figure imgf000038_0001
(XVIII-70)
-75)
Figure imgf000039_0001
Figure imgf000040_0001
Wherein Aa, n, and Q are the same in the Formula (I) or (II). Preferably, Q is 11, Ci~C& of alkyl, alkenyl, alkinyl, aryl, cyclic, cyclohetero, haloalkyl, alkoxy, haloalkoxy alkylamino; or halogen; or -N02; or -CN; -SH; -SSCH3; -SSAc; -SSAr; -SS-Pyridine; -SS~Ar(-N02); -S- cell binding agent; or a function group of NHS ester, pentafluorophenyl ester; alkyloxy amine; aldehyde; ketone; carboxyl acid; hydrazine; amine; or thiolactone; or linked a cell binding agent via Stretcher units (Ww) or via Spacer units (Tt). W, w, T, and t are as defined in
Formula (I); or Q is selected from any one of the following formulas:
Figure imgf000040_0002
Figure imgf000041_0001
Wherein D is H, -N02, SQ3 ~, CN, or F; K | . R2, K ¾. K.|. r, m, and n are described in Formula (1); w and w' are 0 or 1 respectively. Synthesis of theses FB I ) derivatives as cytotoxic agents.
The compounds and process of the present invention can be prepared in a number of ways well known to those skilled in the art. The compounds can be synthesized, for example, by application or adaptation of the methods described in the examples, or variations thereon as appreciated by the skilled artisan. The appropriate modifications and substitutions will be readily apparent and well known or readily obtainable from the scientific literature to those skilled in the art. In particular, such methods can be found in Richard C. Larock, Comprehensive Organic Transformations, A Guide to Functional Group Preparations, Two Volume Set, 2nd Edition, Wiley Publishers, 2010.
Because the cytotoxic agents of the present invention may contain one or more
asymmetrically substituted carbon atoms, and may be isolated in optically active or racemic forms, all chiral, diastereomeric, racemic forms and all geometric isomeric forms of a structure are intended, unless the specific stereochemistry or isomeric form is specifically indicated. It is well known in the art how to prepare and isolate such optically active forms. For example, mixtures of stereoisomers may be separated by standard techniques including, but not limited to, resolution of racemic forms, normal, reverse-phase, and chiral chromatography, preferential salt formation, recrystallization, and the like, or by chiral synthesis either from chiral starting materials or by deliberate synthesis of target chiral centers.
The cytotoxic agents of the present invention may be prepared by a variety of synthetic routes. The reagents and starting materials are commercially available, or readily synthesized by well-known techniques by one of ordinary skill in the arts. All substituents, unless otherwise indicated, are as previously defined.
In the synthetic reactions of the cytotoxic agents of the present invention, it may be necessary to protect reactive functional groups, for example hydroxy, amino, imino, thio or car boxy groups, where these are desired in the final product, to avoid their unwanted participation in the reactions. Conventional protecting groups may be used in accordance with standard practice, for examples see Peter G. M. Wuts, Theodora W. Greene in Greene's Protective Groups in Organic Synthesis, 4th Edition, John Wiley and Sons, 2006; Ian T. Harrison, Shuyen Harrison in Compendium of Organic Synthetic Methods, Vol 1,2 Vols. 1& 2 By Ian T.
Harrison & Shuyen Harrison , Vols 3-5 by Louis S. Hegedus, Leroy Wade Vols 6- Vol 12 by Michael B. Smith, John Wiley and Sons,2006~2012.
Normally the synthetic reactions are carried out in suitable solvents, temperatures and time. A variety of solvents which have no adverse effect on the reaction or on the reagents involved can be used in a synthetic reaction of the cytotoxic agent. Examples of suitable solvents include: hydrocarbons, which may be aromatic, aliphatic or cyeloaliphatie hydrocarbons, such as hexane, cyclohexane, benzene, toluene and xylene; hydrocarbons containing halogens, such as chloroform, dichloromethane, dichloroethane; amides, such as dimethylaclamide or dimethylformamide; alcohols such as ethanol and methanol and ethers, such as diethyl ether and tetrahydrofuran. The reactions can take place over a wide range of temperatures, from -100 °C - 300°C, preferably from 0°C to 100°C. The time required for the synthetic reaction may also vary widely, depending on many factors, notably the reaction temperature and the nature of the reagents and can be from 5 second to 4 weeks, more preferably from 10 min to 20 hours. In addition, the cytotoxic agents prepared may be isolated or purified from the reaction mixture by conventional means, such as evaporating or distilling off the solvent from the reaction mixture, or after distilling off the solvent from the reaction mixture, pouring the residue into water followed by extraction with a water- immiscible organic solvent and then distilling off the solvent from the extract. It may also involve various well known techniques, such as re-ciystallization, re-precipitation or the various chromatography techniques, notably column chromatography, preparative thin layer
chromatography, or high performance liquid chromatography.
Some of the synthetic reactions of the cytotoxic agents and their conjugates to a cell binding agent are further exampled but not restricted in the Figures 1-23 and in the examples 1-73 of the description.
The conjugates of Cell-binding agent - cytotoxic agent
The present invention also provides a conjugate molecule comprising at least one PBD derivative covalently linked to a cell binding agent (CBA) through the linking group of the crosslinker (L). Preferably said conjugate comprises one to twenty molecules of PBD derivatives according to the invention covalently linked to a cell binding agent through the linking group of the linker of the PBD derivatives. As stated above, the conjugates of a cell surface binding molecule - cytotoxic agent are illustrated in the formula (I):
Figure imgf000043_0001
(I) or their pharmaceutically acceptable salts, hydrates, or hydrated salts, or the polymorphic crystalline stractures of these compounds or their optical isomers, racemates, diastereomers or enantiomers.
wherein U, U', V, V, m, m' , n, n', X, X', Y, Y' , Z, // R , . R2, R3, R4, Rr, Rr. R3\ and R4', L are described above. L is preferred a linker-cell binding molecule covalently bound cluster,
When L is R5, OR5, SR5 or NRsR . then R , , R2, R3, R4, Rr, R3\ R»\ U, V, U' or V on the formula (I) can be used to linked to a cell-binding molecule (CBA) via L' , or via Stretcher units (Ww) or via Spacer units (Tt). Wherein CBA, I .* , W, w. T, and t are as described through the patent application.
In certain embodiments, the conjugates of the invention are i llustrated in the formula (
Figure imgf000043_0002
Figure imgf000044_0001
wherein U, U', V, V, m, m', n, n*. X, X' , Y, Y' , Z, /."
Figure imgf000044_0002
R4. R p. R . R3' , and R4',
L are described above in Formula (I). L' is the same or independently L as defined in Formula (I).
Drug loading may range from 1 to 20 drug moieties (D) per cell binding agent and is preferred the average number of 2-8 drug moieties per cell binding agent in a molecule of Formula (IX) - (XIV). When CBA is antibody in preparations of ADC, the preferred drug loading is 3-6 drug per antibody andthe average number of drug moieties per antibody from conjugation reactions may be characterized by conventional means such as mass
spectroscopy, HI .ISA assay, and HPLC. The quantitative distribution of the conjugates in terms of the drug loading may also be determined. In some instances, separation, purification, and characterization of homogeneous the conjugates where drug loading is a certain value from the conjugates with the drug loadings may be achieved by means such as reverse phase HPLC or electrophoresis.
The Cell binding agents (CBA) may be of any kind and include peptides and non-peptides. Generally, the cell binding agents include, but are not limited to, large molecular weight proteins such as, for example, full-length antibodies (polyclonal and monoclonal antibodies); single chain antibodies; fragments of antibodies such as Fab, Fab', F(ab')2, l \ . [Parham, J .
Immunol. 131 , 2895-2902 (1983)], fragments produced by a Fab expression library, anti- idiot ypic (anti-Id) antibodies, CDR's, and epitope-binding fragments of any of the above which immuno-specifically bind to cancer cell antigens, viral antigens or microbial antigens; antibody mimetic, such as an affibody; domain antibodies (dAb); nanobodies; unibodies; DARPins; anticalins; versabodies; duocalins; lipocalins; vimers; interferons (such as type I, II, III);
peptides; lymphokines such as IL-2, 11 . -3, I I -4, IL-6, GM-CSF, interferon-gamma (IFN-γ); hormones such as insulin, TRI I (thyrotropin releasing hormones), M SI I (melanocyte- stimulating hormone), steroid hormones, such as androgens and estrogens, melanocyte - sl i mulating hormone ( MSI I ): growth factors and colony-stimulating factors such as epidermal growth factors (EGF), granulocyte-macrophage colony-stimulating factor (GM-CSF), transforming growth factors (TGF), such as TGFa, ΤΟΡβ, insulin and insulin like growth factors (IGF-I, IGF-II) G-CSF, M-CSF and GM-CSF [Burgess, Immunology Today, 5, 155-158 (1984)] ; vaccinia growth factors (VGF); fibroblast growth factors (FGFs); smaller molecular weight proteins, poly-peptide, peptides and peptide hormones, such as bombesin, gastrin, gastrin-releasing peptide; platelet-derived growth factors; interleukin and cytokines, such as interleukin-2 (IL-2), interleukin-6 (IL-6), leukemia inhibitory factors, granulocyte-macrophage colony-stimulating factor (GM-CSF); vitamins, such as folate; apoproteins and glycoproteins, such as transferrin { O'Keefe et al, 260 J. Biol. Chem. 932-937 (1985) } ; sugar-binding proteins or lipoproteins, such as lectins; cell nutrient-transport molecules; and small molecular inhibitors, such as prostate-specific membrane antigen (PSMA) inhibitors and smal l molecular tyrosine kinase inhibitors (TKI), non-peptides or any other cell binding molecule or substance, such as bioactive polymers (Dhar, et al, Proc. Natl. Acad. Sci. 2008, 105, 17356-61) or a polymer having a cell binding agent on its surface; dendrimers (Lee, et al, Nat. Biotechnol. 2005, 23,
1517-26; Almutairi, et al; Proc. Natl. Acad. Sci. 2009, 106, 685-90) or a dendrimer containing a cell binding agent; nanoparticles (Liong, et al, ACS Nano, 2008, 19, 1309-12; Medarova, et al, Nat. Med. 2007, 13, 372-7; Javier, et al. Bioconjugate Chem. 2008, 19, 1309-12) or a nanoparticles having a cell binding agent on its surface; liposomes (Medinai, et al, Curr. Phar. Des. 2004, 10, 2981 -9) or a liposome having a cell binding agent; viral capsides (Flenniken, et al, Viruses Nanotechnol. 2009, 327, 71-93). In general monoclonal antibodies are preferred as a cell-surface binding agent if an appropriate one is available.
The linker used for the conjugation of this invention includes, but not limited to, a disulfide linker, a thioether linker, an amide bonded linker, a peptidase-labile linker, a photolabile linker, an acid-labile linkers (such as hydrazone liner), an esterase -labile linker, an oxidatively labile linker, a metabolically labile linker, a biochemically labile linker.
Preferably, the linker is linked to the cell binding agent via a function reactive towards for instance thiol and amino functions of the cell binding agent coming from reduced disulfide bonds and lysine residues respectively. More particularly, said derivative is linked through the —CO— group to the amino function of the lysine residue of said cell binding agent, so as to form an amide bond.
In addition, the linker may be composed of one or more linker components. Exemplary linker components include 6-maleimidocaproyl ("MC"), rnaleimidopropanoyl ("MP"), valine - citrulline ("val-cit" or "vc"), alanine -phenylalanine ("ala-phe" or "af '), glycine-glycine, p- aminobenzyloxycarbonyl ("PAB"), N-succinimidyl 4-(2-pyridylthio)pentanoate ("SPP"), N- succinimidyl 4-(N-maleimidomethyl)cyclohexane-l carboxylate ("SMCC"), N-Succinimidyl (4-iodo-acetyl)aminobenzoate ("SIAB"), ethyleneoxy (— CH2CH20— ) as one or more repeating units ("EO" or "PEO"). The linker may be a "cleavable linker," facilitating release of a drug in the cell. Additional linker components are known in the art and some are illustrated below:
Figure imgf000046_0001
Figure imgf000047_0001
Ks. and more pro I erred independently selected from -Ci~Cs alkyl or alkylene-,— Ci~Ci carbocyclo-, -( )-( Ci~Cs alkyl)-, -arylene-,— Ci~Cs alkylene-arylene-, -arylene, -Ci~Cs alkylene-, -Ci~Cs alkylene-( Ci~Cs carbocyclo)-, -(C3~C7 carbocyclo)- Ci~Cs alkylene-, -C3~Cg heterocyclo-, -Ci~Cs alkylene-! C3~Cs heterocyclo)-, -( Ce-Cs heterocyclo)- Ci-Cg alkylene-, - (CH2CH20)k-, -(CH(CH3)CH20)k-, and -( CH2CH20)k-CH2-; k is an integer ranging from 1-30; X' ", Y' " and /.* * * are independently selected from NH, O or S; K| and R2 are described above.
In a preferred embodiment, conjugates of the invention are antibody/cytotoxic agent, antibody ragmen t/cytotox ic agent, diabody/cytotoxic agent, tri(a)body/cytotoxic agent, epidermal growth factor (EGF)/cytotoxic agent, prostate specific membrane antigen (PSMA) inhibitor/cytotoxic agent, melanocyte stimulating hormone (MSH)/cytotoxic agent, thyroid stimulating hormone (TSH)/cytotoxic agent, polyclonal antibody/cytotoxic agent,
somatostatin/cytotoxic agent, folate/cytotoxic agent, matriptase inhibitor/cytotoxic agent, estrogen/cytotoxic agent, estrogen analogue/cytotoxic agent, designed ankyrin repeat proteins (DARPins)/cytotoxic agent, androgen/cytotoxic agent, and androgen analogue/cytotoxic agent. In a more preferred embodiment, conjugates of the invention are monoclonal
antibody/cytotoxic agent. Examples of antibodies used for conjugation of cyotoxic agents in this prevention include, but are not limited to, 3F8 (anti-GD2), Abagovomab (anti CA-125), Abciximab (anti CD41 (integrin alpha-lib), Adalimumab (anti-TNF-a), Adecatumumab (anti- EpCAM, ( '1 )326 ), Afelimomab (anti-TNF-a); Afutuzumab (anti-CD20), Alacizumab pegol (anti-VEGFR2), ALD518 (anti-IL-6), Alemtuzumab (Campath, MabCampath, anti- CD52), Altumomab (anti-CEA), Anatumomab ( anti-TAG-72), Anrukinzumab (IMA-638, anti-IL-13), Apolizumab (anti-HLA-DR), Arcitumomab (anti-CEA), Aselizumab (anti-L-selectin (CD62L), Atlizumab (tocilizumab, Actemra, RoActemra, anti-IL-6 receptor), Atorolimumab ( anti-Rhesus factor), Bapineuzumab (anti-beta amyloid), Basiliximab (Simulect, antiCD25 (a chain of IL-2 receptor), Bavituximab (anti-phosphatidylserine), Bectumomab (LymphoScan, anti-CD22), Belimumab (Benlysta, LymphoStat-B, anti-BAFF), Benralizumab (anti-CD125), Bertilimumab (anti-CCLl l (eotaxin-1)), Besilesomab (Scintimun, anti-CEA -related antigen), Bevacizumab (Avastin, anti-VEGF-A), Biciromab (FibriScint, anti-fibrin II beta chain), Bivatuzumab (anti- CD44 v6), Blinatumomab (BiTE, anti-CD19), Brentuximab (cACIO, anti-CD3() TNFRSF8), Briakinumab (anti-IL-12, 11. -23 ) Canakinumab (Ilaris, anti-IL-1), Cantuzumab (C242, anti- CanAg), Capromab, Catumaxomab (Removab, anti-EpCAM, anti-CD3), CC49 (anti-TAG-72), Cedelizumab (anti-CD4), Certolizumab pegol (Cimzia anti-TNF-a), Cetuximab (Erbitux, IMC- C225, anti-EGFR), Citatuzumab bogatox (anti-EpCAM), Cixutumumab (anti-IGF-1),
Clenoliximab (anti-CD4), Clivatuzumab (anti-MUC l), Conatumumab (anti-TRAIL-R2),
CR6261 (anti-Influenza A hemagglutinin), Dacetuzumab (anti-CD40), Daclizumab (Zenapax, anti-CD25 (a chain of IL-2 receptor)), Daratumumab (anti-CD38 (cyclic ADP ribose hydrolase), Denosumab (Prolia, anti-RAN L), Detumomab (an ti-B -lymphoma cell),
Dorlimomab, Dorlixizumab, Ecromeximab (anti-GD3 ganglioside), Eculizumab (Soliris, anti- C5), Edobacomab (anti-endo toxin), Edrecolomab (Panorex, MAbl7-lA, anti-EpCAM),
Efalizumab (Raptiva, anti-LFA-1 (CD 11a), Efungumab (Mycograb, anti-Hsp90), Flotuzumab (anti-SLAMF7), Elsilimomab (anti-IL-6), Enlimomab pegol (anti-ICAM-1 (CD54)),
Epitumomab (anti-episialin), Epratuzumab (anti-CD22), Erlizumab (anti-ITGB2 (CD 18)), 1 j tumaxomab (Rexomun, anti-HER2/neu, CD3), Llaraci/umab (Abegrin, anti-integrin ανβ3), Exbivirumab ( anti-hepatitis B surface antigen), Fanolesomab (NeutroSpec, anti-CD 15),
Faralimomab (anti-interferon receptor), Farletuzumab (anti-folate receptor 1), Felvizumab (anti- respiratory syncytial virus), Fezakinumab (anti-IL-22), Figitumumab (anti-IGF-1 receptor), Fontolizumab (anti-IFN-γ), Foravirumab (anti-rabies virus glycoprotein), Fresolimumab (anti- TGF-β), Galiximab (anti-CD80), Gantenerumab (anti- beta amyloid), Gavilimomab (anti- CD147 (basigin)), Gemtuzumab (anti-CD33), Girentuximab (anti-carbonic anhydrase 9),
( ilembatumumab (CR011, anti-GPNMB), Golimumab (Simponi, anti-TNF-a ). Gomiliximab (anti-CD23 (IgE receptor)), Ibalizumab (anti-CD4), Ibritumomab (anti-CD20), Igovomab (Indimacis-125, anti-CA-125), Imciromab (Myoscint, anti-cardiac myosin), Infliximab
(Remicade, anti-TNF-a), Intetumumab (anti-CD51), Inolimomab (anti-CD25 (a chain of II . -2 receptor)), Inotuzumab (anti-CD22), Ipilimumab (anti-CD 152), Iratumumab (anti- CD30 (TNFRSF8)), Keliximab (anti-CD4), Labetuzumab (CEA-Cide, anti-CEA), Lebrikizumab (anti- I L- 13 ). Lemalesomab (anti-NCA-90 (granulocyte antigen)), Lerdelimumab (anti-TGF beta 2), Lexatumumab (anti-TRAIL-R2), Libivirumab (anti-hepatitis B surface antigen), Lintuzumab ( anti -( '1)33 ). Lucatumumab (anti-CD40), Lumiliximab (anti- ( "1)23 ( IgE receptor),
Mapatumumab (anti-TRAIL-Rl), Maslimomab (anti- T-cell receptor), Matuzumab (anti- EGFR), Mepolizumab (Bosatria, anti-IL-5), Metelimumab (anti-TGF beta 1), Milatuzumab (anti-CD74), Minretumomab (anti-TAG-72), Mitumomab (BEC-2, anti-GD3 ganglioside), Morolimumab (anti-Rhesus factor), Motavizumab (Numax, anti-respiratory syncytial virus), Muromonab-CD3 (Orthoclone OKT3, anti-CD3), Nacolomab (anti-C242), Naptumomab ( anti- 5T4), Natalizumab (Tysabri, anti-integrin o ). Nebacumab (anti-endotoxin), Necitumumab (anti- EGFR), Nerelimomab (anti-TNF-a), Nimotuzumab (Theracim, Theraloc, anti-EGFR), Nofetumomab, Ocrelizumab (anti-CD20), Odulimomab (y\folimomab, anti-LFA-1 (GDI la)), Ofatumumab (Arzerra, anti-CD20), Olaratumab (anti-PDGF-R a), Omalizumab (Xolair, anti- IgE Fc region), Oportuzumab (anti-EpCAM), Oregovomab (OvaRex, anti-CA-125),
Otelixizumab (anti-CD3), Pagibaximab (anti-lipoteichoic acid), Palivizumab (Synagis, Abbosynagis, anti-respiratory syncytial vims), Panitumumab (Vectibix, ABX-EGF, anti- EGI R ), Panobacumab (anti-Pseudomonas aeruginosa), Pascolizumab (anti-IL-4), Pemtumomab (Theragyn, anti-MUCl), Pertuzumab (Omnitarg, 2C4, anti-IIER2/neu), Pexelizumab (anti-C5), Pintumomab (anti-adenocarcinoma antigen), Priliximab (anti-CD4), Pritumumab (anti- vimentin), PRO 140 (anti-CCR5), Racotumomab (1E10, anti-(N-glycolylneuraminic acid (NeuGc, NGNA)-gangliosides GM3)), Rafivirumab (anti-rabies virus glycoprotein),
Ramucirumab (anti-VEGFR2), Ranibizumab (Lucentis, anti-VEGF-A), Raxibacumab (anti- anthrax toxin, protective antigen), Regavirumab (anti-cytomegalovirus glycoprotein B), Reslizumab (anti-IL-5), Rilotumumab (anti-HGF), Rituximab (MabThera, Rituxanmab, anti- CD20), Robatumumab (anti-IGF-1 receptor), Rontalizumab (anti-IFN-a), Rovelizumab (LeukArrest, anti-CDl l, CD 18), Ruplizumab (Antova, anti-CD 154 (CD40L)), Satumomab (anti-TAG-72), Sevirumab (anti-cytomegalovirus), Sibrotuzumab (anti-FAP), Sifalimumab (anti-IFN-a), Siltuximab (anti-IL-6), Siplizumab (anti-CD2), (Smart) MI95 (anti-CD33), Solanezumab (anti-beta amyloid), Sonepcizumab (anti-sphmgosine-1 -phosphate), Sontuzumab (anti-episialin), Stamulumab (anti-myostatin), Sulesomab (LeukoScan, (anti-NCA-90
(granulocyte antigen), Tacatuzumab (anti-alpha-fetoprotein), Tadocizumab (anti-integrin αω>β3), Talizumab (anti-IgE), Tanezumab (anti-NGF), Taplitumomab (anti-CD 19), Tefibazumab (Aurexis, (anti-clumping factor A), Telimomab, Tenatumomab (anti-tenascin C), Teneliximab (anti-CD40), Teplizumab (anti-CD3), TGN1412 (anti-CD28), Ticilimumab (Tremelimumab, (anti-CTLA-4), Tigatuzumab (anti-TRAIL-R2), TNX-650 (anti-IL-13), Tocilizumab
(Atlizumab, Actemra, RoActemra, (anti-IL-6 receptor), Toralizumab (anti-CD 154 (CD40L)), Tositumomab (anti-CD20), Trastuzumab (Herceptin, (anti-HER2/neu), Tremelimumab (anti- CTLA-4), Tucotuzumab celmoleukin (anti-EpCAM), Tuvirumab (anti-hepatitis B virus),
Urtoxazumab (anti-Escherichia coli), Ustekinumab (Stelara, anti-IL-12, I I -23 ), Vapaliximab (anti-AOC3 (VAP-1)), Vedolizumab, (anti-integrin α4β7), Veltuzumab (anti-CD20),
Vepalimomab (anti-AOC3 (VAP-1), Visilizumab (Nuvion, anti-CD3), Vitaxin (anti-vascular integrin avb3), Volociximab (anti-integrin 5βι), Votumumab (HumaSPECT, anti-tumor antigen CTAA16.88), Zalutumumab (HuMax-EGFr, (anti-EGFR), Zanolimumab (HuMax-CD4, anti- CD4), Ziralimumab (anti-CD 147 (basigin)), Zolimomab (anti-CD5), Etanercept (Enbrel®), Alefacept (Amevive®), Abatacept (Orencia®), Rilonacept (Arcalyst), 14F7 [anti-IRP-2 (Iron Regulatory Protein 2)], 14G2a (anti-GD2 ganglioside, from Nat. Cancer Inst, for melanoma and solid tumors), J591 (anti-PSMA, Weill Cornell Medical School for prostate cancers), 225.28S [anti-HMW-MAA (High molecular weight-melanoma-associated antigen), Sorin Radiofarrnaci S.R.L. (Milan, Italy) for melanoma], COL-1 (anti-CEACAM3, CGM1 , from Nat. Cancer Inst. USA for colorectal and gastric cancers), CY 1 -356 (Oncoltad®, for prostate cancers), HNK20 (OraVax Inc. for respiratory syncytial virus), ImmuRAIT (from Immunomedics for NHL), Lym-1 (anti-IILA-DRlO, Peregrine Pharm. for Cancers), MAK-195F [anti-TNF (tumor necrosis factor; TNFA, TN I '-alpha; TNFSF2), from Abbott / Knoll for Sepsis toxic shock], MEDI-500 [T10B9, anti-CD3, Ί¾αβ (T cell receptor alpha/beta), complex, from Medlmmune Inc for Graft-versus-host disease], RING SCAN [ anti-TAG 72 (tumour associated glycoprotein 72), from Neoprobe Corp. for Breast, Colon and Rectal cancers], Avicidin (anti-EPCAM (epithelial cell adhesion molecule), anti-TACSTDl (Tumor-associated calcium signal transducer 1), anti- GA733-2 (gastrointestinal tumor-associated protein 2), anti-EGP-2 (epithelial glycoprotein 2); anti-KSA; KS 1 /4 antigen; M4S; tumor antigen 1 7- 1 A; CD326, from NeoRx Corp. for Colon, Ovarian, Prostate cancers and NHL] ; LymphoCide (Immunomedics, NJ), Smart ID 10 (Protein Design Labs), Oncolym (Techniclone Inc, CA), Allomune (BioTransplant, CA), anti-VEGF (Genentech, CA); CEAcide (Immunomedics, NJ), IMC-1C11 (ImClone, NJ) and Cetuximab (ImClone, NJ) .
Other antibodies as binding ligands include, but are not limited to, are antibodies against the following antigens: Aminopeptidase N (CD13), Annexin Al, B7-H3 (CD276, various cancers), CA125 (ovarian), CA15-3 (carcinomas), CA19-9 (carcinomas), L6 (carcinomas), Lewis Y (carcinomas), Lewis X (carcinomas), alpha fetoprotein (carcinomas), CA242
(colorectal), placental alkaline phosphatase (carcinomas), prostate specific antigen (prostate), prostatic acid phosphatase (prostate), epidermal growth factor (carcinomas), ( 1)2 (Hodgkin's disease, NHL lymphoma, multiple myeloma), ( 1)3 epsilon (T cell lymphoma, lung, breast, gastric, ovarian cancers, autoimmune diseases, malignant ascites), CD19 (B cell malignancies), ( '1)20 (non-Hodgkin's lymphoma), CD22 (leukemia, lymphoma, multiple myeloma, SLE), ( 1)30 (Hodgkin's lymphoma), CD33 (leukemia, autoimmune diseases), CD38 (multiple myeloma), ( '1)40 (lymphoma, multiple myeloma, leukemia (CLL)), ( "1)5 I (Metastatic melanoma, sarcoma), ( 1 )52 (leukemia), CD56 (small cell lung cancers, ovarian cancer, Merkel cell carcinoma, and the liquid tumor, multiple myeloma), CD66e (cancers), ( '1 )70 (metastatic renal cell carcinoma and non-Hodgkin lymphoma), ( 1)74 (multiple myeloma), CD80
(lymphoma), GD98 (cancers), mucin (carcinomas), CD221 (solid tumors), CD227 (breast, ovarian cancers), ( 1)262 (NSCLC and other cancers), ( '1)309 (ovarian cancers), ( 1)326 (solid tumors), CEACAM3 (colorectal, gastric cancers), CEACAM5 (carcinoembryonic antigen; CEA, CD66e) (breast, colorectal and lung cancers), 1 )1.1.4 (A-like-4), EGFR (Epidermal Growth Factor Receptor, various cancers), ( ΊΊ .Λ4 (melanoma), CXCR4 (CI) 184, Henie- oncology, solid tumors), Endoglin (CD 105, solid tumors), EPCAM (epithelial cell adhesion molecule, bladder, head, neck, colon, NHL prostate, and ovarian cancers), FRBB2 ( Epidermal Growth Factor Receptor 2; lung, breast, prostate cancers), FCGR1 (autoimmune diseases), FOLK (folate receptor, ovarian cancers), GD2 ganglioside (cancers), G-28 (a cell surface antigen glyvolipid, melanoma), GD3 idiotype (cancers), Heat shock proteins (cancers), 11EK 1 (lung, stomach cancers), HER2 (breast, lung and ovarian cancers), HLA-DR10 (NHL), Ι ΙΙ .Λ- DRB (NHL, B cell leukemia), human chorionic gonadotropin (carcinoma), I il l R (insulin-like growth factor 1 receptor, solid tumors, blood cancers), 11. -2 receptor (interleukin 2 receptor. I - cell leukemia and lymphomas), II -6R (interleukin 6 receptor, multiple myeloma, RA,
Castleman's disease, IL6 dependent tumors), Integrins (ανβ3, α5β1, α6β4, α11β3, α5β5, ανβ5, for various cancers), MAGE-1 (carcinomas), MAGF 2 (carcinomas), MAGE-3 (carcinomas), MAGE 4 (carcinomas), anti-transferrin receptor (carcinomas), p97 (melanoma), MS4A1 (membrane-spanning 4-domains subfamily A member 1, Non-Hodgkin's B cell lymphoma, leukemia), MUC1 or MUC1-KLH (breast, ovarian, cervix, bronchus and gastrointestinal cancer), MUC16 (CA125) (Ovarian cancers), CEA (colorectal), gplOO (melanoma), MARTI (melanoma), MPG (melanoma), MS4A1 (membrane-spanning 4-domains subfamily A, small cell lung cancers, NHL), Nucleolin, Neu oncogene product (carcinomas), P21 (carcinomas), Paratope of anti-N-glycolyl neuraminic acid (Breast, Melanoma cancers), PLAP-like testicular alkaline phosphatase (ovarian, testicular cancers), PSMA (prostate tumors), PSA (prostate), ROB04, TAG 72 (tumour associated glycoprotein 72, AML, gastric, colorectal, ovarian cancers), T cell transmembrane protein (cancers), Tie (CD202b), TNFRSF10B (tumor necrosis factor receptor superfamily member 10B, cancers), TNFRSF13B (tumor necrosis factor receptor superfamily member 13B, multiple myeloma, NHL, other cancers, RA and SLE), TPBG (trophoblast glycoprotein, Renal cell carcinoma), TRAIL-R1 (Tumor necrosis apoprosis Inducing ligand Receptor 1 , lymphoma, NHL, colorectal, lung cancers), VCAM-1 (CD106, Melanoma), VL E, VH F-Λ, VF!GF-2 (CD309) (various cancers). Some other tumor associated antigens recognized by antibodies have been reviewed (Gerber, et al, mAbs 1 :3, 247- 253 (2009); Novellino et al, Cancer Immunol Immunother. 54(3), 187-207 (2005). Franke, et al, Cancer Biother Radiopharm. 2000, 15, 459-76). Examples of these antigens that antibodies against are: Many other Cluster of Differentiations (CD4, CDS, CD6, CD7, CD8, CD9, CD10, GDI la, GDI lb, CDl lc, CD12w, CD 14. CD 15. CD 16. CDwl7, CD 1 8. CD21 , CD23, CD24, CD25, CD26, CD27, CD28, CD29, CD31, CD32, CD34, CD35, CD36, CD37, CD41 , CD42, CD43, CD44, CD45, CD46, CD47, CD48, CD49b, CD49c, CD53, CD54, CD55, CD58, CD59, CD61, CD62E, CD62L, CD62P, CD63, CD68, CD69, CD71 , CD72, CD79, CD81 , CD82, CD83, CD86, ( "1 )87. CD88, ( "1)89. CD90, ( "1 )9 1 . CD95, ( "1 )96. CD100, CI ) 103, CD105, CD106, CD 109. CD1 17, ( "1 ) 1 20. CD127, CD133, CD134, CD 135, ( 1 ) 1 38. CD141, CD142, CD 143. CD 144. CD 147. ( "1 ) 15 1 . CD 152. CD 154. CI ) 156. CD 158, CD 163. ( "1 ) 166. .( '1 ) 168. CD184, CDwl 86, CD195, CD202 (a, b), CD209, CD235a, CD271 , CD303, CD304), Annexin A l , Nucleolin, Endoglin (CD 105), ROB04, Amino-peptidase N, A-like-4 (DLL4), VEGFR-2 (CD309), CXCR4 9CD184), Tie2, B7-H3, WT1 , MUC1 , LMP2, HPV E6 E7, EGFRvIII, HER- 2/neu, Idiotype, MAGE A3. p53 nonmutant, NY-ESO-1 , GD2, CEA, MelanA/MART 1 , Ras mutant, gplOO, p53 mutant, Proteinases (PR1), bcr-abl, Tyrosinase, Survivin, hTERT, Sarcoma translocation breakpoints, EphA2, PAP, ML-IAP, AFP, EpCAM, ERG (TMPRSS2 ETS fusion gene), NA17, PAX3, ALK, Androgen receptor, Cyclin B l , Polysialic acid, MYCN, RhoC, TRP-2, GD3, Fucosyl GM1, Mesothelin, PSCA, MAGE Al, sLe(a), CYP1B 1 , PLAC1 , GM3, BORIS, I n. GloboH, ETV6-AML, NY-BR-1 , RGS5, SART3, S i n. Carbonic anhydrase IX, PAX5, OY-TES1 , Sperm protein 17, LC , HMWMAA, A AP-4, SSX2, XAGE 1, B7H3, Legumain, Tie 2, Page4, VEGFR2, MAD-CT-1, FAP, PDGFR-β, MAD-CT-2, Fos-related antigen 1.
Production of antibodies used in the present invention involves in vivo or in vitro procedures or combinations thereof. Methods for producing polyclonal anti-receptor peptide antibodies are well-known in the art, such as in U.S. Pat. No. 4,493,795 (to Nestor et al). A monoclonal antibody is typically made by fusing myeloma cells with the spleen cells from a mouse that has been immunized with the desired antigen (Kohler, G. ; Milstein, C. (1975). Nature 256: 495-497). The detailed procedures are described in "Antibodies— A Laboratory Manual", Harlow and Lane, eds., Cold Spring Harbor Laboratory Press, New York (1988), which is incorporated herein by reference. Particularly monoclonal antibodies are produced by immunizing mice, rats, hamsters or any other mammal with the antigen of interest such as the intact target cell, antigens isolated from the target cell, whole virus, attenuated whole virus, and viral proteins. Splenocytes are typically fused with myeloma cells using polyethylene glycol (PEG) 6000. Fused hybrids are selected by their sensitivity to HAT (hypoxanthine-aminopterin- thymine). I lybridomas producing a monoclonal antibody useful in practicing this invention are identified by their ability to immunoreact specified receptors or inhibit receptor activity on target cells.
A monoclonal antibody used in the present invention can be produced by initiating a monoclonal hybridoma culture comprising a nutrient medium containing a hybridoma that secretes antibody molecules of the appropriate antigen specificity. The culture is maintained under conditions and for a time period sufficient for the hybridoma to secrete the antibody molecules into the medium. The antibody-containing medium is then collected. The antibody molecules can then be further isolated by well-known techniques, such as using protein-A affinity chromatography; anion, cation, hydrophobic, or size exclusive chromatographies (particularly by affinity for the specific antigen after Protein A, and sizing column
chromatography); centrifugation, differential solubility, or by any other standard technique for the purification of proteins.
Media useful for the preparation of these compositions are both well-known in the art and commercially available and include synthetic culture media. An exemplary synthetic medium is Dulbecco's minimal essential medium (DMEM; Dulbecco et al., Virol. 8:396 (1959)) supplemented with 4.5 gm/1 glucose, 20 mm glutamine, 20% fetal calf serum and with an anti- foam ing agent, such as polyoxyethylene-polyoxypropylene block copolymer.
In addition, antibody-producing cell lines can also be created by techniques other than cell fusion, such as direct transformation of B lymphocytes with oncogenic DNA, or transfection with an oncovirus, such as Epstein-Barr virus (EBV, also called human herpesvirus 4 (HHV-4)) or Kaposi's sarcoma-associated herpesvirus (KSHV). See, U.S. Pat. Nos. 4,341,761 ; 4,399,121; 4,427,783; 4,444,887; 4,451,570; 4,466,917; 4,472,500; 4,491,632; 4,493,890. A monoclonal antibody may also be produced via an anti-receptor peptide or peptides containing the carboxyl terminal as described well-known in the art. See Niman et al, Proc. Natl. Acad. Sci. USA, 80: 4949-4953 (1983); Geysen et al, Proc. Natl. Acad. Sci. USA, 82: 178-182 (1985); Lei et al. Biochemistry 34(20): 6675-6688, (1995). Typically, the anti-receptor peptide or a peptide analog is used either alone or conjugated to an immunogenic carrier, as the immunogen for producing anti-receptor peptide monoclonal antibodies.
There are also a number of other well-known techniques for making monoclonal antibodies as binding molecules in this invention. Particularly useful are methods of making fully human antibodies. One method is phage display technology which can be used to select a range of human antibodies binding specifically to the antigen using methods of affinity enrichment. Phage display has been thoroughly described in the literature and the construction and screening of phage display libraries are well known in the art, see, e.g., Dente et al, Gene. 148(1):7-13 (1994); Little et al, Biotechnol Adv. 12( 31:539-55 (1994); Clackson et al., Nature 352:264-628 (1991); Huse et al, Science 246: 1275-1281 (1989), Hoogenboom et al. in Methods in Molecular Biology 178: 1-37 (2001) (O'Brien et al., ed., Human Press, Totowa, N.J.), and in certain embodiments, in Lee et al. J. Mol. Biol. 340:1073-1093 (2004).
Moncolonal antibodies derived by hybridoma technique from another species than human, such as mouse, can be humanized to avoid human anti-mouse antibodies when infused into humans. Among the more common methods of humanization of antibodies are
complementarity-determining region grafting and resurfacing. These methods have been extensively described, see e.g. U.S. Pat. Nos. 5,859,205 and 6,797,492; Liu et al, Immunol Rev. 222:9-27 (2008); Almagro et al, Front Biosci. 1 : 13: 1 19-33 (2008); Lazar et al, Mol Immunol. 44(8): 1986-98 (2007); Li et al, Proc. Natl. Acad. Sci. U S A. 103(10):3557-62 (2006) each incorporated herein by reference. Fully human antibodies can also be prepared by immunizing transgenic mice, rabbits, monkeys, or other mammals, carrying large portions of the human immunoglobulin heavy and light chains, with an immunogen. Examples of such mice are: the Xenomouse (Abgenix/Amgen.), the HuMAb-Mouse (Medarex/BMS), the Veloci. Mouse
(Regeneron), see also U.S. Pat. No. 6,596,541 , 6,207,418, No. 6,150,584, No. 6,11 1,166, No. 6,075,181, No. 5,922,545, Nos. 5,661,016, 5,545,806, 5,436,149 and 5,569,825. In human therapy, murine variable regions and human constant regions can also be fused to construct called "chimeric antibodies" that are considerably less immunogenic in man than murine mAbs ( Kipriyanov et al, Mol Biotechnol. 26: 39-60 (2004); Houdebine, Curr Opin Biotechnol. 13: 625-9 (2002) each incorporated herein by reference). I n addition, site-directed mutagenesis in the variable region of an antibody can result in an antibody with higher affinity and specificity for its antigen (Brannigan et al, Nat Rev Mol Cell Biol. 3: 964-70, (2002)); Adams et al, .1 Immunol Methods. 231 : 249-60 (1999)) and exchanging constant regions of a mAb can improve its ability to mediate effector functions of binding and cytotoxicity.
Antibodies immunospecific for a malignant cell antigen can also be obtained
commercially or produced by any method known to one of skill in the art such as, e.g., chemical synthesis or recombinant expression techniques. The nucleotide sequence encoding antibodies immunospecific for a malignant cell antigen can be obtained commercially, e.g., from the GenBank database or a database like it, the literature publications, or by routine cloning and sequencing.
DNA encoding hybridoma-derived monoclonal antibodies or phage display Fv clones of the antibody can be readily isolated and sequenced using conventional procedures (e.g. by using oligonucleotide primers designed to specifically amplify the heavy and light chain coding regions of interest from hybridoma or phage DNA template). Once isolated, the DNA can be placed into expression vectors, which are then transfected into host cells such as E. coli cells, simian COS cells, Chinese hamster ovary (CHO) cells, or myeloma cells that do not otherwise produce immunoglobulin protein, to obtain the synthesis of the desired monoclonal antibodies in the recombinant host cells (Skerra et al., Curr. Opinion in Immunol, 5: 256 (1993) and Pluckthun, Immunol. Revs, 130: 151 (1992)). Antibodies can also be produced by using an expression system in which the quantitative ratio of expressed polypeptide components can be modulated in order to maximize the yield of secreted and properly assembled antibodies. Such modulation is accomplished at least in part by simultaneously modulating translational strengths for the polypeptide components. After the fermentation which is known in the art, the produced antibody protein is further purified to obtain preparations that are substantially homogeneous for further assays and uses. Standard protein purification methods known in the art can be employed. The exemplary purification procedures: fractionation on immunoaffinity (such as Protein A columns) or ion-exchange columns, ethanol precipitation, reverse phase 1 1 PLC chromatography on silica or on a cation-exchange resin such as DEAE, chromatofocusing, SDS- PAGE, ammonium sulfate precipitation, and gel filtration using, for example, Sephadex G-75.
Apart from an antibody, a peptide or protein that bind/block/target or in some other way interact with the epitopes or corresponding receptors on a targeted cell can be used as a binding molecule. These peptides or proteins could be any random peptide or proteins that have an affinity for the epitopes or corresponding receptors and they don't necessarily have to be of the immunoglobulin family. These peptides can be isolated by similar techniques as for phage display antibodies (Szardenings, J Recept Signal Transduct Res. 23(4): 307-49, 2003). The use of peptides from such random peptide libraries can be similar to antibodies and antibody fragments. The binding molecules of peptides or proteins may be conjugated on or linked to a large molecules or materials, such as, but is not limited, an albumin, a polymer, a liposome, a nano particle, as long as such attachment permits the peptide or protein to retain its antigen binding specificity.
Any one of several different reactive groups on a cell binding agent, preferably on an antibody, can be a conjugation site, such as ε-amino groups in lysine residues, pendant carbohydrate moieties, carboxylic acid groups, disulfide groups, and thiol groups. For reviews on antibody reactive groups suitable for conjugation, see, e.g., Hermanson, G.T.
(2008). Bioconjugate Techniques, Academic Press; Garnett, Adv. Drug Delivery Rev. 53 (2001), 171-216 and Dubowchik and Walker, Pharmacology & Therapeutics 83 (1999), 67-123, the disclosures of which are incorporated herein by reference.
The cytotoxic agents of this invention can be directly conjugated (linked) to a cell binding agent, or via a bifunctional linker or a crosslinking agent to a cell binding agent. The bifunctional linker possess two reactive groups; one of which is capable of reacting with a cell binding agent while the other one reacts with one or more molecules of cytotoxic agent of the invention. The bifunctional crosslinkers are well known in the art (see, for example, U.S. Pat. No. 5,208,020; ] sal m and Dent in Bioconjugation chapter 5, p 218-363, Groves Dictionaries Inc. New York, 1999). Examples of bifunctional linker are: N-succinimidyl-3-(2- pyridyldithi (propionate (SPDP), N-succinimidyl-4-(2-pyridyldithio)butyrate (SPDB), N- succinimidyl-4-(2-pyridyldithio)pentanoate (SPP), N-succinimidyl-3-(2-pyridyldithio)- butyrate (SDPB), 2-iminothiolane, N-succinimidyl-4-(5-nitro-2-pyridyldithio) butyrate
(SNPB), N-succinimidyl 4-(5-nitro-2-pyridyldithio)-pentanoate (SNPP), N-sulfosuccinimidyl- 4-(5-nitro-2-pyridyldithio) butyrate (SSNPB), N-succinimidyl-4-methyl-4-(5-nitro-2- pyridyldithio)pentanoate (SMNP), N-sullosuccinimidyl 4-(5-nitro-2-pyridyldithio)-pentanoate (SSNPP), 4-succinimidyl-oxycarbonyl-a-methyl-a-(2-pyridyldithio)-toluene (SMPT), N- sulfosuccinimidyl-4-methyl-4-(5-nitro-2-pyridyldithio)pentanoate (SSMNP); N-succinimidyl- 4-methyl-4-(2-pyridyldithio)pentanoate (SMPDP), N-succinimidyl-4-(5-N,N-dimethyl- carboxamido-2-pyridyldithio) butyrate (SCPB), N-sulfosuccinimidyl-4-(5-N,N-dimethyl- carboxamido-2-pyridyldithio) butyrate (SSCPB), N-succinimidyl-4,4-dimethyl-4-(2- pyridyldithio)pentanoate (SDMPDP), succinimidyl-4-(N-maleimidomethyl)cyclohexane- 1 - carboxylate (SMCC), N-succinimidyl-4-(iodoacetyl)-aminobenzoate (SIAB), bis- maleimidopolyethyleneglycol (BMPEG), B d i ), N-(P-maleimidopropyloxy)- succinimide ester (BMPS), iminothiolane (IT), dimethyl adipirnidate HQ or derivatives of irnidoesters, active esters (such as disuccinimidyl suberate), aldehydes (such as
glutaraldehyde), bis-azido compounds (such as bis(p-azidobenzoyl) hexanediamine), bis- diazonium derivatives (such as bis-(p-diazoniumbenzoyl)-ethylenedianiine), diisocyanates (such as toluene 2 , 6-diisocyanate) , and bis-active fluorine compounds (such as 1 ,5-difluoro- 2,4-dinitrobenzene), gamma-maleimidobutyric acid N-succinimidyl ester (GMBS), E- maleimidocaproic acid N-hydroxysuccinimide ester (EMCS), 5-maleimidovaleric acid NHS, HBVS, N-succinimidyl-4-(N-maleimidomethyl)-cyclohexane-l-carboxy-(6-amidocaproate) (a "long chain" analog of SMCC (LC-SMCC)), m-maleimidobenzoyl-N-hydroxysuccinimide ester (MBS), 4-(4-N-maleimidophenyl)-butyric acid hydrazide or HQ salt (MPBII), N- succinimidyl 3-(bromoacetamido propionate (SBAP), N-succinimidyl iodoacetate (SIA), kappa-maleimidoundecanoic acid N-succinimidyl ester (K UA), N-succinimidyl 4-(p- maleimidophenyl)-butyrate (SMPB), succinimidyl-6-(beta-maleimidopropionamido)- hexanoate (SMPH), succinimidyl-(4-vinylsulfonyl)benzoate (SVSB), dithiobis- maleimidoethane (DTME), 1 ,4-bis-maleimidobutane (BMB), 1 ,4 bismaleimidyl-2,3- dihydroxybutane (BMDB), bis-maleimidohexane (BMH), bis-maleimidoethane (BMOE), sulfosuccinimidyl 4-(N-maleimido-methyl)cyclohexane- 1 -carboxylate (sulfo-SMCC), sulfosuccinimidyl(4-iodo-acetyl)aminobenzoate (sulfo-SIAB), m-maleimidobenzoyl-N- hydroxysulfosuccinimide ester (sulfo-MBS), N-(gamma-maleimidobutryloxy)sulfo- succinimdeester (sulfo-GMBS), N-(epsilon-maleimidocaproyloxy)sulfosuccimido ester (sulfo- EMCS), N-(kappa-maleimidoundecanoyloxy)sulfosuccinimide ester (sulfo-KMl KS ), and sulfosuccinimidyl 4-(p-maleimidophenyl)butyrate (sulfo-SMPB); or the commercially available linkers (such as from Thermo Scientific's Pierce: Imidoester Crosslinkers: DMA (Dimethyl adipimidate»2 HCl), DMP (Dimethyl pimelimidate»2 HCl), DMS (Dimethyl Suberimidate»2 HCl), DTBP (Dimethyl 3,3'-dithiobispropionimidate»2 HCl); NHS-ester Crosslinkers-Amine Reactive: BS(PEG)s (Bis(succinimidyl) penta(ethylence glycol), BS( PEG )<) (Bis(succinimidyl) nona(ethylence glycol), BS3 (Bis [sulfosuccinimidyl] suberate), BSOCOES (Bis[2-(succinimidooxycarbonyloxy)ethyl]sulfone), DSG (Disuccinimidyl glutarate), DSP (Dithiobis [succinimidyl propionate]), DSS (Disuccinimidyl suberate), DST (Disuccinimidyl tartarate), DTSSP (3,3'-Dithiobis[sulfosuccinimidylpropionate]), EGS (Ethylene glycol bis[succinimidylsuccinate]), Sulfo-EGS (Ethylene glycol
bis [sulf osuccinimidylsuccinate] ), TSAT (Tris-succinimidyl aminotriacetate), DFDNB (1,5- Difluoro-2,4-dinitrobenzene); Λ m i ne-to-Su I I ydryl Crosslinkers: Sulfo-SIAB
(Sulfosuccinimidyl (4-iodoacetyl)aniinobenzoate), SIAB (Succinimidyl (4- iodoacetyl)aminobenzoate), SBAP(Succinimidyl 3-(bromoacetamido)propionate), SI A (Succinimidyl iodoacetate), Sulfo-SMCC (Sulfosuccinimidyl-4-(N-maleimidomethyl)- cyclohexane-l-carboxylate), SM(PEG)n (NHS-PEG-Maleimide Crosslinkers: Succininiidyl- ([N-maleiniidopropionamido])-#ethyleneglycol)ester, # =1 2, 3, 4, 5, 6, 7, 8, 9, 10, 11 , 12, 13, 14, 15, 16, 18, 20, 22, 24), LC-SMCC (Succinimidyl 4-(N-maleimidomethyl) eyclohexane-1- carboxy-(6-amidocaproate)), Sulfo-EMCS (N-epsilon-Maleiniidocaproyl- oxysulfosuccinimide ester), EMCS (N-epsilon~Malemidocaproyl-oxysuccinimide ester), Sulfo-GMBS (N-gamma-Maleimidobutyryl-oxysulfosuccinimide ester), GMBS (N-gamma- Maleimidobutyryl-oxysuccinimide ester), Sulfo- MUS (N-kappa-Maleimidoundecanoyl- oxysulfosuccinimide ester), Sulfo-MBS (m~Maleimidobenzoyl-N~hydroxysulfosuccinimide ester), MBS (m-Maleimidobenzoyl-N-hydroxysuecinimide ester), Sulfo-SMPB
((Sulfosuccinimidyl 4-(p-maleiimidophenyl)butyrate), SMPB (Succinimidyl 4-(p- maleimidophenyl)butyrate), AMAS N-(a-Maleimidoacetoxy) succinimide ester), BMPS ( N- beta-Maleimidopropyl-oxysuccinimide ester), SMPH (Succinimidyl 6-[(beta- maleimidopropionamido)hexanoate]), PEG12-SPDP (2-Pyridyldithiol- tetraoxaoctatriacontane-N-hydroxysuccinimide), PEG4-SPDP (2-Pyridyldithiol- tetraoxatetradecane-N-hydroxysuccinimide), Sulfo-LC-SPDP (Sulfosuccinimidyl 6-[3'-(2- pyridyldithio)propionamido]hexanoate), LC-SPDP (Succinimidyl 6-[3-(2- pyridyldithio)propionamido]hexanoate), SMPT (4-Succinimidyloxycarbonyl-alpha-methyl- alpha(2~pyridyldithio)toluene); Carboxyl-to~ Amine Crosslinkers: DCC
(Dicycl ohexylcarbodiimide) , EDC (l-Etbyl-3-(3-dimethylaminopropyl) carbodiimide);
Photoreactive Crosslinkers: ANB-NOS (N-5-Azido-2-nitrobenzoyloxysuccinimide), N I IS- Diazirine (SDA) Crosslinkers: SDA (NHS-Diazirine) (Succinimidyl 4,4'~azipentanoate), 1 .( '- SDA (NHS-LC-Diazirine) (Succinimidyl 6-(4,4'-azipentanamido)hexanoate), SDA I ) (NHS- SS-Diazirine) (Succinimidyl 2-([4,4'-azipentanamido]ethyl)- 1 ,3'-dithiopropionate), Sulfo- SDA (Sulfo-NHS-Diazirine) (Sulfosuccinimidyl 4,4'~azipentanoate), Sulfo-LC~SDA (Sulfo- NHS-LC-Diazirine) (Sulfosuccinimidyl 6-(4,4'-azipentanamido)hexanoate), Sulfo-SDAD (Sulfo-NHS-SS-Diazirine) (Sulfosuccinimidyl 2-([4,4'-azipentanamido]ethyl)- 1 ,3'- dithiopropionate), Sulfo-SANPAH (Sulfosuccinimidyl 6-(4'-azido-2'-nitrophenylamino)- hexanoate), SPB (Succinimidyl-[4-(psoralen~8-yloxy)]-butyrate); Sulfliydryl-to-Carbohydrate Crosslinkers: BMPH (N-beta-Maleimidopropionic acid hydrazide-TFA), EMCH (N-epsilon- Maleimidocaproic acid hydrazide-TFA), MUH (N-kappa-Maleimidoundecanoic acid hydrazide-TFA), MPBH (4-(4-N-Maleimidophenyl)butyric acid hydrazide-HCl), PDPH (3-(2- Pyridyldithio)propionyl hydrazide); Sulfhydryl-to-Hydroxyl Crosslinkers: PMPI (p- Maleimidophenyl isocyanate); Sulfhydryl-to-Sulfhydryl Crosslinkers: BM(PEG)2 (1,8- Bismaleimido-diethyleneglycol), BM(PEG)3 (1,11 -Bismaleimido-triethyleneglycol),
BMB (1,4-Bismaleiniidobutane), BMDB (l,4-Bismaleiniidyl-2,3-dihydroxybutane),
BMH (Bismaleimidohexane), BMOE (Bismaleimidoethane), DTME (Dithiobismaleimido- ethane), ΤΜΗΛ (Tris(2-maleimidoethyl)amine) and SVSB (succinimidyl-(4- vinylsulfone)benzoate).
The bis-maleknide or bis-2-pyridyldithiol reagents allow the attachment of the thiol group of a thiol-containing cell binding agent (such as antibody) to a thiol-containing drug moiety, label, or linker intermediate, in a sequential or concurrent fashion. Other functional groups besides maleimide and pyridyldithiol, which are reactive with a thiol group of a cell binding agent, drug moiety, label, or linker intermediate include iodoacetamide,
bromoacetamide, vinyl pyridine, disulfide, pyridyl disulfide, isocyanate, and isofhiocyanate.
In additional embodiments, the linker may be composed of one or more linker components. The exemplary linker components are:
-immolative linker components:
Figure imgf000059_0001
additional spacer or releasable linker units, or the cytotoxic agent, and/or the binding molecule (CBA); X1, Υ', /. and Z3 are independently NH, or O, or S; /.' is 1 1, or NH, or O or S independently, v is 0 or 1; Q1 is independently H, OH, Ci~C6 alkyl, (OCH2CH2)n F, CI, Br, I, O 5, or SR.. NKsR . N=NR5, N=R5, NR5 5', N02, SOR5R5., S02R5, S03R5, OS03R5, PR5Rs', POR5R5., P02R5R5-, OPOi OR H OR ). or OCH2PO(OR5(OR5 wherein R5 and R are described in the Formula (I), preferabably R5 and R are independently selected from H, Ci-Cs of alkyl; C2~Cs of alkenyl, alkynyl, heteroalkyl; C3~Cs of aryl, heterocyclic, carbocyclic, cycloalkyl, heterocycloalkyl, heteroaralkyl, alkylcarbonyl; or pharmaceutical cation salts
2. The examples of non-self-immolative linker components: (CH2)nCO(OCH2CH2)rOCH3 (CH2)nCON(CH2CH20)rCOCH3
Figure imgf000060_0001
Figure imgf000061_0001
Wherein the (*) atom is the point of attachment of additional spacer or releaseable linkers, the cytotoxic agents, and/or the binding molecules; X1, Y1 , Q1, K , Rv and r are as defined in Formula (I); m, n and p are 0-6.
3. Exemplary linker components may include 6-maleimidocaproyl ("MC"),
maleimidopropanoyl ("MP"), valine-citrulline ("val-cit" or "vc"), alanine -phenylalanine ("ala- p!ie" or "af '), p-aminobenzyloxy-carbonyl ("PAB"), N-succinimidyl 4-(2- pyridylthio)pentanoate ("SPP"), N-succinimidyl 4-(N-maleimidomethyl)cyclohexane-l carboxylate ("SMCC"), N-Succinimidyl (4-iodo-acetyl)amino-benzoate ("SIAB"), ethyleneoxy (— CH2CH2O— ) as one or more repeating units ("EO" or "PEO"). Additional linker components are known in the art and some are described through this patent application.
In additional embodiments, the linker may comprise amino acid residues. Exemplary amino acid linker components include a dipeptide, a tripeptide, a tetrapeptide or a pentapeptide. Exemplary dipeptides include: valine-citrulline (VC or val-cit), alanine -phenylalanine (af or ala- phe). Exemplary tripeptides include: glycine-valine-citrulline (gly-val-cit) and glycine-glycine- glycine (gly-gly-gly). Amino acid residues which comprise an amino acid linker component include those occurring naturally, as well as minor amino acids and non-natural ly occurring amino acid analogs, such as citruUine. Amino acid linker components can be designed and optimized in their selectivity for enzymatic cleavage by particular enzymes, for example, a tumor-associated protease, cathepsin B, C and D, or a plasmin protease.
In the cell-binding agent - drug conjugates of the invention, cell-binding agent (CBA) is conjugated to one or more drug moieties (Drug, or PBD derivatives), e.g. about 1 to about 20 drug moieties per cell-binding agent, through a bifunctional linker (L). The conjugate of Formula (IX), (X), (XI), (XII), (XIII), and (XIV) may be prepared by several routes, employing organic chemistry reactions, conditions, and reagents known to those skilled in the art, including: (1) the first modification of cell-binding agent (CBA) with a crosslinker (L) in an aqueous buffer pH 3 - 9 having optionally 0 ~ 30% organic co-solvents to introduce reactive disulfide, maleimido, haloacetyl, hydrazide, nitrile, alkynyl, alkyloxyamino or aldehyde groups on the cell-binding agent, to form a covalent bonded CBA-L. The CBA-L molecule then reacts with a drug moiety ( Drug) of formula (I) to generate a cell binding agent - dmg conjugate; or (2) the first modification of dmg moiety (Drug) of the formula (I) with a crosslinker (L) in organic media or in an aqueous buffer i I 3 - 9 having optionally 0 - 99% organic co-solvents to introduce a reactive disulfide, maleimido, haloacetyl, hydrazide, nitrile, alkynyl, alkyloxyamino, aldehyde, N-hydroxysuccinimide (NHS) or pentafluorophenyl ester group on the drug moiety (a covalent bonded Dmg-L molecule). The Drug- 1 , molecule then reacts with a cell binding agent (CBA), or pre-modified CBA to generate a cell binding agent - dmg conjugate; or (3) directly through reaction of a cell - binding agent with drug moieties of formula (I) bearing reactive function groups of disulfide, maleimido, haloacetyl, hydrazide, nitrile, alkynyl, alkyloxyamino, aldehyde, N-hydroxysuccinimide ( NI IS) or pentafluorophenyl esters in an aqueous buffer pH 3 - 9 having optionally 0 - 30% organic co- solvents.
The thiol or amine groups on a cell-binding agents, such as an antibody, are nucleophilic and capable of reacting to form covalent bonds with electrophilic groups on linker reagents and drug-linker intermediates including: (i) active esters such as NHS esters, HOBt esters, haloformates, and acid halides; (ii) alky I and benzyl halides, such as haloacetamides; (iii) aldehydes, ketones, carboxyl, and maleimide groups; and (iv) disulfides, including pyridyl disulfides, via sulfide exchange. Nucleophilic groups on a dmg moiety include, but are not limited to: amine, thiol, hydroxyl, hydrazide, oxime, hydrazine, thiosemicarbazone, hydrazine carboxylate, and arylhydrazide groups capable of reacting to form covalent bonds with electrophilic groups on linker moieties and linker reagents. Nucleophilic groups on antibodies or proteins can react to electrophilic groups on a function linker following by reaction with a cytotoxic agent, or directly react to a linker- cytotoxic agent moiety to form covalent bond conjugate of a cell binding agent-cytotoxic agent. Nucleophilic groups on antibodies or proteins include, but are not limited to: (i) N- terminal amine groups, (ii) side chain amine groups, e.g. lysine, (iii) side chain thiol groups, e.g. cysteine, and (iv) sugar hydr xy I or amino groups where the antibody is glycosylated. Amine, thiol, and hydroxy! groups are nucleophilic and capable of reacting to form covalent bonds with electrophilic groups on linker moieties and linker-cytotoxic agent moieties including: (i) active esters such as Nl IS esters, I lOBt esters, haloformates, and acid halides; (ii) alkyl and benzyl halides such as haloacetamides; (iii) aldehydes, ketones, carboxyl, and maleimide groups. Certain antibodies have reducible interchain disulfides, i.e. cysteine bridges which may be made reactive by treatment with a reducing agent such as I ) IT
(dithiothreitol) or tricarbonylethylphosphine (TCEP) (Getz et al (1999) Anal. Biochem. Vol 273:73-80; S l tee Ventures, Beverly, Mass.). Each cysteine bridge will thus form, theoretically, two reactive thiol nucleophiles. Alternatively, sulfhydryl groups can be introduced into antibodies through modification of lysine residues, e.g., by reacting lysine residues with 2-iminothiolane (Traut's reagent), resulting in conversion of an amine into a thiol. Reactive thiol groups may be introduced into an antibody by introducing one, two, three, four, or more cysteine residues (e.g., by preparing variant antibodies comprising one or more non-native cysteine amino acid residues). Thus free thiol on the cell binding agents can be conjugated to the thiol-reactive groups, such as, a maleimide, an iodoacetamide, a pyridyl disulfide, or other thiol-reactive groups on the cytotoxic agents, or linker-cytotoxic agent intermediates of the invention. Some unconjugated free thiols on the antibodies can be reoxidized to reform interchain and intrachain disulfide bonds.
Antibody-drug conjugates of the invention may also be produced by reaction between an electrophilic group on an antibody, such as an aldehyde or ketone carbonyl group, with a nucleophilic group on a linker reagent or drug. Useful nucleophilic groups on a linker reagent include, but are not limited to, hydrazide, oxime, amino, hydrazine, thiosemicarbazone, hydrazine carboxylate, and arylhydrazide. In one embodiment, an antibody is modified to introduce electrophilic moieties that are capable of reacting with nucleophilic substituents on the linker reagent or drug. In another embodiment, the sugars of glycosylated antibodies may be oxidized, e.g. with periodate oxidizing reagents, to form aldehyde or ketone groups which may react with the amine group of linker reagents or drug moieties. The resulting imine Schil l base groups may form a stable linkage, or may be reduced, e.g. by borohydride reagents to form stable amine linkages. In one embodiment, reaction of the carbohydrate portion of a glycosylated antibody with either galactose oxidase or sodium meta-periodate may yield carbonyl (aldehyde and ketone) groups in the antibody that can react with appropriate groups on the drug (Hermanson, Bioconjugate Techniques). In another embodiment, antibodies containing N-terminal serine or threonine residues can react with sodium meta-periodate, resulting in production of an aldehyde in place of the first amino acid (Geoghegan & Stroh, (1992) Bioconjugate ( "hem. 3: 138-146; U.S. Pat. No. 5,362,852). Such an aldehyde can be reacted with a drug moiety or linker nucleophile.
Examples of these kinds of two-step conjugations are depicted below:
Figure imgf000064_0001
wherein E includes, but is not limited to, such as hydroxysuccinimidyl esters (NHS, Sulfo-NHS, etc), 4-nitrophenyl esters, pentafluorophenyl esters, tetrafluorophenyl (includes sulfo- tetrafluorophenyl) esters, anhydrides, acid chlorides, sulfonyl chlorides, isocyanates and isothiocyanates. K' and R" are independently H or d or ( \l l ; J is F, CI, Br, I, tosylate (TsO), mesylate (MsO), nitrophenol, dinitrophenol, or pentaflourophenol.
It is to be understood that where more than one nucleophilic group on the cell binding agents, such as an antibody, reacts with a drug-linker intermediate or linker reagent followed by drug moiety reagent, then the resulting product is a mixture of the cell binding agent-cytoxic agent conjugates with a distribution of one or more drug moieties attached to an antibody. The average number of drugs per antibody may be calculated from the mixture by a dual HI .ISA antibody assay, which is specific for antibody and specific for the drug. Individual conjugate molecules may be identified in the mixture by mass spectroscopy and separated by HPLC, e.g. hydrophobic interaction chromatography. In certain embodiments, a homogeneous conjugate with a single loading value may be isolated from the conjugation mixture by electrophoresis or chromatography.
In the conjugation, The loading (drug/antibody ratio) of an ADC may be controlled in different ways, e.g., by: (i) limiting the molar excess of drug-linker intermediate or linker reagent relative to antibody, (ii) limiting the conjugation reaction time or temperature, (iii) partial or limiting reductive conditions for cysteine thiol modification, (iv) engineering by recombinant techniques the amino acid sequence of the antibody such that the number and position of lysine or cysteine residues is modified for control of the number and/or position of linker-drug attachments (such as thioMab or thioFab).
Other further examplary methods for preparing ADC are described in Figures 5, 11 , 12,
13, 14, 16, 17, 18, 19, 20, 2 1 , 22, and 23 and examples in the description of the patent.
Treatments of Cell-binding agent-Drug Conjugates
It is contemplated that the cell-binding agent -- drug conjugate, preferably antibody-drug conjugates (ADC) of the present invention may be used to treat various diseases or disorders, e.g. characterized by the overexpression of a tumor antigen. Exemplary conditions or hyperproli lenitive disorders include benign or malignant tumors; leukemia and lymphoid malignancies. Others include neuronal, glial, astrocytal, hypothalamic, glandular, macrophagal, epithelial, stromal, blastocoelic, inflammatory, angiogenic and immunologic, including autoimmune disorders.
In specific embodiment, the conjugates of the invention are used in accordance with the compositions and methods of the invention for the treatment of cancers. The cancers include, but are not limited. Adrenocortical Carcinoma, Anal Cancer, Bladder Cancer, Brain Tumor (Adult, Brain Stem Glioma, Childhood, Cerebellar Astrocytoma, Cerebral Astrocytoma, Ependymoma, Medulloblastoma, Supratentorial Primitive Neuroectodermal and Pineal Tumors, Visual Pathway and Hypothalamic Glioma), Breast Cancer, Carcinoid Tumor, Gastrointestinal, Carcinoma of Unknown Primary, Cervical Cancer, Colon Cancer, Endometrial Cancer, Esophageal Cancer, I ntrahepatic Bile Duct Cancer, Ewings Family of Tumors (PNET), Extracranial Germ Cell Tumor, Eye Cancer, Intraocular Melanoma, Gallbladder Cancer, Gastric Cancer (Stomach), Germ Cell Tumor, Extragonadal, Gestational Trophoblastic Tumor, Head and Neck Cancer, Hypopharyngeal Cancer, Islet Cell Carcinoma, Kidney Cancer (renal cell cancer), Laryngeal Cancer, Leukemia (Acute Lymphoblastic, Acute Myeloid, Chronic
Lymphocytic, Chronic Myelogenous, Hairy Cell), Lip and Oral Cavity Cancer, Liver Cancer, Lung Cancer (Non-Small Cell, Small Cell, Lymphoma (AIDS-Related, Central Nervous System, Cutaneous T-Cell, Hodgkin's Disease, Non-Hodgkin's Disease, Malignant
Mesothelioma, Melanoma, Merkel Cell Carcinoma, Metasatic Squamous Neck Cancer with Occult Primary, Multiple Myeloma, and Other Plasma Cell Neoplasms, Mycosis Fungoides, Myelodysplasia Syndrome, Myeloproliferative Disorders, Nasopharyngeal Cancer,
Neuroblastoma, Oral Cancer, Oropharyngeal Cancer, Osteosarcoma, Ovarian Cancer
(Epithelial, Germ Cell Tumor, Low Malignant Potential Tumor), Pancreatic Cancer (Exocrine, Islet Cell Carcinoma), Paranasal Sinus and Nasal Cavity Cancer, Parathyroid Cancer, Penile Cancer, Pheochromocytoma Cancer, Pituitary Cancer, Plasma Cell Neoplasm, Prostate Cancer Rhabdomyosarcoma, Rectal Cancer, Renal Cell Cancer (kidney cancer), Renal Pelvis and Ureter (Transitional Cell), Salivary Gland Cancer, Sezary Syndrome, Skin Cancer, Skin Cancer (Cutaneous T-Cell Lymphoma, Kaposi's Sarcoma, Melanoma), Small Intestine Cancer, Soft Tissue Sarcoma, Stomach Cancer, Testicular Cancer, Thymoma (Malignant), Thyroid Cancer, Urethral Cancer, Uterine Cancer (Sarcoma), Unusual Cancer of Childhood, Vaginal Cancer, Vulvar Cancer, Wilms' Tumor
In another specific embodiment, the compounds and the conjugates of the invention are used in accordance with the compositions and methods of the invention for the treatment or prevention of an autoimmune disease. The autoimmune diseases include, but are not limited, Achlorhydra Autoimmune Active Chronic Hepatitis, Acute Disseminated Encephalomyelitis, Acute hemorrhagic leukoencephalitis, Addison's Disease, Agammaglobulinemia, Alopecia areata, Amyotrophic Lateral Sclerosis, Ankylosing Spondylitis, Anti-GBM/TBM Nephritis, Antiphospholipid syndrome, Antisynthetase syndrome, Arthritis, Atopic allergy, Atopic Dermatitis, Autoimmune Aplastic Anemia, Autoimmune cardiomyopathy, Autoimmune hemolytic anemia, Autoimmune hepatitis, Autoimmune inner ear disease, Autoimmune lymphoproliferative syndrome, Autoimmune peripheral neuropathy, Autoimmune pancreatitis, Autoimmune polyendocrine syndrome Types I, II, & III, Autoimmune progesterone dermatitis, Autoimmune thrombocytopenic purpura, Autoimmune uveitis, Balo disease/Balo concentric sclerosis, Bechets Syndrome, Berger's disease, Bickerstaffs encephalitis, Blau syndrome, Bullous Pemphigoid, Castleman's disease, Chagas disease, Chronic Fatigue Immune
Dysfunction Syndrome, Chronic inflammatory demyelinating polyneuropathy, Chronic recurrent multifocal ostomyelitis, Chronic lyme disease, Chronic obstructive pulmonary disease, Churg-Strauss syndrome, Cicatricial Pemphigoid, Coeliac Disease, Cogan syndrome, Cold agglutinin disease, Complement component 2 deficiency, Cranial arteritis, CREST syndrome, Crohns Disease (a type of idiopathic inflammatory bowel diseases), Cushing's Syndrome, Cutaneous leukocytoclastic angiitis, Dego's disease, Dercum's disease, Dermatitis herpetiformis, Dermatomyositis, Diabetes mellitus type 1, Diffuse cutaneous systemic sclerosis, Dressler's syndrome, Discoid lupus erythematosus, Eczema, Endometriosis, Enthesitis-related arthritis, Eosinophilic fasciitis, Epidermolysis bullosa acquisita, Erythema nodosum, Essential mixed cryoglobulinemia, Evan's syndrome, I ibn (dysplasia ossificans progressiva, Fibromyalgia, Fibromyositis, Fibrosing aveolitis, Gastritis, Gastrointestinal pemphigoid, Giant cell arteritis, Glomerulonephritis, Goodpasture's syndrome, Graves' disease, Guillain-Barre syndrome, Hashimoto's encephalitis, Hashimoto's thyroiditis, Haemolytic anaemia, Henoch-Schonlein purpura. Herpes gestationis, Hidradenitis suppurativa, Hughes syndrome (See Antiphospholipid syndrome), Hypogammaglobulinemia, Idiopathic Inflammatory Demyelinating Diseases, Idiopathic pulmonary fibrosis, Idiopathic thrombocytopenic purpura (See Autoimmune thrombocytopenic purpura), IgA nephropathy (Also Berger's disease), Inclusion body myositis, Inflammatory demyelinating polyneuopathy, Interstitial cystitis, Irritable Bowel Syndrome , Juvenile idiopathic arthritis, Juvenile rheumatoid arthritis, Kawasaki's Disease, Lambert-Eaton myasthenic syndrome, Leukocytoclastic vasculitis, Lichen planus, Lichen sclerosus, Linear IgA disease (LAD), Lou Gehrig's Disease (Also Amyotrophic lateral sclerosis), Lupoid hepatitis, Lupus erythematosus, Majeed syndrome, Meniere's disease, Microscopic polyangiitis, Miller- Fisher syndrome, Mixed Connective Tissue Disease, Morphea, Mucha-I labermann disease, Muekle-Wells syndrome, Multiple Myeloma, Multiple Sclerosis, Myasthenia gravis, Myositis, Narcolepsy, Neuromyelitis optica (Devic's Disease), Neuromyotonia, Occular cicatricial pemphigoid, Opsoclonus myoclonus syndrome, Ord thyroiditis, Palindromic rheumatism, PANDAS (Pediatric Autoimmune Neuropsychiatric Disorders Associated with Streptococcus), Paraneoplastic cerebellar degeneration, Paroxysmal nocturnal hemoglobinuria, Parry Romberg syndrome, Parsonnage-Turner syndrome, Pars planitis, Pemphigus, Pemphigus vulgaris, Pernicious anaemia, Perivenous encephalomyelitis, POEMS syndrome, Polyarteritis nodosa, Polymyalgia rheumatica, Polymyositis, Primary biliary cirrhosis, Primary sclerosing cholangitis, Progressive inflammatory neuropathy, Psoriasis, Psoriatic Arthritis, Pyoderma gangrenosum, Pure red cell aplasia, Rasmussen's encephalitis, Raynaud phenomenon, Relapsing polychondritis, Reiter's syndrome, Restless leg syndrome, Retroperitoneal fibrosis, Rheumatoid arthritis. Rheumatoid fever, Sarcoidosis, Schizophrenia, Schmidt syndrome, Schnitzler syndrome, Scleritis, Scleroderma, Sjogren's syndrome, Spondyloarthropathy, Sticky blood syndrome, Still's Disease, Stiff person syndrome, Subacute bacterial endocarditis, Susac's syndrome, Sweet syndrome, Sydenham Chorea, Sympathetic ophthalmia, Takayasu's arteritis. Temporal arteritis (giant cell arteritis), Tolosa-Hunt syndrome, Transverse Myelitis, Ulcerative Colitis (a type of idiopathic inflammatory bowel diseases), Undifferentiated connective tissue disease, Undifferentiated spondyloarthropathy, Vasculitis, Vitiligo, Wegener's granulomatosis, Wilson's syndrome, Wiskott-Aldrich syndrome
In another specific embodiment, a binding molecule used for the conjugate for the treatment or prevention of an autoimmune disease includes, but are not limited to, anti-elastin antibody; Abys against epithelial cells antibody; Anti-Basement Membrane Collagen Type IV Protein antibody; Anti-Nuclear Antibody; Anti ds DNA; Anti ss DNA, Anti Cardiolipin Antibody IgM, IgG; anti-celiac antibody; Anti Phospholipid Antibody IgK, IgG; Anti SM Antibody; Anti Mitochondrial Antibody; Thyroid Antibody; Microsomal Antibody, T-cells antibody; Thyroglobulin Antibody, Anti SCI .-70; Anti-Jo; Anti-U.sub. lRNP; Anti-La/SSB; Anti SSA; Anti SSB ; Anti Perital Cells Antibody; Anti Histones; Anti RNP; C-ANCA; P- ANCA; Anti centromere; Anti-Fibrillarin, and Anti GBM Antibody, Anti-ganglioside antibody; Anti-Desmogein 3 antibody; Anti-p62 antibody; Anti-splOO antibody; Anti-Mitochondrial(M2) antibody; Rheumatoid factor antibody; Anti-MCV antibody; Anti-topoisomerase antibody; Anti-neutrophil cytoplasmic(cANCA) antibody.
In certain preferred embodiments, the binding molecule for the conjugate in the present invention, can bind to either a receptor or a receptor complex expressed on an activated lymphocyte which is associated with an autoimmune disease. The receptor or receptor complex can comprise an immunoglobulin gene superfamily member (e.g. CD2, ( 1)3, ( "1 )4. CDS, CD19, CD22, CD28, ( "1)79. CD90, CD 152/CTLA-4, PD-1 , or ICOS), a TNF receptor superfamily member (e.g. CD27, CD40, CD95/Fas, ( "1) 134/0X40. ( 1) 137/4- 1 BB. INF-R1, TNFR-2, RANK, TACI, BCMA, osteoprotegerin, Apo2/TRAIL-Rl, TRAIL-R2, TRAIL-R3, TRAIL-R4, and APO-3), an integrin, a cytokine receptor, a chemokine receptor, a major histocompatibility protein, a lectin (C-type, S-type, or I-type), or a complement control protein.
In another specific embodiment, useful binding ligands that are immunospecific for a viral or a microbial antigen are humanized or human monoclonal antibodies. As used herein, the term "viral antigen" includes, but is not limited to, any viral peptide, polypeptide protein (e.g. HIV gpl2(), HIV nef, RSV F glycoprotein, influenza vims neuraniiniida.se. influenza virus hemagglutinin, HTLV tax, herpes simplex virus glycoprotein (e.g. gB, gC, gD, and gE) and hepatitis B surface antigen) that is capable of eliciting an immune response. As used herein, the term "microbial antigen" includes, but is not limited to, any microbial peptide, polypeptide, protein, saccharide, polysaccharide, or lipid molecule (e.g. a bacteria, fungi, pathogenic protozoa, or yeast polypeptide including, e.g., LPS and capsular polysaccharide 5/8) that is capable of eliciting an immune response. Examples of antibodies available I for the viral or microbial infection include, but are not limited to, Palivizumab which is a humanized anti- respiratory syncytial virus monoclonal antibody for the treatment of RSV infection; PR0542 which is a CD4 fusion antibody for the treatment of HIV infection; Ostavir which is a human antibody for the treatment of hepatitis B virus; PROTVIR which is a humanized IgG.sub.l antibody for the treatment of cytomegalovirus; and anti-LPS antibodies.
The binding molecules -cytotoxic agent conjugates of this invention can be used in the treatment of infectious diseases. These infectious diseases include, but are not limited to,
Acinetobacter infections, Actinomycosis, African sleeping sickness (African trypanosomiasis), AIDS (Acquired immune deficiency syndrome), Amebiasis, Anaplasmosis, Anthrax,
Arcanobacterium haemolyticum infection, Argentine hemorrhagic fever, Ascariasis,
Aspergillosis, Astrovirus infection, Babesiosis, Bacillus cereus infection, Bacterial pneumonia, Bacterial vaginosis, Bacteroides infection, Balantidiasis, Baylisascaris infection, B virus infection, Black piedra, Blastocystis hominis infection, Blastomycosis, Bolivian hemorrhagic fever, Borrelia infection, Botulism (and Infant botulism), Brazilian hemorrhagic fever,
Brucellosis, Burkholderia infection, Buruli ulcer, ( 'alicivirus infection (Noro virus and
Sapovirus), Campylobacteriosis, Candidiasis (Moniliasis; Thrush), Cat-scratch disease,
Cellulitis, Chagas Disease (American trypanosomiasis), Chancroid, Chickenpox, Chlamydia, Chlamydophila pneumoniae infection, Cholera, Chromoblastomycosis, Clonorchiasis,
Clostridium difficile infection, Coccidioidomycosis, Colorado tick fever, Common cold (Acute viral rhinopharyngitis; Acute coryza), Creutzfeldt-jakob disease, Crimean-Congo hemorrhagic fever, Cryptococcosis, Cryptosporidiosis, Cutaneous larva migrans, Cyclosporiasis,
Cysticercosis, Cytomegalovirus infection, Dengue fever, Dientamoebiasis, Diphtheria,
Diphyllobothriasis, Dracunculiasis, Ebola hemorrhagic fever, Echinococcosis, Ehrlichiosis, Enterobiasis (Pinworm infection), Enterococcus infection, Enterovirus infection, Epidemic typhus, Erythema infectiosum (Eifth disease), Exanthem subitum, Fasciolopsiasis, Fasciolosis, Fatal familial insomnia, Filariasis, Food poisoning by Clostridium perfringens, Free-living amebic infection, Fusobacterium infection, Gas gangrene (Clostridial myonecrosis),
Geotrichosis, Gerstmann-Straussler-Scheinker syndrome, Giardiasis, Glanders, Gnathostomiasis, Gonorrhea, Granuloma inguinale (Donovanosis), Group A streptococcal infection, Group B streptococcal infection, Haemophilus influenzae infection, Hand, foot and mouth disease
( I H D ). I lantavirus Pulmonary Syndrome, Helicobacter pylori infection, Hemolytic -uremic syndrome, Hemorrhagic fever with renal syndrome, Hepatitis A, Hepatitis B, Hepatitis C, Hepatitis D, Hepatitis E, Herpes simplex, Histoplasmosis, Hookworm infection, Human bocavirus infection, I luman ewingii ehrlichiosis, I luman granulocytic anaplasmosis, I luman metapneumovirus infection, I luman monocytic ehrlichiosis, I luman papillomavirus infection, I luman parainfluenza virus infection, Hymenolepiasis, Epstein-Barr Virus Infectious
Mononucleosis (Mono), Influenza, Isosporiasis, Kawasaki disease, Keratitis, Kingella kingae infection, Kuru, Lassa fever, Legionellosis (Legionnaires' disease), Legionellosis (Pontiac fever), Leishmaniasis, Leprosy, Leptospirosis, Listeriosis, Lyme disease (Lyme borreliosis), Lymphatic l ilariasis (Elephantiasis), Lymphocytic choriomeningitis, Malaria, Marburg
hemorrhagic fever, Measles, Melioidosis (Whitmore's disease), Meningitis, Meningococcal disease, Metagonimiasis, Microsporidiosis, Molluscum contagiosum, Mumps, Murine typhus (Endemic typhus), Mycoplasma pneumonia, Mycetoma, Myiasis, Neonatal conjunctivitis (Ophthalmia neonatorum), (New) Variant Creutzfeldt- Jakob disease (vCJD, nvCJD),
Nocardiosis, Onchocerciasis (River blindness), Paracoccidioidomycosis (South American blastomycosis), Paragonimiasis, Pasteurellosis, Pediculosis capitis (Head lice), Pediculosis corporis (Body lice), Pediculosis pubis (Pubic lice, Crab lice), Pelvic inflammatory disease, Pertussis (Whooping cough), Plague, Pneumococcal infection, Pneumocystis pneumonia, Pneumonia, Poliomyelitis, Prevotella infection, Primary amoebic meningoencephalitis,
Progressive multifocal leukoencephalopathy, Psittacosis, Q fever, Rabies, Rat-bite fever, Respiratory syncytial virus infection, Rhinosporidiosis, Rhinovirus infection, Rickettsial infection, Rickettsialpox, Rift Valley fever, Rocky mountain spotted fever, Rotavirus infection, Rubella. Salmonellosis, SARS (Severe Acute Respiratory Syndrome), Scabies, Schistosomiasis, Sepsis, Shigellosis (Bacillary dysentery), Shingles (Herpes zoster), Smallpox (Variola), Sporotrichosis, Staphylococcal food poisoning, Staphylococcal infection, Strongyloidiasis, Syphilis, Taeniasis, Tetanus (Lockjaw), Tinea barbae (Barber's itch), Tinea capitis (Ringworm of the Scalp), Tinea corporis (Ringworm of the Body), Tinea cruris (jock itch), Tinea manuum (Ringworm of the I land). Tinea nigra, Tinea pedis (Athlete's foot), Tinea unguium
(Onychomycosis), Tinea versicolor (Pityriasis versicolor), Toxocariasis (Ocular Larva Migrans), Toxocariasis (Visceral Larva Migrans), Toxoplasmosis, Trichinellosis, Trichomoniasis, Trichuriasis (Whipworm infection), Tuberculosis, Tularemia, Ureaplasma urealyticum infection, Venezuelan equine encephalitis, Venezuelan hemorrhagic fever, Viral pneumonia, West Nile Fever, White piedra (Tinea blanca), Yersinia pseudotuberculosis infection, Yersiniosis, Yellow fever, Zygomycosis. The binding molecules, more preferred antibodies described in this patent that are against pathogenic strains include, but are not limit. Acinetobacter baumannii, Actinomyces israelii, Actinomyces gerencseriae and Propionibacterium propionicus, Trypanosoma brucei, H IV (Human immunodeficiency virus), Entamoeba histolytica, Anaplasma genus, Bacillus anthracis, Arcanobacterium haemolyticum, Junin virus, Ascaris lumbricoides, Aspergillus genus, Astroviridae family, Babesia genus, Bacillus cereus, multiple bacteria, Bacteroid.es genus, Balantidium coli, Baylisascaris virus, Piedraia hortae, Blastocystis hominis,
Blastomyces dermatitides, Machupo virus, Borrelia genus, Clostridium botulinum, Sabia, Brucella genus, usually Burkholderia cepacia and other Burkholderia species, Mycobacterium ulcerans, Caliciviridae family, Campylobacter genus, usually Candida albicans and other Candida species, Bartonella henselae, Group A Streptococcus and Staphylococcus,
Trypanosoma cruzi, Haemophilus ducreyi, Varicella zoster virus (VZV), Chlamydia trachomatis, Chlamydophila pneumoniae, Vibrio cholerae, Fonsecaea pedrosoi, Clonorchis sinensis, Clostridium difficile, Coccidioides immitis and Coccidioides posadasii, Colorado tick fever vims, rhinoviruses, coronaviruses, CM ) prion, Crimean-Congo hemorrhagic fever virus, Cryptococcus neoformans, Cryptosporidium genus, Ancylostoma braziliense; multiple parasites, Cyclospora cayetanensis, Taenia solium, Cytomegalovirus, Dengue viruses (DEN-1 , DEN-2, DEN-3 and DEN-4) - I lavi viruses, Dientamoeba fragilis, Corynebacterium
diphtheriae, Diphyllobothrium, Dracunculus medinensis, Ebolavirus, Echinococcus genus, Ehrlichia genus, Enterobius vermicularis, Enterococcus genus, Enterovirus genus, Rickettsia prowazekii, Parvovirus B 19, Human herpesvirus 6 and Human herpesvirus 7, Fasciolopsis buski, Fasciola hepatica and Fasciola gigantica, FFI prion, Filarioidea superfamily, Clostridium perfringens, Fusobacterium genus, Clostridium perfringens; other Clostridium species, Geotrichum candidum, GSS prion, Giardia intestinalis, Burkholderia mallei, Gnathostoma spinigerum and Gnathostoma hispidum, Neisseria gonorrhoeae, Klebsiella granulomatis, Streptococcus pyogenes, Streptococcus agalactiae, Haemophilus influenzae, Enteroviruses, mainly Coxsackie A virus and Enterovirus 71 , Sin Nombre virus, Helicobacter pylori,
Escherichia coli 0157:H7, Bunyaviridae family, Hepatitis A Virus, Hepatitis B Virus, Hepatitis C Virus, Hepatitis D Virus, Hepatitis E Vims, Herpes simplex vims 1 , Heipes simplex vims 2, Histoplasma capsulatum, Ancylostoma duodenale and Necator americanus, Hemophilus influenzae, Human bocavims, Ehrlichia ewingii, Anaplasma phagocytophilum, Human metapneumovirus. Ehrlichia chaffeensis, Human papiUomavims, Human parainfluenza viruses, Hymenolepis nana and Hymenolepis diminuta, Epstein-Barr Vims, Orthomyxoviridae family, Isospora belli, Kingella kingae, Klebsiella pneumoniae, Klebsiella ozaenas, Klebsiella rhinoscleromotis, Kuru prion, Lassa virus, Legionella pneumophila, Legionella pneumophila, Leishmania genus, Mycobacterium leprae and Mycobacterium lepromatosis, Leptospira genus, Listeria monocytogenes, Borrelia burgdorferi and other Borrelia species, Wuchereria bancrofti and Brugia malayi, Lymphocytic choriomeningitis virus (LCMV), Plasmodium genus, Marburg virus, Measles vims, Burkholderia pseudomallei, Neisseria meningitides, Metagonimus yokagawai, Microsporidia phylum, Molluscum contagiosum vi us (MCV), Mumps virus, Rickettsia typhi, Mycoplasma pneumoniae, numerous species of bacteria (Actinomycetoma) and fungi (Eumycetoma), parasitic dipterous fly larvae, Chlamydia trachomatis and Neisseria gonorrhoeae, vCJD prion, Nocardia asteroid.es and other Nocardia species, Onchocerca volvulus, Paracoccidioides brasiliensis, Paragonimus westermani and other Paragonimus species, Pasteurella genus, Pediculus humanus capitis, Pediculus humanus corporis, Phthirus pubis, Bordetella pertussis, Yersinia pestis, Streptococcus pneumoniae, Pneumocystis jirovecii, Poliovirus, Prevotella genus, Naegleria fowleri, JC virus, Chlamydophila psittaci, Coxiella burnetii, Rabies virus, Streptobacillus moniliformis and Spirillum minus, Respiratory syncytial virus, Rhinosporidium seeberi, Rhino virus, Rickettsia genus, Rickettsia akari, Rift Valley fever virus, Rickettsia rickettsii, Rotavirus, Rubella virus, Salmonella genus, SARS coronavirus, Sarcoptes scabiei, Schistosoma genus, Shigella genus, Varicella zoster virus, Variola major or Variola minor, Sporothrix schenckii, Staphylococcus genus, Staphylococcus genus,
Staphylococcus aureus, Streptococcus pyogenes, Strongyloides stercoralis, Treponema pallidum, Taenia genus, Clostridium tetani, Trichophyton genus, Trichophyton tonsurans, Trichophyton genus, Epidermophyton floccosum, Trichophyton rubruni, and Trichophyton mentagrophytes, Trichophyton rubrum, Hortaea werneckii, Trichophyton genus, Malassezia genus, Toxocara canis or Toxocara cati, Toxoplasma gondii, Trichinella spiralis, Trichomonas vaginalis, Trichuris trichiura, Mycobacterium tuberculosis, Francisella tularensis, Ureaplasma urealyticum, Venezuelan equine encephalitis virus, Vibrio colerae, Guanarito virus, West Nile virus, Trichosporon beigelii, Yersinia pseudotuberculosis, Yersinia enterocolitica, Yellow fever virus, Mucorales order (Mucormycosis) and Entomophthorales order (Entomophthoramycosis), Pseudomonas aeruginosa, Campylobacter (Vibrio) fetus, Aeromonas hydrophila, Edwardsiella tarda, Yersinia pestis, Shigella dysenteriae, Shigella flexneri, Shigella sonnei, Salmonella typhimurium, Treponema pertenue, Treponema carateneum, Borrelia vincentii, Borrelia burgdorferi, Leptospira icterohemorrhagiae, Pneumocystis carinii, Brucella abortus, Brucella suis, Brucella melitensis, Mycoplasma spp., Rickettsia prowazeki, Rickettsia tsutsugumushi, Clamydia spp.; pathogenic fungi (Aspergillus fumigatus, Candida albicans, Histoplasma capsulatum); protozoa (Entamoeba histolytica, Trichomonas tenas, Trichomonas hominis, Tryoanosoma gambiense, Trypanosoma rhodesiense, Leishmania donovani, Leishmania tropica, Leishmania braziliensis, Pneumocystis pneumonia, Plasmodium vivax, Plasmodium falciparum, Plasmodium malaria); or Helminiths (Schistosoma japonicum, Schistosoma mansoni,
Schistosoma haematobium, and hookworms).
Other antibodies as a binding ligand in this invention for treatment of viral disease include, but are not limited to, antibodies against antigens of pathogenic viruses, including as examples and not by limitation: Poxyiridae, Herpesviridae, Adenoviridae, Papovaviridae, Enteroviridae, Picornaviridae, Parvoviridae, Reoviridae, Retroviridae, influenza viruses, parainfluenza viruses, mumps, measles, respiratory syncytial virus, rubella, Arboviridae, Rhabdoviridae, Arenaviridae, Non-A/Non-B Hepatitis virus, Rhinoviridae, Coronaviridae,
Rotoviridae, Oncovirus [such as, HBV (Hepatocellular carcinoma), I IPV (Cervical cancer, Anal cancer), Kaposi's sarcoma-associated herpesvirus (Kaposi's sarcoma), Epstein-Barr virus (Nasopharyngeal carcinoma, Burkitt's lymphoma, Primary central nervous system lymphoma), MCPyV (Merkel cell cancer), SV40 (Simian virus 40), HCV (Hepatocellular carcinoma),
I I H .V-1 (Adult T-cell leukemia/lymphoma)], Immune disorders caused virus: [such as Human Immunodeficiency Virus (AIDS)]; Central nervous system virus: [such as, JCV (Progressive multifocal leukoencephalopathy), MeV (Subacute sclerosing panencephalitis), LCV
(Lymphocytic choriomeningitis), Arbovirus encephalitis, Orthomyxoviridae (probable) (Encephalitis lethargical, RV (Rabies), Chandipura virus, Herpesviral meningitis, Ramsay Hunt syndrome type II: Poliovirus (Poliomyelitis, Post-polio syndrome), HTLV-I (Tropical spastic paraparesis)] ; Cytomegalovirus (Cytomegalovirus retinitis, I ISV (Herpetic keratitis));
Cardiovascular virus [such as CBV ( Pericardii is. Myocarditis)]; Respiratory system/acute viral nasopharyngil is/viral pneumonia: [Epstein-Barr virus (EBV infection/Infectious
mononucleosis), Cytomegalovirus; SARS coronavims (Severe acute respiratory syndrome) Orthomyxoviridae: Influenzavirus A/B/C (Influenza/ Avian influenza), Paramyxovirus: I luman parainfluenza viruses (Parainfluenza), RSV (Human respiratory syncytial virus), hMPV |;
Digestive system virus [MuV (Mumps), Cytomegalovirus (Cytomegalovirus esophagitis); Adenovirus (Adenovirus infection); Rotavirus, Noro virus, Astrovirus, Coronavims; HBV (Hepatitis B vims), CBV, HAV (Hepatitis A vims), HCV (Hepatitis C vims), HDV (Hepatitis D virus), HEV (Hepatitis E vims), HGV (Hepatitis G virus)]; Urogenital virus [such as, BK vims, MuV (Mumps)].
According to a further embodiment, the present invention also concerns pharmaceutical compositions comprising the conjugate of the invention together with a pharmaceutically acceptable carrier for treatment of cancer and autoimmune disorders. The method for treatment of cancer, autoimmune disorders, infectious diseases or viral disease can be practiced in vitro, in vivo, or ex vivo. Examples of in vitro uses include treatments of cell cultures in order to kill all cells except for desired variants that do not express the target antigen; or to kill variants that express undesired antigen. Examples of ex vivo uses include treatments of hematopoietic stem cells ( I ISC) prior to the performance of the transplantation (IISCT) into the same patient in order to kill diseased or malignant cells. For instance, clinical ex vivo treatment to remove tumor cells or lymphoid cells from bone marrow prior to autologous transplantation in cancer treatment or in treatment of autoimmune disease, or to remove T cells and other lymphoid cells from allogeneic bone marrow or tissue prior to transplant in order to prevent graft-versus-host disease, can be earned out as follows. Bone marrow is harvested from the patient or other individual and then incubated in medium containing serum to which is added the conjugate of the invention, concentrations range from about 1 pM to 0.1 m.Vl, for about 30 minutes to about 48 hours at about 37 °C. The exact conditions of concentration and time of incubation (=dose) are readily determined by the skilled clinicians. After incubation the bone marrow cells are washed with medium containing serum and returned to the patient by i.v. infusion according to known methods. In circumstances where the patient receives other treatment such as a course of ablative chemotherapy or total-body irradiation between the time of harvest of the marrow and reinfusion of the treated cells, the treated marrow cells are stored frozen in liquid nitrogen using standard medical equipment.
For clinical in vivo use, the cell binding agent -cytotoxic agent conjugates of this invention will be supplied as solutions or as a lyophilized solid that can be redisolved in sterile water for injection. Examples of suitable protocols of conjugate administration are as follows. Conjugates are given weekly for 8 weeks as an i.v. bolus. Bolus doses are given in 50 to 500 ml of normal saline to which human serum albumin (e.g. 0.5 to 1 ml , of a concentrated solution of human serum albumin, 100 mg/mL) can be added. Dosages will be about 50 μ« to 20 mg/kg of body weight per week, i.v. (range of 10 μ« to 200 mg/kg per injection). 8 weeks after treatment, the patient may receive a second course of treatment. Specific clinical protocols with regard to route of administration, excipients, diluents, dosages, times, etc., can be determined by the skilled clinicians.
Examples of medical conditions that can be treated according to the in vivo or ex vivo methods of killing selected cell populations include malignancy of any types of cancer, autoimmune diseases, graft rejections, and infections (viral, bacterial or parasite).
The amount of a conjugate which is required to achieve the desired biological effect, will vary depending upon a number of factors, including the chemical characteristics, the potency, and the bioavailability of the conjugates, the type of disease, the species to which the patient belongs, the diseased state of the patient, the route of administration, all factors which dictate the required dose amounts, delivery and regimen to be administered.
In general terms, the cell binding agent -cytotoxic agent conjugates of this invention may be provided in an aqueous physiological buffer solution containing 0.1 to 10% w/v conjugates for parenteral administration. Typical dose ranges are from 1 g/kg to 0.1 g/kg of body weight per day; a preferred dose range is from 0.01 mg/kg to 20 mg/kg of body weight per day or an equivalent dose in a human child. The preferred dosage of drug to be administered is likely to depend on such variables as the type and extent of progression of the disease or disorder, the overall health status of the particular patient, the relative biological efficacy of the compound selected, the formulation of the compound, the route of administration (intravenous, intramuscular, or other), the
pharmacokinetic properties of the compound by the chosen delivery route, and the speed (bolus or continuous infusion) and schedule of administrations (number of repetitions in a given period of time).
The cell binding agent -cytotoxic agent conjugates of the present invention are also capable of being administered in unit dose forms, wherein the term "unit dose" means a single dose which is capable of being administered to a patient, and which can be readily handled and packaged, remaining as a physically and chemically stable unit dose comprising either the active conjugate itself, or as a pharmaceutically acceptable composition, as described hereinafter. As such, typical total daily dose ranges are from 0.01 to 100 mg/kg of body weight. By way of general guidance, unit doses for humans range from 1 mg to 3000 mg per day. Preferably the unit dose range is from 1 to 500 mg administered one to four times a day, and even more preferably from 10 mg to 500 mg, once a day. Conjugatess provided herein can be formulated into pharmaceutical compositions by admixture with one or more pharmaceutically acceptable excipients. Such unit dose compositions may be prepared for use by oral administration, particularly in the form of tablets, simple capsules or soft gel capsules; or intranasaUy, particularly in the form of powders, nasal drops, or aerosols; or dermal ly. for example, topically in ointments, creams, lotions, gels or sprays, or via trans-dermal patches. The compositions may conveniently be administered in unit dosage form and may be prepared by any of the methods well known in the pharmaceutical art. for example, as described in Remington: The Science and Practice of Pharmacy, 21 th ed.; Lippincott Williams & Wi lkins: Philadelphia, PA, 2005. Preferred formulations include pharmaceutical compositions in which a compound of the present invention is formulated for oral or parenteral administration. For oral administration, tablets, pills, powders, capsules, troches and the like can contain one or more of any of the following ingredients, or compounds of a similar nature: a binder such as microcrystalline cellulose, or gum tragacanth; a diluent such as starch or lactose; a disintegrant such as starch and cellulose derivatives; a lubricant such as magnesium stearate; a glidant such as colloidal silicon dioxide; a sweetening agent such as sucrose or saccharin; or a flavoring agent such as peppermint, or methyl salicylate. Capsules can be in the form of a hard capsule or soft capsule, which are generally made from gelatin blends optionally blended with plasticizers, as well as a starch capsule- In addition, dosage unit forms can contain various other materials that modify the physical form of the dosage unit, for example, coatings of sugar, shellac, or enteric agents. Other oral dosage forms syrup or elixir may contain sweetening agents, preservatives, dyes, colorings, and flavorings. In addition, the active compounds may be incorporated into fast dissolve, modil ied-relea.se or sustained-release preparations and formulations, and wherein such sustained-release formulations are preferably bi-modal. Preferred tablets contain lactose, cornstarch, magnesium silicate, croscarmellose sodium, povidone, magnesium stearate, or talc in any combination. Liquid preparations for parenteral administration include sterile aqueous or non-aqueous solutions, suspensions, and emulsions. The liquid compositions may also include binders, buffers, preservatives, chelating agents, sweetening, flavoring and coloring agents, and the like. Nonaqueous solvents include alcohols, propylene glycol, polyethylene glycol, vegetable oils such as olive oil, and organic esters such as ethyl oleate. Aqueous carriers include mixtures of alcohols and water, buffered media, and saline. In particular, biocompatible, biodegradable lactide polymer, lactide/glycolide copolymer, or polyoxyethylene-polyoxypropylene copolymers may be useful excipients to control the release of the active compounds. Intravenous vehicles can include fluid and nutrient replenishers, electrolyte replenishers, such as those based on Ringer's dextrose, and the like. Other potentially useful parenteral delivery systems for these active compounds include ethylene- vinyl acetate copolymer particles, osmotic pumps, implantable infusion systems, and liposomes.
Alternative modes of administration include formulations for inhalation, which include such means as dry powder, aerosol, or drops. They may be aqueous solutions containing, for example, polyoxyethylene-9-lauryl ether, glycocholate and deoxycholate, or oily solutions for administration in the form of nasal drops, or as a gel to be applied intranasally. Formulations for buccal administration include, for example, lozenges or pastilles and may also include a flavored base, such as sucrose or acacia, and other excipients such as glycocholate. Formulations suitable for rectal administration are preferably presented as unit-dose suppositories, with a solid based carrier, such as cocoa butter, and may include a salicylate. Formulations for topical application to the skin preferably take the form of an ointment, cream, lotion, paste, gel, spray, aerosol, or oil. Carriers which can be used include petroleum jelly, lanolin, polyethylene glycols, alcohols, or their combinations. Formulations suitable for transdermal administration can be presented as discrete patches and can be lipophilic emulsions or buffered, aqueous solutions, dissolved and/or dispersed in a polymer or an adhesive.
In a specific embodiment, the cell binding agent -cytotoxic agent conjugates of this invention are administered concurrently with the other known or will be known therapeutic agents such as the chemotherapeutic agent, the radiation therapy, immunotherapy agents, autoimmune disorder agents, anti-infectious agents or the other antibody-drug conjugates, resulting in a synergistic effect. In another specific embodiment, the synergistic drugs or radiation therapy are administered prior or subsequent to administration of a conjugate, in one aspect at least an hour, 12 hours, a day, a week, a month, in further aspects several months, prior or subsequent to administration of a conjugate of the invention.
In other embodiments, the synergistic drugs include, but not limited to:
1). Chemotherapeutic agents: a). Alkylating agents: such as [Nitrogen mustards:
(chlorambucil, cyclophosphamide, ifosfamide, mechlorethamine, melphalan, trofosf amide); Nitrosoureas: (carmustine, lomustine); Alkylsulphonates: (busulfan, treosulfan); Triazenes: (dacarbazine); Platinum containing compounds: (carboplatin, cisplatin, oxaliplatin)] ; b). Plant Alkaloids: such as [Vinca alkaloids: (vincristine, vinblastine, vindesine, vinorelbine); Taxoids: (paclitaxel, docetaxol)]; c). DNA Topoisomerase Inhibitors: such as [Epipodophyllins: (9- aminocamptothecin, camptothecin, crisnatol, etoposide, etoposide phosphate, irinotecan, teniposide, topotecan,); Mitomycins: (mitomycin C)]; d). Anti- metabolites: such as { [Anti- folate: 1 )1 U K inhibitors: (methotrexate, trimetrexate); IMP dehydrogenase Inhibitors:
(mycophenolic acid, tiazofurin, ribavirin, EICAR); Ribonucleotide reductase Inhibitors:
(hydroxyurea, deferoxamine)]; [Pyrimidine analogs: Uracil analogs: (5-Fluorouracil, doxifluridine, floxuridine, ratitrexed(Tomudex)); Cytosine analogs: (cytarabine, cytosine arabinoside, fludarabine); Purine analogs: (azathioprine, mercaptopurine, thioguanine)] } ; e). Hormonal therapies: such as {Receptor antagonists: [Anti-estrogen: (megestrol, raloxifene, tamoxifen); I .1 IR1 I agonists: (goscrclin, leuprolide acetate); Anti-androgens: (bicalutamide, flutamide)] ; Retinoids/Deltoids: [Vitamin D3 analogs: (CB 1093, EB 1089 KI I 1060, cholecalciferol, ergocalciferol); Photodynamic therapies: (verteporfin, phthalocyanine, photosensitizer Pc4, demethoxy-hypocrellin A); Cytokines: (Interferon-alpha, Interferon- gamma, tumor necrosis factor (TNFs), human proteins containing a TNF domain)] }; f). Kinase inhibitors, such as BIBW 2992 (anti-EGFR/Erb2), imatinib, gefitinib, pegaptanib, sorafenib, dasatinib, sunitinib, erlotinib, nilotinib, lapatinib, axitinib, pazopanib. vandetanib, ΡΓ7080 (anti- VEGFR2), mubritinib, ponatinib (AP24534), bafetinib (INNO-406), bosutinib (SKI-606), cabozantinib, vismodegib, iniparib, raxolitinib, CYT387, axitinib, tivozanib, sorafenib, bevacizumab, cetuximab, Trastuzumab, Ranibizumab, Panitumumab, ispinesib; g). Others: such as gemcitabine, epoxomicins (e. g. carfilzomib), bortezomib, thalidomide, lenalidomide, pomalidomide, tosedostat, zybrestat, PLX4032, STA-9090, Stimuvax, allovectin-7, Xegeva, Provenge, Yervoy, Isoprenylation inhibitors (such as Lovastatin), Dopaminergic neurotoxins (such as l-methyl-4-phenylpyridinium ion), Cell cycle inhibitors (such as staurosporine), Actinomycins (such as Actinomycin IX dactinomycin), Bleomycins (such as bleomycin A2, bleomycin B2, peplomycin), Anthracyclines (such as daunorubicin, doxorubicin (adriamycin), idarubicin, epimbicin. pirarubicin, zorubicin, mtoxantrone, MDR inhibitors (such as verapamil), Ca2+ATPase inhibitors (such as thapsigargin), vismodegib, Histone deacetyla.se inhibitors (Vorinostat, Romidepsin. Panobinostat, Valproic acid, Mocetinostat (MGCD0103), Belinostat, PCI-24781 , Entinostat, SB939, Resminostat, Givinostat, AR-42, CUDC-101 , sulforaphane, Trichostatin A) ; Thapsigargin, Celecoxib, glitazones, epigallocatechin gal late. Disulfiram, Salinosporamide A. More detail lists of known and will be known anti-cancer drugs that can be used as a combination therapy (a synergistic effect) with the compounds and conjugates of the invention can be seen in National Cancer Institute (US) website (www.cancer.gov;
www.cancer.gov/cancertopics/druginfo/alphalist), American Cancer Society
(www.cancer.org/treatment/index) and Cancer Research UK (www.cancerrearchuk.org;
(www.cancerresearchuk.org/cancer-help/about-cancer/treatment/cancer-drugs/)
2) . An anti-autoimmune disease agent includes, but is not limited to, cyclosporine, cyclosporine A, aminocaproic acid, azathioprine, bromocriptine, chlorambucil, chloroquine, cyclophosphamide, corticosteroids (e.g. amcinonide, betamethasone, budesonide,
hydrocortisone, flunisolide, fluticasone propionate, fluocortolone danazol, dexamethasone, Triamcinolone acetonide, beclometasone dipropionate), 1 )1 ΙΚΛ. enanercept,
hydroxychloroquine, infliximab, meloxicam, methotrexate, mofetil, mycophenylate, prednisone, sirolimus, tacrolimus.
3) . An anti-infectious disease agent includes, but is not limited to, a). Aminoglycosides: amikacin, astromicin, gentamicin (netilmicin, sisomicin, isepamicin), hygromycin B, kanamycin (amikacin, arbekacin, be kanamycin. dibekacin, tobramycin), neomycin (framycetin, paromomycin, ribostamycin), netilmicin, spectinomycin, streptomycin, tobramycin, verdamicin; b). Amphenicols: azidamfenicol, chloramphenicol, florfenicol, thiamphenicol ; c). Ansamycins: geldanamycin, herbimycin; d). Carbapenems: biapenem, doripenem, ertapenem,
imipenem/cilastatin, meropenem, panipenem; e). Cephems: carbacephem (loracarbef), cefacetrile, cefaclor, cefradine, cefadroxil, cefalonium, cefaloridine, cefalotin or cefalothin, cefalexin, cefaloglycin, cefamandole, cefapirin, cefatrizine, cefazaflur, cefazedone, cefazolin, cefbuperazone, cefcapene, cefdaloxirne, cefepime, cefminox, cefoxitin, cefprozil, eel Vox ad inc. ceftezole, cefuroxime, cefixime, cefdinir, cefditoren, cefepime, cefetamet, cefmenoxime, cefodizime, cefonicid, cefoperazone, ceforanide, cefotaxime, cefotiam, cefozopran, cephalexin, cefpimizole, cefpiramide, cefpirome, cefpodoxime, cefprozil, cefquinome, cefsulodin, ceftazidime, cefteram, ceitibuten, ceftiolene, ceftizoxime, ceitobiprole, ceftriaxone, cefuroxime, cefuzonam, cephamycin (cefoxitin, cefotetan, cefmetazole), oxacephem (flomoxef, latamoxef); f). Glycopeptides: bleomycin, vancomycin (oritavancin, telavancin), teicoplanin (dalbavancin), ramoplanin; g). Glycylcyclines: e. g. tigecycline; g). β-Lactamase inhibitors: pen am (sulbactam, tazobactam), clavam (clavulanic acid); i). Lincosamid.es: clindamycin, lincomycin; j).
Lipopeptides: daptomycin, A54145, calcium -dependent antibiotics (CDA); k). Macrolides: azithromycin, cethromycin, clarithromycin, dirithromycin, erythromycin, flurithromycin, josamycin, ketolide (telithromycin, cethromycin), midecamycin, miocamycin, oleandomycin, rifamycins (rifampicin, rifampin, rifabutin, rifapentine), rokitamycin, roxithromycin, spectinomycin, spiramycin, tacrolimus (FK506), troleandomycin, telithromycin; 1).
Monobactams: aztreonam, tigemonam; m). Oxazolidinones: linezolid; n). Penicillins:
amoxicillin, ampicillin (pivampicillin, hetacillin, bacampicillin, metampicillin, talampicillin), azidocillin, azlocillin, benzylpenicillin, benzathine benzylpenicillin, benzathine
phenoxymethylpenicillin, clometocillin, procaine benzylpenicillin, carbenicillin (carindacillin), cloxacillin, dicloxacillin, epicillin, flucloxacillin, mecillinam (pivmecillinam), mezlocillin, meticillin, nafcillin, oxacillin, penamecillin, penicillin, pheneticillin, phenoxymethylpenicillin, piperacillin, propicillin, sulbenicillin, temocillin, ticarcillin; o). Polypeptides: bacitracin, colistin, polymyxin B; p). Quinolones: alatrofloxacin, balofloxacin, ciprofloxacin, clinafloxacin, danofloxacin, difloxacin, enoxacin, enrofloxacin, floxin, garenoxacin, gatifloxacin,
gemilloxacin, grepafloxacin, kano trovafloxacin, levofloxacin, lomelloxacin, marbofloxacin, moxifloxacin, nadifloxacin, norfloxacin, orbifloxacin, ofloxacin, pefloxacin, trovafloxacin, grepafloxacin, sitafloxacin, sparfioxacin, temafloxacin, tosufloxacin, trovafloxacin; q).
Strep togramins: pristinamycin, quinupristin/dalfopristin); r). Sulfonamides: mafenide, prontosil, sulfacetamide, sulfamethizole, sulfanilimide, sulfasalazine, sulfisoxazole, trimethoprim, trimethoprim-sulfamethoxazole (co-trimoxazole); s). Steroid antibacterials: e.g. fusidic acid; t). Tetracyclines: doxycycline, chlortetracycline, clomocycline, demeclocycline, lymecycline, meclocycline, metacycline, minocycline, oxytetracycline, penimepicycline, rolitetracycline, tetracycline, glycylcyclines (e.g. tigecycline); u). Other types of antibiotics: annonacin, arsphenamine, bactoprenol inhibitors (Bacitracin), DADAL/A inhibitors (cycloserine), dictyostatin, discodermolide, eleutherobin, epothilone, ethambutol, etoposide, faropenem, fusidic acid, furazolidone, isoniazid, laulimalide, metronidazole, mupirocin, mycolactone, NAM synthesis inhibitors (e. g. fosfomycin), nitrofurantoin, paclitaxel, platensimycin, pyrazinamide, quinupristin/dalfopristin, rifampicin (rifampin), tazobactam tinidazole, uvaricin;
4) . Anti-viral drugs: a). Entry/fusion inhibitors: aplaviroc, maraviroc, vicriviroc, gp41 (enfuvirtide), PRO 140, ( 1)4 (ibalizumab); b). Integrase inhibitors: raltegravir, elvitegravir, globoidnan A; c). Maturation inhibitors: bevirimat, vivecon; d). Neuraminidase inhibitors: oseltamivir, zanamivir, peramivir; e). Nucleosides &_nucleotides: abacavir, aciclovir, adefovir, amdoxovir, apricitabine, brivudine, cidofovir, clevudine, dexelvucitabine, didanosine (ddl), elvucitabine, emtricitabine (FTC), entecavir, famciclovir, fluorouracil (5-FU), 3'-fruoro- substituted 2', 3 ' -dideoxynucleoside analogues (e.g. 3 ' -fluoro-2 ' ,3 ' -dideoxythymidine (FLT) and 3'-fluoro-2',3'-dideoxyguanosine (FLG), fomivirsen, ganciclovir, idoxuridme, lamivudine (3TC), 1-nucleosides (e.g. β-1-thymidine and p-l-2'-deoxycytidine), penciclovir, racivir, ribavirin, stampidine, stavudine (d4T), taribavirin (viramidine), telbivudine, tenofovir, trifluridine valaciclovir, valganciclovir, zalcitabine (ddC), zidovudine (AZT); f). Non- nucleosides: amantadine, ateviridine, capravirine, diarylpyrimidines (etravirine, rilpivirine), delavirdine, docosanol, emivirine, efavirenz, foscarnet (phosphonoformic acid), imiquimod, interferon alfa, loviride, lodenosine, methisazone, nevirapine, NOV-205, peginterferon alfa, podophyllotoxin, rifampicin, rimantadine, resiquimod (R-848), tromantadine; g). Protease inhibitors: amprenavir, atazanavir, boceprevir, darunavir, fosamprenavir, indinavir, lopinavir, nelfinavir, pleconaril, ritonavir, saquinavir, telaprevir (VX-950), tipranavir; h). Other types of anti-virus drugs: abzyme, arbidol, calanolide a, ceragenin, cyanovirin-n, diarylpyrimidines, epigallocatechin gal I ate (EGCG), foscarnet, griffithsin, taribavirin (viramidine), hydroxyurea, KP-1461 , miltefosine, pleconaril, portmanteau inhibitors, ribavirin, seliciclib.
5) . Other immunotheraphy drugs: e.g. imiquimod, interferons (e.g. α, β), granulocyte colony-stimulating factors, cytokines, Interleukins ( II .- 1 ~ 11. -35 ). antibodies (e. g. trastuzumab, pertuzumab, bevacizumab, cetuximab, panitumumab, infliximab, adalimumab, basiliximab, daclizumab, omalizumab), Protein-bound drugs (e.g., Abraxane), an antibody conjugated with drugs selected from calicheamicin derivative, of maytansine derivatives (DM1 and DM4) , ( '( '- 1065 and duocarmycin minor groove binders, potent taxol derivatives, doxorubicin, auristatin antimitotic drugs (e. g. Trastuzumab-DMl , Inotuzumab ozogamicin, Brentuximab vedotin, Glembatumumab vedotin, lorvotuzumab mertansine, AN-152 LMB2, TP-38, VB4-845, Cantuzumab mertansine, AVE9633, SAR3419, CAT-8015 (anti-CD22), IMGN388, milatuzumab-doxorubicin, SGN-75 (anti-CD70), Anti-CD22-MCC-DMl, IMGN853, Anti- CD22-MMAE, Anti-CD22-MMAF, Anti-CD22- calicheamicin. The invention is further illustrated but not restricted by the description in the following examples.
Exam le 1. Tris(2-(benzyloxy)ethyl)phosphine oxide (2)
2). POClj/THF /j
Figure imgf000081_0001
Mg turnings (1.50 g, 61.70 mmol) stirred in THF (80 ml) under Ar was added ((2- bromoethoxy)methyl)benzene (13.10 g, 61.21 mmol) dropwise for 2 h, then kept to stirring for another 3 h. To the mixture was added phosphorus(V) oxychloride (1.90 ml. 20.40 mmol) at -78°C. After stirred at -78°C for 4 h, the mixture was diluted with 0.1 M NaHCQ3 solution (80 ml), NaCl (sat. 100 ml) and EtOAc (50 ml), separated, and the aqueous solution was extracted with EtOAc ( 2 x 50 ml). The organic layers were combined, dried over MgSOj. filtered, concentrated and purified on Si02 column eluted with EtOAc (1 :10 -1:6) to afford the title compound, 6.11 g (66.2% yield). ESI MS m//+ 475.2 (M + Na).
Figure imgf000081_0002
Tris(2~(benzyloxy)ethyl)phosphine oxide (6.03 g, 13.33 mmol) in THF (100 ml) was added Pd/C (0.31 g, 10% Pd/C, 50% wet) in a hydrogenation bottle. The mixture was shaken for 4 h, filtered through Celite (filter aid), concentrated to afford the title compound (2.33 g, 96% yield) without further purification. ESI MS m/z+ 205.8 (M + Na).
Example 3. S-(2-(bis(2-hydroxyethyl)phosphoryl)ethyl) ethanethioate ( 8 )
Figure imgf000081_0003
To a solution of PPh3 (3.30 g, 12.59 mol), thioacetic acid (0.762 g, 10.0 mol), and tris(2~hydroxyethyl)phosphine oxide (2.30 g, 12.58 mmol) in THF (70 mL) was added, at 0-4 °C, DIAD (2.5 mL, 12.69 mol) dropwise over a period of 1 h. The reaction mixture was stirred for 1 h at 0 °C and RT for 1 h. The mixture was diluted with EtOAc (100 ml), then poured into saturated Na2C03 (100 mL). The mixture was separated and the aqueous solution was extracted with EtOAc (2 x 60 ml). The organic layers were combined, dried over Na2S04, filtered, concentrated and purified on SiOj column eluted with MeOH/CI CL. (1 : 15 -1 :8) to afford the title compound (1.75 g, 73% yield). ESI MS m/z+ 263.4 (M + Na).
Example 4. S-(2-(bis(2-bromoethyl)phosphoryl)ethyl) ethanethioate (9) O
Br ^{!^SAc
To a solution of S-(2-(bis(2-hydroxyethyl)phosphoryl)ethyl) ethanethioate (0.9 g, 3.75 mmol) in ( "HjC 'lj (50 ml) was added PPh3 (2.00 g, 7.63 mol) and CBr4(2.46 g, 7.50 mmol) and the reaction mixture was stirred for 6 h. The mixture was concentrated, diluted with EtOAc (80 ml), filtered through Celite, concentrated and purified on S1O2 column eluted with EtOAc/hexane (1 :8 -1 :3) to afford the title compound (1.21 g, 89% yield). ESI MS m/z+ 571.2 (M + Na).
Example 5. S-(2-(bis(2-(tosyloxy)ethyl)phosphoryl)ethyl) ethanethioate (10).
Figure imgf000082_0001
To a solution of S-(2-(bis(2-hydroxyethyl)phosphoryl)ethyl) ethanethioate (0.9 g, 3.75 mmol) in CH2CI2 (30 ml) and pyridine (20 ml) was added TsCl (2.00 g, 10.52 mol) and the reaction mixture was stirred for 6 h. The mixture was concentrated and purified on Si(¾ column eluted with EtOAc/hexane (1 :5 -1 :3) to afford the title compound (1.77 g, 86% yield). ESI MS 386.8 (M + Na).
Example 6. Bis(2-hydroxyethyl)(2-(methylsulfinothioyl)ethyl)phosphine oxide ( 12 )
Figure imgf000082_0002
(2-(bis(2-hydroxyethyl)phosphoryl)ethyl) ethanethioate ( 1.25 g, 5.20 mmol ) in CH3OH (40 ml) and H20 (20 ml) was added NaOH (0.5 M, 20 ml) at 4°C. The mixture was stirred at RT for 1 h, neutralized with HCl (6 M) to pi I 7.0, and then MeSS02Me (1.0 g, 7.93 mmol) was added. The mixture was stirred for 4 h, concentrated, and purified on Si( >2 column eluted with MeOH/CH2Cl2 (1 : 15 -1 :8) to afford the title compound (1.09 g, 83% yield). ESI MS m/z+ 267.4 (M + Na).
Example 7. ((2-(methylsulfinothioyl)ethyl)phosphoryl)bis(ethane-2 , 1 -diyl) bis(4- methylbenzenesulf onate) (13).
O
TsO^^^^SSCH3 TsO Bis(2-hydroxyethyl)(2-(methylsulfinothioyl)ethyl)phosphine oxide ( 1.01 g, 4.13 mmol) in CH2C12 (30 ml) and pyridine (15 ml) was added TsCl (2.00 g, 10.52 mmol). The mixture was stirred at RT for 6 h, concentrated and purified on SK )2 column eluted with EtOAc/hexane (1 :5 -1 :3) to afford the title compound (1.98 g, 87% yield). ESI MS m/z+ 575.2 (M + Na).
Exampl -hydroxyethyl)(2-(pyridin-2-yldisulfanyl)ethyl)phosphine oxide ( 14) .
Figure imgf000083_0001
(2-(bis(2-hydroxyethyl)phosphoryl)ethyl) ethanethioate ( 1.25 g. 5.20 mmol) in CH3OH (40 ml) and H20 (20 ml) was added NaOH (0.5 M, 20 ml) at 4°C. The mixture was stirred at RT for 1 h, neutralized with HQ (6 M) to pH 7.5, and then l,2-di(pyridin-2- yl kiisullanc (4.20 g, 19.09 mmol) in CH3OH (40 ml) was added. The mixture was stirred for 4 h, concentrated, and purified on SiQ2 column eluted with MeOH/CH2Cl2 (from 100% CH2C12 to -1 :8) to afford the title compound (1.26 g, 79% yield). ESI MS m/z+ 330.2 (M + Na). Example 9. ((2-(pyridin-2-yldisulfanyl)ethyl)phosphoryl)bis(ethane-2,l-diyl) bis(4- methylbenzenesulf onate) (15).
Figure imgf000083_0002
Bis(2-hydroxyethyl)(2-(pyridin-2-yldisulfanyl)ethyl)phosphine oxide ( 1.21 g, 3.94 mmol) in CH2C12 (30 ml) and pyridine (15 ml) was added TsCl (2.00 g, 10.52 mmol). The mixture was stirred at RT for 6 h, concentrated and purified on Si02 column eluted with EtOAc/hexane (1 :5 -1 :3) to afford the title compound (1.98 g, 87% yield). ESI MS
575.2 (M + Na).
Exampl ',3"-phosphinetriyltripropanoate (26)
Figure imgf000083_0003
Tris(2-carboxyethyl)phosphine hydrochloride (TCEP ) (7.0 g, 24.42 mmol) was co- evaporated with EtOH (2 x 100 ml), dissolved in CH3OH (200 ml) at 4 °C, and then thionyl chloride (9.0 ml ., 122.29 mmol) was added. The resulting mixture was stirred for at RT overnight, concentrated, and dried over vacuum to provide the title compound (7.0 g, 98% yield), ESI MS m//+ 293.2 (M + H). Example 11. Tris(2-hydroxypropyl)phosphine oxide (27)
Figure imgf000084_0001
Trimethyl 3,3\3''-phosphinetriyltripropanoate (7.0 g, 23.96 mmol) in I I II (100 ml) at 0 °C was added L1AIH4 (2 M) in I I II (70ml). The reaction was stirred for 4 h at 0 °C, quenched with cold water (5 ml), filtered, evaporated to dryness to afford crude 3,3',3"~ phosphinetriyltris (propan-l-ol) (5.1 g, 102% yield) which was used directly for next step. This compound dissolved in HOAc (80 ml) was added I ? ? (20 ml, 33% in water). The mixture was stirred for overnight, concentrated, co-evaporated with water (2 x 100 ml) and toluene, and dried over vacuum to afford the title compound (4.88 g, 91 % yield). ESI MS
Figure imgf000084_0002
Example 12. S-(3-(bis(3-hydroxypropyl)phosphoryl)propyl) ethanethioate (28)
Figure imgf000084_0003
To a solution of PPh3 (3.30 g, 12.59 mol), thioacetic acid (0.762 g, 10.0 mol), and tris(2-hydroxypropyl)phosphine oxide (2.82 g, 12.58 mmol) in THE (70 mL) was added, at 0- 4 °C, DIAD (2.5 mL, 12.69 mol) dropwise over a period of 1 h. The reaction mixture was stirred for 1 h at 0 °C and RT for 1 h. The mixture was diluted with EtOAc (100 ml), then poured into saturated Na2C03 (100 mL). The mixture was separated and the aqueous solution was extracted with EtOAc (2 x 60 ml). The organic layers were combined, dried over Na .SO4. filtered, concentrated and purified on Si02 column e luted with MeOI 1/( 1 L( 'l_> ( 1 : 15 -1 :8) to afford the title compound (1.77 g, 89% yield). ESI MS 305.2 (M + Na).
Examp -hydroxypropyl)(3-(methylsulfinothioyl)propyl)phosphine oxide (32)
Figure imgf000084_0004
S-(3-(Bis(3-hydroxypropyl)phosphoryl)propyl) ethanethioate ( 1.75 g, 6.20 mmol ) in CH3OH (40 ml ) and H20 (20 ml) was added NaOI I (0.5 M, 20 ml) at 4°C. The mixture was stirred at RT for 1 h, neutralized with HCl (6 M) to pi I 7.0, and then MeSS02Me (1.0 g, 7.93 mmol) was added. The mixture was stirred for 4 h, concentrated, and purified on Si02 column eluted with MeOH/CH2Cl2 (1 : 15 -1 :8) to afford the title compound (1.56 g, 88% yield). ESI MS m/z+ 309.4 (M + Na).
Example 14. ((3-(methylsulfinothioyl)propyl)phosphoryl)bis(propane-3, l-diyl) bis(4- methylbenzenesulfonate) (33) HO^s^P ^s^SSCH3 ^ Ts° ^^^P «^^^ SSCH3
O O
Bis(3~hydroxypropyl)(3-(methylsulfinothioyl)propyl)phosphine oxide ( 1.51 g, 5.35 mmol ) in CH2CI2 (30 ml) and pyridine (15 ml) was added TsCl (3.00 g, 15.78 mmol). The mixture was stirred at RT for 6 h, concentrated and purified on S1O2 column eluted witli EtOAc/hexane (1 :5 -1 :3) to afford the title compound (2.73 g, 86% yield). ESI MS m/z+ 617.2 (M + Na).
Example 1 . Methyl 4-(((bis(2-hydroxyethyl)phosphoryl)methyl)amino)-4-oxobutanoate (39)
Figure imgf000085_0001
(Aminomethyl)bis(2-hydroxyethyl)phosphine oxide (1.00 g, 5.98 mmol) and 4- methoxy-4-oxobutanoic acid (0.79 g, 5.98 mmol) in DMA (50 ml) was added EDC (2.40 g, 12.50 mmol). The mixture was stirred for 8 h, concentrated and purified on SiOj column eluted with MeOH/CH2Cl2 (1: 15 -1 :7) to afford the title compound (1.39 g, 83% yield). ESI MS m/z+ 304.2 (M + Na).
Example 16. Methyl 4-(((bis(2-(tosyloxy)ethyl)phosphoryl)methyl)amino)-4-oxobutanoate (40).
Figure imgf000085_0002
Methyl 4-(((bis(2-hydroxyethyl)phosphoryl)methyl)amino)~4-oxobutanoate ( 1.35 g, 4.80 mmol) in CH2CI2 (30 ml) and pyridine (15 ml) was added TsCl (2.50 g, 13. 15 mmol). The mixture was stirred at RT for 6 h, concentrated and purified on Si(¾ column eluted with EtOAc/hexane (1 :5 -1 :3) to afford the title compound (2.34 g, 83% yield). ESI MS m/z+ 612.2 (M + Na).
Example 17. N-((bis(2-hydroxyethyl)phosphoryl)methyl)-4-methyl-4- (methyldisulfanyl)pentanamide 44)
Figure imgf000085_0003
(Aminomethyl)bis(2-hydroxyethyl)phosphine oxide (1.00 g, 5.98 mmol) and 4- methyl~4-(methyldisulfanyl)pentanoic acid (1.16 g, 5.98 mmol) in DMA (50 ml) was added EDC (2.40 g, 12.50 mmol). The mixture was stirred for 8 h, concentrated and purified on SiO: column eluted with MeOI Ι/( Ί IjCb (1 : 15 -1:7) to afford the title compound (1.66 g, 81% yield). ESI MS m//+ 366.2 (M + Na).
Example 18. (((4-methyl~4~(methyldisulfanyl)pentanamido)methyl)phosphoryl)~bis(ethane- 2,1-diyl) dimethanesulfonate (45)
Figure imgf000086_0001
N-((bis(2-hydroxyethyl)phosphoryl)methyl)-4-methyl-4- (methyldisulfanyl)pentanamide ( 1.20 g, 3.49 mmol) in CH2CI2 (30 ml ) and pyridine (15 ml ) was added MsCl (1.50 g, 13.16 mmol). The mixture was stirred at RT for 6 h, concentrated and puriiied on S1O2 column eluted with EtOAc/hexane (1 :5 -1 :3) to afford the title- compound 1.44 g, 83% yield). ESI MS 111//+ 522.1 (M + Na).
Example 19. 4-(benzyloxy)-3-methoxybenzoic acid
Figure imgf000086_0002
4-Hydroxy-3-methoxybenzoic acid (50.0 g, 297.5 mmol) in the mixture of ethanol (350 ml) and NaOH solution (2.0 M, 350 ml) was added BnBr (140.0 g, 823.5 mmol). The mixture was stirred at 65 °C for 8 h, concentrated, co-evaporated with water (2 x 400 ml) to -400 ml. acidified with 6 M HQ to pi I 3.0, filtered the solid, crystallized with EtOH, dried over the oven at 45 °C with vacuum to afford the title compound (63.6 g, 83% yield). ESI MS
Figure imgf000086_0003
Exampl -(benzyloxy)-5-methoxy-2-nitrobenzoic acid
Figure imgf000086_0004
4-(Benzyloxy)-3-methoxybenzoic acid (63.5 g, 246.0 mmol) in the mixture of CH2CI2 (400 ml) and I lOAc (100 ml) was added HNO3 (fuming, 25.0 ml, 528.5 mmol). The mixture was stirred for 6 h, concentrated, crystallized with EtOH, dried over the oven at 40 °C with vacuum to afford the title compound (63.3 g, 85% yield). ESI MS m/z+ 326.1 (M + Na). Example 21. (2S,4R)-methyl 4-hydroxypyrrolidine-2-carboxylate, hydrochloric salt. COOMe
H
Trans-4-hydroxy-L-proline (15.0 g, 114.3 mmol) in dry methanol (250 mL) at 0 - 4 °C, was added dropwise thionyl chloride (17 ml .. 231 mmol). The resulting mixture was sl irrcd for at RT overnight, concentrated, crystallized with EtOH/hexane to provide the title compound (18.0 g, 87% yield), ESI MS m//+ 168.2 (M + Na).
Examp -l-tert-butyl 2-methyl 4-hydroxypyrrolidine~l ,2-dicarboxylate
Figure imgf000087_0001
To a solution of trans-4-hydroxy-l .-proline methyl ester (18.0 g, 107.0 mmol) in the mixture of MeOH (150 ml) and sodium bicarbonate solution (2.0 M, 350 ml) was added (BOQ2O (30.0 g, 137.6 mmol) in three portions in 4 h. After stirring for an additional 4 h, the reaction was concentrated to -350 ml and extracted with EtOAc (4 x 80 mL). The combined organic layers were washed with brine (100 mL), dried ( MgS( ).t ). filtered, concentrated and purified by SiO.-> chromatography (1 : 1 hexanes/EtOAc) to give the title compound (22.54 g, 86% yield). LSI MS m/z+ 268.2 (M + Na).
Example 2 . (S)-l-tert-butyl 2-methyl 4-oxopyiTolidine-l ,2-dicarboxylate
Figure imgf000087_0002
The title compound prepared through Dess-Martin oxidation was described in: Franco Manfre el al. .1. Org. ( 'hem. 1992, 57, 2060-2065. Alternatively Swern oxidation procedure is as following: A solution of (COCl)2 (13.0 ml, 74.38 mmol) in ( ! LCL (350 ml) cooled to -78 °C was added dry DMSO (26.0 mL). The solution was stirred at -78 °C for 15 min and then
(2S,4R)-l-tert-butyl 2-methyl 4-hydroxypyrrolidine-l ,2-dicarboxylate (8.0 g, 32.63 mmol) in CH2CI2 (100 ml). After stirred at -78 °C for 2 h, triethylamine (50 ml, 180.3 mmol) was added dropwise, and the solution was warmed to room temperature (RT). The mixture was diluted with Nal LP( > (400 ml, 1.0 M) solution, separated, and the aqueous layer was extracted with CH2CI2 (2 x 60 ml). The organic layers were combined, dried over .\lgSO4. filtered, concentrated and purified by S1O2 chromatography (7:3 hexanes/EtOAc) to give the title compound (6.73 g, 85% yield). ESI MS 266.2 (M + Na).
Example 24. (S)-l-tert-butyl 2-methyl 4-methylenepyrrolidine-l ,2-dicarboxylate
Figure imgf000088_0001
A solution of methyltriphenylphosphonium bromide (19.62 g, 55.11 mmol) in THE (150 ml .) at 0°C was potassium-t-butoxide (6.20 g, 55.30 mmol) in anliydrous Ti ll (80 mL). After stirred at 0°C for 2 h, the resulting yellow ylide suspension was added the solution of (S)- l- tert-butyl 2-methyl 4-oxopyrrolidine-l ,2-dicarboxylate (6.70 g, 27.55 mmol) in THF (40 mL). After stirring at R for 1 h, the reaction mixture was concentrated, diluted with EtOAc (200 mL), washed with 1 1 >( ) (150 mL), brine (150 mL), dried over MgS( ).», concentrated purified on Si02 flash chromatography (9: 1 hexanes/EtOAc) to yield the title compound (5.77 g, 87% yield). E1MS m/z+ 264 (M + Na).
Examp -methyl 4-methylenepyrrolidine-2-carboxylate
Figure imgf000088_0002
(S)-l-tert-butyl 2-methyl 4-methylenepyrrolidine-l,2-dicarboxylate (5.70 g, 23.63 mmol) in EtOAc (40 ml) at 4 °C was added l l( "I (10 ml, 12 M). The mixture was stirred for 1 h, diluted with toluene (50 ml), concentrated, and crystallized witli EtOH/hexane to yield the title compound as HQ salt (3.85 g, 92% yield). EIMS m//+ 142.2 (M +1 1 ).
Example 26. (S)-methyl l-(4-(benzyloxy)-5-methoxy-2-nitrobenzoyl)-4- me
Figure imgf000088_0003
A catalytic amount of DMF (30 ul) was added to a solution of 4-(benzyloxy)-5- methoxy-2-nitrobenzoic acid (2.70 g, 8.91 mmol) and oxalyl chloride (2.0 mL, 22.50 mmol) in anhydrous CH2CI2 (70 mL) and the resulting mixture was stirred at room temperature (RT) for 2 h. Excess CH2CI2 and oxalyl chloride was removed with rotavap. The actyl chloride was resuspended in fresh ( Ί LCL (70 ml . ) and was added dropwise to a solution of 4-methylene-L- proline methyl ester HC1 salt (1.58 g, 8.91 mmol), Et3N (6 mL) at 0°C under argon atmosphere. The reaction mixture was allowed to warm to RT and stirring was continued for 8 h. After removal of ( Ί LCI : and E N, the residue was partitioned between I LO and EtOAc (70/70 mL). The aqueous layer was further extracted with EtOAc (2 x 60 mL). The combined organic layers were washed with brine (40 mL), dried ( MgSO.t ) and concentrated. Purification of the residue with flash chromatography (silica gel, 2:8 hexanes/EtOAc) yielded (S)-methyl l~(4-(benzyloxy)-5-methoxy-2-nitrobenzoyl)~4~methylenepyrrolidine~2~cai-boxylate (2.88 g, 76.1 % yield); EIMS ml/, 449.1 ([M]++Na).
Example 27. (S)- 1 -(4-(benzyloxy)-5-methoxy-2-nitrobenzoyl)-4-methylenepyrrolidine-2- carb
Figure imgf000089_0001
To a vigorously stirred solution of (S)-methyl l-(4-(benzyloxy)-5-methoxy-2- nitrobenzoyl)-4-methylenepyrrolidine-2-carboxylate (2.80 g, 6.57 mmol) in anhydrous CH2CI2 (60 ml ,) was added drop wise solution of DIB AL-H (10 ml . of a 1M solution in CH2CI2) at -78 °C under argon atmosphere. After the mixture was stirred for an additional 90 min, excess reagent was decomposed by addition of 2 ml of methanol followed by 5% HC1 (10 ml . ). The resulting mixture was allowed to warm to 0°C. Layers were separated and the aqueous layer was further extracted with CH2CI2 (3 x 50 ml .). Combined organic layers were washed with brine, dried (MgS04) and concentrated. Purification of the residue with flash chromatography (silica gel, 95 :5 CHCl3/MeOH) yielded (S)-l-(4-(benzyloxy)-5-methoxy-2- nitrobenzoyl)-4-methylenepynOlidine-2-carbaldehyde (2.19 g, 84% yield). EIMS m/z 419.1 ([M]++Na).
Example 28. (S)-8-(benzyloxy)-7-methoxy-2-methylene-2,3-dihydro-lH-benzo[e]- pyrrolo -a] azepin-5( 11 aH)-one
Figure imgf000089_0002
(S)-l-(4-(benzyloxy)-5-methoxy-2-nitrobenzoyl)-4-methylenepyrrolidine-2-carbaldehyde (2.18 g, 5.50 mmol) and NajSjO.! (8.0 g, 45.97 mmol) in the mixture of THE (60 ml) and H20 (40 ml) were stirred at RT for 20 h. Solvents were removed under high vacuum. The residue was re-suspended in MeOH (60 niL), and HQ (6M) was added dropwise until pH ~ 2. The resulting mixture was stirred at RT for 1 h. The reaction was work-up by removing most of MeOH, then diluted with EtOAc (100 ml . ). The EtOAc solution was washed with sat. aq. NaHCC , brine, dried (MgSC^), and concentrated. Purification of the residue with flash chromatography (silica gel, 97:3 ( Ί l( "h/Me( )l 1 ) yielded (S)-8-(benzyloxy)-7-methoxy-2- methylene-2,3-dihydro-lH-benzo[e]pyrrolo[l ,2-a]azepin-5(l laH)-one (1.52 g, 80%). EIMS m/z 372.1 ([M]++Na). Example 29. (S)-8-hydroxy-7-methoxy-2-methylene-2 -dihydro-lH-benzo[e]pyrrolo[l,2- a |a/epi -5( 1 l aI I )-one
Figure imgf000090_0001
(S)-8-(benzyloxy)-7-methoxy-2-methylene-2,3-dmydro-lH-benzo[e]pyrrolo[l,2- a |a/epin-5( 1 l al D-one (1.50 g, 4.32 mmol) in 70 ml of CILC . at 0°C was added 25 ml of CH2SO3II. The mixture was stirred at 0°C for 10 niin then RT for 2 h, diluted with CH2CI2, neutralized with cold 1.0 M Nal !( '( )¾ to pi I 4, filtered. The aqueous layer was extracted with CH2CT2 (3x 60 ml). The organic layers were combined, dried over Na2S04, filtered, evaporated and purified on S1O2 chromatography eluted with CH3OH/CH2CI2 (1 : 15) to afford 811 mg (73% yield) of the title product. LI MS ml 281.1 ([M]++Na).
Example 30. (S)-Methyl piperidine~2-carboxylate, 1 salt
Figure imgf000090_0002
(S)-Piperidme-2-carboxylic acid (10.00 g, 77.46 mmol) in methanol (200ml) at 0°Cwas added thionyl chloride (15.0 ml, 205.61 mmol) under Ar. The mixture was stirred at 0°C for 30 min, then RT overnight, evaporated and crystallized with EtOH to afford the title product (9.90 g, 92% yield). EIMS m/z 144.1 ( | M ]++I I ).
Example 3 1. (S)-Methyl l-(4-(benzyloxy)-5-methoxy-2-nitrobenzoyl)piperidine-2- carboxylate
Figure imgf000090_0003
A catalytic amount of DMF (20 ul) was added to a solution of 4-(benzyloxy)-5- methoxy-2-nitrobenzoic acid ( 1.35 g, 4.45 mmol) and oxalyl chloride (1.0 mL, 11.25 mmol) in anhydrous ( Ί L( 'l_> (40 ml .) and the resulting mixture was stirred at room temperature (RT) for 2 h. Excess CH2CI2 and oxalyl chloride was removed with rotavap. The chloride compound was resuspended in fresh CH2CI2 (40 mL) and was added dropwise to a solution of (S)-methyl piperidine-2-carboxylate HQ salt (0.80 g, 4.46 mmol), Et3N (4 mL) at 0°C under argon atmosphere. The reaction mixture was allowed to warm to RT and stirring was continued for 8 h. After removal of CH2CI2 and Et3N, the residue was partitioned between 11 >( ) and EtOAc (70/70 mL). The aqueous layer was further extracted with EtOAc (2 x 60 ml .). The combined organic layers were washed with brine (30 mL), dried (MgS04) and concentrated. Purification of the residue with flash chromatography (silica gel, 2:8 hexanes/EtOAc) (R)-methyl l-(4-(benzoyloxy)-5-methoxy-2-nitrobenzoyl)piperidine-2- carboxylate (1.51 g, 73.1% yield); EIMS m/z 465.1 ([M]++Na).
Example 32. (S)- 1 -(4-(benzyloxy)-5-methoxy-2-nitrobenzoyl)piperidine-2-carbaldehyde
Figure imgf000091_0001
(S)-Methyl l~(4-(benzoyloxy)-5-methoxy-2-nitrobenzoyl)piperidine~2-carboxylate (1.50 g, 3.50 mmol) in CH2C12 (50 ml) at -78°C was added DIBAL (7.5 ml, 1.0 M ) in toluene under Ar in 30 min. The mixture was stirred at -78°C for 3 lir and the reaction was quenched with 0.5 ml of methanol. The mixture was diluted with EtAc (150 ml) and HQ (100 ml, 0.2 M). The organic was separated and the aqueous was extracted with EtAc (3 x 80 ml). The organics were combined, dried over M»S( ).j. filtered, concentrated and purified on SiOj chromatography eluted with EtAc/hexane (3:2) to afford 1.52 g (90% yield) of the title product, ' i l NMK (CDC13), 9.60 (s, 1H), 7.70 (s, 1H), 7.65 - 7.28 (m, 5H), 6.78 (m, 1H), 5.16 (s, 211 ), 3.92 (s, 311 ), 3.22, (m, I I I ), 3.01 (m, 1 11 ). 2.20 (m, I I I ). 1.84 (m, 111 ), 1.65 - 1.40 (m, 411 ); 'V NMK 200.24. 171.31, 155.13, 154.78, 148.41, 146.20, 137.57, 135.47, 129.03, 128.73, 127.31, 109.83, 109.41 , 71.61, 64.50, 56.96, 45.98, 25.25, 23.42, 18.70; MS m/z+ 42 1. 1 (M + Na).
Example 33. (S)-3-(benzyloxy)-2-methoxy-7,8,9,10-tetrahydrobenzo[e]pyrido[l,2- a][l,4
Figure imgf000091_0002
(S)-l-(4-(benzyloxy)-5-methoxy-2-nitrobenzoyl)piperidine-2-carbaldehyde (1.50 g, 3.77 mmol) in a mixture solution of THE (50 ml) and water (50 ml) was added
Figure imgf000091_0003
(5.0 g, 28.73 mmol). The mixture was stirred for 8 h, diluted with dioxane (50 ml), evaporated and co-evaporated with dioxane (3 x 60 ml) to dryness. The solid was sonicated with a mixture of CH3OH/CH2CI2 (1 : 1 , 80 ml), filtered and evaporated to solid. The yield solid was dissolved in CH3OH (100 ml) followed added 0.4 ml of HQ (cone). The mixture was stirred for 1 h, neutralized to pH 3.0 with 0.1 M NaHC03, concentrated, and extracted with CH2Q2 (4 x 60 ml), The organic layers were combined, washed with 1M Nal l( '()3/Na( 'l (cone), dried over Na2S04, filtered, evaporated and purified on Si02 chromatography eluted with EtAc/CH2Cl2 (1:3) to afford the title product (950 mg, 72% yield), Ή NMR (CDCI3), 7.81 (d, 1H, J = 5.7 Hz), 7.38 ~ 7.23 (m, 611).6.74 (s, III), 5.12 (dd, 211. J = 2.3, 21.8 Hz), 4.18 (m, 111).3.88 (d, 311).3.69 (m, 111).3.15 (m, III).1.99 (m, III).1.87 (m, 111).1.79 ~ 1.65 (m, 411): 13C NMR 167.76, 163.31, 150.72, 148.48, 140.09, 136.46, 128.87, 128.28, 127.53, 121.77, 111.01, 71.02, 56.41, 49.84, 39.93, 24.76, 23.21, 18.62; MS m/z+ 373.2 (M + Na), 391.2 (M + Na + H20).
Example 34. (S)~34iydroxy-2-methoxy-7,8,9,10~tetrahydiObenzo[e]pyrido[l,2- a] [ 1 ,4]diazepin- 12 (6a ID-one
Figure imgf000092_0001
(S)~3-(benzyloxy)~2~methoxy-7,8,9,10~tetrahydrobenzo[e]pyrido[l,2-a][l,4]diazepin- 12(6aH)-one (925 mg, 2.64 mmol) in CH2C12 (50 ml) at 0°C was added CH2S03H (25 ml). The mixture was stirred at 0°C for 10 min then RT for 2 h, diluted with CH2C12, neutralized with cold 1.0 M NaHC03i extracted with CH2Cl2i dried over Na2S04, filtered, evaporated and purified on Si02 chromatography eluted with CH30H/CH2C12 (1:15) to afford the title product (555 mg, 81% yield), 'll NMR (CDCI3), 7.75 (d, III. J = 5.7 Hz), 7.28 (s, 111).6.70 (s, 111). 4.08 (m, 111).3.83 (d, 311).3. 1 (m, 111).3.08 (m, III).1.91 (m, III).1.81 (m, 111).1.71 ~ 1.55 (m, 411); 1C NMR 167.81, 163.46.148.53, 145.71.140.84, 121.23, 111.89, 111.39, 56.45, 49.83, 39.96, 24.71, 23.22, 18.60; MS m/z+ 283.7 (M + Na).
Example 35. (S)-methyl l-(4-(benzyloxy)-5-methoxy-2-nitrobenzoyl)pyrrolidine-2- carboxylate
Figure imgf000092_0002
4-(benzyloxy)-5-methoxy-2-nitrobenzoic acid (2.00 g, 6.60 mmol), L-proline methyl ester HC1 salt (1.09 g, 6.60 mmol), EDC (3.50 g, 18.22 mmol) and DIPEA (1.0 ml, 5.75 mmol) was stirred in 25 ml of DMA over night. The mixture was evaporated, diluted with IX M. washed with washed 1M NaH2P04/NaCl (cone) and 0.1 M NaHC03/NaCl (cone) separately. The organic was dried over MgSQ4, filtered, concentrated and purified on Si02 chromatography eluted with EtOAc/DCM (1:15) to afford 1.96 g (72%) of the title product. EIMS m/ 437.1 (M + Na). Example 36. (S)- 1 -(4-(benzyloxy)-5-methoxy-2-nitrobenzoyl)pyrrolidine-2-carbaldehyde
Figure imgf000093_0001
(S)-methyl l-(4-(benzyloxy)-5-methoxy-2-nitrobenzoyl)pyrrolidine-2-carboxylate (1.90 g, 4.59 mmol) in CH2CI2 (50 ml) at -78°C was added DIBAL (7.5 ml, 1.0 M ) in toluene under Ar in 30 min. The mixture was stirred at -78°C for 3 hr and the reaction was quenched with 0.5 ml of methanol. The mixture was diluted with EtAc (150 ml) and HQ (100 ml, 0.2 M). The organic was separated and the aqueous was extracted with EtAc (3 x 80 ml). The organics were combined, dried over MgS04, filtered, concentrated and purified on Si02 chromatography eluted with EtAc/hexane (3:2) to afford the title product (1.34 g, 76% yield).
Figure imgf000093_0002
Example 37. (S)-8-(benzyloxy)-7-methoxy-2,3-dihydro-lH-benzo[e]pyrrolo[l,2- a] [ 1 ,4]diazepin-5(l 1 aH)-one
Figure imgf000093_0003
(S)-l-(4-(benzyloxy)-5-methoxy-2-nitrobenzoyl)pyrrolidine-2-cai'baldehyde (1.30 g, 3.38 mmol) in a mixture solution of THE (50 ml) and water (50 ml) was added Na.'S.'( )4 (5.0 g, 28.73 mmol). The mixture was stirred for 8 h, diluted with dioxane (50 ml), evaporated and co-evaporated with dioxane (3 x 60 ml) to dryness. The solid was sonicated with a mixture of CH3OH/CH2CI2 (1 : 1, 80 ml), filtered and evaporated to solid. The yield solid was dissolved in CH3OH (100 ml) followed added 0.4 ml of HC1 (cone). The mixture was stirred for 1 h, neutralized to pH 3.0 with 0.1 M Nal !( '( )¾ concentrated, and extracted with CH2CI2 (4 x 60 ml), The organic layers were combined, washed with 1M NaHCOs/NaCl (cone), dried over Na2S04, filtered, evaporated and purified on Si02 chromatography eluted with EtAc/CH2Cl2 (1:3) to afford the title product (807 mg, 71% yield). EIMS m/z+ 359.2 (M + Na), 377.2 (M + Na + H?0).
Example 38. (S)-8-hydroxy-7-methoxy-2,3-dihydro-lH-benzo[e]pynOlo[l,2-a][l,4]diazepin- 5(1 la -one
Figure imgf000093_0004
( K )-8-( lx i/yloxy)-7-melhi>.\y-2.3-dihydro- 1 1 l-ben/o| e |pyrrolo| 1 ,2-a ]| 1.4|dia/epin- 5( 1 l al l )-one (795 mg. 2.36 mmol) in CH2C12 (30 ml) at 0°C was added CH2S03H (15 ml). The mixture was stirred at 0°C for 10 min then RT for 2 h, diluted with CH2CI2, neutralized with cold 1.0 M Nal !( '( )¾. extracted with CH2CI2, dried over Na2S04, filtered, evaporated and purified on SiO? chromatography eluted with CH3OH/CH2CI2 (1 : 15) to afford the title product (477 mg, 82% yield). HI. MS m/z+ 269.2 (M + Na), 287.2 (M + Na + H20), 301.2 (M + Na+ CH3OH).
Example 39. (l laS,l la'S)-8,8'-((((2-(methylsulfmothioyl)ethyl)phosphoryl)bis(ethane-2,l- diyl))bis(oxy))-bis(7~methoxy-2-methylene-2,3-dihydro-lH~benzo[e]pyrrolo[l,2- a] [ 1 ,4]diazepin-5( 11 aH)-one)
Figure imgf000094_0001
To the stining solution of (S)-8-hydroxy-7-methoxy-2-methylene-2,3-dihydro-lH- benzo[e]pyrrolo[l,2-a][l,4]diazepin-5(l laH)-one (60.1 mg, 0.232 mmol), CS2CO3 (100 mg, 0.307 mmol), Kl (3.2 mg, 0.018 mmol) in 5 ml of acetone was added ((2-
(methylsulfinothioyl)-ethyl)phosphoryl)-bis(ethane-2,l-diyl) bis(4-methylbenzenesulfonate) (13) (67.2 mg, 0.121 mmol). The mixture was stirred over night, evaporated and purified on HPLC preparative ( '- 1 column (Φ10 mm x 200 mm column, flow rate 9 ml ./min and a gradient solvent system going from 80:20 solvent A:B at time 0-5 min to 50:50 A:B at 15 min then to 30:70 A:B at 25 min until to 10:90 A:B at 30 min. Solvent A - water, solvent B - dioxane) and lyophilized to afford a white solid 54.6 mg (64%) of the title compound. EIMS 111//+ 747.2 (M + Na), 763.3 (M + K), 781.3 (M + + H20); MS m/z- 723.2 (M - H).
The compound was highly potent towards Raj i cells, with IC50 values between 5.0-11 pM measured at 37 °C, 5 days incubation.
Example 40. Sodium (1 I S, 1 l aS. l l 'S, 1 l a'S)-8,8'-((((2-mercaptoethyl )phosphory )bis-(ethane- 2,l -diyl))bis(oxy))bis(7-methoxy-2-methylene-5-oxo-2,3,5,10,l l,l la-hexahydro-lH- benzo[e] pyrrole [ 1 ,2-a] [ 1 ,4]diazepine- 1 1 -sulfonate)
Na03Sv H O H S03Na ( 11 aS , 11 a'S)-8 , 8'-((((2-(methylsulf inothioyl)ethyl)phosphoryl)bis(ethane-2, 1 - diyl))bis(oxy)) ~bis(7-methoxy~2-methylene-2,3~dihydiO-lH-benzo[e]pyrrolo[ l,2~ a] [l,4]diazepin-5(l laH)-one) (25 mg, 0.034 mmol) in the mixture of isopropanol (5 ml ) and H20 (5 mL) was added NaIIS(¾ (9 mg, 0.086 mmol) and the mixture was stirred at RT for 4 hr. Then TCEP (29.1 mg, 0.102 mmol) and Nai LP( ) (3.0 ml, 2.5 M, pi I 7.5) were added. After stirred for 4 h, the mixture was concentrated, purified on I I PI . (C-18 column, mobile phase A: water, mobile phase B : methanol from 10% of B to 75% of B in 30 mmin). The fractions were pooled and lyophilized to give the title compound (14.5 mg, 49.3% yield), ESI m/z- 841.2 ([M] - H); and a side product of (l laS, l la'S)-8,8'-((((2- mercaptoethyl)phosphoryl)bis(ethane-2,l-diyl))bis(oxy))bis(7-methoxy-2-methylene-2,3- dihydro-lH-benzo[e]pyrrolo[l,2-a] [l ,4]diazepin-5(l laH)-one) (2.5 mg, 10% yield), ESI m/z- + 701.2 ([M] + Na), 717.2 ([M] + Na+ K)
Example 41. Sodium (1 lS, l laS,l l'S, l la'S)-8,8'-((((2-((l-(4-((2,5-dioxopyrrolidin-l-yl)oxy)- 4-oxobutyl)-2,5-dioxopyrrolidin-3-yl)thio)ethyl)phosphoryl)bis(ethane-2, l - diyl))bis(oxy))bis(7-methoxy-2-mefhylene-5-oxo-2, 3,5, 10, 11, 1 la-hexahydro-lll- benz
Figure imgf000095_0001
Succinimidyl 4-(N-maleimido) butyrate (3.4 mg, 0.012 mmol) in DMA (0.5 ml . ) was added sodium (11S, 1 laS,l l'S, l l a'S)-8,8'-((((2-mercaptoethyl)phosphoryl)bis(ethane-2, l- diyl))bis(oxy))bis(7-methoxy-2-mefhylene-5-oxo-2, 3,5, 10, 11, 1 la-hexahydro-lH- benzo[e]pyrrolo[l ,2-a] [l,4]diazepine-l l~sulfonate) (5.0 mg, 0.0059 mmol). After stirred for 2 h, the mixture was concentrated, purified on HPLC (C-18 column, mobile phase A: water, mobile phase B : dioxane, from 10% of B to 75% of B in 30 mmin). The fractions were pooled and lyophilized to give the title compound (4.9 mg, 72% yield), ESI MS m/z- 1165.2 ([M] - H).
Example 42. A conjugate of a PBD derivative to an antibody with a thioether linkage and its specific antitumor activity of the patent.
Figure imgf000095_0002
A reaction containing 2.5 mg/mL anti-CD20 antibody and 5 molar equivalents of sodium (l lS, l laS,irS, l la'S)-8,8'~((((2-((l-(4-((2,5-dioxopyrrolidin~ l-yl)oxy)-4-oxobutyl)- 2,5-dioxopyrrolidin-3-yl)mio)ethyl)ph^
2-methylene-5-oxo-2 ,3 ,5, 10, 1 1 , 11 a-hexahydro- 1 H-benzo[e]pyrrolo [ 1 ,2-a] [ 1 ,4] diazepine-11 - sulfonate) in 50 mM IIEPES (4-(2-hydroxyethyl)-l-piperazine ethanesulfonic acid) pi I 7.5 buffer containing 10% v/v DMA (N,N-Dimethylacetamide) was stirred for 6 hours at 30 °C. The conjugate was purified and buffer exchanged into 250 mM Glycine, 10 mM Histidine, 1 % sucrose, 0.01 %' Tween-20, 50 μΜ sodium bisulfite formulation buffer, pi I 6.0, using NAP desalting columns (Illustra Sephadex G-25 DNA Grade, GE Healthcare). Dialysis was performed in the same buffer for 4 hours at room temperature utilizing Slide-a-Lyzer dialysis cassettes (ThermoScientific 20,000 MWCO). The purified conjugate was found to have an average of 3.8 PBD derivative molecules linked per antibody (by LC-MS), 99% monomer (by size exclusion chromatography), <0.1 % unconjugated drug (by dual-column reverse -phase HPLC analysis) and a final protein concentration of 1.1 mg/ml.
In vitro potency measurements for conjugates of antiCD20 antibody with the PBD derivative dimer. The conjugates were highly potent towards antigen-positive Raji cells, with IC50 values between 1.0-2.1 pM. Antigen blocking with 1 μΜ unconjugated antiCD20 antibody significantly diminished the potency, demonstrating the antigen specificity of the cytotoxic effect.
In Vitro potency measurement against Raji cells in 37 °C, 5 day incubation
Figure imgf000096_0001
Example 43. (11 aS)-7-Methoxy-8-(2-((2-(((S)-7-methoxy-2-methylene-5-oxo- 2,3,5, 10, 1 1, 1 la-hexahydro-l H-benzo[e]pyrrolo[l,2-a] [l,4]diazepin-8-yl)oxy)ethyl)(2- (methylsulfinothioyl)ethyl)phosphoryl)-ethoxy)-2-methylene-2,3-dihydro- lH- benzo[e]pyrrolo[l ,2-a] [ 1 ,4]diazepin-5( 1 laH)-one
Figure imgf000097_0001
To a stirred solution of (llaS,lla'S)-8,8'-((((2-(methylsulfinothioyl)ethyl)phosphoiyl)- bis(ethane-2,l-diyl))bis(oxy))bis(7-methoxy-2-methyle^
[ 1 ,2-a] [ 1 ,4]diazepin-5(l 1 aH)-one) (150 mg, 0.207 mmol) in anhydrous dichloromethane (1 mL) and absolute ethanol (1.5 ml.) was added sodium borohydride in methoxyethyl ether (82μ1, 0.5 M, 0.041 mmol) at 0 °C. The ice bath was removed after 5 minutes and the mixture was stirred at room temperature for 3 hours, then cooled to 0 °C, quenched with saturated ammonium chloride, diluted with dichloromethane, and separated. The organic layer was washed with brine, dried over anhydrous Na_>S()4 and filtered through Celite and concentrated. The residue was purified by reverse phase HPLC (CI 8 column, acetonitrile/ water). The corresponding fractions were extracted witli dichloromethane and concentrated to afford (llaS)-7-Methoxy-8-(2-((2-(((S)-7-methoxy-2~methylene~5-oxo~2,3,5,10,ll,lla-hexahydro- lH-benzo[e]pyrrolo[l,2-a][l,4]-diazepin-8-yl)oxy)ethyl)(2-(methylsulfinothioyl)- ethyl)phosphoryl)-ethoxy)-2-methylene-2,3-dihydro- lH-benzo[e]pyrrolo[ 1 ,2-a] [ 1 ,4]diazepin- 5(1 lull )-onc (63.1 mg, 42%), MS m//+ 749.2 (M + Na), 765.3 (M + K), 767.2 (M + Na+ H20); and (1 laS,l la'S)-8,8'-((((2-(methylsulfino-thioyl)ethyl)phosphoryl)bis(ethane-2,l- diyl))bis(oxy))bis(7-methoxy-2-methylene-2,3,ll,lla-tetrahydiO-lH-benzo[e]pyrrolo[l,2- a][l,4]diazepin-5(10H)-one) (1 .5 mg, 10.9%), MS m/z+ 751.2 (M + Na), 767.2 (M + K), 769.2 (M + Na+ H20); and the unreacted starting material (10.2 mg, 6.8%), MS m/z+ 747.2 (M + Na), 765.2 (M + Na+ H20).
Example 44. ( 1 laS)-8-(2-((2-n capti>ethyl)(2-(((S)-7-inetht).xy-2-n]cthylene-5-oxi>-
2,3,5,10,ll,lla-hexahydro-lH~benzo[e]pyrrolo[l,2~a][l,4]diazepin-8- yl)oxy)ethyl)phosphoryl)ethoxy)-7-methoxy-2-methylene-2,3-dihydro-lH- benzo[e]pyrrolo[l,2-a][l,4]diazepin-5(llaIi)-one
Figure imgf000097_0002
To a stirred solution of (l laS)-7-Methoxy-8-(2-((2-(((S)-7-methoxy-2-rnethylene-5-oxo- 2,3,5, 10, 11 , l la-hexahydro-lH-benzo[e]pyrrolo[l,2-a] [l,4]-diazepin-8-yl)oxy)ethyl)(2- (methylsulfinothioyl)ethyl)phosphoryl)-ethoxy)~2-methylene-2,3-dihydro- lH~
benzo[e]pyrrolo[l ,2-a] [l,4]diazepin-5(l laH)-one (30 mg, 0.041 mmol) in acetonitrile (2 mL) and methanol (5 ml . ) was added freshly prepared TCEP solution (30 mg of TCEP HC1 salt was neutralized with saturated sodium bicarbonate to pi I 6.5 then diluted with 0.4 ml ., 1.0 M of pH 6.5 phosphate buffer) at room temperature. The mixture was stirred at room temperature for 3.5 hours and then diluted with dichloromethane and deionized water, separated. The organic layer was concentrated and puri ied by reverse phase HPLC (CI 8 column, acetonitrile/water) to give the title compound as a white solid (20.2 mg, 72% yield). ESI MS m/z+ 703.2 (M + Na), 721.2 (M + Na+ H20), m/z- 697.2 (M + H20- I I ).
Example 45. 2,5-Dioxopyrrolidin-l-yl 4-( ( 2-( ( 2-( ( ( S )-7-methoxy-2-methylene-5-oxo- 2,3,5, 10, l l, l la-hexahydro-lH-benzo[e]pyrrolo[l,2-a] [l,4]diazepin-8-yl)oxy)ethyl)(2-(((S)-7- methoxy-2-methylene-5-oxo-2,3,5, l la-tetrahydro-lH-benzo[e]pyrrolo[l,2-a] [l,4]diazepin-8-
Figure imgf000098_0001
2,5-DioxopyiTolidin- l-yl 4-methyl-4-((5-nitropyridin-2-yl)disulfanyl)pentanoate linker (5.2 mg, 0.013 mol) in DMA (0.5 mL) was added (1 l aS)-8-(2-((2-mercaptoethyl)(2-(((S)-7- methoxy-2~methylene-5-oxo~2,3,5, 10, l l ,l la-hexahydro-lH-benzo[e]pyrrolo[l,2~ a] [l,4]diazepin~8-yl)oxy)ethyl)phosphoryl)ethoxy)~7~methoxy-2-methylene~2,3-dihydro~lH~ benzo[e]pyrrolo[l ,2-a] [l ,4]diazepin-5(l laII)-one (5.0 mg, 0.0073 mmol) and Nal LP( ) buffer (0.5 M, 0.3 ml, pi I 6.0). After stirred for 2 h, the mixture was concentrated, purified on HPLC (C-18 column, mobile phase A: water, mobile phase B: dioxane, from 10% of B to 65% of B in 30 mmin). The fractions were pooled and lyophilized to give the title compound (4.9 mg, 73% yield), ESI MS m//+ 946.3 ([M] + Na), 964.3 ([M] + Na + H20).
Example 46. A conjugate of a PBD derivative to an antibody with a disulfide bond linkage and its specific antitumor activity of the patent.
Figure imgf000099_0001
A reaction containing 2.5 mg/mL anti-CD20 antibody and 5 molar equivalents of 2,5- Dioxopyrrolidin- 1-yl 4-((2-((2-(((S)-7-methoxy-2-methylene-5-oxo-2,3,5, 10, 11 , 1 l a- hexahydro~lH-benzo[e]pyrrolo[l ,2~a] [ l,4]diazepin-8~yl)oxy)ethyl)(2-(((S)-7-methoxy~2- methylene-5-oxo~2,3,5, l la-tetrahydro-lH~benzo[e]pyriOlo[l,2~a] [l,4]diazepin-8- yl)oxy)ethyl)phosphoryl)ethyl)-disulfanyl)-4-methylpentanoate in 50 mM HEPES (4-(2- hydroxyethyl)-l-piperazine ethanesulfonic acid) pi I 7.5 buffer containing 10% v/v DMA and 1 mM sodium bisulfite was stirred for 6 hours at 30 °C. The conjugate was purified and buffer exchanged into 250 mM Glycine, 10 mM Histidine, 1 % sucrose, 0.01 % Tween-20, 50 μΜ sodium bisulfite formulation buffer, pH 6.0, using NAP desalting columns ( Illustra Sephadex G-25 DNA Grade, GE Healthcare). Di lysis was performed in the same buffer for 4 hours at room temperature utilizing Slide-a-Lyzer dialysis cassettes (ThermoScientific 20,000 MWCO). The purified conjugate was found to have an average of 3.6 PBD derivative molecules linked per antibody (by LC-MS), 99% monomer (by size exclusion
chromatography), <0.1 % unconjugated drug (by dual-column reverse-phase HPLC analysis) and a final protein concentration of 1.5 mg/ml.
In vitro potency measurements for conjugates of antiCD20 antibody with the PBD derivative dimer. The conjugates were highly potent towards antigen-positive Raji cells, with IC50 values between 1.6-2.5 pM. Antigen blocking with 1 μΜ unconjugated antiCD20 antibody significantly diminished the potency, demonstrating the antigen specificity of the cytotoxic effect.
In Vitro potency measurement against Raji cells in 37 °C, 5 day incubation
Figure imgf000099_0002
Example 47. (6aS,6a'S)-3,3'-((((2-(methylsulfinothioyl)ethyl)phosphoryl)bis(ethane-2, l- diyl))bis(oxy))-bis(2-methoxy-7 ,8,9, 10-tetrahydrobenz.o [ejpyrido [ 1 ,2-a] [ 1 ,4]diazepin- 12(6aII)-one)
Figure imgf000100_0001
To the stirring solution of (S)-3-hydroxy-2-methoxy-7,8,9,10-tetrahydrobenzo[e]pyrido [l,2-a][l,4]diazepin-12(6aH)-one (65 mg, 0.25 mmol), CS2CO3 (100 mg, 0.307 mmol), KI (3.2 mg, 0.018 mmol) in 5 ml of acetone was added ((2-(methylsulfinothioyl)ethyl)- phosphoryl)bis(ethane-2,l -diyl) bis(4-methylbenzenesulfonate) (13) (71 mg, 0.123 mmol). The mixture was stirred over night, evaporated and purified on HPLC preparative C-18 column (Φ10 mm x 200 mm column, flow rate 9 mL/min and a gradient solvent system going from 80:20 solvent A:B at time 0-5 min to 50:50 A:B at 15 min then to 30:70 A:B at 25 min until to 10:90 A:B at 30 min. Solvent A - water, solvent B - dioxane) and lyophilized to afford a white solid 54.7 mg (61%) of the title compound. LI MS m/z+ 75 1.2 (M + Na), 767.3 (M + K), 785.3 (M + K+ H20); MS m/z- 727.2 (M - I D.
Example 48. (l laS,l la'S)-8,8'-((((2-(methylsulfinothioyl)ethyl)phosphoryl)bis(ethane-2,l - diyl))bis(oxy))bis(7-methoxy-2,3-dihydro-lH-benzo[e]pyrrolo[l,2-a][l,4]diazepin-5(l laH)- one)
Figure imgf000100_0002
To the stirring solution of (S)-8-hydroxy-7-methoxy-2,3-dihydro-lH- benzo[e]pyrrolo[l ,2-a][l,4]diazepin-5(l laH)-one (60.4 mg, 0.245 mmol), CS2CO3 (100 mg, 0.307 mmol), KI (3.2 mg, 0.018 mmol) in 5 ml of acetone was added ((2- (methylsulfinothioyl)ethyl)phosphoryl)-bis(ethane-2,l-diyl)bis(4-methylbenzenesulfonate) (71 mg, 0.123 mmol). The mixture was stirred over night, evaporated and purified on HPLC preparative C-18 column (Φ10 mm x 200 mm column, flow rate 9 mL/min and a gradient solvent system going from 80:20 solvent A:B at time 0-5 min to 50:50 A:B at 1 min then to 30:70 A:B at 25 min until to 10:90 A:B at 30 min. Solvent A - water, solvent B - dioxane) and lyophilized to afford a white solid 54.7 mg (61 %) of the title compound. EIMS 111//+ 723.2 (M + Na), 739.3 (M + K), 757.3 (M + K+ H20); MS m/z- 699.2 (M - I I ).
Example 49. Bis(2-bromoethyl)phosphinic acid
Figure imgf000100_0003
A mixture of ammonium hypophosphite (8.00 g, 96 mmol) and hexamethydisilazane (20.0 ml .. 96 mmol) was heated at 120 °C for 1 h under argon. After the mixture was cooled to RT, dibromoethane (60.0 ml . ) was added, and the mixture was stirred for 8 h at 120 °C. The formed trimethylbromosilane and excess dibromoethane were removed under vacuum. Then 100 ml , of aqueous ethanol (1 : 1) were added dropwise to the residue and refluxed for 0.5 h. Then the solvent was removed under vacuum and extracted with ethyl acetate. The organic layer was dried over magnesium sulfate and the solvent was removed under vacuum to give the title compound (16.53 g, 61% yield). ESI MS ml/- { Α\ \^ι )?Ϋ (M - 1 1 ). cacld. 276.8, found 276.8.
Exam -bronioefhyl)phosphinate
Figure imgf000101_0001
Bis(2-bromoethyl)phosphinic acid (5.00 g, 18.0 mmol) in triethyl orthoformate (100.0 ml .) was refluxed with a Dean-Stark trap to remove ethanol and ethyl formate. Excess triethyl orthoformate was removed under vacuum. The mixture was purified with Si02 column eluted with EtOAc/ Hexane (1 : 15 to 1 :4) to give the title compound (2.86 g, 52% yield). ESI MS m//+ 328.9 (M + Na), 330.9 (M + Na+2), 332.9 (M + Na+4).
Example 51. Ethyl bis(2-(((S)-7-methoxy-5-oxo-2,3,5,l la-tetrahydro-lH-benzo[e]pyrrolo[l ,2- a] [l,4]diazepin-8-yl)oxy)ethyl)phosphinate
Figure imgf000101_0002
To the stirring solution of (S)-8-hydroxy-7-methoxy-2,3-dihydro- lH-benzo[e]pyrrolo[l ,2- a | | l ,4 |dia/epin-5( 1 l aI I )-one (60.1 mg, 0.244 mmol), Cs2C03 (100 mg, 0.307 mmol), KI (3.2 mg, 0.018 mmol) in 5 ml of butanone was added ethyl bis(2-bromoethyl)phosphinate (37.1 mg, 0.122 mmol). The mixture was stirred over night, evaporated and purified on HPLC preparative C-18 column (Φ10 mm x 200 mm column, flow rate 9 mL/min and a gradient solvent system going from 80:20 solvent A:B at time 0-5 min to 50:50 A:B at 15 min then to 30:70 A:B at 25 min until to 10:90 A:B at 30 min. Solvent A - water, solvent B - dioxane) and lyophilized to afford the title compound as a white solid (52.9 mg, 68% yield). ESI MS m/z+ 6 1 .2 (M + Na), 677.3 (M + K), 679. (M + Na+ H20).
Example 52. Ethyl (2-(((S)-7 -methoxy-5-oxo-2 ,3 ,5 , 10, 1 1 ,1 la-hexahydro-lH-benzo[e]pyrrolo[l ,2- a] [l,4]diazepin-8-yl)oxy)ethyl)(2-(((S)-7-methoxy-5-oxo-2,3,5, l la-tetrahydro- lH- benzo[e]pyrrolo[l ,2-a] [l,4]diazepin-8-yl)oxy)ethyl)phosphinate
Figure imgf000102_0001
To a stirred solution of ethyl bis(2-(((S)-7-methoxy-5-oxo-2,3,5,l la-tetraliydro-lH- benzo[e]pyrrolo[l,2~a] [l,4]diazepin-8~yl)oxy)ethyl)phosphinate (100 mg, 0.156 mmol) in anhydrous dichloromethane (1 mL) and absolute ethanol (1.5 mL) was added sodium borohydride in methoxyethyl ether! 63 μΐ, 0.5 M, 0.031 mmol) at 0 °C. The ice bath was removed after 5 minutes and the mixture was stirred at room temperature for 3 hours and then cooled to 0 °C. and quenched with saturated ammonium chloride, diluted with dichloromethane, separated. The organic layer was washed with brine, dried over anhydrous Na iS( ) and filtered through ( elite and concentrated. The residue was purified by reverse phase 11 PLC (CI 8 column, acetonitrile/water). The corresponding fractions were extracted with dichloromethane and concentrated to afford ethyl (2- (((S)-7-methoxy-5-oxo-2,3,5, 10,11,1 la-hexahydro-lH-benzo[e]pyrrolo[l,2-a] [l,4]diazepin-8- yl)oxy)ethyl)(2-(((S)-7-methoxy-5-oxo-2,3,5,l la-tetrahydro-lH-benzo[e]pyrrolo[l,2- a][l,4]diazepin~8-yl)oxy)ethyl)~phosphinate (43.1 mg, 43% yield), MS m/z+ 663.3 (M + Na), 679.3 (M + K), 681.3 (M + Na+ H20); and ethyl bis(2-(((S)-7-methoxy-5-oxo-2,3,5,10,l l , l la- hexahydro-lH-benzo[e]pyrrolo[l,2-a][l,4]diazepin-8-yl)oxy)ethyl)phosphinate (9.2 mg, 9.2% yield), MS m//+ 665.2 (M + Na), 681.3 (M + K), 683.2 (M + Na+ H20); and the unreacted starting material (9.6 mg, 9.6% yield), MS 661.2 (M + Na), 679.2 (M + Na+ I O ).
Example 53. Ethyl (2-(((S)-7-methoxy-5-oxo-10-(4-(pyridin-2-yldisulfanyl)butanoyl)- 2,3,5,10,l l,l la-hexaliydro-lH-benzo[e]pyrrolo[l,2-a] [l,4]diazepin-8-yl)oxy)ethyl)(2-(((S)-7- methoxy-5-oxo-2,3,5,l la-tetrahydro-lH-benzo[e]pyrrolo[l ,2-a][T,4]diazepin-8-
Figure imgf000102_0002
A catalytic amount of DM I ' (5 ul) was added to a solution of 4-(pyridin-2- yldisulfanyl)butanoic acid (51.1 mg, 0.223 mmol) and oxalyl chloride (0.10 mL, 1.125 mmol) in anhydrous CH2CI2 (4.0 mL) and the resulting mixture was stirred at room temperature ( R I ) for 2 h. Excess CI LCL and oxalyl chloride was removed with rotavap. The yielded chloride compound was resuspended in fresh Cl LClj (3.0 mL) and was added Ethyl (2-(((S)-7- methoxy-5-oxo-2,3,5. I . I 1 . 1 l a-hexahydro- 1 1 l-ben/o|e |pyrrolo| l .2-a|[ l ,4|dia/epin-8- yl)oxy)ethyl)(2-(((S)-7-methoxy-5-oxo-2 ,5,l la-tetrahydro-lH-benzo[e]pyrrolo[l,2- a][l,4]diazepin-8-yl)oxy)ethyl)phosphinate (40.0 mg, 0.062 mmol) Et3N (0.4 niL) at 0°C under argon atmosphere. The reaction mixture was allowed to warm to RT and stirring was continued for 8 h. After removal of 0¾(¾ and Et3N, the residue was partitioned between H20 and EtOAc (6/6 ml ,). The aqueous layer was further extracted with EtOAc (2 x 6 ml .).
The combined organic layers were washed with brine (3 ml .), dried (MgSC^) and
concentrated. Purification of the residue with flash chromatography (silica gel, Hl( )Ac/( "H ( "l.> 1 :20 to 1 :8 ) afforded the title compound (38.1 mg, 72.1% yield); EIMS m/z+ 874.2
([M]++Na), 892.2 ([M]++Na + I !.,()).
Example 54. A conjugate of a PBD derivative to an antibody with a disulfide bond linkage and it
Figure imgf000103_0001
The mAbs (5 mg/mL, especially engineered cysteine -riched CD22 or ( 1)20 antibodies ) in PBS buffer containing 50 mM sodium borate, pH 7.8, were treated with dithiothreitol (DDT) (10 mM final) at 37 °C for 30 min. After gel filtration (G-25, PBS containing ImM DTPA), thiol determination using 5,5 '-dithiobis(2-nitrobenzoic acid) indicated that there were approximately 7-8 thiols per mAb. To the reduced mAb in a PBS buffer pi I 7.5 containing 10% v/v D A and 1 mM sodium bisulfite at 4 °C was added the ethyl (2-(((S)-7-methoxy-5-oxo-10-(4-(pyridin-2- yldisulfanyl)butanoyl)-2,3,5,10,l 1,1 la-hexahydro-lH-benzo[e]pyrrolo[l,2-a][l ,4]diazepin-8- yl)oxy)ethyl)(2-(((S)-7-methoxy-5-oxo-2,3,5,l la-tetrahydro-lH-benzo[e]pyrrolo[l,2- a][l,4]diazepin-8-yl)oxy)ethyl)-phosphinate at the drug derivatives (1.2 equiv/SH group). The reaction was stirred for 6 hours at 30 °C. The reactions were quenched with excess cysteine. The conjugate was purified and buffer exchanged into 250 mM Glycine, 10 mM Histidine, 1% sucrose, 0.01% Tween-20, 50 μΜ sodium bisulfite formulation buffer, pH 6.0, using NAP desalting columns (Illustra Sephadex G-25 DNA Grade, GE Healthcare). Dialysis was performed in the same buffer for 4 hours at room temperature utilizing Slide-a-Lyzer dialysis cassettes
(ThermoScientific 20,000 MWCO). The purified conjugate was found to have an average of 3-4 PBD derivative molecules linked per antibody (by I .( '-MS ). 99% monomer (by size exclusion chromatography), <0.2% unconjugated cysteine-quenched drug (by dual-column reverse-phase IIPLC analysis) and a final protein concentration of 2. mg/ml (Protein concentration and drug loading were determined by spectral analysis at 280 and 254 nm, respectively) In Vitro potency measurement against Raji cells in 37 °C, 5 day incubation
Figure imgf000104_0002
Example 55. Bis(2-(benzyloxy)ethyl)phosphine oxide
O 11
Br
BnO BnO OBn
H
In a three-neck flask was fixed with a dropping funnel, reflux condenser and charged with Mg turnings (1.20 g, 50.0 mmol) and Et20 was added (50 mL). The dropping funnel was charged with ((2-bromoethoxy)methyl)benzene (10.70 g, 50.0 mmol) in Et20 (50 mL). The solution in the dropping funnel was added dropwise to the Mg slurry and gently heated to initiate the reaction. Once initiated heating was no longer required and the solution was added at such a rate to maintain refluxing conditions. After the solution has been completely added to the Mg slurry, the flask was heated for 1 hour to reflux. After 1 hour, the solution was cooled to 0 °C and a solution of diethylphosphite (3.10 mL, 24.0 mmol) was added to the dropping funnel in Et20 (10 mL). Once added the ice bath was removed and heated to reflux for 1 hour. After 1 hour, the mixture was cooled with an ice bath and 10% HQ solution (50 ml .) and H20 (50 mL) were added slowly with stirring. The ether layer was separated, dried over MgSQ t, filtered, evaporated and purified on Si02 column eluted with EtOAc/CH2Cl2 (1 :20 -1 : 10) to provide the title product (6.26 g, 82% yield). MS ( LSI ) m//+ for Ci8H23Na03P calcd. 341.1 (M + Na), found 341.1.
Example 56. P,P~bis(2-hydroxyethyl)-N-(3~(pyridin-2-yldisulfanyl)propyl)phosphinic amide
Figure imgf000104_0001
Bis(2-(benzyloxy)ethyl)phosphine oxide (1.0 g, 3.14 mmol) and Pd/C (0.20 g, 10% Pd on C) in THE (30 ml) in a 250 ml hydrogenation bottle was conducted with H2 (30 psi). After shaken for 2 h, the mixture was filtered through ( elite bed, concentrated and co-evaporated with CH2Cl2/toluene. The mixture was redissolved in CH2C12 (30 ml) and CCI4 (3 ml) on ice bath, followed by dropwise addition of 3-(pyridin-2-yldisulfanyl)propan-l -amine (1.10 g, 5.50 mol) in a 20% aqueous solution of NaOH (10 ml). The reaction mixture was stirred at 20- 25 °C for 2 h. The organic layer was separated, washed with a saturated solution of K >( Ό¾ (2 x30 mL) and water (3x30 mL), dried with Na iS( ) , concentrated in vacuo and
chromatographed on silica gel to afford the title compound (665 mg, 63% yield). MS (ESI) for C ' ljl Li NjNai PS: calcd. 359.1 (M + Na), found 359.1.
Example 57. P,P-bis(2-(benzyloxy)ethyl)-N-methyl-N-(3-(methylamino)propyl)-phosphinic amide
Figure imgf000105_0001
To a mixture of optically pure bis(2-(benzyloxy)ethyl)phosphine oxide (1.00 g, 3.14 mmol), LhN (5 ml), and CCI4 (25 mL) was added N,N-dimethylpropane- l,3-diamine (1.80 g, 1 7.6 mmol) at 0 °C. The resulted mixture was kept at 0 °C for 30 min and then warmed up to room temperature. After the mixture was stirred overnight, solvent was removed under a reduced pressure, and water was added. The mixture was extracted with EtOAc, and the organic layers were dried over anhydrous MgSC^. After fi ltration and removal of the solvent, the residues were purified with flash SiOj chromatography to afford the title compound (1.09 g, 83% yield). MS (ESI) m z+ for C^HasN^aOsP calcd. 441.2 (M + Na), found 441.2.
Example 58. P,P-bis(2-hydroxyethyl)-N-methyl-N-(3-(methylamino)propyl)phosphinic amide
Figure imgf000105_0002
P,P-bis(2-(benzyloxy)ethyl)-N-methyl-N-(3-(methylamino)propyl)phosphinic amide (1.00 g, 2.39 mmol) and Pd/C (0.20 g, 10% I 'd on C) in methanol (40 ml) in a hydrogenation bottle was conducted H2 (30 psi). The mixture was shaken for 4 h, filtered through celite bed, concentrated and used for the next step reaction without further purification. Yield 0.566 g, 99% crude yield). MS (ESI) m/z+ for ( \,,I L,N:Na( )¾P calcd. 261.1 (M + Na), found 261.1. Example 59. N-(3-((bis(2-hydroxyethyl)phosphoryl)(methyl)amino)propyl)-4-(2,5-dioxo-2,5- dihydro- 1 H-pyrrol- 1 -yl)-N-me thylbutanamide
Figure imgf000105_0003
4-( 2.5-dioxo-2.5-dihydro- 1 1 l-pyrrol- 1 -yl Sbutanoic acid (0.60 g, 3.27 mmol) in CII2CI2
(25 ml) was added (COCl)2 (1.00 g, 7.87 mmol) and DMF (20 μΐ). The mixture was stirred for 2 h, evaporated to dryness and then redissolved in I I II (20 ml). To the fresh made P,P-bis(2- hydroxyethyl)-N-methyl-N-(3-(methylamino)propyl)phosphinic amide (0.566 g, -2.38 mmol) in the mixture of THF (20 ml) and saturated Na2HP(¾ buffer (60 ml, pH 10) at 4 °C was added dropwise the fresh made 4~(2,5~dioxo~2,5~dihydro~lH-pyrrol-l~yl)butanoic acid chloride mixture in THF (20 ml) in 1 h. After addition, the mixture was stirred at RT for 3 h, neutrated with H3PO4 (cone.) to pi I -7.5, concentrated to ~ 65 ml, and extracted with CH2CI2 (3 x 40 ml). The organic layers were combined, dried over Na2S04, filtered, concerntrated and purified on a Si02 column eluted with MeOH/CH2Cl2 (1 : 10 ~ 1 :5) to afford the title compound (601 mg, 63% yield). MS (ESI) m/z+ for C17H30N3NaO6P calcd. 426.2 (M + Na), found 426.2.
Example 60. (((3-(4-(2,5-dioxo-2,5-dihydro-lH-pyrrol-l-yl)-N-methylbutanamido)- propyl)(methyl)-amino)phosphoryl)bis(ethane-2,l -diyl)
Figure imgf000106_0001
N-(3-((bis(2-hydroxyethyl)phosphoryl)(methyl)amino)propyl)-4-(2,5-dioxo-2,5-dihydro- lH-pyrrol-l-yl)-N-methylbutanamide (590 mg, 1.46 mmol) in the mixture of CH2C12 (20 ml) and Et3N (5 ml) was added mesyl chloride (0.40 ml, 5.16 mmol). The mixture was stirred for 4 h, concentrated and purified on a Si02 column eluted with EtOAc/CH2Cl2 (1: 15-1: 10) to afford the title compound (710 mg, 87% yield). MS (ESI) m/z+ for Ci H34N3NaOioPS2 calcd. 582.1 (M + Na), found 582.1.
Example 61. N-(3-((bis(2-hydroxyethyl)phosphoryl)(methyl)amino)propyl)-N-methyl-4-
Figure imgf000106_0002
4-(pyridin-2-yldisulfanyl)butanoic acid (1.05 g, 4.58 mmol) in CH2C12 (40 ml) was added (COCl)2 (1.20 g, 9.44 mmol) and DMF (20 μΐ). The mixture was stirred for 2 h, evaporated to dryness and then redissolved in THF (30 ml). To the fresh made P,P-bis(2- hydroxyethyl)-N-methyl-N-(3-(methylamino)propyl)phosphinic amide (0.566 g, -2.38 mmol) in the mixture of ΊΊ IF (20 ml) and saturated Na2l IP( )¾ buffer (70 ml, pi I 10) at 4 °C was added dropwise the fresh made 4-(pyridin-2-yldisulfanyl)butanoic acid chloride mixture in THF (30 ml) in 1 h. After addition, the mixture was stirred at RT for 3 h, neutrated with H3PO4 (cone.) to pi I -7.5, concentrated to - 75 ml, and extracted with CH2C12 (3 x 50 ml). The organic layers were combined, dried over Na2S04, filtered, concerntrated and purified on a Si02 column eluted with MeOI 1/( 1 1 >( Ί ι (1 : 10 ~ 1 :5) to afford the title compound (640 mg, 60% yield). MS (ESI) m z+ for
Figure imgf000107_0001
calcd. 472.2 (M + Na), found 472.2.
Example 62. ((Methyl(3-(N~methyl-4~(pyridin~2~yldisulfanyl)butanamido)propyl)-
Figure imgf000107_0002
N-(3-((bis(2-hydroxyethyl)phosphoryl)(methyl)amino)propyl)-N-methyl-4-(pyridin-2- yldisult anyl lbutanamide (630 mg, 1.40 mmol) in the mixture of CH2Q2 (20 ml) and Et3N (5 ml) was added mesyl chloride (0.40 ml, 5.16 mmol). The mixture was stirred for 4 h, concentrated and purified on a S1O2 column eluted with Kt( )Ac/( 'I l >( 'I? (1 : 15-1 : 10) to afford the title compound (720 mg, 85% yield). MS (ESI) 111//+ for
Figure imgf000107_0003
calcd. 628.1 (M + Na), found 628.1.
Example 63. (((3-(pyridin-2-yldisulfanyl)propyl)amino)phosphoryl)bis(ethane-2, 1 -diyl) bis(4- methylbenzenesulfonate)
Figure imgf000107_0004
P,P~bis(2-hydroxyethyl)-N-(3-(pyridin-2-yldisulfanyl)propyl)phosphinic amide (502 mg,
1.50 mmol) in the mixture of CH2CI2 (20 ml) and Et3N (5 ml) was added tosyl chloride (1.15 g, 6.03 mmol). The mixture was stirred for 4 h, concentrated and purified on a SiO > column eluted with EtOAc/CH2Cl2 (1 : 15-1 : 10) to afford the title compound (802 mg, 83% yield). MS (ESI) m/z+ for
Figure imgf000107_0005
calcd. 667.1 (M + Na), found 667.1.
Exam
Figure imgf000107_0006
To a stirred solution of PCI3 (5 ml, 2.0 M in CH2CI2) in benzene (100 ml) was added Hu iSnCHjCOi e (7.29 g, 20.0 mmol) under Ar. After refluxed 30 min, the mixture gave -85% ( ΊΡ(( Ί l iCOi e l.i, which was confirmed by N K and GC-MS after small portion was worked-up. Then reaction mixture was filtered through a thick celite bed, washed the bed with benzene, cooled to 0 °C, and bubbled with dry oxygen through the solution for 6 h. Then the solution was quickly evaporated at 0 °C, purged with argon and used without any purification. The mixture was around -85% pure of the title product checked by N.MR. MS (ESI) m/z+ for C6H10ClNaO5P calcd. 251.0 (M + Na), found 251.0.
Figure imgf000108_0001
To a stirred solution of PCI3 (5 ml, 2.0 M in CH2.CI2) in benzene (100 ml) was added Bu iSnCI l >( ( ) >Me (11.67 g, 32.0 mmol) under Ar. After refluxed 30 min, the mixture gave -93% P 'l l iC 'OjMe h, which was checked by NMR and GC after small portion was worked- up. Then reaction mixture was filtered through a thick eel he bed, washed the bed with benzene, cooled to 0 °C, and bubbled with dry oxygen through the solution for 6 h. Then the solution was evaporated, purified on S1O2 column eluted with EtAc/CH2Cl2 (1 : 15 - 1 :8) to afford the title compound (2.31 g, 87%). MS (ESI) m/z+ for („I I ,sNa( )7P calcd. 289.0 (M + Na), found 289.0.
Alternatively, To a stirred solution of P(SiMe3)3 (2.50 g, 10.0 mmol) in benzene (100 ml) was added Br( I I >( '( );>( I h (4.70 g, 30.90 mmol) under Ar. After refluxed 30 min, the mixture gave -89% P(( 'I !.->( '( ).->Me h. which was checked by NMR and GC after small portion was worked-up. Then reaction mixture was filtered through a thick celite bed, washed the bed with CH2CI2, evaporated, redissolved in CH2C12, charged with m-CPBA (2.07 g, 12.1 mmol), and then vigorously stirred for 1 h at room temperature. 6 h. Then the solution was evaporated, purified on S1O2 column eluted with EtAc/CH2Cl2 (1 : 15 - 1 :8) to afford the title compound (2.25 g, 85% yield). MS (ESI) for C9Hi5Na07P calcd. 289.0 (M + Na), found 289.0.
Exam -hydroxyethyl)phosphine oxide
Figure imgf000108_0002
Trimethyl 2,2',2"-phosphoryltriacetate (2.20 g, 8.27 mmol) in THF (50 ml) at 0 oC was added L1AIH4 (20 ml, 1.0 M in THE, 20 mmol). The mixture was stirred at 0 °C for 2.5 h, then quenched with MeOH (5 ml), diluted with CH2CI2 (100 ml), filtered through a short Si ( )j column eluted with MeOI 1/( 1 l.>CU concentrated and crystallized with EtOH/Hexane to afford the title compound (1.23 g, 82% yield). MS (ESI) m/z+ for ( '„I I , sNa( ).,P calcd. 205.07 (M + Na), found 205.07. Example 67. P,P-bis(chkiromethyl)-N-(3-(pyridin-2-yldisulfanyl)propyl)phosphinic amide
Figure imgf000109_0001
To 3-( pyndi n-2-yldisuHanyl )propan- 1 -amine (0.60 g, 3.00 mmol) in the mixture of CH2CI2 (20 ml) and Et3N (5ml) at 0 ~ 4 °C was added dropwise bis(chloromethyl)phosphinic chloride (0.54 g, 3.00 mmol from Ι ( Ί I Group) in CH2CI2 (5 ml) in 30 min. After addition, the mixture was stirred at RT for 1 h, evaporated, and purified on Si( 2 column eluted with EtAc/CH2Cl2 (1 :20 ~ 1 : 10) to afford the title compound (887 mg, 86% yield). MS (ESI) m/z+ for ( '„,l l Ls( 'l:N:Na( )PS: calcd. 367.0 ( M + Na), found 367.0.
Example 68. P,P-Bis((((2S,3aR)-2-fluoro-8-methoxy- 10-oxo-l ,2,3,3a, 10, 10a-hexahydro- benzo[b]cyclo-penta[e]azepin-7-yl)oxy)methyl)-N-(3-(pyridin-2-yldisulfanyl)propyl)- phosphinic amide
Figure imgf000109_0002
(2S,3aR)-2-fluoro-7-hydroxy-8-methoxy-l,3,3a, 10a-tetrahydrobenzo[b]cyclopenta[e]-azepin-
10(2H)-one (C2-fluoro substituted pyrrolo[2,l-c] [l ,4]benzodiazepines, Ret : Kamal, A. et al, Bioorg. Med. ( 'hem. Lett. (2004), 14, 2669-2672) (80 mg, 0.30 mmol) and Cs2C03 (112 mg, 0.34 mmol) were stirred in butanone (5 ml) for 5 min, followed by addition of P,P- bis(chloromethyl)-N-(3-(pyridin-2-yldisulfanyl)propyl)phosphinic amide (50 mg, 0. 145 mmol) and KI (4 mg, 0.024 mmol). The mixture was stirred under Ar for 24 h, concentrated and purified on preparative IIPLC C-18 column (25 x 2 cm) eluted with H2O/CH3CN (from 5% CH3CN to 60% CH3CN in 45 min, v = 9 ml/min ) to afford the title compound (73 mg, 63% yield). MS (ESI) m/z+ for C38H41F2N4O7PS2 calcd. 821.2 (M + Na), found 821.2, 837.3 (M + K), 839.2 (M + Na + H20), 857.2 (M + Na + 2H20).
The in vitro potency measurement against Ramos cells in 37 °C, 5 day incubation was IC5o = 0.1 ~ 0.5 nM.
Example 69. N-(3-((bis(2-(((2S,3aR)-2-fluoro-8-methoxy-10-oxo-l ,2,3,3a, 10, 10a- hexahydrobenzo[b]cyclopenta[e] azepin-7-yl)oxy)ethyl)phosphoryl)(methyl)amino)-propyl)- -(2,5-dioxo-2,5-dihydro- 1 H-pyrrol- 1 -yl)-N-methylbutanamide
Figure imgf000110_0001
(2S a )-2-fluoro-7-hydroxy-8-methoxy-1 ,3a 10a-tetrahydrobenzo[b]cyclopenta[e]- azepin-10(2H)-one (80 nig, 0.30 rnniol) and Cs2C03 (110 nig, 0.33 mmol) were stirred in butanone (5 ml) for 5 min, followed by addition of (((3-(4-(2,5-dioxo-2,5-dihydro-lH-pyrrol-
1 -yl)-N-methylbutanamido)propyl)(methyl)amino)phosphoryl)bis(ethane-2,l -diyl) dimethanesulfonate (82 mg, 0.146 mmol) and l (4 mg, 0.024 mmol). The mixture was stirred under Ar for 24 h, concentrated and purified on preparative HPLC C-18 column (25 x
2 cm) eluted with H20/CH3CN (from 5% CH3CN to 60% CH3CN in 45 min, v = 9 ml/min) to afford the title compound (79 mg, 61% yield). MS (ESI) m//+ ( 'j I L41 ·'_-> N Na( ) 1 nP ca 1 cd .
916.3 (M + Na), found 916.3, 932.3 (M + K), 934.3 (M + Na + H20), 952.3 (M + Na + 2H20).
Example 70. N-(3-((bis(2-(((2S,3aR)-2-fluoro-8-methoxy-10-oxo-l ,2,3,3a,10,10a- hexahydrobenzo[b]cyclopenta[e]azepin-7-yl)oxy)ethyl)phosphoryl)(methyl)amino)~propyl)~ -methy] -4-(pyridin-2-yldisulfanyl)butanamide
Figure imgf000110_0002
(2S,3aR)~2-fluoro-7~hydroxy~8~methoxy-l,3,3a,10a-tetrahydrobenzo[b]cyclopenta[e]~ a/epin- 10(211 )-one (80 mg, 0.30 mmol) and Cs2C03 (110 mg, 0.33 mmol) were stirred in butanone (5 ml ) for 5 min, followed by addition of ((methyl(3-(N-methyl-4-(pyridin-2- yldisulfanyl)~butanamido)propyl)amino)phosphoryl)bis(ethane~2, l~diyl) dimethanesulfonate (87 mg, 0.144 mmol) and KI (4 mg, 0.024 mmol). The mixture was stirred under Ar for 24 h, concentrated and purified on preparative HPLC C-18 column (25 x 2 cm) eluted with H20/CH3CN (from 5% CH3CN to 60% CH3CN in 45 min, v = 9 ml/min) to afford the title compound (82 mg, 61 % yield). MS (ESI) m/z+ QeHseFaNsOgPSz calcd. 962.3 (M + Na), found 962.3 ( M + Na), 978.3 (M + K), 980.3 ( M + Na + I !_,( )). 996.3 ( M + Na + 2H20). Example 71. Sodium (2R,2'R,3a ,3a' ,4S,4'S)-7,7'-(((((3-(4-mercapto-N-methylbutan- amido)propyl)(methyl)amino)phosphoryl)bis(ethane-2, l-diyl))bis(oxy))bis(2-fluoro~8- me enta[e] azepine~4-sulfonate)
Figure imgf000111_0001
N-(3-((bis(2-(((2S,3aR)-2-fluoro-8-methoxy-10-oxo-l ,2,3,3a, 10, 10a- hexahydrobenzo[b]-cyclopenta[e]a7 pin-7-yl)oxy)ethyl)phosphoryl)(methyl)amino)propyl)- N-methyl-4-(pyridin-2-yldisulfanyl)butanamide (70 mg, 0.074 mmol) in Na2I IP )4 (50 niM, 5 ml) buffer containing 10% DMA (v/v), and 2 niM sodium bisulfite pi I 7.8 was stirred for lh,followed by treated with I CEP (40 mg, 0.139 mmol, neutralized with Nal !( "( )¾ sat.). The mixture was stirred for 1 , concentrated and purified on preparative IIPLC C-18 column (25 x 2 cm) eluted with H20/CH3CN (from 2% CH3CN to 50% CH3CN in 45 min, v = 9 ml/mi n ) to afford the title compound (52 mg, 68% yield). MS (ESI) m/z- C4iH54 2N4Na2Oi4PS3 calcd. 1037.2 (M - I I ), found 1037.2.
Example 72. Preparation of Conjugates of the PBD derivative dimers containing free thiol to
Figure imgf000111_0002
An amount of 1.0 equiv of linkers (SMCC or SMPDP, ~2 mM) in DMA was added to PBS buffer ( pi I 6.0) containing 1.5 equiv of Sodium (2R,2'R,3aR,3a'R,4S,4'S)-7,7'-(((((3-(4- mercapto~N~methylbutanamido)propyl) (methyl)amino)phosphoryl)bis(ethane-2, 1 - diyl))bis(oxy))bis(2-fluoro-8-methoxy-10-oxo-l , 2, 3,3a,4,5, 10,10a- octahydrobenzo[b]cyclopenta[e]azepine-4-sulfonate), and the mixtures were incubated for 45-120 min at 4 -20 °C. Then 0.1-0.25 equiv of mAb in a buffer solution (~pH 8) was added to the linker-drug mixture and the final pi I adjusted to 7.0-8.0. After incubating for 2-24 h at room temperature, the mixture was purified using a Sephadex G25 column equilibrated with PBS, pH 6.5. The number of PBD derivative dimer molecules incorporated was determined by UV at 254 11 m and 280 nm, or by QTOF mass spectrum.
In Vitro potency measurement against Ramos cells in 37 °C, 5 day incubation
Figure imgf000112_0001
Example 73. In Vitro Cytotoxicity Assays.
General Procedure Used: Samples of unconjugated free drug compounds or drug conjugates were added to 96- we 11 flat bottomed tissue culture plates and titrated using serial dilutions to cover the desired molar range. Antigen positive (Ag+) or Antigen negative (Ag~) cells were added to the wells in specific cell densities (1000 ~ 10000 cells/wall) in such a way that there were triplicate samples for each drug concentration for each corresponding cell line. All other cell lines were grown in RPMI-1640 (catalog no. 11875-085, Invitrogen), supplemented with 10% fetal bovine serumand gentamycin. The plates were then incubated at 37 °C in an atmosphere of 5% C(¾ for 5 days. At the end of the incubation period cytotoxic potencies were then assessed using a WS 1 -8 based cell viability assay and surviving cells were measured by developing with WST-8 (2-7 hours). The absorbance in each well was measured and the surviving fraction of cells at each concentration was plotted to reveal the cytotoxicity and/or antigen specificity (of the conjugates). The potency and specificity of the antibody-drug conjugates were measured against antigen-expressing cells, with and without the additions of an excess amount of blocking unconjugated antibody to show specificity of the killing effect.
REFERENCES
(1) Ma, C; et al. Acta Crystallogr Sect E Struct Rep Online 2012, 68, ol26.
(2) amal, A. ; et al. Bioorg Med Chem Lett 2012, 22, 571.
(3) Hartley, J. A. ; et al. Invest New Drugs 2012, 30, 950.
(4) Bose, D. S. ; et al. Eur J Med Chem 2012, 50, 27.
(5) Shankaraiah, N. ; et al. .1 Org Chem 2011, 76, 7017.
(6) Rahman, K. M.; et al. Nucleic Acids Res 201 1 , 39, 5800.
(7) Ourahou, S.; et al. Acta Crystallogr Sect E Struct Rep Online 2011, 67, ol906. (8) Kamal. A.; et al. ChemMedChem 2011, 6, 1665.
(9) Kamal. A.; et al. Bioorg Med Chem 2011, 19, 2565.
(10) Kamal, A.; et al. Eur .1 Med Chem 2011, 46, 3820.
(11) Jebani, A.; et al. Acta Crystallogr Sect E Struct Rep Online 2011, 67, o2003.
(12) Ilsieh. M. C; et al. Toxicol Appl Pharmacol 2011, 255, 150.
(13) Hopton, S. R.; Thompson, A. S. Biochemistry 2011, 50, 4720.
(14) Guerrini, G.; et al. Bioorg Med Chem 2011, 19, 3074.
(15) Araujo, A. C; et al..1 Med Chem 2011, 54, 1266.
(16) Antonov. I).; Thurston, D. E. Chem Rev 2011, 111, 2815.
(17) Rettig, M.; et al. Org Biomol Chem 2010, 8, 3179.
(18) Ourahou, S.; et al. Acta Crystallogr Sect E Struct Rep Online 2010, 66, ol653.
(19) Ourahou, S.; et al. Acta Crystallogr Sect E Struct Rep Online 2010, 66, o732.
(20) Kamal, A.: et al. Bioorg Med Chem Lett 2010, 20, 3310.
(21) Kamal. A.: et al. Bioorg Med Chem 2010.18, 526.
(22) Kamal, A.; et al. Bioorg Med Chem 2010.18, 4747.
(23) Kamal, A.; et al. Eur J Med Chem 2010, 45, 3924.
(24) Kamal, A.; et al. Bioorg Med Chem Lett 2010, 20, 5232.
(25) Kamal. A.; et al. Bioorg Med Chem 2010, 18, 6666.
(26) Kamal, A.; et al. Eur J Med Chem 2010, 45, 3870.
(27) Kamal, A.; et al. Mini Rev Med Chem 2010, 10, 405.
(28) Antonow, I).: et al..1 Med Chem 2010, 53.2927.
(29) Rettig, M.; et al. Biochemistry 2009, 48, 12223.
(30) Rettig, M.; et al. Bioorg Med Chem 2009, 17, 919.
(31) Lee, C. II.; et al. Chem Biol Interact 2009, 180, 360.
(32) Kamal, A.; et al. Bioorg Med Chem 2009, 17, 1557.
(33) Kamal, A.; et al. Chemistry 2009, 15, 7215.
(34) IIu. W. P.; et al. Bioorg Med Chem 2009.17, 1172.
(35) Howard. P. W.: et al. Bioorg Med Chem Lett 2009, 19, 6463.
(36) Doyle, M.; et al. J Antimicrob Chemother 2009, 64, 949.
(37) Cipolla, I,; et al. Anticancer Agents Med Chem 2009, 9, 1.
(38) Benzeid. II.; et al. Acta Crystallogr Sect E Stmct Rep Online 2009, 65, o2322.
(39) Wells, G.; et al. Bioorg Med Chem Lett 2008, 18, 2147.
(40) Wade Calculi. M.; et al. J Mass Spectrom 2008, 43, 42.
(41) Tiberghien, A. C; et al. Bioorg Med Chem Lett 2008, 18, 2073. (42) Tamazyan. R.; et al. Acta Crystallogr Sect E Struct Rep Online 2008, 64, o587.
(43) Kamal. A.; et al. Bioorg Med Chem Lett 2008, 18, 3769.
(44) Kamal, A.; et al. ChemMedChem 2008, 3, 794.
(45) Kamal, A. ; et al. Bioorg Med Chem Lett 2008, 18, 2434.
(46) Kamal, A.; et al. Bioorg Med Chem 2008, 16, 7218.
(47) Kamal, A.; et al. Bioorg Med Chem Lett 2008, 18, 2594.
(48) Kamal, A.; et al. Bioorg Med Chem 2008, 16, 3895.
(49) Kamal, A.: et al. Bioorg Med Chem 2008. 16, 7804.
(50) I lu, W. Pet al. Chem Res Toxicol 2008, 21. 1330.
(51 ) Antonow, I ).; et al. Biochemistry 2008, 47, 11818.
(52) Zhao, D. M.; et al. Acta Crystallogr Sect E Struct Rep Online 2007, 64, o266.
(53) Kamal, A. ; et al. J Comb Chem 2007, 9, 29.
(54) Kamal, A.; et al. Bioorg Med Chem 2007, 15, 6868.
(55) Kamal, A.; et al. Bioorg Med Chem Lett 2007, 17, 5345.
(56) Hu, W. P.; et al. Chem Res Toxicol 2007. 20, 905.
(57) Antonow, I ).; et al. Bioorg Med Chem 2007, 15, 3041.
(58) Antonow, I).; et al. J Comb Chem 2007, 9, 437.
(59) Wang, J. J.; et al. .1 Med Chem 2006, 49, 1442.
(60) Masterson, L. A.; et al. Bioorg Med Chem Lett 2006, 16, 252.
(61) Khom, S.: et al. Mol Pharmacol 2006, 69, 640.
(62) Kamal, A.; et alBioorg Med Chem Lett 2006, 16, 1160.
(63) Venkatesan, A. M.; et al. Bioorg Med Chem Lett 2005, 15, 5003.
(64) Piatt, I). M.; et al. J Pharmacol Exp Ther 2005, 313, 658.
(65) Kamal, A.; et al. Bioorg Med Chem 2005, 13, 2021.
(66) Kamal, A.; et al. Bioorg Med Chem Lett 2005, 15, 2621.
(67) Hadjivassiieva, Ί .; et al. J Antimicrob Chemother 2005, 56, 513.
(68) Correa, A. ; et al. J Org Chem 2005, 70, 2256.
(69) Clingen, P. 11.: et al. Nucleic Acids Res 2005, 33, 3283.
(70) Cheung, A.; et al. J Chromatogr B Analyt Techno! Biomed Life Sci 2005, 822, 10. (71 ) Tiberghien, A. C; et al. Bioorg Med Chem Lett 2004, 14, 5041.
(72) Mischiati, C; et al. Biochem Pharmacol 2004, 67, 401.
(73) Masterson. L. A.; et al. Bioorg Med Chem Lett 2004, 14, 901.
(74) Kamal, A.; et al. Bioorg Med Chem 2004, 12, 4337.
(75) Kamal, A.; et al. Bioorg Med Chem Lett 2004, 14, 4107. (76) Kamal, A. ; et al. Bioorg Med Chem Lett 2004, 14, 4791.
(77) Kamal, A. ; et al. Bioorg Med Chem Lett 2004, 14, 4907.
(78) Kamal, A. ; et al. Bioorg Med Chem Lett 2004, 14, 471.
(79) Gregson, S. J. ; et al. J Med Chem 2004, 47, 1161.
(80) Chen, /, : et al. Bioorg Med Chem Lett 2004, 14, 1547.
(81) Alley, M. C; et al. Cancer Res 2004, 64, 6700.
(82) Tercel, M. ; et al. J Med Chem 2003, 46, 2132.
(83) Smellie, M.; et al. Biochemistry 2003, 42, 8232.
(84) Kumar, K. : Lown, .1. W. Oncol Res 2003, 13, 221.
(85) Kumar, R. ; Lown, j. W. Mini Rev Med Chem 2003, 3, 323.
(86) Kumar, R. ; Lown, J. W. Org Biomol Chem 2003, 1 , 3327.
(87) Kamal, A. ; et al. Bioorg Med Chem Lett 2003, 13, 3577.
(88) Kamal, A. ; et al. Bioorg Med Chem Lett 2003, 13, 3955.
(89) Kamal, A. ; et al. Bioorg Med Chem Lett 2003, 13, 3451.
(90) James. A. M. ; et al. Eur J Biochem 2003, 270, 2827.
(91 ) Hu, W. P. ; et al. Kaohsiung J Med Sci 2003, 19, 6.
(92) Gregson, S. J. ; et al. Bioorg Med Chem Lett 2003, 13, 2277.
(93) Lisowski, V. ; et al. .1 Enzyme Inhib Med Chem 2002, 17, 403.
(94) Kamal . A. ; Reddyet al. Bioorg Med Chem Lett 2002, 12, 1933.
(95) Kamal, A. ; et al. Curr Med Chem Anticancer Agents 2002, 2, 215.
(96) Kamal, A. ; et al. Bioorg Med Chem Lett 2002, 12, 1917.
(97) Berry, J. M.; et al. Bioorg Med Chem Lett 2002, 12, 1413.
(98) Li, M.; et al. Eur J Pharmacol 2001, 413, 63.
(99) Langlois, N. ; et al. J Med Chem 2001, 44, 3754.
(100) Kamal, A. ; et al. Bioorg Med Chem Lett 2001 , 1 1 , 387.
(101) Hu, W. P. ; et al. J Org Chem 2001 , 66, 2881.
(102) Gregson, S. J. ; et al. Bioorg Med Chem Lett 2001 , 11, 2859.
(103) Reddy, B. S. ; et al. Anticancer Drug Des 2000, 15, 225.
(104) Kamal. A. ; et al. Bioorg Med Chem Lett 2000, 10, 2311.
(105) Gregson. S. J. ; et al. Bioorg Med Chem Lett 2000, 10. 1845.
(106) Gregson, S. J. ; et al. Bioorg Med Chem Lett 2000, 10, 1849.
(107) Baraldi, P. G. ; et al. Nucleosides Nucleotides Nucleic Acids 2000,
(108) Ashwell, M. A.; et al. Bioorg Med Chem Lett 2000, 10, 783.
(109) Wilson, S. C ; et al. J Med Chem 1999, 42, 4028. 110) Thurston, D. E.; et al. J Med Chem 1999, 42, 1951.
11) Reddy, B. S. ; Sondhi, S. M. ; Lown, J. W. Pharmacol Ther 1999, 84, 1. ;i l2) Ohtake, Y. ; et al. Bioorg Med Chem 1999, 7, 1247.
113) Damayanthi, Y.; et al. J Org Chem 1999, 64, 290.
114) Baraldi, P. G. ; et al. Farmaco 1999, 54, 15.
115) Baraldi, P. G. ; et al. J Med Chem 1999, 42, 5131.
116) Aranapakam, V.; et al. Bioorg Med Chem Lett 1999, 9, 1737.
117) Aranapakam, V.; et al. Bioorg Med Chem Lett 1999, 9, 1733.
118) Guiotto, A. ; et al. Bioorg Med Chem Lett 1998, 8, 3017.
119) Baraldi, P. G. ; et al. Curr Pharm Des 1998, 4, 249.
120) Baraldi, P. G. : et al. Bioorg Med Chem Lett 1998, 8, 3019.
121) Puvvada, M. S. ; et al. Biochemistry 1997, 36, 2478.
122) Kossakowski, J. ; et al. Acta Pol Pharm 1997, 54, 483.
123) Walton, M. I.; et al. Cancer Chemother Pharmacol 1996, 38, 431.
124) Thurston, D. E.; et al. J Org Chem 1996, 61, 8141.
125) Mickelson, J. W. ; et al. J Med Chem 1996, 39, 4654.
126) Aoyama, T. ; Shioiri, T. Yakugaku Zasshi 1995, 1 15, 446.
127) Acri, J. B.; et al. Eur J Pharmacol 1995. 278, 213.
128) TenBrink, R. E.; et al. J Med Chem 1994, 37, 758.
129) Baraldi, P. G. ; et al. J Med Chem 1994. 37, 4329.
130) Puvvada, M. S. ; et al. Nucleic Acids Res 1993, 21, 3671.
131 ) Serra, M. ; et al. J Pharmacol Exp Ther 1992, 263, 1360.
132) Massa, S. ; et al. J Med Chem 1992, 35, 4533.
133) Werner, W. ; et al. Biophys Chem 1990, 35, 271.
134) Trapani. G. ; et al. Farmaco 1990, 45, 577.
135) Osada, I . ; et al. Agric Biol Chem 1990, 54, 2883.
136) Morris, S. J. ; et al. J Antibiot (Tokyo) 1990, 43, 1286.
137) Jones, G. B. ; et al. Anticancer Drug Des 1990, 5, 249.
138) Kaneko, T. ; et al. J Med Chem 1985, 28, 388.
139) Konishi, M.; et al. J Antibiot (Tokyo) 1984, 37, 200.
140) Wright, W. B., Jr. ; et al. J Med Chem 1980, 23, 462.
141) Porretta, G. C ; et al. Farmaco Sci 1979, 34, 914.
142) Wright, W. B., Jr. ; et al. J Med Chem 1978, 21, 1087.
143) Scalzo, M.; et al. Farmaco Sci 1977, 32, 579. (144) Chimenti, F.; et al. Farrnaco Sci 1977, 32, 339.
(145) Vomero, S. ; et al. Farrnaco Sci 1976, 31, 681.
(146) De Martino, G. ; et al. Farrnaco Sci 1976, 31, 785.
(147) Scalzo, M.; et al. Farrnaco Sci 1974, 29, 459.

Claims

1. Compounds of formula (I)
Figure imgf000118_0001
Wherein
— represents an optional single bond;
== represents either a single bond or a double bond ;
It provided that when == represents a single bond, U and U', the same or different, independently represent H, R5, or an amine protecting moiety, or the linking group (L') with the reactive group or a cell binding agent bonded thereto.
V and V, the same or different, are independently selected from the group consisting of H, OH, -NHOH; an ether (-OR5); an ester (-OCOR5,e.g. an acetate); a carbonate ( -OCOOR5); an amine ( -NR5R5', -NR5COR5', -NR5NR5'NR5"); a carbamate ( -OCONR5R5'); a guanidinum (- NR5(C=NH)NR5'R5"); an amino acid, or peptide (-NRsCO(Aa)t, wherein Aa is an amino acid or a polypeptide containing between t =1- 100 amino acid units; a optionally substituted 5- or 6- membered nitrogen-containing heterocycle (such as piperidine, tetrahydropyrrole, pyrazole, morpholine); a cyclic carbamate, such that U and V, and/or U'and V are a part of the cycle; a urea ( -NR5CONR5'R5"); a thiocarbamate ( -OCSNHR5); a cyclic thiocarbamate such that U and V, and U'and V are a part of the cycle; a thiol (-SH); a sulfide such as -SR5; a sulphoxide ( -SOR5); a sulfone ( -SOOR5); a sulphite (-SO3, HSO3, HS02, or a salt of HSO3", S03 2" or -HS02 ~); a bisulphite (-OSO3); a sulfonamide (-NR5SOOR5'); metabisulfite ( H2S205 or a salt of S205 2"); Mono-,di-, tri-, and tetra-thiophosphate (PO3SH3, P02S2H2, POS3H2, PS4H2 or a salt of PO3S3", P02S2 3", POS3 3", PS4 3"); thiophosphate ester (R50)2POSR5'); thiosulfate ( HS203 or a salt of S203 2"); dithionite (HS204 or a salt of S2C¼ "); phosphorodithioate(P(=S)(OR5)(S)(OH) or a salt thereof form with a cation); optionally cyclic amine such that U and V, and U'and V are a part of the cycle; a hydroxylamine derivative (-NR5OR5'); hydroxamic acid (R5C(=0)NOH or a salt formed with a cation);
formaldehyde sulfoxylate (HOCH2S02 ~, or its salts); an amide ( -NR5COR5 ); an azido (-N3); a cyano; a halo; a trialkyl, a phosphoramidate (phosphoramidic acid), or triarylphosphonium; an aminoacid-derived group; or the linking group (L') with the reactive group or a cell binding agent bonded thereto. The R5, R5' and R5" are described below.
and when == represents a double bond, U and LP are absent; V and V represent H, a linear or branched alkyl having 1 to 4 carbon atoms
1, m, n, Γ, m' and n' are the number 0, 1, 2, 3, 4, 5 or 6.
X, X', Y and Y' the same or different, independently, represent N, O, S, an alkyl, such as CH2 or CHR5, an alkene, such as =CH- or =CR5-, an ether, such as -C(OR5)H-.
Z and Z' the same or different, independently, represent N, CH, C-R5, COH or COR5.
Ri, R2, R3, R4, Ri', R2', R3' , and R4' are the same or different and independently chosen from -H, an optionally substituted linear, branched or cyclic alkyl, alkenyl, alkynyl or aryl having from 1 to 10 carbon atoms, a polyethylene glycol unit— (OCH2CH2)tRs, halogen, guanidinium [-NH(C=NH)NH2], -OR5, -NR5R5', -N<¾, -NCO, -NR5COR5', --SR5, a sulfoxide represented by -SOR5, a sulfone represented by— S02R5, a sulfonate— SO3 M"1",— SO3H, a sulfate -OSO3 M"1", OSO3H, a sulfonamide represented by -SC NRsRs', cyano, an azido,— COR5, -OCOR5, -OCONR5R5', CF3, OR5, aryl, heterocycle, or P(0)R5R5'R5" or the linking group (L') with the reactive group, or a cell binding agent bonded thereto;
R5, R5' and R5" are independently selected from H, linear, branched or cyclic alkyl, alkenyl alkynyl or aryl having from 1 to 10 carbon atoms, a polyethylene glycol unit— (CH2CH20)r-Ri, an optionally substituted aryl having 6 to 18 carbon atoms, an optionally substituted 5- to 18- membered heteroaryl ring containing one or more heteroatoms independently selected from nitrogen, oxygen, and sulfur, and an optionally substituted 3- to 18-membered heterocyclic ring containing 1 to 6 heteroatoms independently selected from O, S, N and P; R5 R5' and R5" can further be substituted with at least one substituent selected from -N(Ri)(R2), -C02H, -SO3H, - ORi, -C02Ri, -CONRi, -P02RiR2, PORiR2R3 or -PO3H, or pharmaceutical salts.
q = 0, 1 or 2.
In addition, R2 and R3 join together, or R2' and R3' join together to form a = (double bond), =0 (ketone), =S, =NR5, -C(=0)R5, or a double bond containing group =CRsR5' ; and Ri and R2 join together, or Ri' and R2' join together, or R3 and R4join together or R3' and R4' join together form an aromatic, heterocyclic, or heteroaryl ring. L and L' are the same or inpendently a linker or a linker-cell binding molecule (Q) covalently bound cluster, or a linker which has a functional group on the linker that enables reaction with a cell-binding agent (CBA). L, when is a linker, is preferred a releasable linker, which has the formula of:— Ww— (Aa)r— Tt— ; or— Ww— (Aa)r— Tt— Q; or Q— Ww—
(Aa)r— Tt— ; wherein: W is a Stretcher unit; w is 0 or 1 ; Aa is independently an Amino Acid unit; r is independently an integer ranging from 0 to 100. The Stretcher unit W independently contains a self-immolative or a non-self-immolative component, peptidyl units, a hydrazone bond, a disulfide, an ester, an oxime, an amide, or a thioether bond. The self-immolative unit include, but are not limited to, aromatic compounds that are electronically similar to the para- aminobenzylcarbamoyl (PAB) groups such as 2-aminoimidazol-5 -methanol derivatives, heterocyclic PAB analogs, beta-glucuronide, and ortho or para-aminobenzylacetals. Preferably,
Figure imgf000120_0001
wherein the (*) atom is the point of attachment of additional spacer or releasable linker units, or the cytotoxic agent, and/or the binding molecule (CBA); X 1 , Y1 , Z2 and Z 3 are independently NH, or O, or S; Z1 is H, or NH, or O or S independently, v is 0 or 1; Q1 is independently H, OH, Ci~C6 alkyl, (OCH2CH2)n F, CI, Br, I, OR5, or SR5, NR5R5', N=NR5, N=R5 , NR5R5 , N02, SOR5R5 , S02R5, SO3R5, OSO3R5, PR5R5', POR5R5', P02R5R5', OPO(OR5)(OR5 , or OCH2PO(OR5(OR5 wherein R5 and R5' are as defined above, preferably R5 and R5' are independently selected from H, Ci-Cs of alkyl; C2~Cs of alkenyl, alkynyl, heteroalkyl; C3~Cs of aryl, heterocyclic, carbocyclic, cycloalkyl, heterocycloalkyl, heteroaralkyl, alkylcarbonyl; or pharmaceutical cation salts.
The non-self-immolative linker component is any one of the following structures: (CH2)nCO(OCH2CH2)rOCH3 (CH2)nCON(CH2CH20)rCOCH3 (CH2CH20)r* *CH*
Figure imgf000121_0001
Figure imgf000122_0001
Wherein the (*) atom is the point of attachment of additional spacer or releaseable linkers, the cytotoxic agents, and/or the binding molecules; X1, Y1, Q1, R5, R5' are as defined above; r is 0-100; m, n and p are 0-6.
Spacers (T) is a linear, branched or cyclic alkyl, alkenyl, alkynyl or aryl having from 1 to 10 carbon atoms, or polyethylene glycol (-CH2CH2O- ) spacer; and t is 0, or 1-100. T can also be that undergo cyclization upon amide bond hydrolysis, such as substituted and unsubstituted 4- aminobutyric acid amides, appropriately substituted bicyclo[2.2.1] and bicyclo[2.2.2] ring systems, and 2-aminophenylpropionic acid amides.
In addition L can be R5, OR5, SR5, NHR5, or NR5R5 , thus Rls R2, R3, R4, Rr, R2>, R3\ or R4 ' , or U, or U', or V, or V on the formula (I) can be used to linked to Q via Stretcher units (Ww) or via Spacer units (Tt) when the compound is used for conjugation to a cell binding agent. Q is a cell binding molecule (CBA), or a functional group that enables reaction with a cell- binding agent, or a functional group capable of reacting with a linker attached on a cell binding agent. The function group is chosen from a thiol, an amine, a hydrazine, an alkoxylamino, a disulfide substituent, a maleimido, a haloacetyl group, a carboxy acid, anN-hydroxy succinimide ester, a ketone, an ester, an aldehyde, an alkynyl, an alkenyl, or protected thiol or disulfide group, such as SAc, SSRi or SSAr. Ar is aromatic group or hetero aromatic group.
or a pharmaceutically acceptable salt, hydrates, or hydrated salt, or the polymorphic crystalline structure of the compounds thereof,
or the optical isomers, racemates, diastereomers or enantiomers.
2. A compound according to claim 1 of formula (I) having the following entiomer formula (la), (lb) and (Ic).
Figure imgf000123_0001
— represents an optional single bond;
== represents either a single bond or a double bond ; X, Χ', Y, Υ', Ζ, Ζ', 1, 1', m, η ', η, η', R Rr, R2, RT, R3, R3', R4, R4', L are as defined in formula (I).
3. A compound according to claim 1 of formula (I) having the following formula (II), (III), (IV).
Figure imgf000124_0001
wherein X, X', Y, Y', Z, Z', 1, 1', m, m', n, n', R Ri', R2, R2', R3, R3', R4, R4', L are as defined in formula (I).
V and V the same or different are independently selected from the group consisting of OH, an ether such as -OR5, an ester (e.g. an acetate), such as -OCOR5, -COOR5, a carbonate such as - OCOOR5, a carbamate such as -OCONR5R5', a cyclic carbamate, such that N10 and CI 1 are a part of the cycle, a urea such as -NRCONR5R5', a thiocarbamate such as -OCSNHR5, a cyclic thiocarbamate such that N10 and CI 1 are a part of the cycle, -SH, a sulfide such as -SR5, a sulphoxide such as -SOR5, a sulfone such as -SOOR5, a sulphite (sulfite) such as -S03 ", a bisulphite such as -OS03 ~, a sulfonamide such as -NRSOOR, an amine such as -NRR', optionally cyclic amine such that N10 and CI 1 are a part of the cycle, a hydroxylamine derivative such as -NR5OR5', an amide such as -NR5COR5', -NR5CONR5 R5", an azido such as -N3, a cyano, a halo, a trialkyl or triarylphosphonium, an aminoacid-derived group.
V" is (=)0, (=)NH, (=)N-CONR5R5', (=)N-COR5, (=)N-COOR5, (=)N-0-R5
R5, R5' and R5" are independently selected from H, Ci-Cs of alkyl, alkenyl, alkinyl, heteroalkyl, aryl, arylalkyl, carbonylalkyl, or pharmaceutical salts. Rs, R5' and R5" can further be substituted with at least one substituent selected from -N(Ri)(R2), -C02H, -SO3H, -ORi, -C02Ri, -CONRi, -P02RiR2, PORiR2R3 and -P03H or M (Na, K, Ca, ammonium or the other
pharmaceutically acceptable salt), or linked a cell binding agent via Stretcher units (Ww) or via Spacer units (Tt). W, w, T and t are as defined in formula (I).
or a pharmaceutically acceptable salt, hydrates, or hydrated salt, or the polymorphic crystalline structure of the compounds thereof,
or the optical isomers, racemates, diastereomers or enantiomers.
4. A compound according to claim 1 of formula (I) having the following formula (V), (VI), (VII), (VIII), (IX), (X), (XI), (XII), (XIII), (XIV), (XV), (XVI), (XVII).
Figure imgf000125_0001
124
Figure imgf000126_0001
Figure imgf000127_0001
Wherein
— represents an optional single bond;
=== represents either a single bond or a double bond ;
wherein U, LP, V, V, n, n', X, X' and L are the same as defined in formula (I). R6 and Rg' are the same as R5 as defined in formula (I),preferably selected independently from Ci~Cio of alkyl, alkenyl, alkinyl, aryl, cyclic, cyclohetero, haloalkyl, alkoxy, haloalkoxy or of alkylamino; or halogen, or dihalogens, -CF3, -N02, -CN or H; or linked a cell binding agent via Stretcher units (Ww) or via Spacer units (Tt). W, w, T and t are as defined in formula (I).
or a pharmaceutically acceptable salt, hydrates, or hydrated salt, or the polymorphic crystalline structure of the compounds thereof,
or the optical isomers, racemates, diastereomers or enantiomers.
5. The compound according to claim 1 wherein the linker L is selected from the group consisting of: R5, OR5, SR5 or NR5R5 , or: -(CR5R6)m(Aa)r(CR7R8)n(OCH2CH2)tQ, -(CR5R6)m(CR7R8)n(Aa)r(OCH2CH2)tQ, -(Aa)r(CR5R 6)m(CR7R8)n(OCH2CH2)tQ, -(CR5R6)m(CR7R8)n(OCH2CH2)r(Aa)tQ, -(CR5R6)m- (CR7=CR8)(CR9Rio)n(Aa) t(OCH2CH2)rQ, -(CR5R6)m(NR11CO)(Aa)t(CR9Rio)n-(OCH2CH2)rQ, - (CR5R6)m(Aa)t(NRiiCO)(CR9Rio)n(OCH2CH2)rQ,-(CR5R6)m(OCO)(Aa)t(CR9Rio)n-(OCH2CH2)rQ, -(CR5R6)m(OCNR7)(Aa)t(CR9Rio)n(OCH2CH2)rQ, -(CR5R6)m(CO)(Aa)t.(CR9Rio)n(OCH2CH2)rQ, -(CR5R6)m(NRiiCO)(Aa)t(CR9Rio)„(OCH2CH2)rQ, -(CR5R6)m-(OCO)(Aa)t(CR9Rio)„- (OCH2CH2)rQ, -(CR5R6)m(OCNR7)(Aa)t(CR9Rio)„(OCH2CH2)rQ, -(CR5R6)m(CO)(Aa)t.
(CR9R10)„(OCH2CH2)rQ, -(CR5R6)m-phenyl-CO(Aa)t(CR7R8)nQ, -(CR5R6)m-furyl-CO- (Aa)t(CR7R8)nQ, -(CR5R6)m-oxazolyl-CO(Aa)t(CR7R8)nQ, -(CR5R6)m-thiazolyl-CO(Aa)t.
(CCR7R8)nQ, -(CR5R6)t-thienyl-CO(CR7R8)nQ, -(CR5R6)t-imidazolyl-CO(CR7R8)nQ, -(CR5R6)t- morpholino-CO(Aa)t(CR7R8)nQ, -(CR5R6)tpiperazino-CO(Aa)t(CR7R8)nQ, -(CR5R6)t- N-methylpiperazin-CO(Aa)t(CR7R8)nQ, -(CR5R)m-(Aa)tphenyl-Q, -(CR5R6)m-(Aa)tfuryl-Q, - (CR5R6)m-oxazolyl(Aa)t-Q, -(CR5R6)m-thiazolyl(Aa)t-Q, -(CR5R6)m-thienyl-(Aa)tQ, -(CR5R6)m- imidazolyl(Aa)t-Q, -(C R5R6)m-morpholino-(Aa)tQ, -(CR5R6)m-piperazino-(Aa)tQ, -(CR5R6)m- N-methylpiperazino-(Aa)tQ, -K(CR5R6)m(Aa)r(CR7R8)n(OCH2CH2)tQ, -K(CR5R6)m(CR7R8)n(Aa )r(OCH2CH2)tQ, -K(Aa)r(CR5R6)m(CR7R8)n(OCH2CH2)tQ, -K(CR5R6)m(CR7R8)n(OCH2CH2)r(Aa )tQ, -K(CR5R6)m(CR7=CR8)(CR9R10)„(Aa)t(OCH2CH2)rQ, -K(CR5R6)m(NR11CO)(Aa)t(CR9R10)„( OCH2CH2)rQ, -K(CR5R6)m(Aa)t(NRi iCO)(CR9Ri0)n(OCH2CH2)rQ, -K(CR5R6)m(OCO)(Aa)t(CR9 Rio)„(OCH2CH2)rQ, -K(CR5R6)m(OCNR7)(Aa)t(CR9Rio)„(OCH2CH2)rQ, -K(CR5R6)m(CO)(Aa)t( CR9Rio)„(OCH2CH2)rQ, -K(CR5R6)m(NRi iCO)(Aa)t(CR9Ri0)„(OCH2CH2)rQ, -K(CR5R6)m(OCO) (Aa)t(CR9Rio)„(OCH2CH2)rQ, -K(CR5R6)m(OCNR7)(Aa)t(CR9Rio)„(OCH2CH2)rQ, -K(CR5R6)m( CO)(Aa)t(CR9R10)„(OCH2CH2)rQ, -K(CR5R6)m-phenyl-CO(Aa)t(CR7R8)nQ, -K(CR5R6)m- furyl-CO(Aa)t(CR7R8)nQ, -K(CR5R6)m-oxazolyl-CO(Aa)t(CR7R8)nQ, -K(CR5R6)m- thiazolyl-CO(Aa)t(CCR7R8)nQ, -K(CR5R6)t-thienyl-CO(CR7R8)nQ, -K(CR5R6)t- imidazolyl-CO(CR7R8)nQ, -K(CR5R6)tmorpholino-CO(Aa)t(CR7R8)nQ, -K(CR5R6)tpiperazino- CO(Aa)t(CR7R8)nQ, -K(CR5R6)t-N-methylpiperazin-CO(Aa)t(CR7R8)nQ, -K(CR5R)m- (Aa)tphenyl-Q, -K(CR5R6)m-(Aa)tfuryl-Q, -K(CR5R6)m-oxazolyl(Aa)t-Q, -K(CR5R6)m- thiazolyl(Aa)t-Q, -K(CR5R6)m-thienyl-(Aa)tQ, -K(CR5R6)m-imidazolyl(Aa)t -Q, -K(CR5R6)m- morpholino-(Aa)tQ, -K(CR5R6)m-piperazino-(Aa)tQ, -K(CR5R6)mN-methylpiperazino-(Aa)tQ.
Wherein m, Aa, t, n, Q, R1 ; R2, R3, R4, and R5 are as defined in formula (I). R6, R7, and R8 are the same or different and independently chosen from H; halide; Ci~C8 of alkyl, aryl, alkenyl, alkynyl, ether, ester, amine or amide, which optionally substituted by one or more halide, CN, NRiR2, CF3, ORi, Aryl, heterocycle, S(0)Rls S02Ri, -C02H, -S03H, -ORi, -C02Ri, -CONRi, - P02RiR2, -P03H or P(0)RiR2R3; K is NRb O, S, Se, B or Het.
6. The compounds of any one of claims 1, 2, 3 and 4, wherein when L is R5, OR5, SR5 or NR5R5', one of U, U', V, V, Ri, Ri', R2, R2', R3, R3', R4, R4', R6, R6' is a linking group independently selected from:
-(CR5R6)m(Aa)r(CR7R8)n(OCH2CH2)tQ, -(CR5R6)m(CR7R8)n(Aa)r(OCH2CH2)tQ, -(Aa)r(CR5R6)m (CR7R8)n(OCH2CH2)tQ, -(CR5R6)m(CR7R8)n(OCH2CH2)r(Aa)tQ, -(CR5R6)m- (CR7=CR8)(CR9Rio)n(Aa) t(OCH2CH2)rQ, -(CR5R6)m(NR11CO)(Aa)t(CR9Rio)n-(OCH2CH2)rQ, - (CR5R6)m(Aa)t(NRiiCO)(CR9Rio)n(OCH2CH2)rQ,-(CR5R6)m(OCO)(Aa)t(CR9Rio)n-(OCH2CH2)rQ, -(CR5R6)m(OCNR7)(Aa)t(CR9Rio)n(OCH2CH2)rQ, -(CR5R6)m(CO)(Aa)t.(CR9Rio)n(OCH2CH2)rQ, -(CR5R6)m(NRiiCO)(Aa)t(CR9Rio)„(OCH2CH2)rQ, -(CR5R6)m-(OCO)(Aa)t(CR9Rio)„- (OCH2CH2)rQ, -(CR5R6)m(OCNR7)(Aa)t(CR9Rio)„(OCH2CH2)rQ, -(CR5R6)m(CO)(Aa)t.
(CR9R10)„(OCH2CH2)rQ, -(CR5R6)m-phenyl-CO(Aa)t(CR7R8)nQ, -(CR5R6)m-furyl-CO- (Aa)t(CR7R8)nQ, -(CR5R6)m-oxazolyl-CO(Aa)t(CR7R8)nQ, -(CR5R6)m-thiazolyl-CO(Aa)t.
(CCR7R8)nQ, -(CR5R6)t-thienyl-CO(CR7R8)nQ, -(CR5R6)t-imidazolyl-CO(CR7R8)nQ, -(CR5R6)t- morpholino-CO(Aa)t(CR7R8)nQ, -(CR5R6)tpiperazino-CO(Aa)t(CR7R8)nQ, -(CR5R6)t- N-methylpiperazin-CO(Aa)t(CR7R8)nQ, -(CR5R)m-(Aa)tphenyl-Q, -(CR5R6)m-(Aa)tfuryl-Q, - (CR5R6)m-oxazolyl(Aa)t-Q, -(CR5R6)m-thiazolyl(Aa)t-Q, -(CR5R6)m-thienyl-(Aa)tQ, -(CR5R6)m- imidazolyl(Aa)t-Q, -(C R5R6)m-morpholino-(Aa)tQ, -(CR5R6)m-piperazino-(Aa)tQ, -(CR5R6)m- N-methylpiperazino-(Aa)tQ, -K(CR5R6)m(Aa)r(CR7R8)n(OCH2CH2)tQ, -K(CR5R6)m(CR7R8)n(Aa )r(OCH2CH2)tQ, -K(Aa)r(CR5R6)m(CR7R8)n(OCH2CH2)tQ, -K(CR5R6)m(CR7R8)n(OCH2CH2)r(Aa )tQ, -K(CR5R6)m(CR7=CR8)(CR9R10)„(Aa)t(OCH2CH2)rQ, -K(CR5R6)m(NR11CO)(Aa)t(CR9R10)„( OCH2CH2)rQ, -K(CR5R6)m(Aa)t(NRi iCO)(CR9Ri0)n(OCH2CH2)rQ, -K(CR5R6)m(OCO)(Aa)t(CR9 Rio)„(OCH2CH2)rQ, -K(CR5R6)m(OCNR7)(Aa)t(CR9Rio)„(OCH2CH2)rQ, -K(CR5R6)m(CO)(Aa)t( CR9Rio)„(OCH2CH2)rQ, -K(CR5R6)m(NRi iCO)(Aa)t(CR9Ri0)„(OCH2CH2)rQ, -K(CR5R6)m(OCO) (Aa)t(CR9Rio)„(OCH2CH2)rQ, -K(CR5R6)m(OCNR7)(Aa)t(CR9Rio)„(OCH2CH2)rQ, -K(CR5R6)m( CO)(Aa)t(CR9R10)„(OCH2CH2)rQ, -K(CR5R6)m-phenyl-CO(Aa)t(CR7R8)nQ, -K(CR5R6)m- furyl-CO(Aa)t(CR7R8)nQ, -K(CR5R6)m-oxazolyl-CO(Aa)t(CR7R8)nQ, -K(CR5R6)m- thiazolyl-CO(Aa)t(CCR7R8)nQ, -K(CR5R6)t-thienyl-CO(CR7R8)nQ, -K(CR5R6)t- imidazolyl-CO(CR7R8)nQ, -K(CR5R6)tmorpholino-CO(Aa)t(CR7R8)nQ, -K(CR5R6)tpiperazino- CO(Aa)t(CR7R8)nQ, -K(CR5R6)t-N-methylpiperazin-CO(Aa)t(CR7R8)nQ, -K(CR5R)m- (Aa)tphenyl-Q, -K(CR5R6)m-(Aa)tfuryl-Q, -K(CR5R6)m-oxazolyl(Aa)t-Q, -K(CR5R6)m- thiazolyl(Aa)t-Q, -K(CR5R6)m-thienyl-(Aa)tQ, -K(CR5R6)m-imidazolyl(Aa)t -Q, -K(CR5R6)m- morpholino-(Aa)tQ, -K(CR5R6)m-piperazino-(Aa)tQ, -K(CR5R6)mN-methylpiperazino-(Aa)tQ.
Wherein m, Aa, t, n, Q, R1 ; R2, R3, R4, and R5 are as defined in formula (I). R6, R7, and R8 are the same or different and independently chosen from H; halide; Ci~C8 of alkyl, aryl, alkenyl, alkynyl, ether, ester, amine or amide, which optionally substituted by one or more halide, CN, NR1R2, CF3, ORi, Aryl, heterocycle, S(0)Rls S02Ri, -C02H, -S03H, -ORi, -C02Ri, -CONRi, - P02RiR2, -P03H or P(0)RiR2R3; K is NRb O, S, Se, B or Het.
7. A compound according to claim 1 of formula (I) having the following formula (XVIII- l)~(XVIII-79) described in the application.
8. A compound according to claim 1 of formula (I) having the following formula (XIX), (XX), (X - drug conjugate.
Figure imgf000130_0001
Figure imgf000131_0001
wherein U, U', V, V, m, m', n, n\ X, X', Y, Y\ Z, Z' Ri, R2, R3, 4, Rr, R2', R3', and R4' , are as defined in formula (I). CBA is a cell binding agent.
L and L' independently have the formula of :— Ww— (Aa)r— Tt— ; or— Ww— (Aa)r— Tt— Q; or Q— Ww— (Aa)r— Tt— ; wherein: W, w, Aa, r, T, t and Q are as defined in Formula (I).
9. A cell binding agent (CBA) according to claims 1 and 8 is a full-length antibody
(polyclonal and monoclonal antibody); a single chain antibody; a diabody, a triabody, a fragments of antibody (Fab, Fab', F(ab')2, Fv, a fragment produced by a Fab expression library, an antiidiotype (anti-Id) antibody, CDR's, and an epitope-binding fragment of any of the above which immuno-specifically bind to cancer cell antigens, viral antigens or microbial antigens; interferon (such as type I, II, III); a peptide; a lymphokine such as IL-2, IL-3, IL-4, IL-6, GM-CSF, interferon-gamma (IFN-γ); a hormone such as insulin, TRH (thyrotropin releasing hormone), MSH (melanocyte-stimulating hormone), a steroid hormone, such as androgens and estrogens, melanocyte-stimulating hormone (MSH); a growth factor and a colony-stimulating factor such as an epidermal growth factors (EGF), a granulocyte-macrophage colony-stimulating factor (GM- CSF), a transforming growth factors (TGF), such as TGFa, TGF ; a insulin and insulin like growth factor (IGF-I, IGF-II) G-CSF, M-CSF and GM-CSF; a vaccinia growth factor (VGF); a fibroblast growth factor (FGFs); a smaller molecular weight protein, poly-peptide, peptides and peptide hormones, e.g. bombesin, gastrin, gastrin-releasing peptide; a platelet-derived growth factor; an interleukin and a cytokine, such as interleukin-2 (IL-2), interleukin-6 (IL-6), a leukemia inhibitory factor, a granulocyte-macrophage colony-stimulating factor (GM-CSF); a vitamin, such as folate; an apoprotein and a lycoproteis; such as transferring sugar-binding protein or a lipoproteins, such as a lectin; a cell nutrient-transport molecule (e.g. transferrin); and a small molecular inhibitor, such as a prostate-specific membrane antigen (PSMA) inhibitor and small molecular tyrosine kinase inhibitors (TKI); peptides, or peptide analogs, proteins including conjugated proteins that able to bind targeted cells; a non-peptides or any other cell binding molecule or substance, such as a bioactive polymer, a bioactive dendrimer, nanoparticle, liposome, or viral capside.
10. A pharmaceutical composition comprising a compound of claim 1 or 2, or 3, or 4, or 7, or 8, and a pharmaceutically acceptable carrier.
11. A method of inhibiting abnormal cell growth or treating a proliferative disorder including cancers, benign or malignant tumors; leukemia and lymphoid malignancies; neuronal, glial, astrocytal, hypothalamic, glandular, macrophagal, epithelial, stromal, blastocoelic, angiogenic and immunologic disorders; inflammatory; autoimmune disorders; destructive disorders; bone disorder; infectious disease; viral disease; fibrotic disease; neurodegenerative disorder;
pancreatitis or kidney disease in a mammal comprising administering to said mammal a therapeutically effective amount of the compound of any one of claim 1, 2, 3, 4, 7 or 8.
12. The method of claim 11, wherein optionally, a synergistic drug, which is a
chemotherapeutic agent, or an anti-autoimmune disease agent, or an anti-infectious disease agent, or anti-viral drug, or the other immunotherapeutic agent, is administered to a mammal sequentially or consecutively with a therapeutically effective amount of the compound of any one of claim 1, 2, 3, 4, 7 or 8.
13. A conjugate according to claim 1 or 8 is preferably antibody/cytotoxic agent, antibody fragment/cytotoxic agent, diabody/cytotoxic agent, tri(a)body/cytotoxic agent, epidermal growth factor (EGF)/cytotoxic agent, prostate specific membrane antigen (PSMA) inhibitor/cytotoxic agent, melanocyte stimulating hormone (MSH)/cytotoxic agent, thyroid stimulating hormone (TSH)/cytotoxic agent, polyclonal antibody/cytotoxic agent, somatostatin/cytotoxic agent, folate/cytotoxic agent, matriptase inhibitor/cytotoxic agent, estrogen/cytotoxic agent, estrogen analogue/cytotoxic agent, designed ankyrin repeat proteins (DARPins)/cytotoxic agent, androgen/cytotoxic agent, and androgen analogue/cytotoxic agent.
14. A process for the preparation of the compound of claims 1, 2, 3, 4, 5, 6, 7, and 8
comprising the reagents, intermediates, products, methods, conditions and steps in the examples 1- 73 and Figures 1 - 23.
15. The conjugate of claim 13, wherein the antibody is a resurfaced antibody, a resurfaced single chain antibody, or a resurfaced antibody fragment.
16. The conjugate of claim 13, wherein the antibody is a humanized antibody, a humanized single chain antibody, a humanized antibody fragment, a chimeric antibody, a chimeric antibody fragment, a domain antibody, or a domain antibody fragment.
17. The conjugate of claim 1, 2, 3, 4, 7 or 8, wherein the cell-binding agent binds to target cells preferably selected from tumor cells; virus infected cells; microorganism infected cells; parasite infected cells; autoimmune cells; activated cells; myeloid cells; activated T-cells, B cells, or melanocytes; or cells expressing the CD4, CD6, CD19, CD20, CD22, CD30, CD33, CD37, CD38, CD40, CD44, CD51, CD56, CD66, CD70, CD74, CD79b, CD80, CD98, CD105, CD106, CD125, CD221, CD227, CD262, CD309, CD326, CEACAM3 , CEACAM5, DLL4, cMet, EpCAM, CanAg, CALLA, EGFR, CTLA4 , CXCR4, Endoglin, ERBB2, FCGR1 , FOLR, GD2, G-28, GD3 idiotype, Heat shock proteins, HER1, HLA-DR10, HLA-DRB, IGF1R, IL-2 receptor, IL-6R, Integrins (ανβ3, α5β1, α6β4, α11β3, α5β5, ανβ5), MAGE-1, MAGE-2 , MAGE-3, MAGE 4 , anti-transferrin receptor, ρ97, MS4A1, MUC1 or MUC1-KLH, MUC16, CA125, CEA, gplOO, MARTI, MPG,Nucleolin, Neu oncogene product, P21, Paratope of anti-N-glycolylneuraminic acid, PLAP-like testicular alkaline phosphatase, PSMA, PSA, ROB04, TAG 72, T cell transmembrane protein, Tie (CD202b), TNFRSFIOB, TNFRSF13B, TPBG, TRAIL-Rl, VCAM- 1, VEGF, VEGF-A, VEGF-2 (CD309), Her-2 antigens, Her-3 antigens; or cells expressing insulin growth factor receptors, epidermal growth factor receptors, or folate receptors.
18. The conjugate according to claim 8 are prepared through the first modification of cell- binding agent (CBA) with a crosslinker (L) in an aqueous buffer pH 3 - 9 having optionally 0 ~ 30% organic co-solvents to introduce reactive disulfide, maleimido, haloacetyl, hydrazide, nitrile, alkynyl, alkyloxyamino or aldehyde groups on the cell-binding agent (forming a covalent bonded CBA-L molecule). The CBA-L molecule then reacts with a drug moiety (Drug) of formula (I) in an aqueous buffer pH 3 - 9 having optionally 0 - 30% organic co-solvents to generate a cell binding agent - drug conjugate.
19. The conjugate according to claim 8 are prepared through the first modification of drug moiety (Drug) of the formula (I) with a crosslinker (L) in organic media or in an aqueous buffer pH 3 - 9 having optionally 0 - 99% organic co-solvents to introduce a reactive disulfide, maleimido, haloacetyl, hydrazide, nitrile, alkynyl, alkyloxyamino, aldehyde,
N-hydroxysuccinimide (NHS) ester or pentafluorophenyl ester group on the drug moiety (forming a covalent bonded Drug-L molecule). The Drug-L molecule then reacts with a cell binding agent (CBA), or pre-modified CBA in an aqueous buffer pH 3 - 9 having optionally 0 - 30% organic co-solvents to generate a cell binding agent - drug conjugate.
20. The conjugate according to claim 8 are prepared directly through reaction of a cell - binding agent with drug moieties of formula (I) bearing reactive function groups of disulfide, maleimido, haloacetyl, hydrazide, nitrile, alkynyl, alkyloxyamino, aldehyde,
N-hydroxysuccinimide (NHS) ester or pentafluorophenyl ester in an aqueous buffer pH 3 - 9 having optionally 0 - 30% organic co-solvents.
21. The method for treatment of cancer, autoimmune disorders, infectious diseases or viral disease can be practiced in vitro, in vivo, or ex vivo comprising administering to said mammal a therapeutically effective amount of the compound of any one of claim 1, 2, 3, 4, 7 or 8.
PCT/IB2013/058229 2013-09-02 2013-09-02 Novel cytotoxic agents for conjugation of drugs to cell binding molecule WO2015028850A1 (en)

Priority Applications (9)

Application Number Priority Date Filing Date Title
CN202210139534.7A CN115124573A (en) 2013-09-02 2013-09-02 Novel cytotoxic molecules for use in cell binding molecule-drug conjugates
PCT/IB2013/058229 WO2015028850A1 (en) 2013-09-02 2013-09-02 Novel cytotoxic agents for conjugation of drugs to cell binding molecule
EP13892435.2A EP3041846B1 (en) 2013-09-02 2013-09-02 Novel cytotoxic agents for conjugation of drugs to cell binding molecule
NZ717003A NZ717003A (en) 2013-09-02 2013-09-02 Novel cytotoxic agents for conjugation of drugs to cell binding molecule
US14/914,739 US9988408B2 (en) 2013-09-02 2013-09-02 Cytotoxic agents for conjugation to a cell binding molecule
CA2921982A CA2921982C (en) 2013-09-02 2013-09-02 Novel cytotoxic agents for conjugation of drugs to cell binding molecule
AU2013399485A AU2013399485B2 (en) 2013-09-02 2013-09-02 Novel cytotoxic agents for conjugation of drugs to cell binding molecule
CN201380079042.2A CN107074879B (en) 2013-09-02 2013-09-02 Novel cytotoxic molecules for use in cell binding molecule-drug conjugates
JP2016537393A JP6332773B2 (en) 2013-09-02 2013-09-02 Novel cytotoxic molecules for conjugation of drugs and cell binding molecules

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/IB2013/058229 WO2015028850A1 (en) 2013-09-02 2013-09-02 Novel cytotoxic agents for conjugation of drugs to cell binding molecule

Publications (1)

Publication Number Publication Date
WO2015028850A1 true WO2015028850A1 (en) 2015-03-05

Family

ID=52585656

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2013/058229 WO2015028850A1 (en) 2013-09-02 2013-09-02 Novel cytotoxic agents for conjugation of drugs to cell binding molecule

Country Status (8)

Country Link
US (1) US9988408B2 (en)
EP (1) EP3041846B1 (en)
JP (1) JP6332773B2 (en)
CN (2) CN107074879B (en)
AU (1) AU2013399485B2 (en)
CA (1) CA2921982C (en)
NZ (1) NZ717003A (en)
WO (1) WO2015028850A1 (en)

Cited By (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104844495A (en) * 2015-06-05 2015-08-19 武汉理工大学 Synthesis method of (2S,4S)-4-thiophenyl-L-proline hydrochloride
WO2015151081A2 (en) 2015-07-12 2015-10-08 Suzhou M-Conj Biotech Co., Ltd Bridge linkers for conjugation of a cell-binding molecule
WO2016044396A1 (en) * 2014-09-17 2016-03-24 Genentech, Inc. Immunoconjugates comprising anti-her2 antibodies and pyrrolobenzodiazepines
WO2015151080A3 (en) * 2015-07-04 2016-06-02 Suzhou M-Conj Biotech Co., Ltd Specific conjugation of cell-binding molecules
WO2016147031A2 (en) 2015-03-19 2016-09-22 Hangzhou Dac Biotech Co., Ltd Novel hydrophilic linkers and ligand-drug conjugates thereof
WO2016198869A1 (en) * 2015-06-09 2016-12-15 Femtogenix Limited Pdd and bpd compounds
WO2017032983A1 (en) * 2015-08-21 2017-03-02 Femtogenix Limited Piperidinobenzodiazepine compounds with anti proliferative activity
JP2018510163A (en) * 2015-03-19 2018-04-12 セレラント セラピューティクス インコーポレイテッド Isoquinolidinobenzodiazepine
WO2019043417A1 (en) * 2017-09-04 2019-03-07 Femtogenix Limited Cytotoxic agents
CN109689107A (en) * 2016-04-20 2019-04-26 杭州多禧生物科技有限公司 The derivative of amatoxin and its coupling with cell-binding molecules
CN110392685A (en) * 2016-11-23 2019-10-29 伊缪诺金公司 The selective sulfonation of Benzodiazepine derivative
WO2020006722A1 (en) * 2018-07-05 2020-01-09 Hangzhou Dac Biotech Co., Ltd Cross-linked pyrrolobenzodiazepine dimer (pbd) derivative and its conjugates
WO2020019108A1 (en) * 2018-07-23 2020-01-30 Guangzhou Othrotx Co., Ltd. Bisphosphonate drug conjugates
US10646585B2 (en) 2017-09-15 2020-05-12 Hangzhou Dac Biotech Co., Ltd. Hydrophilic linkers and ligand-drug conjugates thereof
WO2020157491A1 (en) 2019-01-29 2020-08-06 Femtogenix Limited G-a crosslinking cytotoxic agents
US10975074B2 (en) 2015-08-21 2021-04-13 Femtogenix Limited Anti-liferative agents comprising substituted benzo[e]pyrido[1,2-a][1,4]diazepines
US11007251B2 (en) 2015-12-17 2021-05-18 The Johns Hopkins University Ameliorating systemic sclerosis with death receptor agonists
US11084879B2 (en) 2016-04-07 2021-08-10 The Johns Hopkins University Compositions and methods for treating pancreatitis and pain with death receptor agonists
US11299528B2 (en) 2014-03-11 2022-04-12 D&D Pharmatech Inc. Long acting TRAIL receptor agonists for treatment of autoimmune diseases
US11352324B2 (en) 2018-03-01 2022-06-07 Medimmune Limited Methods
AU2021201765B2 (en) * 2015-06-15 2022-12-08 Hangzhou Dac Biotech Co., Ltd Hydrophilic Linkers for Conjugate
US11524969B2 (en) 2018-04-12 2022-12-13 Medimmune Limited Pyrrolobenzodiazepines and conjugates thereof as antitumour agents
US11583590B2 (en) 2017-09-29 2023-02-21 Daiichi Sankyo Company, Limited Antibody-pyrrolobenzodiazepine derivative conjugate and method of use thereof for treating a tumor
US11767353B2 (en) 2020-06-05 2023-09-26 Theraly Fibrosis, Inc. Trail compositions with reduced immunogenicity

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2960619T3 (en) 2014-02-28 2024-03-05 Hangzhou Dac Biotech Co Ltd Loaded Linkers and Their Uses for Conjugation
US20220079952A1 (en) * 2019-05-24 2022-03-17 Emory University Uses of Radiation and Benzodiazepine Derivatives in Cancer Therapies
WO2021041171A1 (en) * 2019-08-23 2021-03-04 Children's Medical Center Corporation Intercellular adhesion molecule 1 (icam1) antibody drug conjugate and uses thereof
CN110508029B (en) * 2019-09-04 2022-01-28 武玉香 Immunoaffinity column for simultaneously extracting florfenicol, chloramphenicol and thiamphenicol
WO2021202919A1 (en) * 2020-04-01 2021-10-07 The University Of Chicago Tocilizumab for the treatment of viral infections
EP4297783A1 (en) * 2021-02-23 2024-01-03 Children's Medical Center Corporation Intercellular adhesion molecule 1 (icam1) antibody drug conjugate and uses thereof
CN114478450A (en) * 2022-01-10 2022-05-13 四川大学 Benzyloxybelphthalide compound, preparation method and application thereof

Citations (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4341761A (en) 1980-07-25 1982-07-27 E. I. Du Pont De Nemours And Company Antibodies to immunogenic peptides and their use to purify human fibroblast interferon
US4399121A (en) 1981-11-04 1983-08-16 Miles Laboratories, Inc. Iodothyronine immunogens and antibodies
US4427783A (en) 1981-12-14 1984-01-24 Hoffmann-La Roche Inc. Immunoassay of thymosin α1
US4444887A (en) 1979-12-10 1984-04-24 Sloan-Kettering Institute Process for making human antibody producing B-lymphocytes
US4451570A (en) 1981-03-26 1984-05-29 The Regents Of The University Of California Immunoglobulin-secreting human hybridomas from a cultured human lymphoblastoid cell line
US4466917A (en) 1981-02-12 1984-08-21 New York University Malaria vaccine
US4472500A (en) 1980-07-07 1984-09-18 National Research Development Corporation Rat myeloma cell lines
US4491632A (en) 1979-10-22 1985-01-01 The Massachusetts General Hospital Process for producing antibodies to hepatitis virus and cell lines therefor
US4493890A (en) 1981-03-23 1985-01-15 Miles Laboratories, Inc. Activated apoglucose oxidase and its use in specific binding assays
US4493795A (en) 1983-10-17 1985-01-15 Syntex (U.S.A.) Inc. Synthetic peptide sequences useful in biological and pharmaceutical applications and methods of manufacture
US5208020A (en) 1989-10-25 1993-05-04 Immunogen Inc. Cytotoxic agents comprising maytansinoids and their therapeutic use
US5436149A (en) 1993-02-19 1995-07-25 Barnes; Wayne M. Thermostable DNA polymerase with enhanced thermostability and enhanced length and efficiency of primer extension
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5569825A (en) 1990-08-29 1996-10-29 Genpharm International Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5859205A (en) 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
US5922545A (en) 1993-10-29 1999-07-13 Affymax Technologies N.V. In vitro peptide and antibody display libraries
US6075181A (en) 1990-01-12 2000-06-13 Abgenix, Inc. Human antibodies derived from immunized xenomice
US6111166A (en) 1994-09-19 2000-08-29 Medarex, Incorporated Transgenic mice expressing human Fcα and β receptors
US6150584A (en) 1990-01-12 2000-11-21 Abgenix, Inc. Human antibodies derived from immunized xenomice
US6207418B1 (en) 1996-10-11 2001-03-27 Abgenix, Inc. Production of a multimeric protein by cell fusion method
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
US6797492B2 (en) 1991-05-17 2004-09-28 Merck & Co., Inc. Method for reducing the immunogenicity of antibody variable domains
WO2005040170A2 (en) * 2003-10-22 2005-05-06 Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services Pyrrolobenzodiazepine derivatives, compositions comprising the same and methods related thereto
EP1813614A1 (en) * 2006-01-25 2007-08-01 Sanofi-Aventis Cytotoxic agents comprising new tomaymycin derivatives
US20120244171A1 (en) * 2011-02-15 2012-09-27 Immunogen, Inc. Cytotoxic benzodiazepine derivatives
WO2013041606A1 (en) * 2011-09-20 2013-03-28 Spirogen Sàrl Pyrrolobenzodiazepines as unsymmetrical dimeric pbd compounds for inclusion in targeted conjugates

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9242013B2 (en) 2010-04-15 2016-01-26 Seattle Genetics Inc. Targeted pyrrolobenzodiazapine conjugates

Patent Citations (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4491632A (en) 1979-10-22 1985-01-01 The Massachusetts General Hospital Process for producing antibodies to hepatitis virus and cell lines therefor
US4444887A (en) 1979-12-10 1984-04-24 Sloan-Kettering Institute Process for making human antibody producing B-lymphocytes
US4472500A (en) 1980-07-07 1984-09-18 National Research Development Corporation Rat myeloma cell lines
US4341761A (en) 1980-07-25 1982-07-27 E. I. Du Pont De Nemours And Company Antibodies to immunogenic peptides and their use to purify human fibroblast interferon
US4466917A (en) 1981-02-12 1984-08-21 New York University Malaria vaccine
US4493890A (en) 1981-03-23 1985-01-15 Miles Laboratories, Inc. Activated apoglucose oxidase and its use in specific binding assays
US4451570A (en) 1981-03-26 1984-05-29 The Regents Of The University Of California Immunoglobulin-secreting human hybridomas from a cultured human lymphoblastoid cell line
US4399121A (en) 1981-11-04 1983-08-16 Miles Laboratories, Inc. Iodothyronine immunogens and antibodies
US4427783A (en) 1981-12-14 1984-01-24 Hoffmann-La Roche Inc. Immunoassay of thymosin α1
US4493795A (en) 1983-10-17 1985-01-15 Syntex (U.S.A.) Inc. Synthetic peptide sequences useful in biological and pharmaceutical applications and methods of manufacture
US5208020A (en) 1989-10-25 1993-05-04 Immunogen Inc. Cytotoxic agents comprising maytansinoids and their therapeutic use
US5859205A (en) 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
US6150584A (en) 1990-01-12 2000-11-21 Abgenix, Inc. Human antibodies derived from immunized xenomice
US6075181A (en) 1990-01-12 2000-06-13 Abgenix, Inc. Human antibodies derived from immunized xenomice
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5569825A (en) 1990-08-29 1996-10-29 Genpharm International Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US6797492B2 (en) 1991-05-17 2004-09-28 Merck & Co., Inc. Method for reducing the immunogenicity of antibody variable domains
US5436149A (en) 1993-02-19 1995-07-25 Barnes; Wayne M. Thermostable DNA polymerase with enhanced thermostability and enhanced length and efficiency of primer extension
US5922545A (en) 1993-10-29 1999-07-13 Affymax Technologies N.V. In vitro peptide and antibody display libraries
US6111166A (en) 1994-09-19 2000-08-29 Medarex, Incorporated Transgenic mice expressing human Fcα and β receptors
US6207418B1 (en) 1996-10-11 2001-03-27 Abgenix, Inc. Production of a multimeric protein by cell fusion method
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
WO2005040170A2 (en) * 2003-10-22 2005-05-06 Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services Pyrrolobenzodiazepine derivatives, compositions comprising the same and methods related thereto
EP1813614A1 (en) * 2006-01-25 2007-08-01 Sanofi-Aventis Cytotoxic agents comprising new tomaymycin derivatives
CN101374846A (en) * 2006-01-25 2009-02-25 赛诺菲-安万特 Cytotoxic agents containing novel tomaymycin derivatives and their therapeutic use
US20120244171A1 (en) * 2011-02-15 2012-09-27 Immunogen, Inc. Cytotoxic benzodiazepine derivatives
WO2013041606A1 (en) * 2011-09-20 2013-03-28 Spirogen Sàrl Pyrrolobenzodiazepines as unsymmetrical dimeric pbd compounds for inclusion in targeted conjugates

Non-Patent Citations (43)

* Cited by examiner, † Cited by third party
Title
"Antibodies—A Laboratory Manual", 1988, COLD SPRING HARBOR LABORATORY PRESS
"Remington: The Science and Practice of Pharmacy", 2005, LIPPINCOTT WILLIAMS & WILKINS
"Remington's Pharmaceutical Sciences", 1985, MACK PUBLISHING COMPANY, pages: l418
"The Handbook of Chemistry and Physics", 1995, CRC PRESS, INC., pages: 2-25 - 2-26
ADAMS ET AL., J IMMUNOL METHODS, vol. 231, 1999, pages 249 - 60
ALMAGRO ET AL., FRONT BIOSCI., vol. 1, no. 13, 2008, pages 1619 - 33
AMSBERRY ET AL., J. ORG. CHEM., vol. 55, 1990, pages 5867
BRANNIGAN ET AL., NAT REV MOL CELL BIOL., vol. 3, 2002, pages 964 - 70
CLACKSON ET AL., NATURE, vol. 352, 1991, pages 264 - 628
DENTE ET AL., GENE, vol. 148, no. 1, 1994, pages 7 - 13
DES., vol. 10, 2004, pages 2981 - 9
DUBOWCHIK; WALKER, PHARMACOLOGY & THERAPEUTICS, vol. 83, 1999, pages 67 - 123
DULBECCO ET AL., VIROL, vol. 8, 1959, pages 396
FLENNIKEN ET AL., VIRUSES NANOTECHNOL., vol. 327, 2009, pages 71 - 93
GARNETT, ADV. DRUG DELIVERY REV., vol. 53, 2001, pages 171 - 216
GETZ ET AL., ANAL. BIOCHEM., vol. 273, 1999, pages 73 - 80
GEYSEN ET AL., PROC. NATL. ACAD. SCI. USA, vol. 82, 1985, pages 178 - 182
HERMANSON, G.T.: "Bioconjugate Techniques", 2008, ACADEMIC PRESS
HOOGENBOOM ET AL.: "Methods in Molecular Biology", vol. 178, 2001, HUMAN PRESS, pages: 1 - 37
HOUDEBINE, CURR OPIN BIOTECHNOL., vol. 13, 2002, pages 625 - 9
HUSE ET AL., SCIENCE, vol. 246, 1989, pages 1275 - 1281
IAN T. HARRISON; SHUYEN HARRISON, COMPENDIUM OF ORGANIC SYNTEHTIC METHODS, vol. 1& 2
IAN T. HARRISON; SHUYEN HARRISON, COMPENDIUM OF ORGANIC SYNTHETIC METHODS, vol. 1,2
ISALM; DENT: "Bioconjugation", vol. 5, 1999, GROVES DICTIONARIES INC., pages: 218 - 363
KINGSBURY ET AL., J. MED. CHEM., vol. 27, 1984, pages 1447
KIPRIYANOV ET AL., MOL BIOTECHNOL., vol. 26, 2004, pages 39 - 60
KOHLER, G.; MILSTEIN, C., NATURE, vol. 256, 1975, pages 495 - 497
LAZAR ET AL., MOL IMMUNOL., vol. 44, no. 8, 2007, pages 1986 - 98
LEE ET AL., J. MOL. BIOL., vol. 340, 2004, pages 1073 - 1093
LEI ET AL., BIOCHEMISTRY, vol. 34, no. 20, 1995, pages 6675 - 6688
LI ET AL., PROC. NATL. ACAD. SCI. U S A., vol. 103, no. 10, 2006, pages 3557 - 62
LITTLE ET AL., BIOTECHNOL ADV., vol. 12, no. 3, 1994, pages 539 - 55
LIU ET AL., IMMUNOL REV., vol. 222, 2008, pages 9 - 27
LOUIS S. HEGEDUS; LEROY WADE, COMPENDIUM OF ORGANIC SYNTEHTIC METHODS, vol. 3-5
MICHAEL B. SMITH: "COMPENDIUM OF ORGANIC SYNTEHTIC METHODS", vol. Vols 6-V, 2006, JOHN WILEY AND SONS
NIMAN ET AL., PROC. NATL. ACAD. SCI. USA, vol. 80, 1983, pages 4949 - 4953
PETER G. M. WUTS; THEODORA W. GREENE: "Greene's Protective Groups in Organic Synthesis", 2006, JOHN WILEY AND SONS
PLUCKTHUN, IMMUNOL. REVS, vol. 130, 1992, pages 151
RICHARD C. LAROCK: "A Guide to Functional Group Preparations", vol. Two, 2010, WILEY PUBLISHERS, article "Comprehensive Organic Transformations"
RODRIGUES ET AL., CHEMISTRY BIOLOGY, vol. 2, 1995, pages 223
SKERRA ET AL., CURR. OPINION IN IMMUNOL., vol. 5, 1993, pages 256
STORM ET AL., J. AMER. CHEM. SOC., vol. 94, 1972, pages 5815
SZARDENINGS, J RECEPT SIGNAL TRANSDUCT RES., vol. 23, no. 4, 2003, pages 307 - 49

Cited By (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11299528B2 (en) 2014-03-11 2022-04-12 D&D Pharmatech Inc. Long acting TRAIL receptor agonists for treatment of autoimmune diseases
US10314846B2 (en) 2014-09-17 2019-06-11 Genentech, Inc. Immunoconjugates comprising anti-HER2 antibodies and pyrrolobenzodiazepines
WO2016044396A1 (en) * 2014-09-17 2016-03-24 Genentech, Inc. Immunoconjugates comprising anti-her2 antibodies and pyrrolobenzodiazepines
EP3271359A4 (en) * 2015-03-19 2018-12-05 Cellerant Therapeutics, Inc. Isoquinolidinobenzodiazepines
CN108472301A (en) * 2015-03-19 2018-08-31 塞勒兰特治疗公司 Tetrahydroisoquinoline acene phenodiazine * classes
WO2016147031A2 (en) 2015-03-19 2016-09-22 Hangzhou Dac Biotech Co., Ltd Novel hydrophilic linkers and ligand-drug conjugates thereof
JP2018510163A (en) * 2015-03-19 2018-04-12 セレラント セラピューティクス インコーポレイテッド Isoquinolidinobenzodiazepine
US10898580B2 (en) 2015-03-19 2021-01-26 Cellerant Therapeutics, Inc. Isoquinolidinobenzodiazepines
CN107614488A (en) * 2015-03-19 2018-01-19 杭州多禧生物科技有限公司 Novel hydrophilic connector and its application on ligand drug conjugation conjugate
EP3271329A4 (en) * 2015-03-19 2019-05-01 Hangzhou Dac Biotech Co., Ltd Novel hydrophilic linkers and ligand-drug conjugates thereof
US10456479B2 (en) 2015-03-19 2019-10-29 Hangzhou Dac Biotech Co., Ltd. Hydrophilic linkers and ligand-drug conjugates thereof
EP3912982A1 (en) * 2015-03-19 2021-11-24 Hangzhou Dac Biotech Co., Ltd Novel hydrophilic linkers and ligand-drug conjugates thereof
CN104844495A (en) * 2015-06-05 2015-08-19 武汉理工大学 Synthesis method of (2S,4S)-4-thiophenyl-L-proline hydrochloride
US10399970B2 (en) 2015-06-09 2019-09-03 Femtogenix Limited Pyrridinobenzodiazepine and benzopyrridodiazecine compounds
WO2016198869A1 (en) * 2015-06-09 2016-12-15 Femtogenix Limited Pdd and bpd compounds
AU2021201765B2 (en) * 2015-06-15 2022-12-08 Hangzhou Dac Biotech Co., Ltd Hydrophilic Linkers for Conjugate
WO2015151080A3 (en) * 2015-07-04 2016-06-02 Suzhou M-Conj Biotech Co., Ltd Specific conjugation of cell-binding molecules
CN108449940A (en) * 2015-07-12 2018-08-24 苏州美康加生物科技有限公司 With the bridging junctor of the conjugation coupling of cell-binding molecules
WO2015151081A3 (en) * 2015-07-12 2016-06-02 Suzhou M-Conj Biotech Co., Ltd Bridge linkers for conjugation of cell-binding molecules
CN108449940B (en) * 2015-07-12 2021-06-08 杭州多禧生物科技有限公司 Conjugated bridge linkers to cell binding molecules
WO2015151081A2 (en) 2015-07-12 2015-10-08 Suzhou M-Conj Biotech Co., Ltd Bridge linkers for conjugation of a cell-binding molecule
US10975072B2 (en) 2015-08-21 2021-04-13 Femtogenix Limited Substituted 6a,7,8,9,10,12-hexahydrobenzo[e]pyrido[1,2-a][1,4]diazepines as anti-proliferative agents
JP2021152063A (en) * 2015-08-21 2021-09-30 フェムトジェニックス リミテッドFemtogenix Limited Piperidinobenzodiazepine compounds with anti proliferative activity
CN108602803A (en) * 2015-08-21 2018-09-28 福姆通格尼克斯有限公司 Piperidines with antiproliferative activity and benzodiazepine * compounds
EP4086251A1 (en) 2015-08-21 2022-11-09 Femtogenix Limited Piperidinobenzodiazepine compounds with anti proliferative activity
CN114907345A (en) * 2015-08-21 2022-08-16 福姆通格尼克斯有限公司 Piperidine-benzodiazepine compound having anti-proliferative activity
JP2018525405A (en) * 2015-08-21 2018-09-06 フェムトジェニックス リミテッドＦｅｍｔｏｇｅｎｉｘ Ｌｉｍｉｔｅｄ Piperidinobenzodiazepine compounds with antiproliferative activity
IL257650A (en) * 2015-08-21 2018-04-30 Femtogenix Ltd Piperidinobenzodiazepine compounds with anti proliferative activity
KR102710425B1 (en) * 2015-08-21 2024-09-25 펨토제닉스 리미티드 Piperidinobenzodiazepine compounds having antiproliferative activity
US10975074B2 (en) 2015-08-21 2021-04-13 Femtogenix Limited Anti-liferative agents comprising substituted benzo[e]pyrido[1,2-a][1,4]diazepines
KR20180043314A (en) * 2015-08-21 2018-04-27 펨토제닉스 리미티드 Piperidinobenzodiazepine compounds having antiproliferative activity
WO2017032983A1 (en) * 2015-08-21 2017-03-02 Femtogenix Limited Piperidinobenzodiazepine compounds with anti proliferative activity
US11912700B2 (en) 2015-08-21 2024-02-27 Pheon Therapeutics Ltd Anti-proliferative agents comprising substituted benzo[e]pyrido[1,2-a][1,4]diazepines
US11007251B2 (en) 2015-12-17 2021-05-18 The Johns Hopkins University Ameliorating systemic sclerosis with death receptor agonists
US11084879B2 (en) 2016-04-07 2021-08-10 The Johns Hopkins University Compositions and methods for treating pancreatitis and pain with death receptor agonists
US10836796B2 (en) 2016-04-20 2020-11-17 Hangzhou Dac Biotech Co., Ltd. Derivatives of amanita toxins and their conjugation to a cell binding molecule
CN109689107A (en) * 2016-04-20 2019-04-26 杭州多禧生物科技有限公司 The derivative of amatoxin and its coupling with cell-binding molecules
EP3445401A4 (en) * 2016-04-20 2019-11-20 Hangzhou DAC Biotech Co, Ltd Derivatives of amanita toxins and their conjugation to a cell binding molecule
CN109689107B (en) * 2016-04-20 2022-08-16 杭州多禧生物科技有限公司 Derivatives of amatoxins and their coupling to cell binding molecules
JP7295640B2 (en) 2016-04-20 2023-06-21 ハンジョウ ディーエーシー バイオテック シーオー．，エルティディ． Derivatives of amanita toxin and their conjugates with cell binding molecules
TWI845890B (en) * 2016-11-23 2024-06-21 美商伊繆諾金公司 Selective sulfonation of benzodiazepine derivatives
JP2023036842A (en) * 2016-11-23 2023-03-14 イミュノジェン・インコーポレーテッド Selective sulfonation of benzodiazepine derivatives
CN110392685B (en) * 2016-11-23 2023-07-04 伊缪诺金公司 Selective sulfonation of benzodiazepine derivatives
JP2020512276A (en) * 2016-11-23 2020-04-23 イミュノジェン・インコーポレーテッド Selective sulfonation of benzodiazepine derivatives.
CN110392685A (en) * 2016-11-23 2019-10-29 伊缪诺金公司 The selective sulfonation of Benzodiazepine derivative
JP7203729B2 (en) 2016-11-23 2023-01-13 イミュノジェン・インコーポレーテッド Selective sulfonation of benzodiazepine derivatives
US11572349B2 (en) 2016-11-23 2023-02-07 Immunogen, Inc. Selective sulfonation of benzodiazepine derivatives
US11466032B2 (en) 2017-09-04 2022-10-11 Femtogenix Limited Cytotoxic agents
WO2019043417A1 (en) * 2017-09-04 2019-03-07 Femtogenix Limited Cytotoxic agents
US10646585B2 (en) 2017-09-15 2020-05-12 Hangzhou Dac Biotech Co., Ltd. Hydrophilic linkers and ligand-drug conjugates thereof
US11628223B2 (en) 2017-09-29 2023-04-18 Daiichi Sankyo Company, Limited Antibody-drug conjugates comprising substituted benzo[e]pyrrolo[1,2-α][1,4]diazepines
US11583590B2 (en) 2017-09-29 2023-02-21 Daiichi Sankyo Company, Limited Antibody-pyrrolobenzodiazepine derivative conjugate and method of use thereof for treating a tumor
US11352324B2 (en) 2018-03-01 2022-06-07 Medimmune Limited Methods
US11524969B2 (en) 2018-04-12 2022-12-13 Medimmune Limited Pyrrolobenzodiazepines and conjugates thereof as antitumour agents
WO2020006722A1 (en) * 2018-07-05 2020-01-09 Hangzhou Dac Biotech Co., Ltd Cross-linked pyrrolobenzodiazepine dimer (pbd) derivative and its conjugates
AU2018430758B2 (en) * 2018-07-05 2022-01-27 Hangzhou Dac Biotech Co., Ltd Cross-linked pyrrolobenzodiazepine dimer (PBD) derivative and its conjugates
CN112867724A (en) * 2018-07-23 2021-05-28 广州噢斯荣医药技术有限公司 Bisphosphonate drug conjugates
WO2020019108A1 (en) * 2018-07-23 2020-01-30 Guangzhou Othrotx Co., Ltd. Bisphosphonate drug conjugates
CN112867724B (en) * 2018-07-23 2024-06-04 熙源安健医药(北京)有限公司 Bisphosphonate drug conjugates
US12049475B2 (en) 2018-07-23 2024-07-30 Brise Pharmaceuticals Co., Ltd. Bisphosphonate drug conjugates
WO2020157491A1 (en) 2019-01-29 2020-08-06 Femtogenix Limited G-a crosslinking cytotoxic agents
US11767353B2 (en) 2020-06-05 2023-09-26 Theraly Fibrosis, Inc. Trail compositions with reduced immunogenicity

Also Published As

Publication number Publication date
EP3041846A1 (en) 2016-07-13
CA2921982A1 (en) 2015-03-05
JP2016536328A (en) 2016-11-24
US9988408B2 (en) 2018-06-05
AU2013399485B2 (en) 2019-07-25
JP6332773B2 (en) 2018-05-30
AU2013399485A1 (en) 2016-03-10
CN107074879B (en) 2022-04-15
CA2921982C (en) 2020-08-25
CN115124573A (en) 2022-09-30
US20160207949A1 (en) 2016-07-21
CN107074879A (en) 2017-08-18
EP3041846B1 (en) 2018-11-07
NZ717003A (en) 2019-05-31

Similar Documents

Publication Publication Date Title
EP3041846B1 (en) Novel cytotoxic agents for conjugation of drugs to cell binding molecule
AU2016322708B2 (en) Derivatives of Amanita toxins and their conjugation to a cell binding molecule
US11767294B2 (en) Conjugates of cell binding molecules with cytotoxic agents
WO2014080251A1 (en) Hydrophilic linkers and their uses for conjugation of drugs to cell binding molecules
NZ719369B2 (en) Conjugates of Cell Binding Molecules with Cytotoxic Agents

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 13892435

Country of ref document: EP

Kind code of ref document: A1

ENP Entry into the national phase

Ref document number: 2921982

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 14914739

Country of ref document: US

ENP Entry into the national phase

Ref document number: 2016537393

Country of ref document: JP

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 2013399485

Country of ref document: AU

Date of ref document: 20130902

Kind code of ref document: A

REEP Request for entry into the european phase

Ref document number: 2013892435

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2013892435

Country of ref document: EP